symptoms,diseases,diagnosis
"['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis and decreased methylmalonyl-CoA mutase activity are hallmark features of methylmalonic acidemia (MMA), an autosomal recessive disorder impairing methylmalonyl-CoA metabolism. Accumulation of methylmalonic acid leads to systemic toxicity, explaining early mortality. The presentation aligns with MMA’s severe neonatal/early infantile form, where rapid metabolic decompensation causes death in infancy or childhood if untreated.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Directly linked to the documented **decreased methylmalonyl-CoA mutase activity**, this subtype involves mutations in the *MUT* gene, rendering the enzyme nonfunctional. Unlike B12-responsive forms, supplementation is ineffective, resulting in refractory metabolic acidosis and poor prognosis. Early death reflects the severity of enzyme deficiency, as residual activity <1% is typically incompatible with long-term survival."
"['Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Pneumonia', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Motor delay and generalized hypotonia**: These are hallmark neurological symptoms of SSADHD, caused by disrupted GABA metabolism. Accumulation of GABA and its metabolite gamma-hydroxybutyrate (GHB) leads to excessive neuronal inhibition, impairing motor development and muscle tone.  
2. **Elevated urinary carboxylic acid**: SSADHD results in elevated GHB, a carboxylic acid, in urine due to the enzyme deficiency blocking succinic semialdehyde conversion to succinate. This biochemical marker is specific to the disorder.  
3. **Pneumonia**: Hypotonia increases aspiration risk, predisposing infants to recurrent respiratory infections like pneumonia.  
4. **Death in infancy**: While SSADHD is typically non-lethal, severe metabolic instability, respiratory complications (e.g., pneumonia), or delayed diagnosis may contribute to early mortality in rare cases.  

The combination of neurological deficits, characteristic urinary metabolite elevation, and secondary respiratory complications aligns conclusively with SSADHD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low/normal). This may indicate a transient neonatal tyrosinemia, a co-occurring metabolic disorder, or potential misreporting of lab results.  
3. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome (if the mother had untreated PKU during pregnancy), causing congenital anomalies in the infant.  
4. **Neonatal death/Death in infancy** suggests severe metabolic derangement if untreated. Untreated PKU can lead to progressive neurologic damage, seizures, and fatal complications, though neonatal death is rare unless compounded by other factors (e.g., maternal PKU effects).  
5. PKU is prioritized due to **hyperphenylalaninemia**, the most specific symptom. Conflicting hypertyrosinemia warrants further investigation (e.g., BH4 deficiency or tyrosinemia), but the core presentation fits PKU as the primary diagnosis."
"['Congenital diaphragmatic hernia', 'Motor delay', 'Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Hiatus hernia', 'Lipodystrophy', 'Abnormal muscle physiology', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis and motor delay**: Hallmark neurological features of PMM2-CDG due to impaired glycosylation of proteins critical for cerebellar development and neuronal function.  
2. **Failure to thrive and death in infancy**: Common in severe PMM2-CDG cases due to multi-organ dysfunction, feeding difficulties, and metabolic instability.  
3. **Congenital diaphragmatic hernia (CDH) and hiatus hernia**: Rare but reported in PMM2-CDG, linked to abnormal connective tissue and muscle physiology from glycosylation defects.  
4. **Lipodystrophy and abnormal muscle physiology**: Reflect systemic metabolic disturbances caused by disrupted glycosylation of enzymes and structural proteins.  
5. **Consistent multisystem involvement**: Matches PMM2-CDG’s presentation, which combines neurological, gastrointestinal, musculoskeletal, and metabolic abnormalities.  

This pattern aligns with PMM2-CDG’s pathophysiology of defective N-glycosylation, confirmed by genetic testing for *PMM2* mutations."
"['Hydronephrosis', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Fever', 'Opisthotonus', 'Athetosis', 'Kyphoscoliosis', 'Neonatal death', 'Death in childhood', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning: The patient exhibits elevated branched-chain amino acids (Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia) and elevated urinary carboxylic acids, indicative of a defect in branched-chain amino acid metabolism. Neurological symptoms (Opisthotonus, Athetosis, Intellectual disability, Motor delay) and feeding difficulties align with neurotoxicity caused by BCAA accumulation. Life-threatening metabolic crises explain early mortality (Neonatal death, Death in infancy/childhood/adolescence). Generalized hypotonia and developmental delays are secondary to metabolic dysfunction. While Hydronephrosis is atypical, it may reflect systemic metabolic stress or comorbid congenital factors. The biochemical and clinical profile is pathognomonic for MSUD."
"['Skin rash', 'Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Diarrhea', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule', 'Hernia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Central to PKU diagnosis, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Skin manifestations (rash, erythematous plaques/macules/papules)**: Result from phenylalanine toxicity affecting skin integrity or secondary eczema-like reactions.  
3. **Prenatal abnormalities/neonatal or childhood death**: Likely due to maternal PKU syndrome, where uncontrolled maternal phenylalanine levels during pregnancy cause congenital defects (e.g., cardiac, microcephaly) or fetal loss.  
4. **Obesity**: May arise from a high-carbohydrate, low-protein diet used to manage PKU.  
5. **Gastrointestinal inflammation/diarrhea**: Linked to dietary restrictions or metabolic stress from amino acid imbalances.  
6. **Hypertyrosinemia**: Atypical for PKU but may reflect transient tyrosine fluctuations, lab misinterpretation, or secondary inhibition of tyrosine metabolism by excess phenylalanine.  
7. **Recurrent infections**: Poor metabolic control may weaken immune response or correlate with comorbid conditions.  
8. **Hernia**: Incidental or related to connective tissue changes from chronic metabolic stress.  

While neonatal death and hypertyrosinemia are uncommon in classical PKU, maternal PKU syndrome and severe untreated cases explain the broader phenotype."
"['Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Alopecia', 'Increased serum lactate', 'Increased CSF lactate']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Eczematoid dermatitis/Skin rash**: Biotinidase deficiency impairs biotin recycling, leading to biotin-dependent carboxylase dysfunction. This disrupts fatty acid synthesis and skin barrier integrity, causing dermatitis and rashes.  
2. **Alopecia**: Biotin is critical for keratinocyte function and hair follicle health. Deficiency results in hair loss due to impaired protein synthesis and cellular repair.  
3. **Increased serum/CSF lactate**: Dysfunctional carboxylases (e.g., pyruvate carboxylase) disrupt gluconeogenesis and the tricarboxylic acid cycle, causing lactic acidosis from pyruvate accumulation. Elevated lactate in both serum and CSF reflects systemic metabolic dysfunction.  
4. **Death in infancy**: Untreated biotinidase deficiency leads to progressive metabolic crises (acidosis, hyperammonemia), seizures, and neurologic deterioration, often fatal in early childhood without biotin supplementation.  
5. **Consistency with late-onset multiple carboxylase deficiency**: The term ""late-onset"" refers to partial enzyme activity delaying symptom onset, but severe cases (as implied by infant mortality) align with complete biotinidase deficiency.  

This constellation of dermatologic, metabolic, and neurologic features is pathognomonic for biotinidase deficiency."
"['Rod-cone dystrophy', 'Intellectual disability', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
- **Rod-cone dystrophy**: PMM2-CDG commonly causes retinal abnormalities, including progressive vision loss due to rod-cone dystrophy, linked to defective glycosylation of photoreceptor proteins.  
- **Intellectual disability**: A hallmark of PMM2-CDG due to impaired glycosylation critical for neurodevelopment, leading to global developmental delays and cognitive deficits.  
- **Cerebellar atrophy/agenesis**: Structural cerebellar defects (atrophy or agenesis) arise from disrupted glycosylation during brain development, contributing to hypotonia, ataxia, and motor deficits.  
- **Death in infancy**: Severe PMM2-CDG cases often result in early mortality from multiorgan failure, infections, or complications like liver disease and thromboembolism.  
- **Thromboembolism**: Coagulation factor glycosylation defects (e.g., antithrombin III deficiency) predispose to thrombotic events.  
- **Abnormal facial shape/calvaria morphology**: Characteristic dysmorphic features (e.g., high forehead, large ears) and skull abnormalities stem from glycosylation-dependent craniofacial development disruptions.  
- **Lipodystrophy**: Subcutaneous fat redistribution or loss may occur due to metabolic dysregulation from glycosylation defects in adipose tissue signaling.  
- **Acute/chronic hepatitis**: Persistent liver dysfunction (elevated transaminases, hepatomegaly) is common, progressing to fibrosis in severe cases, driven by glycosylation-dependent hepatic protein misfolding.  

**Conclusion**: The multisystemic presentation—neurological, hepatic, coagulopathic, and dysmorphic—aligns pathognomonically with PMM2-CDG, a disorder of N-linked glycosylation caused by PMM2 mutations."
"['Macrocephaly', 'Cystic hygroma', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly** and **cystic hygroma** may reflect early cerebral abnormalities or fluid-filled lesions, though cystic hygroma is atypical and warrants further evaluation for comorbidities.  
3. **Neurological symptoms** (lethargy, generalized hypotonia, dystonia, dyskinesia, drowsiness) align with basal ganglia damage, a hallmark of GA-I-induced striatal injury during metabolic crises.  
4. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from conjugation with glutaric acid, impairing fatty acid metabolism.  
5. **Acute metabolic decompensation** (fever, vomiting, diarrhea, dyspnea) triggers encephalopathic crises, often precipitated by infections or fasting, explaining rapid deterioration and **neonatal/infant death** if untreated.  
6. **Sleep disturbances** may stem from neurochemical imbalances caused by accumulating metabolites.  
7. GA-I’s clinical trajectory—progressive neurological decline and early lethality without dietary/interventional management—matches the symptom constellation.  

*Note: Cystic hygroma is uncommon in GA-I and may suggest a coincidental finding or misdiagnosis; however, the remaining features strongly support GA-I as the primary diagnosis.*"
"['Abnormality of prenatal development or birth', 'Lethargy', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia & Lethargy/Drowsiness**: IVA disrupts leucine metabolism, causing toxic isovaleric acid accumulation. This inhibits the urea cycle, leading to hyperammonemia, resulting in encephalopathic symptoms (lethargy, drowsiness).  
2. **Abnormal Glycine & Carnitine Levels**: Isovaleric acid conjugates with glycine (forming isovalerylglycine) and carnitine (isovaleryl-carnitine), depleting carnitine and elevating glycine conjugates in blood/urine, key diagnostic markers for IVA.  
3. **Feeding Difficulties & Neonatal/Infant Death**: IVA typically manifests neonatally after protein intake begins. Acute metabolic crises cause vomiting, poor feeding, and rapid deterioration, leading to death without prompt treatment (e.g., dietary leucine restriction, carnitine supplementation).  
4. **Prenatal Abnormalities**: While IVA usually presents postnatally, severe maternal-fetal metabolite exchange might cause subtle prenatal growth issues, though this is less common.  
5. **Sleep Disturbances**: Linked to neurotoxicity from ammonia and organic acid accumulation, disrupting neurotransmitter balance.  
6. **Differentiation from Other Organic Acidemias**: Elevated isovalerylglycine and specific carnitine profile distinguish IVA from propionic/methylmalonic acidemias, which show different metabolite patterns (e.g., propionylglycine).  

The constellation of hyperammonemia, glycine/carnitine abnormalities, and acute neonatal metabolic crisis strongly supports IVA. Early recognition is critical to prevent fatal outcomes."
"['Microcephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological and developmental features**: Intellectual disability, motor delay, ataxia, and generalized hypotonia align with PMM2-CDG’s hallmark cerebellar dysfunction.  
2. **Cerebellar abnormalities**: Cerebellar atrophy and agenesis are consistent with structural brain defects seen in severe PMM2-CDG cases.  
3. **Ocular signs**: Strabismus and nystagmus are common due to cerebellar and brainstem involvement.  
4. **Systemic involvement**: Growth delay, microcephaly, and infantile death reflect multisystem pathology from impaired glycosylation.  
5. **Hyporeflexia and encephalopathy**: Indicate widespread neurological dysfunction, typical of PMM2-CDG’s metabolic derangements.  
6. **Diagnostic confirmation**: While genetic testing for *PMM2* mutations is definitive, the clinical triad of cerebellar hypoplasia, developmental delay, and multisystem involvement strongly supports this diagnosis."
"['Strabismus', 'Nystagmus', 'Optic atrophy', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Ventricular septal defect', 'Hyperammonemia', 'Hyperhomocystinemia', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Elevated urinary carboxylic acid']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, **elevated urinary carboxylic acids**, and **hyperammonemia**, hallmark features of MMA caused by impaired methylmalonyl-CoA mutase activity or cobalamin metabolism. **Generalized hypotonia**, **motor delay**, **optic atrophy**, and **abnormal carnitine levels** align with MMA’s neurological and metabolic sequelae. **Death in infancy/childhood** and **neonatal death** reflect the severe, early-onset nature of the disease.  

Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning: The coexistence of **hyperhomocystinemia** with methylmalonic aciduria strongly indicates **cblC subtype**, a cobalamin metabolism defect. **Ventricular septal defect** and **abnormality of prenatal development** correlate with cblC’s systemic effects, including cardiovascular malformations. **Hyperalaninemia** and **hyperammonemia** suggest secondary urea cycle disruption, while **strabismus**, **nystagmus**, and **optic atrophy** reflect neurologic/ophthalmic damage from toxic metabolite accumulation (homocysteine, methylmalonic acid). This dual biochemical profile (MMA + homocystinuria) is pathognomonic for cblC."
"['Death in infancy', 'Hypoglycemia', 'Vomiting', 'Diarrhea', 'Elevated hepatic transaminase', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Medium chain acyl-CoA dehydrogenase deficiency (MCADD):  
1. **Hypoglycemia**: MCADD impairs the breakdown of medium-chain fatty acids, a critical energy source during fasting. This leads to hypoglycemia due to the inability to generate ketones as an alternative fuel.  
2. **Vomiting/Diarrhea**: Metabolic decompensation during fasting or infection triggers gastrointestinal symptoms.  
3. **Elevated hepatic transaminases**: Accumulation of toxic metabolites (e.g., medium-chain acylcarnitines) causes hepatocellular damage.  
4. **Abnormal carnitine profile**: Secondary carnitine deficiency occurs due to urinary loss of carnitine bound to unmetabolized fatty acids (elevated C8-C10 acylcarnitines on bloodspot analysis).  
5. **Death in infancy**: Untreated MCADD carries high mortality from hypoglycemia, encephalopathy, and liver failure during catabolic stress. Neonatal screening and avoidance of fasting are lifesaving."
"['Coma', 'Death in infancy', 'Hyperkalemia', 'Hyponatremia', 'Neonatal death', 'Respiratory acidosis', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acids**: SSADHD causes accumulation of γ-hydroxybutyrate (GHB), a carboxylic acid derivative, due to defective succinic semialdehyde dehydrogenase. This aligns with elevated urinary GHB (detected as a carboxylic acid).  
2. **Neurological symptoms (Coma)**: GHB is neurotoxic and a CNS depressant, leading to coma in severe neonatal presentations.  
3. **Respiratory acidosis**: CNS depression from GHB toxicity impairs respiratory drive, causing hypoventilation and CO₂ retention.  
4. **Hyperkalemia/Hyponatremia**: Secondary to metabolic dysregulation or renal tubular dysfunction in critically ill infants, though not a primary feature of SSADHD.  
5. **Early lethality (Neonatal death/Death in infancy)**: Severe enzyme deficiency leads to rapid toxic metabolite accumulation, resulting in life-threatening neurological and respiratory compromise.  
6. **Exclusion of other organic acidurias**: Symptoms align with SSADHD-specific markers (GHB elevation) rather than classic organic acidemias (e.g., propionic/methylmalonic acidemia), which typically present with metabolic acidosis and hyperammonemia."
"['Ptosis', 'Ectopia lentis', 'Large hands', 'Intellectual disability', 'Motor delay', 'Long foot', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Death in childhood', 'Death in adolescence', 'Fatigue']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning: The patient exhibits **hyperhomocystinemia** and **hypermethioninemia**, biochemical hallmarks of homocystinuria. Symptoms like **ectopia lentis** (lens dislocation) and **ptosis** are classic ocular manifestations. **Intellectual disability** and **motor delay** align with neurological complications from toxic homocysteine accumulation. **Long foot** and **large hands** suggest Marfanoid habitus, a skeletal feature of this disorder. Early mortality (**death in childhood/adolescence**) reflects severe untreated metabolic dysfunction.  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: This subtype is confirmed by **hypermethioninemia**, as cystathionine beta-synthase (CBS) deficiency impairs homocysteine-to-cystathionine conversion, causing methionine buildup. **Ectopia lentis** and skeletal abnormalities are pathognomonic for CBS-deficient homocystinuria. **Fatigue** may stem from metabolic stress, while early death underscores disease severity without intervention (e.g., pyridoxine responsiveness or dietary methionine restriction). The absence of cystathionine beta-synthase activity directly links to this diagnosis."
"['Wide mouth', 'Epicanthus', 'Carious teeth', 'Hyperinsulinemia', 'Sparse hair', 'Seizure', 'Death in infancy', 'Hypoglycemia', 'Neonatal death', 'Death in childhood', 'Abnormal hemoglobin', 'Feeding difficulties']","['Hyperinsulinemic hypoglycemia, familial, 2', 'Congenital hyperinsulinemic hypoglycemia; CHI']","Disease: Hyperinsulinemic hypoglycemia, familial, 2  
Reasoning: The patient exhibits **hyperinsulinemia** and **hypoglycemia**, core features of this condition. Persistent hypoglycemia explains **seizures** and **feeding difficulties**, while severe, unmanaged cases can lead to **neonatal death**, **death in infancy**, or **death in childhood**. Familial type 2 is linked to *ABCC8* mutations, which disrupt insulin regulation. Although dysmorphic features (e.g., **wide mouth**, **epicanthus**) are atypical for isolated hyperinsulinemia, they may arise from syndromic forms or secondary effects of chronic metabolic stress. **Abnormal hemoglobin** could indicate compensatory erythropoiesis due to hypoxia from hypoglycemic episodes.  

Disease: Congenital hyperinsulinemic hypoglycemia (CHI)  
Reasoning: CHI encompasses genetic causes of hyperinsulinemic hypoglycemia, including *ABCC8/KCNJ11* mutations. Symptoms align with severe neonatal-onset hypoglycemia (**hypoglycemia**, **hyperinsulinemia**), leading to **seizures** and high mortality (**neonatal/childhood death**). **Sparse hair** and **carious teeth** may reflect chronic malnutrition or metabolic derangements. While **epicanthus** and **wide mouth** are not classic CHI features, they could suggest an overlapping genetic syndrome or phenocopy. **Abnormal hemoglobin** might be incidental or related to oxidative stress from recurrent hypoglycemia. CHI is the broader diagnostic category, with familial type 2 representing a specific genetic subtype."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Anemia', 'Hyperammonemia', 'Hyperglycinemia', 'Hepatomegaly', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Hypoglycinemia']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Metabolic Dysregulation**: Propionic acidemia (PA) is caused by defective propionyl-CoA carboxylase, leading to toxic accumulation of propionate. This disrupts amino acid (isoleucine, valine, methionine, threonine) and fatty acid metabolism.  
2. **Hyperammonemia & Hyperglycinemia**: Propionate overload inhibits the urea cycle (causing hyperammonemia) and disrupts glycine metabolism, resulting in elevated glycine (hyperglycinemia).  
3. **Carnitine Abnormalities**: Secondary carnitine deficiency occurs as carnitine conjugates with propionate for excretion, explaining ""abnormal circulating carnitine concentration.""  
4. **Neurological Symptoms**: Intellectual disability, seizures, and motor delay arise from neurotoxic metabolites (e.g., propionate, ammonia) and energy deficiency.  
5. **Hepatomegaly & Anemia**: Liver enlargement stems from metabolic stress; anemia results from bone marrow suppression by toxic metabolites.  
6. **Early Mortality**: Neonatal/infant/childhood death aligns with acute metabolic crises (acidosis, hypoglycemia) in untreated PA.  
7. **Prenatal Abnormalities**: Intrauterine accumulation of metabolites may cause growth restriction or structural defects.  
*Note*: The listed ""hypoglycinemia"" may be an inconsistency, as PA typically elevates glycine. This could reflect transient fluctuations or a documentation error."
"['Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Metabolic acidosis', 'Apnea', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Feeding difficulties', 'Methylmalonic aciduria', 'Abnormal nervous system physiology']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria** and **decreased methylmalonyl-CoA mutase activity**, hallmark biochemical features of MMA. Symptoms like **metabolic acidosis**, **apnea**, **feeding difficulties**, and **abnormal nervous system physiology** align with MMA's pathophysiology, where toxic methylmalonic acid accumulates, disrupting energy metabolism and causing multi-organ dysfunction. **Thrombocytopenia** and **leukopenia** may result from bone marrow suppression secondary to metabolic stress. **Neonatal death** and **death in infancy** are consistent with severe, untreated MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **decreased methylmalonyl-CoA mutase activity** directly indicates a defect in the MUT gene, causing the B12-unresponsive subtype of MMA. This subtype does not improve with vitamin B12 supplementation, distinguishing it from B12-responsive forms. Symptoms such as **generalized hypotonia**, **metabolic acidosis**, and **methylmalonic aciduria** are classic for this genetic enzyme deficiency. Early lethality (**neonatal death**, **death in infancy**) is characteristic of severe mutase deficiency (mut⁰ or mut⁻ variants), where residual enzyme activity is minimal or absent."
"['Coma', 'Death in infancy', 'Sudden death', 'Hypoglycemia', 'Vomiting', 'Elevated circulating alkaline phosphatase concentration', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by mutations in the *SLC22A5* gene impairing carnitine transport.  
2. **Hypoglycemia** occurs due to defective fatty acid oxidation (FAO), forcing reliance on glucose metabolism and depleting glycogen stores, particularly during fasting or metabolic stress.  
3. **Sudden death in infancy** and **coma** result from metabolic crises triggered by hypoglycemia and hyperammonemia, exacerbated by the inability to utilize fatty acids for energy in critical tissues (e.g., heart, liver).  
4. **Elevated lactate dehydrogenase (LDH)** and **abnormal alanine/aspartate family amino acids** reflect secondary mitochondrial dysfunction and anaerobic glycolysis activation under energy-deficient states.  
5. **Vomiting** and **hepatic involvement** (elevated alkaline phosphatase) stem from hepatic steatosis and impaired hepatic FAO.  
6. PCD aligns with the acute metabolic decompensation pattern in infancy, distinguishing it from other FAO disorders (e.g., MCAD deficiency lacks carnitine deficiency). Genetic testing for *SLC22A5* variants would confirm the diagnosis."
"['Lethargy', 'Death in infancy', 'Clumsiness', 'Drowsiness', 'Sleep disturbance', 'Poor coordination', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Feeding difficulties']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient presents with lethargy, drowsiness, feeding difficulties, and decreased plasma free carnitine, consistent with a metabolic disorder. 3-Methylcrotonyl-CoA carboxylase (3-MCC) deficiency disrupts leucine catabolism, leading to toxic metabolite accumulation (e.g., 3-methylcrotonylglycine), which sequesters carnitine, causing secondary deficiency. Symptoms like poor coordination, clumsiness, and sleep disturbances align with metabolic encephalopathy. Severe forms can trigger life-threatening metabolic crises, explaining neonatal/childhood death if untreated.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis encompasses both MCCC1 and MCCC2 gene defects. The patient’s symptoms—lethargy, feeding difficulties, and early mortality—reflect acute metabolic decompensation. Decreased carnitine results from organic acid conjugation and renal loss. Neonatal death suggests a severe phenotype with rapid progression, often due to delayed diagnosis or metabolic stressors (e.g., fasting, infection). The clinical overlap between subtypes makes biochemical/genetic testing critical, but the symptom profile strongly supports 3-MCC deficiency as the underlying etiology."
"['Delayed speech and language development', 'Hypothyroidism', 'Dysarthria', 'Spastic diplegia', 'Encephalopathy', 'Hyperreflexia', 'Spastic tetraplegia', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Death in adolescence', 'Death in early adulthood']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Ethylmalonic aciduria** and **cytochrome C oxidase-negative muscle fibers** are hallmark biochemical and histopathological findings in mitochondrial complex IV (cytochrome c oxidase) deficiency, directly implicating impaired oxidative phosphorylation.  
2. **Encephalopathy**, **hyperreflexia**, **spastic tetraplegia/diplegia**, and **dysarthria** reflect severe neurological dysfunction due to energy failure in neurons and corticospinal tract damage.  
3. **Delayed speech/language development** aligns with global neurodevelopmental delays caused by chronic cerebral energy deficits.  
4. **Hypothyroidism** and **recurrent viral infections** suggest multisystem involvement, as mitochondrial dysfunction affects thyroid metabolism and immune cell energetics.  
5. **Abnormal circulating glycine concentration** may arise from disrupted mitochondrial metabolism of amino acids.  
6. **Death in adolescence/early adulthood** is consistent with progressive neurodegeneration and multisystem failure in severe mitochondrial disorders.  
7. Nuclear type 1 (OMIM 220110) specifically involves mutations in *SURF1*, a gene critical for complex IV assembly, explaining the COX-negative fibers and systemic phenotype."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to secondary carnitine deficiency due to accumulation of toxic metabolites (e.g., medium-chain acylcarnitines like C8, C10), which are excreted, depleting free carnitine.  
2. **Neonatal death/Death in infancy**: MCADD causes life-threatening hypoglycemia and metabolic crises triggered by fasting (common in newborns/infants), leading to encephalopathy, liver failure, or cardiac arrest if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe fetal metabolic stress or maternal metabolic disturbances during pregnancy (e.g., maternal fasting) may contribute to subtle prenatal abnormalities.  
4. **Supporting biochemical hallmarks**: MCADD is confirmed by elevated C6-C10 acylcarnitines on tandem mass spectrometry and genetic testing for *ACADM* gene mutations.  
5. **Exclusion of alternatives**: Symptoms align with MCADD rather than other fatty acid oxidation disorders (e.g., VLCADD presents with cardiomyopathy, LCHADD with retinopathy) or organic acidemias (e.g., distinct organic aciduria)."
"['Macrocephaly', 'Cystic hygroma', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Key Biochemical Markers**: Elevated glutaric acid in urine (glutaric aciduria) and blood, combined with decreased plasma free carnitine, strongly suggest a defect in lysine, hydroxylysine, and tryptophan metabolism. GA-I is caused by mutations in the *GCDH* gene, leading to glutaryl-CoA dehydrogenase deficiency and subsequent toxic accumulation of glutaric acid.  
2. **Neurological Symptoms**: Macrocephaly (often due to frontotemporal atrophy), dystonia, dyskinesia, generalized hypotonia, and lethargy align with striatal degeneration caused by neurotoxic metabolites (e.g., glutaric acid, 3-hydroxyglutaric acid) during metabolic crises.  
3. **Acute Metabolic Crises**: Fever, vomiting, diarrhea, dyspnea, and metabolic acidosis are triggered by catabolic stressors (e.g., infections), characteristic of GA-I decompensation.  
4. **Poor Prognosis**: Neonatal death or death in childhood is common if untreated, as crises cause irreversible brain damage.  
5. **Supporting Features**: Hyperhidrosis and sleep disturbances may reflect autonomic dysfunction, while drowsiness and lethargy correlate with encephalopathic phases.  
6. **Exclusion of Cystic Hygroma**: While cystic hygroma is listed, it is likely incidental or a prenatal finding unrelated to GA-I, which primarily affects metabolic and neurological systems.  

The constellation of metabolic acidosis, glutaric acid accumulation, neurological deterioration, and carnitine deficiency confirms GA-I as the definitive diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine. This aligns with the patient’s lab findings.  
2. **Abnormality of prenatal development/birth** and **neonatal death** may reflect *maternal PKU syndrome* (if the mother had untreated PKU during pregnancy), causing congenital anomalies (e.g., microcephaly, cardiac defects) in the infant.  
3. **Death in infancy/childhood/adolescence** correlates with untreated PKU progression: severe neurological damage, seizures, and organ failure due to phenylalanine toxicity. Without early dietary intervention, fatal outcomes are likely.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are typically low). This may suggest a co-occurring condition (e.g., tyrosinemia type II) or transient neonatal tyrosinemia, but PKU remains primary due to hyperphenylalaninemia.  
5. The absence of tyrosine hydroxylase cofactors (e.g., BH4 deficiency) could exacerbate metabolic dysregulation, though this is a PKU subtype.  

**Conclusion**: PKU is confirmed by hyperphenylalaninemia and clinical progression. Early mortality and prenatal abnormalities reflect untreated/severe disease. Hypertyrosinemia warrants further investigation but does not override the PKU diagnosis."
"['Delayed speech and language development', 'Intellectual disability', 'Hyperreflexia', 'Death in infancy', 'Difficulty walking', 'Abnormal cerebral white matter morphology', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Neurological and developmental symptoms**: Delayed speech/language development and intellectual disability align with the progressive neurocognitive decline seen in L-2-hydroxyglutaric aciduria (L-2-HGA).  
2. **Motor dysfunction**: Difficulty walking, climbing stairs, and running correlate with cerebellar ataxia and pyramidal involvement (hyperreflexia), common in this disorder.  
3. **Neuroimaging findings**: Abnormal cerebral white matter morphology is characteristic of L-2-HGA, often showing leukoencephalopathy on MRI.  
4. **Early mortality**: Death in infancy/childhood occurs in severe cases due to metabolic crises or progressive neurological deterioration.  
5. **Metabolic hallmark**: Excess L-2-hydroxyglutaric acid in urine/CSF confirms the diagnosis, though clinical and imaging features strongly support it here.  
6. **Exclusion of mimics**: Symptoms differentiate it from other leukodystrophies (e.g., Canavan disease) due to specific motor and imaging patterns."
"['Apathy', 'Spasticity', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hypoglycemia', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in early adulthood']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Key biochemical markers**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in branched-chain amino acid (BCAA) metabolism, the hallmark of MSUD.  
2. **Neurological symptoms**: Spasticity, generalized hypotonia, and apathy arise from neurotoxicity caused by accumulated BCAAs and their ketoacid derivatives.  
3. **Early mortality**: Neonatal death, death in infancy, or early adulthood aligns with severe MSUD phenotypes, where metabolic crises lead to rapid deterioration without dietary intervention.  
4. **Hypoglycemia**: Reflects metabolic instability during catabolic states (e.g., infections or fasting), common in MSUD due to disrupted energy metabolism.  
5. **Obesity**: May result from high-calorie dietary regimens used to manage MSUD or secondary metabolic dysfunction.  
6. **Exclusion of mimics**: The triad of elevated BCAAs rules out isolated hypervalinemia or other aminoacidurias, solidifying MSUD as the diagnosis.  

(Note: Classic MSUD also features a maple syrup odor in bodily fluids, which may not have been reported here but is not essential for diagnosis when biochemical and clinical criteria are met.)"
"['Delayed speech and language development', 'Obesity', 'Death in infancy', 'Hyperalaninemia', 'Aminoaciduria', 'Increased total bilirubin', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating tyrosine concentration', 'Death in adolescence', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient exhibits hypergalactosemia and an abnormality of galactoside metabolism, directly implicating impaired galactose processing. Classic galactosemia (GALT deficiency) results in toxic accumulation of galactose-1-phosphate, leading to liver dysfunction (elevated bilirubin, hyperalaninemia, aminoaciduria) and metabolic derangements (abnormal tyrosine/aspartate family amino acids). Neonatal/infant mortality and adolescent death align with untreated cases due to liver failure, sepsis, or chronic complications. Delayed speech may reflect neurological damage from metabolite toxicity. Obesity is atypical but could arise from dietary adjustments or metabolic dysregulation.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning: This term encompasses broader galactose metabolism defects, including GALT, GALK1, or GALE deficiencies. The patient’s hypergalactosemia, galactoside metabolism abnormalities, and liver-related symptoms (increased bilirubin, aminoaciduria) are consistent with this category. Abnormal tyrosine/aspartate levels may reflect secondary disruptions in hepatic amino acid handling. Early mortality and developmental delays further support a severe, systemic galactosemia variant."
"['Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Central features of HMG-CoA lyase deficiency, caused by impaired leucine catabolism and ketogenesis, leading to toxic accumulation of 3-hydroxy-3-methylglutaric acid and secondary urea cycle disruption.  
2. **Dicarboxylic aciduria and 3-methylglutaric aciduria**: Pathognomonic urinary biomarkers due to defective HMG-CoA lyase activity, which prevents cleavage of HMG-CoA into acetoacetate and acetyl-CoA, resulting in excretion of these metabolites.  
3. **Elevated urinary carboxylic acids**: Reflects systemic organic acidemia from blocked ketone body synthesis and mitochondrial energy dysfunction.  
4. **Abnormal circulating glycine**: Secondary glycine elevation occurs as glycine conjugation attempts to detoxify accumulating organic acids (e.g., 3-methylglutaconate).  
5. **Vomiting, fever, and infantile lethality**: Episodic crises triggered by catabolic stress (e.g., fasting, infection), causing acute metabolic decompensation. Untreated, this leads to rapid neurological decline and early mortality.  
6. **Exclusion of mimics**: The specific organic acid profile (3-methylglutaric aciduria) distinguishes it from other organic acidurias (e.g., propionic acidemia), which lack this marker."
"['Jaundice', 'Generalized hypotonia', 'Anemia', 'Hyperhomocystinemia', 'Progressive neurologic deterioration', 'Hypomethioninemia', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormality of folate metabolism']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia** is the hallmark of homocystinuria, caused by impaired cystathionine beta-synthase (CBS) activity, blocking homocysteine-to-cystathionine conversion.  
2. **Hypomethioninemia** is atypical for CBS deficiency (typically *elevated* methionine), but may occur in rare variants or secondary folate metabolism disturbances affecting remethylation pathways.  
3. **Progressive neurologic deterioration** aligns with untreated homocystinuria, as excess homocysteine is neurotoxic, causing seizures, intellectual disability, and neurodegeneration.  
4. **Abnormality of folate metabolism** may exacerbate remethylation defects, worsening homocysteine accumulation and methionine depletion.  
5. **Recurrent viral infections** and **anemia** could stem from immune dysfunction due to metabolic stress or folate-related hematologic abnormalities.  
6. **Jaundice** and **abnormal porphyrins** suggest hepatic involvement, possibly from oxidative stress or secondary porphyrin pathway disruption.  
7. **Death in childhood** correlates with severe, untreated CBS deficiency, often due to thromboembolic events or neurologic complications.  

Disease: Homocysteinemia/Homocystinuria (general)  
Reasoning:  
1. **Hyperhomocystinemia** directly defines this disorder, encompassing both CBS deficiency and remethylation defects (e.g., MTHFR deficiency).  
2. **Hypomethioninemia** suggests a remethylation defect (e.g., MTHFR or cobalamin disorders), where homocysteine cannot recycle to methionine, but this overlaps with CBS deficiency in clinical presentation.  
3. **Abnormal folate metabolism** supports a broader homocysteinemia diagnosis, as folate is critical for homocysteine remethylation.  
4. **Neurologic deterioration** and **hypotonia** are nonspecific but consistent with systemic metabolic dysfunction from homocysteine toxicity.  
5. **Recurrent infections** and **anemia** may reflect multisystemic failure or secondary nutritional deficiencies (e.g., B12/folate).  

**Final Diagnosis**: Classic homocystinuria (CBS deficiency) is prioritized due to progressive neurologic decline and hyperhomocystinemia, though hypomethioninemia suggests a complex presentation, possibly with coexisting folate pathway disruption."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother has uncontrolled PKU during pregnancy, though this is rare in the patient’s own presentation.  
3. **Death in infancy/childhood/adolescence/early adulthood** reflects untreated PKU’s natural history: severe neurotoxicity, seizures, and organ failure without dietary intervention.  
4. **Hypertyrosinemia** is atypical for classic PKU (which usually causes *low* tyrosine due to PAH deficiency) but may suggest a rare PAH variant or secondary metabolic disruption.  
5. **Upper airway/chronic pulmonary obstruction** could stem from comorbid infections or neuromuscular dysfunction from chronic metabolic damage.  
6. **Neonatal death** is uncommon with modern screening but plausible in undiagnosed/severe cases.  

Note: While hypertyrosinemia and respiratory symptoms are unusual, PKU is strongly supported by hyperphenylalaninemia and the fatal progression described. Tyrosinemia or combined metabolic disorders should be ruled out clinically."
"['Apathy', 'Seizure', 'Spasticity', 'Death in infancy', 'Alopecia', 'Dyspnea', 'Fatigue', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acid**: Directly links to impaired carboxylase function (propionyl-CoA carboxylase, pyruvate carboxylase, etc.), which require biotin as a cofactor. Deficiency reduces enzyme activity, causing organic acid accumulation.  
2. **Seizures & spasticity**: Neurological manifestations arise from metabolic acidosis, hyperammonemia, or disrupted neurotransmitter synthesis due to defective biotin-dependent enzymes.  
3. **Alopecia**: Biotin is critical for keratin synthesis; deficiency leads to hair fragility and loss.  
4. **Dyspnea & fatigue**: Metabolic acidosis from accumulated organic acids triggers respiratory compensation (Kussmaul breathing) and systemic energy depletion.  
5. **Apathy**: Reflects global encephalopathy secondary to metabolic derangements.  
6. **Death in infancy**: Untreated BTDD causes progressive neurological decline, metabolic crises, and fatal outcomes without biotin supplementation.  
7. **Late-onset presentation**: Aligns with partial biotinidase deficiency, where symptoms manifest after the neonatal period but escalate rapidly without intervention.  

The constellation of metabolic, neurological, and dermatological signs, coupled with urinary carboxylic acid elevation, is pathognomonic for biotinidase deficiency. Early biotin replacement reverses symptoms, underscoring the urgency of diagnosis."
"['Obesity', 'Death in infancy', 'Fever', 'Vomiting', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Neonatal death**, **death in infancy/childhood/adolescence** align with untreated PKU, where toxic phenylalanine accumulation leads to severe neurological damage, organ failure, and early mortality without dietary intervention.  
3. **Vomiting** and **gastrointestinal inflammation** may reflect metabolic crises or protein intolerance due to impaired phenylalanine metabolism.  
4. **Obesity** could stem from restrictive dietary management (high-carbohydrate, low-protein diets) often used in PKU, predisposing to weight gain.  
5. **Hypertyrosinemia** is atypical in classic PKU (which typically causes *low* tyrosine levels). This may indicate a concurrent condition (e.g., tyrosinemia Type II), a PAH deficiency variant affecting tyrosine regulation, or a reporting error.  
6. **Fever** is non-specific but could arise from secondary infections or metabolic instability in severe cases.  
**Conclusion**: Hyperphenylalaninemia is pathognomonic for PKU. Early lethality and systemic symptoms reflect untreated disease progression, though hypertyrosinemia warrants further investigation for comorbidities or diagnostic inaccuracies."
"['Skin rash', 'Death in infancy', 'Alopecia', 'Metabolic acidosis', 'Increased CSF lactate', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Core metabolic features**: Metabolic acidosis, elevated CSF lactate, and elevated urinary carboxylic acids indicate mitochondrial dysfunction in energy metabolism. These findings align with impaired activity of biotin-dependent carboxylases (propionyl-CoA, pyruvate, and 3-methylcrotonyl-CoA carboxylases), which require biotin as a cofactor.  
2. **Cutaneous manifestations**: Skin rash, erythematous plaques/macules/papules, and alopecia are classic signs of biotin deficiency, as biotin is critical for keratinocyte integrity and hair follicle health.  
3. **Neurological and systemic involvement**: Increased CSF lactate suggests central nervous system energy failure. Death in infancy reflects rapid metabolic decompensation if untreated.  
4. **Biochemical hallmarks**: Aminoaciduria and abnormal glycine levels arise from disrupted amino acid catabolism due to carboxylase deficiencies. Elevated urinary carboxylic acids (e.g., 3-hydroxyisovalerate, propionylglycine) directly reflect carboxylase dysfunction.  
5. **Diagnostic confirmation**: Biotinidase deficiency (BTDD) specifically disrupts biotin recycling, causing late-onset multiple carboxylase deficiency. Symptoms manifest after neonatal biotin stores are depleted, distinguishing it from holocarboxylase synthetase deficiency (early-onset). Rapid clinical improvement with biotin supplementation further supports BTDD."
"['Death in infancy', 'Dehydration', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Feeding difficulties']","['甲基丙二酸血症; 甲基丙二酸尿症/Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **decreased methylmalonyl-CoA mutase activity**, a hallmark of methylmalonic acidemia (MMA). This enzyme deficiency disrupts the breakdown of methylmalonyl-CoA, leading to toxic accumulation of methylmalonic acid. Symptoms like **feeding difficulties**, **dehydration**, and **neonatal/infant death** align with acute metabolic decompensation, a critical feature of MMA. Early-onset life-threatening crises are typical in severe forms of the disease.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **decreased methylmalonyl-CoA mutase activity** specifically indicates a defect in the MUT gene encoding this enzyme, categorizing the condition as a **vitamin B12-unresponsive** subtype. Unlike B12-responsive MMA, this form does not improve with B12 supplementation. The severity of symptoms (e.g., **neonatal death**, **feeding difficulties**) reflects complete or near-complete loss of enzyme function, causing rapid metabolic instability and poor prognosis without aggressive intervention (e.g., dietary protein restriction, organ transplantation)."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Stomatitis', 'Stridor', 'Abnormal circulating glycine concentration', 'Fatigue', 'Elevated urinary carboxylic acid', 'Gangrene']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Carboxylase Deficiencies**: Decreased pyruvate carboxylase activity and propionyl-CoA carboxylase deficiency directly implicate biotin-dependent carboxylase dysfunction. Biotinidase deficiency prevents biotin recycling, critical for these enzymes.  
2. **Metabolic Acidosis & Lactate Elevation**: Impaired gluconeogenesis (pyruvate carboxylase) and disrupted citric acid cycle lead to lactic acidosis (↑ serum lactate) and metabolic acidosis. Elevated urinary carboxylic acids reflect accumulated metabolites.  
3. **Neurological Symptoms**: Lethargy, drowsiness, hypotonia, and sleep disturbance arise from biotin’s role in neuronal energy metabolism and neurotransmitter regulation.  
4. **Dermatological/Mucosal Involvement**: Stomatitis and gangrene suggest biotin deficiency, as biotin is essential for skin/mucosal integrity.  
5. **Aminoaciduria & Glycine Abnormalities**: Renal tubular acidosis (from metabolic stress) and disrupted amino acid metabolism explain aminoaciduria and abnormal glycine levels.  
6. **Fever & Infant Mortality**: Metabolic crises and susceptibility to infections (due to immune dysfunction) may cause fever. Untreated BTDD leads to fatal metabolic decompensation in infancy.  
7. **Stridor**: Neuromuscular weakness or laryngeal dysfunction secondary to metabolic encephalopathy could manifest as stridor.  
**Conclusion**: The constellation of multi-carboxylase deficiencies, metabolic acidosis, neurological/dermatological signs, and infantile lethality aligns with late-onset BTDD. Biotin supplementation would reverse symptoms if diagnosed early."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine. This aligns with the listed symptom.  
2. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome (untreated phenylalanine elevation during pregnancy) rather than the infant’s own PKU, though severe neonatal metabolic instability could contribute.  
3. **Death in infancy/childhood and neonatal death** are rare in treated PKU but plausible in undiagnosed/severe cases due to metabolic crises, neurological deterioration, or secondary complications (e.g., seizures, failure to thrive).  
4. **Hypertyrosinemia** is atypical in classic PKU (tyrosine levels are usually normal/low). This could suggest a comorbid condition (e.g., transient tyrosinemia in liver immaturity) or a BH4-deficient PKU variant, where disrupted tyrosine metabolism may occur alongside phenylalanine accumulation.  
5. The combination of **hyperphenylalaninemia + early lethality** strongly prioritizes PKU as the primary diagnosis, with hypertyrosinemia requiring further investigation for confounding factors."
"['Death in infancy', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Death in infancy**: HMG-CoA lyase deficiency is a severe autosomal recessive metabolic disorder that typically manifests in infancy with life-threatening episodes of hypoglycemia and metabolic acidosis, often leading to early mortality if undiagnosed or untreated.  
2. **Dicarboxylic aciduria**: Impaired fatty acid β-oxidation due to deficient HMG-CoA lyase activity results in incomplete fatty acid breakdown, causing urinary excretion of dicarboxylic acids (e.g., adipic, suberic acids).  
3. **3-Methylglutaric aciduria**: The enzyme deficiency disrupts leucine catabolism, leading to accumulation of 3-hydroxy-3-methylglutaryl-CoA, which is diverted to 3-methylglutaric acid and 3-methylglutaconic acid via alternative pathways.  
4. **Elevated urinary carboxylic acids**: The block in ketogenesis (HMG-CoA lyase converts HMG-CoA to acetoacetate) and leucine degradation causes systemic buildup of multiple carboxylic acids (e.g., 3-hydroxy-3-methylglutaric, 3-methylglutaric, and 3-methylglutaconic acids), which are excreted in urine.  
**Conclusion**: The biochemical profile aligns with HMG-CoA lyase deficiency, where disrupted ketogenesis and leucine metabolism lead to characteristic organic aciduria, hypoglycemia, and metabolic crises in infancy."
"['Carious teeth', 'Obesity', 'Elevated hepatic transaminase', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased circulating copper concentration', 'Decreased serum iron']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin concentration**: A hallmark of Wilson disease, as impaired copper transport due to ATP7B gene mutations prevents copper incorporation into ceruloplasmin, reducing its serum levels.  
2. **Increased urinary copper concentration**: Excess copper is excreted via urine due to systemic overload, a key diagnostic criterion.  
3. **Elevated hepatic transaminase**: Reflects liver injury from copper accumulation, a common early manifestation.  
4. **Decreased circulating copper concentration**: Paradoxically low serum copper occurs because unbound copper (non-ceruloplasmin-bound) is rapidly cleared, though total body copper is elevated.  
5. **Abnormal circulating aspartate family amino acid/alanine concentration**: Liver dysfunction disrupts amino acid metabolism, elevating serum levels.  
6. **Decreased serum iron**: Secondary to hepatic damage impairing iron regulation or coexisting malnutrition.  
7. **Abnormal circulating porphyrin concentration**: May arise from hepatic dysfunction or oxidative stress due to copper toxicity.  
8. **Carious teeth**: Chronic copper toxicity can cause salivary gland dysfunction or enamel defects.  
9. **Obesity**: Atypical but possible due to metabolic disturbances or comorbidities.  
10. **Death in childhood**: Untreated Wilson disease leads to fatal liver failure or neurological deterioration, emphasizing early diagnosis.  

The combination of copper metabolism abnormalities (ceruloplasmin, urinary/serum copper) with hepatic and systemic manifestations confirms Wilson disease."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The symptoms of neonatal death, death in infancy, and abnormal circulating carnitine concentration align with MCADD, a fatty acid oxidation disorder. MCADD impairs the breakdown of medium-chain fatty acids, leading to energy deficits during fasting. Hypoglycemia and metabolic crises in infancy can result in sudden death. Abnormal carnitine levels occur due to secondary carnitine depletion from conjugation with accumulating toxic acyl-CoA intermediates. While prenatal abnormalities are less typical, severe metabolic stress in utero or delayed postnatal adaptation may contribute to complications. MCADD is a common cause of metabolic emergencies in neonates and is detectable via newborn screening (elevated C8-C10 acylcarnitines)."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Death in infancy/childhood** aligns with untreated PKU, as elevated phenylalanine causes irreversible neurotoxicity, seizures, and failure to thrive.  
3. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low due to blocked PAH activity). This may suggest a secondary metabolic disturbance, comorbid tyrosinemia, or misdiagnosis of lab values.  
4. **Recurrent viral infections** are not characteristic of PKU and could indicate an unrelated immune disorder or complications from metabolic instability (e.g., malnutrition).  
5. The diagnosis prioritizes hyperphenylalaninemia and early lethality as primary PKU indicators, while acknowledging inconsistencies (hypertyrosinemia, infections) that warrant further investigation for overlapping disorders."
"['Aminoaciduria', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency / 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** (e.g., 3-hydroxyisovaleric acid, 3-methylcrotonylglycine) arise due to impaired leucine catabolism from deficient 3-methylcrotonyl-CoA carboxylase (3-MCC), a biotin-dependent enzyme.  
2. **Abnormal circulating carnitine concentration** (secondary carnitine deficiency) occurs as carnitine conjugates with toxic metabolites (e.g., 3-methylcrotonyl-CoA) for urinary excretion, depleting free carnitine.  
3. **Aminoaciduria** may result from renal tubular dysfunction caused by accumulated metabolites or secondary mitochondrial stress.  
4. **Abnormal circulating glycine concentration** (often elevated) stems from glycine conjugation with excess organic acids (e.g., 3-methylcrotonylglycine formation), altering glycine homeostasis.  
*Note: Both terms refer to the same disorder, with the nomenclature difference reflecting gene-specific (MCCC1) vs. enzymatic classification.*"
"['Generalized hypotonia', 'Death in infancy', 'Hepatomegaly', 'Tachypnea', '3-Methylglutaconic aciduria', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency), hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia**: CPS1 deficiency disrupts the urea cycle, causing toxic ammonia accumulation. This aligns with neonatal lethality, feeding difficulties, and hypotonia due to neurotoxicity.  
2. **3-Methylglutaconic aciduria**: Though atypical for urea cycle disorders, it may arise secondary to mitochondrial dysfunction or metabolic stress from hyperammonemia.  
3. **Respiratory symptoms (tachypnea)**: Compensatory respiratory alkalosis from hyperammonemia-induced metabolic acidosis drives rapid breathing.  
4. **Hepatomegaly**: While uncommon in CPS1 deficiency, liver enlargement could reflect metabolic strain or secondary dysfunction from ammonia toxicity.  
5. **Neonatal/Infantile death**: Severe urea cycle defects like CPS1 deficiency often present acutely in infancy with fatal hyperammonemic crises if untreated.  
6. **Feeding difficulties and hypotonia**: Neurological impairment from ammonia toxicity leads to poor feeding and generalized muscle weakness.  

The constellation of symptoms, despite some atypical features (e.g., 3-methylglutaconic aciduria), strongly supports CPS1 deficiency as the primary diagnosis, with hyperammonemia as the central pathological mechanism."
"['Delayed speech and language development', 'Hyperhidrosis', 'Abnormality of prenatal development or birth', 'Lethargy', 'Motor delay', 'Obesity', 'Death in infancy', 'Hypoglycemia', 'Respiratory alkalosis', 'Hyperammonemia', 'Hypothermia', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Oroticaciduria', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline', 'Pustule', 'Acute hepatitis', 'Chronic hepatitis']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia, Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Hyperammonemia & Elevated Plasma Citrulline**: Core features of citrullinemia type I due to argininosuccinate synthetase (ASS1) deficiency, disrupting the urea cycle and causing citrulline accumulation.  
2. **Oroticaciduria**: Secondary to carbamoyl phosphate shunting into pyrimidine synthesis, a hallmark of urea cycle disorders.  
3. **Neonatal/Infantile Crisis**: Symptoms like lethargy, drowsiness, hypothermia, tachypnea, and respiratory alkalosis reflect acute hyperammonemic encephalopathy. Death in infancy/childhood aligns with severe untreated cases.  
4. **Hepatic Dysfunction**: Acute/chronic hepatitis and hypoglycemia suggest metabolic liver stress, common in urea cycle defects.  
5. **Neurological & Developmental Delays**: Motor delay, speech delays, and sleep disturbances result from chronic ammonia toxicity affecting the CNS.  
6. **Prenatal/Perinatal Abnormalities**: Intrauterine growth restriction or birth complications may occur due to metabolic derangements.  
7. **Hyperhidrosis & Pustules**: Possible secondary effects of metabolic acidosis or autonomic dysregulation.  
8. **Obesity**: Uncommon but reported in late-onset cases due to dietary management or metabolic adaptations.  

This constellation of urea cycle dysfunction, citrulline elevation, and multisystemic involvement confirms **citrullinemia type I**."
"['Macrocephaly', 'Abnormality of visual evoked potentials', 'Irritability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Neonatal death']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly**: A hallmark of GA-I, often present at birth due to frontotemporal atrophy or enlarged subarachnoid spaces.  
3. **Neurological symptoms (Seizure, Irritability, Athetosis)**: Result from neurotoxic metabolite accumulation, causing striatal injury (basal ganglia damage) and movement disorders (e.g., dystonia, athetosis).  
4. **Generalized hypotonia**: Early manifestation of metabolic encephalopathy, progressing to spasticity or dystonia after metabolic crises.  
5. **Abnormality of visual evoked potentials**: Reflects metabolic damage to the central nervous system, potentially involving optic pathways or cortical processing.  
6. **Death in infancy/Neonatal death**: Severe untreated GA-I leads to acute metabolic decompensation (often triggered by catabolic stress), resulting in irreversible neurological damage or fatal cerebral edema.  
7. **Consistency with GA-I phenotype**: The combination of macrocephaly, neurodevelopmental regression, movement disorders, and organic aciduria aligns definitively with GA-I pathophysiology."
"['Delayed speech and language development', '4-Hydroxyphenylpyruvic aciduria', 'Elevated urinary delta-aminolevulinic acid', 'Hypertyrosinemia', 'Death in childhood', 'Abnormal circulating phenylalanine concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia I; hepatorenal tyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I  
Reasoning:  
1. **Hypertyrosinemia** directly indicates impaired tyrosine metabolism, a hallmark of tyrosinemia.  
2. **4-Hydroxyphenylpyruvic aciduria** arises from a block in tyrosine catabolism at fumarylacetoacetate hydrolase (FAH), causing upstream accumulation of toxic intermediates like 4-hydroxyphenylpyruvate (4-HPP).  
3. **Elevated urinary delta-aminolevulinic acid (ALA)** is due to inhibition of ALA dehydratase by succinylacetone, a toxic metabolite unique to Tyrosinemia I.  
4. **Abnormal circulating phenylalanine** may reflect secondary disruption of phenylalanine metabolism or assay interference from tyrosine metabolites.  
5. **Delayed speech/language development** aligns with neurotoxicity from succinylacetone and chronic liver/kidney dysfunction.  
6. **Death in childhood** correlates with untreated HT-1 progression to liver failure, renal Fanconi syndrome, or porphyria-like crises.  
The combination of hepatic, renal, and neurological involvement with specific biochemical markers confirms Tyrosinemia type I."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids**: PKU causes excess phenylalanine to be metabolized into phenylketones (e.g., phenylpyruvate), which are carboxylic acids excreted in urine.  
3. **Neonatal death/Death in infancy/childhood**: Untreated PKU results in severe neurological damage, seizures, and metabolic instability, often fatal in early life without dietary intervention.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) can cause congenital anomalies like microcephaly or cardiac defects in the infant.  
5. **Hypertyrosinemia**: While classic PKU typically reduces tyrosine levels (due to blocked PAH), transient hypertyrosinemia may occur in metabolic crises or overlapping disorders (e.g., BH4 deficiency), though this is atypical and suggests possible complex metabolic interplay.  
6. **Obesity**: May arise from high-calorie, low-protein diets used to manage PKU or secondary metabolic dysregulation.  

While hypertyrosinemia is not a classic PKU feature, the dominant hyperphenylalaninemia and urinary carboxylic acids strongly support PKU as the primary diagnosis, with other symptoms explained by untreated disease or maternal effects."
"['Hyperactivity', 'Intellectual disability', 'Seizure', 'Obesity', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Core feature of PKU due to deficient phenylalanine hydroxylase (PAH), causing phenylalanine accumulation.  
2. **Intellectual disability & Hyperactivity**: Untreated PKU results in neurotoxic phenylalanine buildup, impairing brain development and function.  
3. **Seizures**: Neurological damage from elevated phenylalanine can manifest as seizures.  
4. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) excreted in urine, classified as carboxylic acids.  
5. **Severe short stature & Obesity**: Less typical but possible in poorly managed cases due to metabolic dysregulation or restrictive diets altering growth/weight.  
6. **Early mortality (childhood/adolescence/adulthood)**: Historically, untreated PKU led to severe complications (e.g., neurodegeneration, infections), but modern neonatal screening and dietary management mitigate this.  

**Conflicts/Discordant Symptoms**:  
- **Hypertyrosinemia**: PKU classically causes *low* tyrosine (PAH converts phenylalanine to tyrosine). This symptom suggests possible comorbid tyrosinemia type II or lab error.  
- **Obesity**: Rare in PKU; may reflect dietary adjustments (high-carb/low-protein intake) or unrelated factors.  

**Conclusion**: Dominant PKU features (hyperphenylalaninemia, neurodevelopmental issues, urinary metabolites) align with the diagnosis. Discordant symptoms may require further investigation for comorbidities or testing inaccuracies."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Methylmalonic acidemia', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic acidemia** and **methylmalonic aciduria**, which are hallmark biochemical markers of MMA. Symptoms like **metabolic acidosis**, **hyperammonemia**, **vomiting**, and **seizures** align with metabolic decompensation caused by MMA. **Thrombocytopenia** and **leukopenia** may result from bone marrow suppression due to toxic metabolite accumulation. **Generalized hypotonia** and **neonatal death/death in infancy** reflect the severe, early-onset nature of this disorder.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the absence of B12 deficiency symptoms) and the inclusion of **neonatal death** strongly suggest a **mutase deficiency subtype**. This subtype is caused by defects in the *MUT* gene, leading to impaired methylmalonyl-CoA mutase activity. The severe clinical course (death in infancy) and biochemical features (persistent methylmalonic aciduria despite B12 levels) confirm this diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to secondary carnitine depletion as carnitine conjugates with unmetabolized acyl-CoA intermediates (e.g., octanoylcarnitine), reducing free carnitine levels.  
2. **Neonatal death/Death in infancy**: MCADD typically manifests during fasting or metabolic stress (e.g., infections), causing hypoketotic hypoglycemia, encephalopathy, and hepatic dysfunction. Untreated, this rapidly progresses to coma or fatal metabolic crisis, especially in infancy.  
3. **Abnormality of prenatal development or birth**: While MCADD does not cause structural congenital anomalies, biochemical abnormalities (e.g., elevated C8-C10 acylcarnitines) may be detectable prenatally or at birth via newborn screening. Severe undiagnosed cases may present as sudden infant death syndrome (SIDS), aligning with ""abnormality of birth.""  
4. **Supporting evidence**: MCADD is included in newborn screening panels globally due to its preventable morbidity/mortality. The symptom constellation aligns with impaired energy metabolism during catabolic states, hallmark of fatty acid oxidation disorders."
"['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits metabolic acidosis, hyperammonemia, vomiting, and methylmalonic aciduria—hallmark features of MMA. This autosomal recessive disorder disrupts methylmalonyl-CoA metabolism, leading to toxic metabolite accumulation. Death in infancy aligns with severe, untreated cases. Methylmalonic aciduria directly confirms impaired propionate pathway function.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity of vitamin B12-unresponsive MMA stems from mutations in the *MUT* gene, encoding methylmalonyl-CoA mutase. B12-unresponsiveness indicates defective enzyme activity (not cofactor deficiency). Hyperammonemia arises secondary to metabolic decompensation, disrupting the urea cycle. Early lethality underscores the severity of mutase deficiency, which lacks therapeutic response to B12."
"['Seizure', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Oroticaciduria', 'Neonatal death']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), where impaired ammonia detoxification occurs.  
2. **Oroticaciduria** specifically indicates a defect in the urea cycle enzyme ornithine transcarbamylase (OTC). OTC deficiency causes carbamoyl phosphate to accumulate, diverting into pyrimidine synthesis and producing excess orotic acid.  
3. **Cerebral edema** and **seizures** are secondary to acute hyperammonemia, as ammonia toxicity disrupts cerebral metabolism and osmotic balance.  
4. **Neonatal death**/**death in infancy** aligns with severe OTCD, an X-linked disorder that typically presents catastrophically in males shortly after birth due to metabolic collapse.  
5. The absence of other UCD-specific markers (e.g., citrullinemia, argininosuccinic aciduria) further narrows the diagnosis to OTCD."
"['Seizure', 'Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Alopecia', 'Fasciculations', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency  
Reasoning:  
1. **Seizures & Hypotonia**: Biotinidase deficiency disrupts biotin recycling, impairing carboxylase enzymes critical for energy metabolism and neurotransmitter synthesis, leading to neurological dysfunction.  
2. **Elevated Urinary Carboxylic Acids**: Biotin-dependent carboxylases (e.g., propionyl-CoA carboxylase) malfunction, causing organic acid accumulation (e.g., 3-hydroxyisovaleric acid), detectable in urine.  
3. **Alopecia**: Biotin is essential for keratin synthesis; deficiency results in hair loss.  
4. **Growth Delay & Death in Infancy**: Metabolic crises from untreated acidosis, hyperammonemia, and catabolism impair growth and are fatal without biotin supplementation.  
5. **Fasciculations**: Secondary to neuronal hyperexcitability from metabolic disturbances.  
6. **Diagnostic Confirmation**: The term ""late-onset multiple carboxylase deficiency"" refers to partial biotinidase deficiency, but severe infantile forms present acutely with this symptom cluster. Early biotin treatment reverses symptoms, underscoring urgency in diagnosis."
"['Obesity', 'Hypercholesterolemia', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning: Hyperphenylalaninemia is pathognomonic for PKU, caused by phenylalanine hydroxylase (PAH) deficiency. Classic PKU typically results in **low tyrosine** due to impaired phenylalanine-to-tyrosine conversion. However, the reported hypertyrosinemia could suggest an atypical variant (e.g., partial PAH activity with compensatory dietary tyrosine intake) or secondary metabolic dysregulation. Obesity and hypercholesterolemia may stem from carbohydrate-rich diets used to restrict phenylalanine. Early adulthood mortality aligns with untreated or poorly managed PKU, leading to severe neurological decline, cardiovascular complications, or metabolic instability."
"['Hypospadias', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Hyperphenylalaninemia', 'Hernia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU but may suggest **BH4 (tetrahydrobiopterin) deficiency**, a rare PKU variant. BH4 is a cofactor for PAH and tyrosine/tryptophan hydroxylases; its deficiency disrupts both phenylalanine and tyrosine metabolism.  
3. **Severe short stature** aligns with chronic metabolic disruption and malnutrition if untreated.  
4. **Premature birth**, **neonatal death**, and **death in infancy** correlate with severe metabolic crises in untreated PKU/BH4 deficiency, leading to neurological deterioration and organ failure.  
5. **Hypospadias** and **hernia** are not typical PKU features but may represent coincidental congenital anomalies or part of a broader syndromic form (e.g., chromosomal or epigenetic interactions).  

Note: While classic PKU does not explain hypertyrosinemia, BH4 deficiency (a PKU subtype) accounts for both hyperphenylalaninemia and hypertyrosinemia, supporting the diagnosis. Other symptoms may reflect complications of metabolic instability or unrelated congenital factors."
"['Microcephaly', 'Low-set ears', 'Wide nasal bridge', 'Strabismus', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Difficulty walking', 'Elevated 8-dehydrocholesterol', 'Severe short stature', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Difficulty running', 'Elevated 7-dehydrocholesterol', 'Severe hearing impairment']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical Markers**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by a defect in the *DHCR7* gene, which disrupts cholesterol biosynthesis.  
2. **Craniofacial Features**: Microcephaly, low-set ears, and wide nasal bridge are classic dysmorphic traits in SLOS.  
3. **Limb Anomalies**: Syndactyly (often of toes 2-3) is a hallmark of SLOS.  
4. **Neurodevelopmental Delays**: Intellectual disability, motor delays, and speech/language delays align with impaired cholesterol-dependent myelination and synaptic function.  
5. **Growth and Survival**: Severe short stature, neonatal/childhood death, and early mortality correlate with severe SLOS phenotypes.  
6. **Sensory and Motor Issues**: Strabismus, severe hearing impairment, and difficulty walking/climbing stairs reflect multisystem involvement from cholesterol deficiency.  
7. **Consistency with Severity**: The combination of life-threatening outcomes (infancy/childhood death) and biochemical abnormalities confirms a severe SLOS diagnosis."
"['Ataxia', 'Death in infancy', 'Dehydration', 'Fever', 'Diarrhea', 'Opisthotonus', 'Athetosis', 'Progressive neurologic deterioration', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating acetylcarnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Core biochemical markers**: Elevated glutaric acid (glutaric aciduria, elevated circulating glutaric acid) and carnitine deficiency (decreased plasma free carnitine, abnormal acetylcarnitine) directly indicate a defect in glutaryl-CoA dehydrogenase, the enzyme deficient in GA-I.  
2. **Neurological features**: Ataxia, opisthotonus, athetosis, and progressive neurologic deterioration align with basal ganglia damage, a hallmark of GA-I due to toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
3. **Metabolic crises**: Fever, dehydration, and diarrhea are typical triggers of acute metabolic decompensation in GA-I, exacerbating neurological injury.  
4. **Early mortality**: Death in infancy/childhood reflects untreated GA-I’s severe natural course, as crises lead to irreversible brain damage.  
5. **Exclusion of mimics**: Symptoms collectively rule out other organic acidemias (e.g., GA-II lacks prominent basal ganglia injury) and confirm GA-I’s distinct phenotype."
"['Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Hip dysplasia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently due to secondary metabolic disruptions or overlapping enzyme deficiencies (e.g., tyrosine metabolism defects).  
3. **Generalized hypotonia** and **motor delay** align with untreated PKU, where toxic phenylalanine accumulation disrupts neurotransmitter synthesis and myelination.  
4. **Abnormality of prenatal development or birth** and **hip dysplasia** are uncommon in PKU but may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy.  
5. **Death in infancy/neonatal death** is rare in isolated PKU but could indicate severe metabolic crises (e.g., rapid phenylalanine accumulation) or comorbid conditions.  

Note: Hypertyrosinemia and neonatal lethality suggest atypical presentations (e.g., BH4-deficient PKU or dual metabolic disorders), warranting genetic testing for PAH/BH4 pathway mutations and tyrosine metabolism enzymes (e.g., TAT, HPD)."
"['Retrognathia', 'Abnormality of prenatal development or birth', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Apnea', 'Opisthotonus', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Neurological symptoms (Seizure, Hypotonia, Apnea, Opisthotonus)**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting neurotransmitter synthesis and causing severe neurological damage.  
3. **Poor prognosis (Death in infancy/childhood, Neonatal death)**: Without early dietary intervention, progressive neurodegeneration results in fatal outcomes.  
4. **Hypertyrosinemia discrepancy**: Typically, PKU causes *low* tyrosine due to blocked PAH-mediated conversion of phenylalanine to tyrosine. This may indicate a coexisting metabolic disorder, lab error, or atypical PKU variant.  
5. **Retrognathia/prenatal abnormalities**: Uncommon in classic PKU but could suggest maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy) affecting fetal development.  

Key confirmation: Hyperphenylalaninemia + neurological decline aligns with PKU. Early diagnosis via newborn screening and dietary management are critical to prevent symptoms."
"['Autistic behavior', 'Self-mutilation', 'Hyperactivity', 'Intellectual disability', 'Seizure', 'Motor delay', 'Obesity', 'Death in infancy', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased serum iron']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia** and **hyperphenylalaninemia** directly indicate a defect in tyrosine metabolism, a hallmark of Tyrosinemia type 1 (HT-1) caused by fumarylacetoacetate hydrolase deficiency.  
2. **Elevated circulating alpha-fetoprotein (AFP)** and **alkaline phosphatase** suggest liver damage, consistent with HT-1’s hepatotoxic effects.  
3. **Seizures**, **intellectual disability**, **motor delay**, and **autistic behavior** align with neurotoxic effects of tyrosine byproducts (e.g., succinylacetone).  
4. **Self-mutilation** and **hyperactivity** may reflect neurological dysfunction or peripheral neuropathy from metabolite accumulation.  
5. **Abnormal aspartate/alanine concentrations** and **decreased serum iron** reflect disrupted amino acid metabolism and secondary liver dysfunction.  
6. **Death in infancy/childhood** and **neonatal death** correlate with HT-1’s acute and chronic forms, often due to liver failure or metabolic crises.  
7. **Obesity** is atypical but may arise from metabolic dysregulation or dietary management complications.  
8. **Elevated AFP** and liver-related symptoms differentiate HT-1 from other amino acid disorders (e.g., PKU), which lack severe hepatic involvement.  

This constellation of hepatic, neurological, and metabolic abnormalities strongly supports Tyrosinemia type 1."
"['Death in infancy', 'Vomiting', 'Increased total bilirubin', 'Neonatal death', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Galactosemia; GAL/Galactosemia  
Reasoning: Hypergalactosemia (elevated galactose in blood) is a hallmark of galactosemia, a rare metabolic disorder caused by impaired galactose metabolism. The symptoms of vomiting, jaundice (elevated bilirubin), and neonatal death align with the rapid deterioration seen in untreated galactosemia, as infants cannot process galactose from lactose in breast milk or formula, leading to toxic accumulation and multi-organ failure.  

Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: Classic galactosemia (GALT deficiency, Type I) is the most severe form. Neonatal death and infant mortality are typical without early dietary intervention. Increased bilirubin reflects liver damage, a key feature, while vomiting and hypergalactosemia directly result from the inability to metabolize galactose. This subtype is distinguished by complete GALT enzyme deficiency, consistent with the acute presentation described."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), leading to impaired conversion of phenylalanine to tyrosine. This results in toxic accumulation of phenylalanine in the blood, consistent with hyperphenylalaninemia.  
2. **Abnormal circulating tyrosine concentration**: Reduced PAH activity decreases tyrosine synthesis, explaining low tyrosine levels (""abnormal"" in this context).  
3. **Neonatal death/Death in infancy**: Untreated PKU causes severe neurological damage, seizures, and failure to thrive. Without early dietary intervention (low-phenylalanine diet), metabolic derangements and complications may lead to early mortality.  
4. **Abnormality of prenatal development or birth**: While PKU itself does not directly affect prenatal development, maternal PKU (untreated high phenylalanine during pregnancy) can cause congenital anomalies (e.g., microcephaly) in the fetus. If the patient’s mother had uncontrolled PKU, this could explain prenatal abnormalities.  
5. **Consistency with PKU**: The combination of metabolic findings (elevated phenylalanine, low tyrosine) and clinical outcomes aligns with severe, untreated PKU. Neonatal screening typically identifies PKU, but delayed diagnosis or lack of treatment could result in the described fatal course."
"['Obesity', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Death in adolescence']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: Biotinidase deficiency disrupts carboxylase function, leading to organic acid accumulation. This forces carnitine to conjugate with toxic metabolites, depleting carnitine stores and causing secondary deficiency.  
2. **Death in childhood/adolescence**: Untreated BTDD results in severe metabolic crises (e.g., ketoacidosis, hyperammonemia), neurological deterioration, and fatal outcomes without early biotin supplementation.  
3. **Obesity**: While atypical, disrupted fatty acid oxidation due to carnitine deficiency may impair energy production, shifting metabolism toward fat storage. Altered acetyl-CoA carboxylase activity (biotin-dependent) could further dysregulate lipid synthesis pathways.  
4. **Consistency with late-onset multiple carboxylase deficiency**: The phenotype aligns with delayed presentations, where partial enzyme activity permits survival into childhood/adolescence before metabolic decompensation occurs."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Intellectual disability** arises from untreated phenylalanine toxicity, damaging brain development postnatally.  
3. **Hypertyrosinemia** is atypical in classic PKU (which typically causes *low* tyrosine). This may suggest a PAH deficiency variant, secondary metabolic disruptions, or a co-occurring tyrosinemia (e.g., type II), though PKU remains primary due to hyperphenylalaninemia dominance.  
4. **Neonatal death/Death in infancy/adolescence** reflects severe metabolic complications (e.g., seizures, organ failure) in untreated or late-diagnosed cases.  
5. **Abnormality of prenatal development** is inconsistent with isolated PKU (as fetal PAH is inactive; symptoms manifest postnatally). This may indicate maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy) affecting the fetus, aligning with the patient’s congenital anomalies.  

Note: Hypertyrosinemia and prenatal anomalies require further investigation for overlapping metabolic disorders, but hyperphenylalaninemia and clinical progression prioritize PKU as the primary diagnosis."
"['Cryptorchidism', 'Hypospadias', 'Microcephaly', 'Low-set ears', 'Strabismus', 'Ptosis', 'Hypermetropia', 'Eczematoid dermatitis', 'Skin rash', 'Syndactyly', 'Intellectual disability', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Vomiting', 'Constipation', 'Drowsiness', 'Sleep disturbance', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties', 'Hypoxemia', 'Severe hearing impairment']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Cholesterol biosynthesis defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) with hypocholesterolemia are pathognomonic for SLOS, caused by mutations in *DHCR7*, impairing 7-DHC reductase activity.  
2. **Congenital anomalies**: Syndactyly (especially 2nd–3rd toe), cryptorchidism, hypospadias, microcephaly, and low-set ears align with SLOS-associated malformations.  
3. **Neurodevelopmental features**: Intellectual disability, motor delay, generalized hypotonia, dystonia, and lethargy reflect disrupted cholesterol-dependent myelination and neuronal development.  
4. **Ocular findings**: Ptosis, strabismus, and hypermetropia are common in SLOS due to craniofacial dysmorphism and connective tissue abnormalities.  
5. **Gastrointestinal/dysautonomia symptoms**: Feeding difficulties, vomiting, constipation, and sleep disturbances correlate with autonomic dysfunction and gastrointestinal dysmotility.  
6. **Cutaneous manifestations**: Eczematoid dermatitis and skin rash result from defective epidermal barrier function due to cholesterol deficiency.  
7. **Severe outcomes**: Neonatal/childhood death, hypoxemia, and recurrent infections reflect multisystem failure and immune dysfunction from cholesterol insufficiency.  
8. **Supporting biochemical markers**: Elevated 7-DHC/8-DHC on sterol analysis confirms the diagnosis.  

This constellation of structural, metabolic, and developmental abnormalities is diagnostic of Smith-Lemli-Opitz syndrome."
"['Strabismus', 'Hyporeflexia', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Fever', 'Cerebral atrophy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Cerebral atrophy**: A hallmark of Canavan disease due to spongy degeneration of white matter caused by aspartoacylase deficiency.  
2. **Abnormal circulating aspartate family amino acid concentration**: Directly linked to elevated N-acetylaspartic acid (NAA) levels, a diagnostic biomarker for Canavan disease.  
3. **Generalized hypotonia and hyporeflexia**: Result from progressive neurological deterioration and impaired myelination.  
4. **Strabismus**: Associated with disrupted motor neuron function and cerebral damage.  
5. **Death in infancy**: Consistent with the severe infantile form of the disease, which leads to rapid neurological decline.  
6. **Fever**: Likely secondary to complications (e.g., aspiration pneumonia) due to dysphagia or immobility.  
7. **Obesity**: Atypical for Canavan disease; may indicate comorbid factors or misreporting, but does not exclude the diagnosis given other pathognomonic features.  

Exclusion of other leukodystrophies is supported by the specific biochemical profile (NAA accumulation) and clinical progression."
"['Obesity', 'Death in infancy', 'Coarctation of aorta', 'Fever', 'Pneumonia', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants (e.g., BH4 deficiency) or secondary metabolic disruptions from untreated phenylalanine toxicity.  
3. **Early mortality** (infancy/childhood/adolescence) aligns with severe, untreated PKU, where neurotoxicity, seizures, and organ failure lead to premature death without dietary intervention.  
4. **Obesity** may reflect poor dietary management (high-carbohydrate/low-protein diets) or metabolic dysregulation.  
5. **Coarctation of the aorta** and **pneumonia/fever** are likely incidental or secondary complications (e.g., immune vulnerability due to chronic metabolic stress).  
6. **Neonatal death** suggests an acute presentation, though rare in isolated PKU, potentially indicating comorbid conditions or diagnostic delays.  

Key exclusion: Tyrosinemia type I (hypertyrosinemia + liver/kidney symptoms) and other metabolic disorders were considered but excluded due to the primary hyperphenylalaninemia and stated diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning: The presence of **hyperhomocystinemia** and **aminoaciduria** directly indicates impaired homocysteine metabolism, a hallmark of homocystinuria. Elevated homocysteine levels disrupt connective tissue, vascular, and nervous systems, which aligns with **abnormality of prenatal development** and early mortality (**neonatal death**, **death in infancy/childhood**).  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: **Hypermethioninemia** is specific to cystathionine beta-synthase (CBS) deficiency, as methionine cannot be converted to homocysteine in this disorder. CBS deficiency causes accumulation of both homocysteine and methionine, explaining the biochemical findings. Severe forms of this autosomal recessive condition lead to life-threatening complications (e.g., thromboembolism, organ failure) during early life, consistent with **death in infancy/childhood** and developmental abnormalities."
"['Ataxia', 'Generalized hypotonia', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency (DPYD deficiency)  
Reasoning:  
1. **Uraciluria** and **abnormal circulating pyrimidine concentration** directly indicate a defect in pyrimidine catabolism, as dihydropyrimidine dehydrogenase (DPD) is responsible for degrading uracil and thymine. Deficiency leads to urinary excretion of unmetabolized uracil.  
2. **Ataxia** and **generalized hypotonia** are neurological manifestations linked to elevated pyrimidine metabolites (e.g., uracil), which may interfere with CNS function or neurotransmitter pathways.  
3. **Death in childhood** aligns with severe forms of DPYD deficiency, where toxic metabolite accumulation causes intractable seizures, developmental delay, and early mortality.  
4. The absence of other pyrimidine-related abnormalities (e.g., orotic aciduria) rules out disorders like urea cycle defects or orotic aciduria, narrowing the diagnosis to DPYD deficiency."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency of phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This defect results in phenylalanine accumulation, directly explaining hyperphenylalaninemia.  
2. **Hypertyrosinemia**: Classic PKU typically presents with **low/normal tyrosine levels** due to impaired PAH activity. However, this case’s hypertyrosinemia may suggest atypical factors, such as:  
   - Concurrent liver dysfunction (unrelated to PKU) impairing tyrosine metabolism.  
   - Dietary mismanagement (e.g., excessive tyrosine intake in a PKU-specific diet).  
   - A rare PKU variant with secondary metabolic disruptions.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early mortality aligns with untreated or poorly managed cases, compounded by potential complications from hypertyrosinemia (e.g., hepatic/renal stress).  

**Note**: Hypertyrosinemia is atypical for PKU and warrants investigation for comorbid conditions (e.g., tyrosinemia type II) or diagnostic reevaluation. However, hyperphenylalaninemia remains the hallmark feature, prioritizing PKU as the primary diagnosis."
"['Death in infancy', 'Respiratory insufficiency', 'Neonatal death', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency  
Reasoning:  
1. **Uraciluria** and **abnormal circulating pyrimidine concentration** are hallmark biochemical features of dihydropyrimidine dehydrogenase (DPD) deficiency, as the enzyme catalyzes the first step in pyrimidine degradation.  
2. DPD deficiency leads to accumulation of uracil and thymine in body fluids, which correlates with the observed metabolic abnormalities.  
3. **Respiratory insufficiency** and **neonatal death** are consistent with severe presentations of DPD deficiency, often due to neurological dysfunction or metabolic crises.  
4. **Death in infancy** aligns with the life-threatening nature of this autosomal recessive disorder, particularly in cases with complete enzyme deficiency.  
5. The combination of metabolic derangements and catastrophic early clinical course strongly supports this diagnosis over other rare pyrimidine metabolism disorders."
"['Pallor', 'Death in infancy', 'Ascites', 'Thrombocytosis', 'Anemia', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Aminoaciduria', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hernia']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
**Reasoning**:  
1. **Hypertyrosinemia & aminoaciduria**: Direct biochemical hallmarks of tyrosinemia type 1, caused by deficiency of fumarylacetoacetate hydrolase (FAH), leading to tyrosine accumulation and renal tubular dysfunction (Fanconi syndrome).  
2. **Elevated alpha-fetoprotein (AFP) & abnormal porphyrins**: Succinylacetone (a toxic metabolite in FAH deficiency) inhibits porphobilinogen synthase, causing porphyrin abnormalities. Elevated AFP reflects hepatic injury or regeneration, common in HT-1.  
3. **Hepatic manifestations (ascites, hypoalbuminemia, hypoproteinemia, elevated alkaline phosphatase)**: FAH deficiency causes severe liver dysfunction, progressing to cirrhosis, synthetic failure, and cholestasis. Ascites results from portal hypertension and hypoalbuminemia.  
4. **Thrombocytosis**: Reactive thrombocytosis secondary to chronic liver disease or splenic dysfunction.  
5. **Anemia & pallor**: Due to liver failure (coagulopathy, malnutrition) and/or porphyrin-related hemolysis.  
6. **Hernia**: Increased intra-abdominal pressure from ascites.  
7. **Death in infancy**: Untreated HT-1 often leads to fatal liver failure or neurologic crises in early childhood.  

The constellation of hepatic, renal, and metabolic abnormalities (succinylacetone, tyrosine) is pathognomonic for tyrosinemia type 1."
"['Seizure', 'Motor delay', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Seizures**: A hallmark of Canavan disease due to progressive leukodystrophy and severe neurological degeneration.  
2. **Motor delay**: Caused by impaired myelination and spongiform degeneration of white matter in the brain.  
3. **Death in infancy**: Severe forms of Canavan disease often lead to early mortality due to rapid neurological decline.  
4. **Abnormal circulating aspartate family amino acid concentration**: Specifically, elevated *N-acetylaspartic acid (NAA)* in urine/blood, resulting from *aspartoacylase enzyme deficiency*, a pathognomonic feature of Canavan disease.  
5. **Confirmatory evidence**: Genetic testing for *ASPA gene mutations* would validate the diagnosis."
"['Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Abdominal pain', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Body odor']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Metabolic crisis & early mortality**: Symptoms like death in infancy/childhood/adolescence and neonatal death align with IVA's acute metabolic decompensation episodes, often triggered by catabolic stress (e.g., infections).  
2. **Gastrointestinal involvement**: Vomiting, diarrhea, and abdominal pain are classic during crises due to toxic metabolite accumulation (isovaleric acid).  
3. **Characteristic biochemical markers**:  
   - **Abnormal circulating carnitine**: Secondary carnitine depletion occurs as carnitine conjugates isovaleric acid (forming isovalerylcarnitine) for excretion.  
   - **Abnormal glycine**: Elevated glycine due to increased conjugation of isovaleric acid with glycine (isovalerylglycine), a diagnostic urinary marker.  
4. **Body odor**: Distinctive ""sweaty feet"" odor from excess isovaleric acid.  
5. **Immunological vulnerability**: Recurrent viral infections may reflect metabolic instability during illnesses, precipitating crises.  
6. **Inflammatory overlap**: Gastrointestinal inflammation mimics enterocolitis, a known IVA complication.  

IVA is confirmed via elevated isovalerylglycine in urine and genetic testing for *IVD* gene mutations. Early diagnosis enables dietary management (low-protein, leucine-restricted diet) and emergency protocols to prevent fatal metabolic crises."
"['Hypertension', 'Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), preventing phenylalanine conversion to tyrosine.  
2. **Intellectual disability** aligns with untreated PKU, as excess phenylalanine disrupts neurotransmitter synthesis and myelination.  
3. **Elevated urinary carboxylic acid** reflects phenylalanine metabolism via alternative pathways (e.g., phenylpyruvate), excreted as phenylketones.  
4. **Obesity and hypertension** may result from carbohydrate-rich diets used to restrict phenylalanine intake, leading to metabolic complications.  
5. **Early mortality** correlates with untreated PKU complications, including neurological decline and metabolic instability.  
6. **Hypertyrosinemia** is atypical for classic PKU (where tyrosine is typically low) but may arise from dietary tyrosine supplementation or secondary metabolic adaptations.  

Note: Hypertyrosinemia and hyperphenylalaninemia coexistence suggests potential diagnostic complexity (e.g., BH4 deficiency or tyrosinemia overlap), but PKU remains the primary diagnosis based on core features."
"['Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Severe hearing impairment']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hyperalaninemia**: Elevated alanine levels suggest disrupted amino acid metabolism, often secondary to energy crises from impaired fatty acid oxidation (FAO). MCADD disrupts medium-chain fatty acid breakdown, forcing reliance on glycolysis, increasing pyruvate (converted to alanine).  
2. **Abnormal circulating carnitine**: MCADD causes secondary carnitine deficiency due to accumulation of medium-chain acylcarnitines, which are excreted in urine, depleting free carnitine.  
3. **Neonatal/infant/childhood death**: MCADD presents with life-threatening hypoglycemia and metabolic decompensation during fasting (e.g., infections), leading to sudden death if untreated.  
4. **Small for gestational age (SGA)**: Impaired placental fatty acid metabolism in MCADD may restrict fetal energy supply, causing growth restriction.  
5. **Severe hearing impairment**: Rarely reported in MCADD but may occur due to metabolic acidosis or energy deficits affecting cochlear function during crises.  
6. **Exclusion of alternatives**: Symptoms align with FAO disorders (not urea cycle defects or mitochondrial diseases). MCADD is the most common FAO defect with this phenotype.  

Key diagnostic confirmation would require plasma acylcarnitine profiling (elevated C6-C10 species, especially C8) and genetic testing for *ACADM* mutations."
"['Lethargy', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Abnormal circulating ornithine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Oroticaciduria** is a hallmark of OTCD, caused by carbamoyl phosphate accumulation due to the enzyme defect, shunting into pyrimidine synthesis and producing excess orotic acid.  
2. **Abnormal circulating ornithine concentration** aligns with disrupted urea cycle dynamics, as ornithine is not efficiently converted to citrulline.  
3. **Lethargy, drowsiness, and sleep disturbances** reflect hyperammonemia-induced neurotoxicity, a critical feature of urea cycle disorders.  
4. **Death in infancy** is consistent with severe neonatal-onset OTCD, where hyperammonemia rapidly progresses without intervention.  
5. OTCD’s X-linked inheritance explains severe male presentations, though symptomatic females may also occur due to skewed X-inactivation.  
6. Exclusion of other urea cycle disorders (e.g., citrullinemia) is supported by the absence of specific amino acid elevations (e.g., citrulline) and the presence of oroticaciduria."
"['Ataxia', 'Dystonia', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal myelination']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Directly links to GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Neurological symptoms (Ataxia, Dystonia)**: Toxic metabolites damage the basal ganglia and striatum, causing movement disorders.  
3. **Abnormal cerebral morphology**: Macrocephaly (often seen in infancy) and frontotemporal atrophy due to metabolic injury.  
4. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to glutaric acid for excretion.  
5. **Abnormal myelination**: Delayed or disrupted white matter development from neurotoxic metabolites.  
6. **Death in childhood**: Untreated GA-I leads to irreversible neurological damage, metabolic crises, and early mortality.  
7. **Consistency with GA-I**: Symptom constellation (organic aciduria, neurological deficits, imaging findings) is pathognomonic for this disorder."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Neonatal death** or **death in infancy** in untreated cases may occur due to severe metabolic derangements, progressive neurological damage, or secondary complications (e.g., seizures, failure to thrive).  
3. Classic PKU is identified via newborn screening, but in unscreened populations or severe variants, rapid phenylalanine buildup can cause acute encephalopathy and early lethality.  
4. The triad of symptoms aligns with untreated PKU, where delayed diagnosis or lack of dietary intervention results in catastrophic outcomes."
"['Irritability', 'Coma', 'Generalized hypotonia', 'Encephalopathy', 'Cardiomyopathy', 'Anemia', 'Hypoglycemia', 'Vomiting', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency (PCD)  
Reasoning:  
1. **Decreased plasma free carnitine**: A hallmark of PCD due to defective carnitine transporter (OCTN2), impairing cellular carnitine uptake.  
2. **Hypoglycemia**: Carnitine is essential for fatty acid oxidation (FAO); its deficiency forces reliance on glucose, depleting reserves and causing hypoglycemia, especially during fasting/metabolic stress.  
3. **Cardiomyopathy and generalized hypotonia**: Impaired FAO reduces ATP production in cardiac and skeletal muscles, leading to energy-deficient states.  
4. **Hepatomegaly and elevated hepatic transaminases**: Hepatic fat accumulation (steatosis) from defective fat metabolism causes liver enlargement and inflammation.  
5. **Encephalopathy, irritability, coma**: Hypoglycemia and potential hyperammonemia (secondary to disrupted urea cycle intermediates) induce neurotoxicity.  
6. **Abnormal circulating amino acids (aspartate family, alanine)**: Dysregulated gluconeogenesis and Krebs cycle intermediates alter amino acid metabolism.  
7. **Anemia**: Chronic energy deprivation affects erythropoiesis; mitochondrial dysfunction in bone marrow may contribute.  
8. **Abnormal porphyrins**: Secondary disruption of heme biosynthesis pathways due to hepatic mitochondrial dysfunction.  
9. **Death in childhood**: Untreated PCD causes recurrent metabolic crises, cardiac failure, or sudden death, consistent with the natural history of severe cases.  

PCD unifies all symptoms via disrupted fatty acid metabolism, energy deficiency, and multi-organ dysfunction. Confirmatory testing would involve genetic analysis of *SLC22A5* mutations."
"['Strabismus', 'Nystagmus', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
**Step 1:** The symptoms **cerebellar atrophy** and **cerebellar agenesis** indicate severe structural brain abnormalities, a hallmark of PMM2-CDG due to disrupted glycosylation during neurodevelopment.  
**Step 2:** **Ataxia**, **motor delay**, and **generalized hypotonia** align with cerebellar dysfunction, a core feature of PMM2-CDG.  
**Step 3:** **Strabismus** and **nystagmus** are linked to brainstem/cerebellar defects affecting ocular motor control.  
**Step 4:** **Encephalopathy** and **hyporeflexia** reflect global neurological impairment from abnormal glycosylation of neuronal proteins.  
**Step 5:** **Growth delay** and **death in infancy** are systemic consequences of glycosylation failure, impacting metabolism and organ function.  
**Step 6:** PMM2-CDG is confirmed by genetic testing for *PMM2* mutations and abnormal transferrin glycosylation patterns, which correlate with the severity of cerebellar and multisystemic symptoms."
"['Myopia', 'Delayed speech and language development', 'Ectopia lentis', 'Intellectual disability', 'Death in infancy', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Aminoaciduria', 'Death in childhood', 'Abnormal circulating alanine concentration', 'Dyskinesia']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia and Hypermethioninemia**: Elevated homocysteine and methionine levels are hallmark biochemical features of cystathionine beta-synthase (CBS) deficiency. CBS deficiency blocks the conversion of homocysteine to cystathionine, causing homocysteine accumulation. Concurrent hypermethioninemia occurs due to compensatory remethylation of homocysteine to methionine via the folate-B12 pathway.  
2. **Ectopia Lentis and Myopia**: Homocysteine disrupts collagen cross-linking, weakening zonular fibers of the lens, leading to lens dislocation (ectopia lentis) and secondary myopia.  
3. **Intellectual Disability and Delayed Speech**: Elevated homocysteine is neurotoxic, impairing neuronal development and function, resulting in intellectual disability and language delays.  
4. **Aminoaciduria**: Generalized aminoaciduria may occur due to renal tubular dysfunction secondary to metabolic stress or homocysteine toxicity.  
5. **Early Mortality**: Untreated CBS deficiency predisposes to life-threatening thromboembolic events (e.g., stroke, pulmonary embolism), explaining infant/childhood mortality.  
6. **Dyskinesia**: Rarely reported in severe cases, possibly due to basal ganglia or cerebellar damage from vascular insults or direct homocysteine neurotoxicity.  
7. **Abnormal Alanine**: Non-specific but may reflect secondary metabolic disturbances (e.g., disrupted gluconeogenesis or mitochondrial dysfunction).  

Disease: Homocysteinemia/Homocystinuria  
Reasoning:  
- This is a broader diagnostic category encompassing CBS deficiency. The reasoning above applies here as well, but the specificity of hypermethioninemia and ectopia lentis narrows it to the CBS-deficient subtype. Other forms of homocystinuria (e.g., remethylation defects) would show low methionine and lack ocular manifestations."
"['Seizure', 'Ataxia', 'Lethargy', 'Hyperreflexia', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Oroticaciduria', 'Death in childhood', 'Death in adolescence']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as OTC is a urea cycle enzyme. Deficiency causes impaired ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate enters pyrimidine synthesis, producing excess orotic acid.  
3. **Neurological symptoms** (seizures, ataxia, lethargy, drowsiness, hyperreflexia, fasciculations): Result from ammonia-induced neurotoxicity and cerebral edema.  
4. **Metabolic acidosis**: Secondary to organic acid accumulation from alternative ammonia detoxification pathways.  
5. **Gastrointestinal symptoms** (diarrhea): Common in urea cycle disorders due to metabolic stress.  
6. **Early mortality**: Untreated OTCD causes recurrent hyperammonemic crises, leading to death in childhood/adolescence without intervention.  
7. **Fever**: May trigger metabolic decompensation (e.g., infection-induced catabolism exacerbating ammonia accumulation).  
8. **Sleep disturbance**: Linked to encephalopathy from chronic hyperammonemia.  
*Exclusion of other urea cycle disorders*: Oroticaciduria distinguishes OTCD from CPS1 or NAGS deficiencies, which share hyperammonemia but lack this feature."
"['Microcephaly', 'Pointed chin', 'Short chin', 'Strabismus', 'Ptosis', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Ataxia', 'Generalized hypotonia', 'Hyperreflexia', 'Failure to thrive', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties', 'Fatigue']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Metabolic markers**: Elevated 7-dehydrocholesterol (7-DHC) and hypocholesterolemia are pathognomonic for SLOS, caused by mutations in *DHCR7*, which disrupts cholesterol synthesis. Elevated 8-dehydrocholesterol may also occur due to secondary biochemical instability.  
2. **Craniofacial features**: Microcephaly, pointed chin, short chin, ptosis, and strabismus align with SLOS-associated dysmorphism.  
3. **Neurological/developmental**: Intellectual disability, generalized hypotonia, hyperreflexia, ataxia, and hyperactivity reflect neurodevelopmental deficits typical of SLOS.  
4. **Growth/feeding issues**: Failure to thrive, feeding difficulties, and fatigue correlate with metabolic dysfunction and poor cholesterol-dependent growth.  
5. **Congenital anomalies**: Syndactyly (often 2-3 toe) is a hallmark structural defect in SLOS.  
6. **Severity/mortality**: Death in infancy or childhood occurs in severe cases due to metabolic instability or organ malformations.  

All findings coalesce into a diagnosis of Smith-Lemli-Opitz syndrome, confirmed by biochemical/genetic testing."
"['Generalized hypotonia', 'Death in infancy', 'Increased serum lactate', 'Hypertriglyceridemia', 'Hepatomegaly', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration', 'Abnormal circulating creatine kinase concentration']",['Glycogen storage disease due to glycogen debranching enzyme deficiency/Glycogen storage disease III'],"Disease: Glycogen storage disease due to glycogen debranching enzyme deficiency/Glycogen storage disease III  
Reasoning:  
1. **Hepatomegaly**: Caused by abnormal glycogen accumulation in the liver due to debranching enzyme deficiency.  
2. **Hypertriglyceridemia**: Impaired glycogenolysis leads to secondary lipid metabolism dysfunction and increased triglyceride synthesis.  
3. **Increased serum lactate**: Anaerobic glycolysis compensates for defective glycogen breakdown, generating excess lactate.  
4. **Abnormal circulating aspartate/alanine concentrations**: Disrupted gluconeogenesis and amino acid metabolism from liver dysfunction.  
5. **Elevated lactate dehydrogenase (LDH) and creatine kinase (CK)**: Muscle involvement (myopathy) due to glycogen accumulation, causing enzyme leakage.  
6. **Generalized hypotonia**: Result of muscle weakness from impaired glycogen-derived glucose availability.  
7. **Neonatal death/Death in infancy**: Severe metabolic derangements (e.g., hypoglycemia, cardiomyopathy) in critical early stages without intervention.  
8. **Differentiation from other GSDs**: Muscle symptoms (elevated CK, hypotonia) and absence of severe hypoglycemia (common in GSD I) support GSD III over other glycogenoses.  

This pattern aligns with GSD III’s hallmark dual hepatic and muscular involvement due to AGL gene mutations affecting glycogen debranching."
"['Microcephaly', 'Generalized hypotonia', 'Death in infancy', 'Cerebral cortical atrophy', 'Athetosis', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine', 'Death in adolescence', 'Abnormal circulating acetylcarnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Cerebral cortical atrophy** and **microcephaly** reflect neurodegenerative changes from neurotoxic metabolite accumulation, particularly affecting the basal ganglia (evidenced by **athetosis**) and cortical neurons.  
3. **Generalized hypotonia** aligns with early neurological dysfunction in GA-I, often preceding acute metabolic crises triggered by catabolic stressors.  
4. **Decreased plasma free carnitine** and **abnormal acetylcarnitine** levels occur due to secondary carnitine depletion from conjugating glutaric acid, a hallmark of GA-I.  
5. **Death in infancy/adolescence** correlates with untreated or severe cases, as metabolic crises cause irreversible brain damage, while neonatal death is atypical but possible in profound enzyme deficiency.  
6. The symptom constellation (neurodegeneration, organic aciduria, carnitine derangements) is diagnostic for GA-I, distinguishing it from other organic acidemias."
"['Death in infancy', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperglycinuria', 'Hyperalaninemia', 'Death in childhood', 'Ichthyosis', 'Abnormal circulating glutamine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
- **Hyperammonemia**: Due to inhibition of urea cycle enzymes by accumulated propionyl-CoA metabolites.  
- **Hyperglycinemia/Hyperglycinuria**: Propionyl-CoA inhibits glycine cleavage enzyme, impairing glycine metabolism.  
- **Elevated urinary carboxylic acids**: Propionate derivatives (e.g., 3-hydroxypropionate, methylcitrate) are excreted in urine.  
- **Abnormal carnitine concentration**: Secondary carnitine deficiency from conjugation with propionate (propionylcarnitine).  
- **Vomiting, Death in infancy/childhood**: Metabolic decompensation episodes cause acute crises, leading to fatal outcomes.  
- **Hyperalaninemia**: Secondary disruption of amino acid metabolism due to mitochondrial dysfunction.  
- **Ichthyosis**: Rarely reported, possibly linked to metabolic stress or lipid metabolism abnormalities.  

The combination of organic acidemia markers (elevated urinary carboxylic acids, hyperammonemia) with glycine metabolism abnormalities and carnitine depletion is pathognomonic for propionic acidemia."
"['Intellectual disability', 'Motor delay', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Death in childhood', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Metabolic Pathway Disruption**: The symptoms ""abnormal circulating monocarboxylic acid concentration"" and ""elevated urinary carboxylic acid"" align with the accumulation of γ-hydroxybutyric acid (GHB) and succinic semialdehyde (SSA) due to SSADH enzyme deficiency, disrupting GABA degradation.  
2. **Neurological Manifestations**: ""Intellectual disability"" and ""motor delay"" are hallmark features of SSADHD, stemming from GABA and GHB neurotoxicity, leading to developmental delays and hypotonia.  
3. **Urinary Biomarkers**: Elevated urinary GHB (a carboxylic acid) is pathognomonic for SSADHD, explaining the ""elevated urinary carboxylic acid"" finding.  
4. **Severe Prognosis**: While death in childhood is rare, severe cases may involve intractable seizures, metabolic crises, or respiratory failure, consistent with the listed symptom.  
5. **Dysmorphic Features**: ""Abnormal facial shape"" and ""abnormal calvaria morphology"" are atypical but reported in some SSADHD cases, potentially linked to chronic metabolic stress or co-occurring genetic factors.  
6. **Exclusion of Alternatives**: Other organic acidurias (e.g., glutaric aciduria) were considered but ruled out due to the specificity of GHB elevation and lack of characteristic crises (e.g., ketoacidosis)."
"['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Hepatic failure', 'Death in infancy', 'Premature birth', 'Diarrhea', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with hypergalactosemia and an abnormality in galactoside metabolism, hallmark features of galactosemia. Neonatal symptoms like hepatic failure, prolonged partial thromboplastin time (indicating coagulopathy), diarrhea, and increased bilirubin align with acute metabolic decompensation due to galactose toxicity. Premature birth and early mortality (neonatal/infant/childhood death) reflect severe disease progression. Intellectual disability and motor delays suggest chronic neurological damage from toxic metabolite accumulation (e.g., galactitol). Abnormal aspartate and alanine concentrations point to secondary liver dysfunction disrupting amino acid metabolism. Classic galactosemia (GALT deficiency) is confirmed by this triad: failure to thrive, liver injury, and hypergalactosemia."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating proline concentration', 'Elevated plasma citrulline']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia, elevated plasma citrulline, and aminoaciduria, which are hallmark features of citrullinemia type I (ASS1 deficiency). Severe neonatal-onset hyperammonemia leads to rapid metabolic decompensation, explaining neonatal death or death in infancy. Aminoaciduria occurs due to overflow excretion of citrulline and other amino acids. Abnormal circulating proline may arise secondarily from metabolic instability or renal tubular stress. Early mortality aligns with the acute urea cycle dysfunction characteristic of this disorder.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Elevated citrulline and hyperammonemia are consistent with citrin deficiency (SLC25A13 mutations). Neonatal intrahepatic cholestasis, though not explicitly listed, is intrinsic to this diagnosis. Abnormal proline levels and aminoaciduria may reflect broader hepatic dysfunction or disrupted mitochondrial transport affecting multiple amino acids. Neonatal death could occur in severe cases with liver failure or metabolic crises, while citrin deficiency’s variable expressivity might also explain childhood mortality in progressive cases. However, the absence of explicit cholestasis-related symptoms (e.g., jaundice, hepatomegaly) makes this diagnosis less definitive."
"['Death in infancy', 'Fever', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity. This enzyme converts phenylalanine to tyrosine, and its absence leads to toxic phenylalanine accumulation.  
2. **Hypertyrosinemia**: While atypical in classic PKU (which typically shows normal/low tyrosine), this may indicate a rare variant (e.g., PAH deficiency with secondary tyrosine dysregulation) or coexisting liver dysfunction from chronic metabolic stress.  
3. **Abnormal urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate) may mimic carboxylic acid excretion patterns, though organic acidemias should be ruled out.  
4. **Decreased ferritin**: Chronic dietary restriction (low-protein PKU management) or malabsorption could contribute to iron deficiency.  
5. **Recurrent infections**: Untreated PKU causes severe neurological decline and immunosuppression due to metabolic derangements, increasing infection susceptibility.  
6. **Early mortality (infancy/childhood/adolescence)**: Reflects untreated/severe PKU, where toxic phenylalanine levels lead to neurodegeneration, seizures, and organ failure. Neonatal screening often prevents this, but delayed diagnosis results in fatal outcomes.  

Note: Hypertyrosinemia and porphyrin abnormalities are not classic PKU features, suggesting potential comorbidities (e.g., secondary mitochondrial dysfunction) or misattributed lab findings. However, hyperphenylalaninemia remains the diagnostic anchor."
"['Lethargy', 'Generalized hypotonia', 'Tremor', 'Death in infancy', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Elevated urinary carboxylic acid', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Abnormal circulating leucine concentration**: MSUD is caused by a defect in the branched-chain alpha-keto acid dehydrogenase complex, leading to accumulation of branched-chain amino acids (BCAAs: leucine, isoleucine, valine). Elevated leucine is neurotoxic and a hallmark of MSUD.  
2. **Elevated urinary carboxylic acid**: Excess BCAAs are metabolized into ketoacids, which are excreted in urine as carboxylic acids (e.g., α-ketoisocaproic acid), detectable via urine organic acid analysis.  
3. **Body odor**: The presence of sotolon, a metabolite of isoleucine, produces a distinctive maple syrup or burnt sugar odor in bodily fluids.  
4. **Neurological symptoms (Lethargy, Hypotonia, Tremor, Opisthotonus, Drowsiness)**: Leucine toxicity disrupts neurotransmitter synthesis and cerebral energy metabolism, causing encephalopathy, hypotonia, and hypertonic posturing (opisthotonus).  
5. **Sleep disturbance, Neonatal/Infant death**: Untreated classic MSUD rapidly progresses to cerebral edema, seizures, coma, and death within weeks to months of birth due to metabolic crisis.  
6. **Early mortality**: Classic MSUD manifests neonatally; without dietary BCAA restriction and metabolic support, fatal outcomes are inevitable.  

The combination of metabolic derangements (leucine elevation, urinary ketoacids), neurotoxicity, and pathognomonic odor confirms MSUD."
"['Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Anemia', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ferritin concentration', 'Pregnancy exposure', 'Decreased serum iron', 'Abnormality of vitamin D metabolism']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Pregnancy exposure**: Maternal PKU syndrome, where untreated maternal hyperphenylalaninemia during pregnancy results in congenital anomalies (e.g., premature birth, developmental issues) and neonatal complications (e.g., neonatal death).  
3. **Decreased serum iron/ferritin & anemia**: Likely secondary to restrictive dietary management of PKU, which may limit iron-rich protein sources.  
4. **Vitamin D metabolism abnormality**: Due to dietary restrictions (low-phenylalanine diets often lack fortified foods or natural sources of vitamin D).  
5. **Hypertyrosinemia**: Uncommon in classic PKU but may occur transiently due to metabolic stress or concurrent hepatic dysfunction (e.g., tyrosine catabolism disruption).  
6. **Early mortality (infancy/childhood)**: Untreated PKU causes severe neurological damage; maternal PKU syndrome exacerbates risks (cardiac/developmental defects).  
**Key exclusion**: Tyrosinemia or BH4 deficiencies were considered but ruled out as the diagnosis explicitly aligns with PKU. Hypertyrosinemia here is atypical but explained contextually."
"['Hypertelorism', 'Anteverted nares', 'Self-mutilation', 'Delayed speech and language development', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Abnormal foot morphology', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Severe hearing impairment']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Hypocholesterolemia and elevated 7-/8-dehydrocholesterol are pathognomonic for SLOS, caused by *DHCR7* mutations impairing cholesterol biosynthesis.  
2. **Craniofacial features**: Hypertelorism and anteverted nares align with SLOS-associated dysmorphism.  
3. **Limb/skeletal anomalies**: Syndactyly and abnormal foot morphology are classic SLOS findings (e.g., 2-3 toe syndactyly).  
4. **Neurodevelopmental issues**: Intellectual disability, speech/motor delays, seizures, and hyperactivity reflect SLOS’s neurological impact.  
5. **Sensory deficits**: Severe hearing impairment is a recognized but variable feature.  
6. **Self-injurious behavior**: Rarely reported in SLOS, potentially linked to neurodevelopmental severity.  
7. **Mortality**: Neonatal/childhood death correlates with severe SLOS phenotypes, often due to organ malformations or metabolic complications.  
*Conclusion*: Combined biochemical, dysmorphic, and developmental features confirm SLOS. Cholesterol precursor testing is diagnostic."
"['Microcephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Small for gestational age', 'Death in infancy', 'Splenomegaly', 'Anemia', 'Acute kidney injury', 'Metabolic acidosis', 'Hypoglycemia', 'Dehydration', 'Fever', 'Hyperammonemia', 'Hypothermia', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Hepatomegaly', 'Methylmalonic acidemia', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating homocysteine concentration', 'Elevated circulating C-reactive protein concentration', 'Feeding difficulties', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Elevated urinary carboxylic acid']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Key biochemical markers**: Elevated methylmalonic acid in blood (methylmalonic acidemia) and urine (methylmalonic aciduria), decreased methylmalonyl-CoA mutase activity, hyperammonemia, metabolic acidosis, and increased serum lactate directly indicate a defect in methylmalonyl-CoA metabolism.  
2. **Clinical features**: Neonatal death, failure to thrive, intellectual disability, motor delay, and generalized hypotonia align with severe mitochondrial energy deficiency caused by MMA.  
3. **Metabolic instability**: Hypoglycemia, hyperuricemia, hyperglycinemia, and abnormal amino acid profiles (e.g., aspartate, alanine, homocysteine) reflect disrupted intermediary metabolism and secondary mitochondrial dysfunction.  
4. **Organ involvement**: Hepatomegaly, splenomegaly, acute/chronic kidney injury, and elevated creatinine/blood urea nitrogen suggest toxic metabolite accumulation (methylmalonic acid) damaging organs.  
5. **Systemic complications**: Feeding difficulties, gastrointestinal inflammation, and recurrent infections (pneumonia) are consistent with chronic metabolic stress and immune dysfunction.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Enzyme deficiency confirmation**: Decreased methylmalonyl-CoA mutase activity explicitly identifies the molecular defect, distinguishing it from B12-responsive forms (e.g., cblA/cblB defects).  
2. **B12-unresponsiveness**: Persistence of methylmalonic acidemia despite B12 supplementation (implied by classification) and severe phenotypes (neonatal death, death in childhood) are hallmarks of mutase deficiency.  
3. **Carnitine depletion**: Decreased plasma free carnitine occurs due to excessive conjugation with toxic metabolites (e.g., propionyl-CoA derivatives), exacerbating energy crisis.  
4. **Chronic multisystem disease**: Chronic kidney disease, severe short stature, and abnormal porphyrin metabolism indicate long-term sequelae of uncontrolled MMA.  
5. **Laboratory correlations**: Elevated CRP, hyperlactatemia, and abnormal urinary carboxylic acids further support chronic metabolic decompensation and oxidative stress.  

Both diagnoses are intrinsically linked, with the second specifying the mutase-deficient, B12-unresponsive subtype underlying the patient’s catastrophic clinical course."
"['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency  
Reasoning:  
1. **Abnormal Pyrimidine Metabolism**: The presence of **abnormal circulating pyrimidine concentration** and **uraciluria** directly points to a defect in pyrimidine catabolism, as uracil accumulation occurs due to impaired breakdown.  
2. **Enzyme Deficiency**: Dihydropyrimidine dehydrogenase (DPD) is responsible for the first step in pyrimidine degradation. Deficiency leads to elevated uracil and thymine in blood/urine.  
3. **Neurological Symptoms**: **Ataxia**, **lethargy**, **drowsiness**, and **generalized hypotonia** align with neurotoxicity caused by excess pyrimidines or their metabolites disrupting CNS function.  
4. **Severe Infantile Presentation**: **Death in infancy** and **sleep disturbance** are consistent with severe neonatal-onset forms of the disorder, where metabolic crises and neurological decline are common.  
5. **Confirmatory Biomarkers**: The combination of uraciluria and abnormal pyrimidine levels is pathognomonic for DPD deficiency, distinguishing it from other metabolic disorders."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia**: Common in organic acidemias due to secondary inhibition of the urea cycle.  
2. **Abnormal carnitine**: IVA causes carnitine depletion via conjugation with isovaleric acid (isovalerylcarnitine excretion).  
3. **Abnormal glycine**: Excess isovaleric acid is detoxified via glycine conjugation (elevated isovalerylglycine in urine).  
4. **Neonatal/Infancy death**: Untreated IVA leads to metabolic crises, encephalopathy, and early mortality.  
5. **Prenatal abnormalities**: Severe metabolic stress may indirectly affect fetal development, though IVA typically manifests postnatally.  
6. **Exclusion of mimics**: Differentiated from other organic acidemias (e.g., propionic/methylmalonic acidemia) by specific biomarkers (isovalerylglycine, C5 acylcarnitine)."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiency/multiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Elevated urinary carboxylic acid**: Biotinidase deficiency impairs biotin recycling, reducing activity of carboxylase enzymes (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). This disrupts organic acid metabolism, leading to urinary accumulation of carboxylic acids (e.g., 3-hydroxyisovaleric acid, lactic acid).  
2. **Seizures**: Biotin-dependent carboxylases are critical for fatty acid synthesis, gluconeogenesis, and neurotransmitter regulation. Deficiency causes metabolic acidosis and energy deficits, triggering neuroexcitability and seizures.  
3. **Generalized hypotonia**: Metabolic acidosis and disrupted mitochondrial energy production impair muscle function, manifesting as hypotonia.  
4. **Death in infancy**: Untreated biotinidase deficiency progresses to severe metabolic crises, respiratory failure, and neurological damage, often fatal within the first year without biotin supplementation.  
**Diagnostic confirmation**: Low serum biotinidase enzyme activity (<10% normal activity) and genetic testing for *BTD* gene mutations. Early biotin supplementation reverses symptoms, emphasizing urgency in diagnosis."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts medium-chain fatty acid oxidation, leading to accumulation of medium-chain acylcarnitines and secondary carnitine deficiency.  
2. **Neonatal death/Death in infancy/childhood**: Untreated MCADD causes hypoketotic hypoglycemia during fasting, triggering metabolic crises that can be fatal, especially in early life.  
3. **Delayed speech/language development**: Neurological damage from prior hypoglycemic episodes or metabolic instability may impair development in undiagnosed cases.  
4. **Abnormality of prenatal development or birth**: Though atypical, severe metabolic stress *in utero* or maternal factors (e.g., placental insufficiency) might contribute to prenatal abnormalities.  
5. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects misinterpretation of acylcarnitine profile data or secondary metabolic disruption; MCADD primarily involves MCAD enzyme deficiency (not 3-hydroxyacyl-CoA dehydrogenase).  

Key confirmation relies on genetic testing for *ACADM* mutations and characteristic acylcarnitine profile (elevated C6-C10 species, notably C8)."
"['Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Dyspnea', 'Apnea', 'Opisthotonus', 'Spastic tetraplegia', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated branched-chain amino acids (BCAAs):** Hypervalinemia, hyperleucinemia, and hyperisoleucinemia are pathognomonic for MSUD, as the disease disrupts the breakdown of BCAAs due to a deficiency in the branched-chain α-keto acid dehydrogenase complex.  
2. **Metabolic acidosis:** Accumulation of toxic keto acids (from BCAAs) overwhelms buffering systems, leading to acidosis.  
3. **Neurological symptoms:** Seizures, spastic diplegia/tetraplegia, motor delay, and opisthotonus result from neurotoxicity caused by elevated leucine and its metabolites.  
4. **Respiratory and feeding issues:** Dyspnea, apnea, and feeding difficulties arise from metabolic decompensation and neurological dysfunction.  
5. **Odor and fatal course:** The characteristic ""maple syrup"" body odor (due to alloisoleucine) and neonatal death/infant mortality align with classic severe MSUD phenotypes.  
6. **Generalized hypotonia:** Reflects acute metabolic encephalopathy and impaired energy metabolism in neurons.  

The combination of BCAA elevation, metabolic derangements, and rapid neurological decline confirms MSUD as the diagnosis."
"['Psychosis', 'Osteoporosis', 'Intellectual disability', 'Anemia', 'Hyperammonemia', 'Cerebral atrophy', 'Hyperglycinemia', 'Kyphoscoliosis', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Elevated urinary carboxylic acid', 'Death in early adulthood', 'Body odor']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic abnormalities**: Hyperammonemia, hyperglycinemia, hyperalaninemia, and elevated urinary carboxylic acids align with PA, a disorder of propionyl-CoA carboxylase deficiency. This causes accumulation of propionic acid derivatives (e.g., methylcitrate, 3-hydroxypropionate), disrupting amino acid metabolism and urea cycle function.  
2. **Neurological involvement**: Psychosis, intellectual disability, and cerebral atrophy result from neurotoxic effects of ammonia and organic acids, compounded by energy deficits in the brain.  
3. **Hematological/renal signs**: Anemia arises from bone marrow suppression by toxic metabolites. Elevated blood urea nitrogen (BUN) and creatinine reflect renal stress due to chronic metabolic acidosis.  
4. **Skeletal/growth issues**: Severe short stature, osteoporosis, and kyphoscoliosis stem from chronic protein catabolism, malnutrition, and metabolic bone disease.  
5. **Odor/abnormal metabolites**: Body odor (sweaty feet) and abnormal carnitine/porphyrin levels reflect disrupted fatty acid oxidation and heme synthesis secondary to propionyl-CoA accumulation.  
6. **Early mortality**: Death in adolescence/early adulthood is typical in severe PA due to metabolic crises, cardiac complications, or neurodegeneration.  
7. **Hyperglycinemia**: Propionyl-CoA inhibits glycine cleavage enzyme, leading to secondary glycine elevation.  
8. **Hearing impairment**: Sensorineural deafness may occur due to mitochondrial dysfunction in cochlear cells.  

PA explains all symptoms via defective propionate metabolism, mitochondrial toxicity, and multi-organ sequelae."
"['Intellectual disability', 'Seizure', 'Ataxia', 'Tremor', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Biochemical Marker**: The presence of L-2-hydroxyglutaric aciduria in urine is pathognomonic for this disorder, confirming a defect in the L2HGDH gene, which disrupts lysine and tryptophan metabolism.  
2. **Neurological Symptoms**: Intellectual disability, seizures, ataxia, and tremor align with progressive neurodegeneration caused by toxic accumulation of L-2-hydroxyglutaric acid in the central nervous system.  
3. **Disease Progression**: Early-onset symptoms (e.g., developmental delay) progressing to severe neurological deterioration and death in childhood reflect the aggressive nature of the disorder.  
4. **Exclusion of Mimics**: Specific biochemical findings rule out other organic acidurias (e.g., D-2-hydroxyglutaric aciduria) or mitochondrial disorders with overlapping symptoms.  
5. **Genetic Confirmation**: While not explicitly stated here, the biochemical evidence (urinary acid elevation) is sufficient for clinical diagnosis, with genetic testing as confirmatory."
"['Motor delay', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Motor delay** aligns with Canavan disease, a leukodystrophy causing progressive neurological deterioration due to defective myelination.  
2. **Death in infancy** is consistent with severe, early-onset forms of Canavan disease, which can lead to rapid neurological decline and fatal outcomes.  
3. **Abnormal circulating aspartate family amino acids** (specifically elevated *N-acetylaspartic acid [NAA]*) directly results from aspartoacylase deficiency, the enzyme defect in Canavan disease. This biochemical marker confirms the diagnosis.  
4. The triad of neurological regression, fatal infantile course, and NAA accumulation is pathognomonic for Canavan disease, ruling out other leukodystrophies or metabolic disorders with overlapping symptoms."
"['Death in infancy', 'Hyperammonemia', 'Increased total bilirubin', 'Neonatal death', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline directly indicates a urea cycle defect, specifically argininosuccinate synthetase (ASS1) deficiency, which defines citrullinemia. Hyperammonemia arises from impaired ammonia detoxification in the urea cycle. Neonatal death and infant mortality align with the severe, early-onset nature of this disorder. Increased bilirubin suggests secondary liver dysfunction due to metabolic crisis.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: The specificity of ""type I"" refers to the classic ASS1-deficient form (OMIM #215700), distinguishing it from type II (adult-onset citrullinemia II, SLC25A13-related). The neonatal presentation with hyperammonemia, citrulline elevation, and rapid progression to death is pathognomonic for type I. Elevated citrulline confirms the enzyme block at the ASS1 step, excluding other urea cycle defects (e.g., ornithine transcarbamylase deficiency)."
"['Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency  
Reasoning:  
1. **Metabolic acidosis and hypoglycemia**: Central features of HMG-CoA lyase deficiency due to impaired ketogenesis (critical for energy during fasting) and accumulation of toxic metabolites.  
2. **Dicarboxylic aciduria and 3-methylglutaric aciduria**: Direct biochemical markers of the disorder, caused by defective leucine catabolism and incomplete fatty acid oxidation.  
3. **Hyperammonemia**: Secondary to metabolic decompensation and carnitine depletion, disrupting the urea cycle.  
4. **Hepatomegaly**: Linked to fatty liver infiltration from disrupted fatty acid metabolism.  
5. **Recurrent viral infections**: Immune stress from metabolic crises and energy deficiency impairing immune function.  
6. **Vomiting/diarrhea/drowsiness**: Acute metabolic decompensation episodes triggered by catabolic states (e.g., fasting, infection).  
7. **Early lethality (infancy/childhood)**: Characteristic of untreated cases due to rapid metabolic deterioration and cerebral edema.  
8. **Elevated urinary carboxylic acids**: Reflects systemic accumulation of 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-methylglutaric acids, pathognomonic for HMG-CoA lyase deficiency.  

The constellation of organic aciduria, hypoglycemia without ketosis, hyperammonemia, and hepatomegaly is diagnostic for this autosomal recessive disorder of ketone body synthesis and leucine metabolism."
"['Seizure', 'Death in infancy', 'Splenomegaly', 'Respiratory insufficiency']",['Cystinuria/Cystinuria'],"Cystinuria: Cystinuria is a genetic disorder characterized by impaired transport of cystine and other amino acids in the kidneys, leading to recurrent kidney stone formation. However, the listed symptoms—seizures, death in infancy, splenomegaly, and respiratory insufficiency—do not align with cystinuria. Cystinuria primarily manifests with urinary tract symptoms (e.g., nephrolithiasis, hematuria) and is not associated with neurological deficits, splenomegaly, or life-threatening respiratory failure in infancy. The diagnosis provided is inconsistent with the clinical presentation.  

**Likely Alternative Diagnosis (not cystinuria):**  
The symptoms suggest a severe metabolic or lysosomal storage disorder, such as:  
- **Niemann-Pick disease type A (ASMD):** Presents with hepatosplenomegaly, progressive neurodegeneration, seizures, and respiratory failure in infancy.  
- **Gaucher disease type 2:** Features splenomegaly, neurological deterioration, and respiratory complications, though seizures are less common.  
- **Mitochondrial respiratory chain disorders:** May cause multisystem involvement, including seizures, respiratory insufficiency, and organomegaly due to energy deficiency.  

**Conclusion:** The provided diagnosis of cystinuria is incorrect for this clinical scenario. Further evaluation (e.g., enzyme assays, genetic testing, imaging) is critical to identify the underlying condition."
"['Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Hyperthreoninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hypervalinemia', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Decreased serum creatinine', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark of MMA, alongside metabolic crises (hyperammonemia, vomiting, feeding difficulties). Elevated branched-chain amino acid derivatives (hypervalinemia, abnormal isoleucine) align with impaired propionate metabolism due to defective methylmalonyl-CoA mutase or vitamin B12 metabolism. Neonatal/childhood death and hypotonia reflect severe enzymatic dysfunction, while hypoproteinemia and abnormal carnitine levels suggest secondary metabolic stress.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: **Recurrent viral infections** and **death in infancy** indicate a severe, B12-unresponsive subtype. Mutase deficiency prevents methylmalonyl-CoA conversion to succinyl-CoA, causing toxic metabolite accumulation (hyperammonemia, methylmalonic aciduria). **Decreased serum creatinine** and **increased blood urea nitrogen** point to renal dysfunction from metabolic acidosis. Neurological symptoms (intellectual disability, motor delay) and neonatal mortality are consistent with irreversible cellular damage from chronic toxicity."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency of phenylalanine hydroxylase (PAH), leading to the accumulation of phenylalanine in the blood. This directly explains the elevated phenylalanine levels.  
2. **Elevated urinary carboxylic acids**: In PKU, phenylalanine is metabolized via alternative pathways, producing phenylketones (e.g., phenylpyruvate, phenyllactate), which are carboxylic acids excreted in urine.  
3. **Death in infancy/childhood**: Untreated PKU results in severe neurological damage, seizures, and developmental failure, often leading to early mortality if dietary phenylalanine restriction is not implemented.  
4. **Hypertyrosinemia discrepancy**: Classic PKU typically causes *low* tyrosine due to blocked PAH activity. Hypertyrosinemia here may reflect a lab error, concurrent tyrosine supplementation, or an atypical presentation (e.g., transient tyrosinemia from liver dysfunction).  
5. **Recurrent viral infections**: Unrelated to PKU pathophysiology but could arise from secondary complications (e.g., malnutrition, immunosuppression due to systemic metabolic stress).  

Conclusion: Core symptoms (hyperphenylalaninemia, urinary phenylketones) align with PKU. Atypical features (hypertyrosinemia, infections) require further investigation but do not override the primary diagnosis."
"['Strabismus', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Intellectual disability**: Untreated PKU results in neurotoxicity from elevated phenylalanine, impairing brain development.  
3. **Strabismus**: Neurological damage from phenylalanine toxicity can affect cranial nerve function, including ocular motor control.  
4. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) causes fetal developmental anomalies; alternatively, severe neonatal hyperphenylalaninemia may disrupt early development.  
5. **Early mortality (infancy, adolescence, adulthood)**: Untreated PKU leads to progressive neurological decline, seizures, and organ damage, potentially causing premature death.  
6. **Hypertyrosinemia**: Uncommon in classic PKU but may arise secondary to metabolic dysregulation or overlapping enzyme deficiencies (e.g., tetrahydrobiopterin (BH4) defects).  
7. **Obesity**: Linked to dietary management challenges (high-carbohydrate, low-protein diets) or metabolic disturbances in later stages.  

Note: Neonatal death and hypertyrosinemia are atypical for classical PKU and may suggest a comorbid condition (e.g., BH4 deficiency) or severe phenotypic variants. However, hyperphenylalaninemia remains the primary diagnostic anchor."
"['Death in infancy', 'Abnormal bleeding', 'Hyperammonemia', 'Vomiting', 'Oroticaciduria', 'Abnormality of the coagulation cascade']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency  
Reasoning:  
1. **Hyperammonemia** is a cardinal feature of urea cycle disorders (UCDs), specifically implicating OTCD as ornithine transcarbamylase (OTC) is critical for ammonia detoxification in the urea cycle.  
2. **Oroticaciduria** is pathognomonic for OTCD. The enzyme deficiency causes carbamoyl phosphate to divert into pyrimidine synthesis, overproducing orotic acid.  
3. **Vomiting** and **death in infancy** align with acute neonatal-onset OTCD, where hyperammonemic crises trigger neurological deterioration and multi-organ failure.  
4. **Abnormal bleeding/coagulation cascade abnormalities** arise from hyperammonemia-induced platelet dysfunction and potential secondary liver impairment (reduced clotting factor synthesis).  
5. Exclusion of other UCDs (e.g., CPS1 deficiency lacks oroticaciduria; arginase deficiency presents later). The symptom constellation is specific to OTCD."
"['Intellectual disability', 'Generalized hypotonia', 'Hyperreflexia', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Death in childhood', 'Abnormal myelination', 'L-2-hydroxyglutaric acidemia']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **L-2-hydroxyglutaric acidemia** is pathognomonic for L-2-hydroxyglutaric aciduria (L-2-HGA), a rare autosomal recessive neurometabolic disorder caused by mutations in the *L2HGDH* gene, leading to toxic accumulation of L-2-hydroxyglutaric acid.  
2. **Intellectual disability**, **generalized hypotonia**, and **hyperreflexia** align with the progressive neurological deterioration characteristic of L-2-HGA, affecting both cortical and subcortical structures.  
3. **Abnormal cerebral morphology** and **abnormal myelination** are consistent with leukoencephalopathy and cystic/white matter changes seen on neuroimaging in L-2-HGA.  
4. **Death in childhood** reflects the severe phenotype of the disease, often due to complications like seizures, respiratory infections, or metabolic crises.  
5. **Hyperammonemia**, though atypical, may occur secondary to mitochondrial dysfunction or intercurrent metabolic stressors in advanced disease.  
The combination of elevated L-2-hydroxyglutaric acid, neurodevelopmental regression, and neuroimaging abnormalities confirms the diagnosis."
"['Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Stroke-like episode', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis and ataxia**: PMM2-CDG commonly presents with cerebellar hypoplasia/atrophy due to impaired glycosylation of proteins critical for cerebellar development, leading to motor dysfunction (ataxia).  
2. **Intellectual disability**: Global neurodevelopmental deficits are a hallmark of PMM2-CDG, resulting from disrupted glycosylation-dependent brain maturation.  
3. **Thromboembolism/stroke-like episodes**: Hypoglycosylation of coagulation factors (e.g., antithrombin III, protein C/S) causes a hypercoagulable state, predisposing to thrombotic events and vascular insults mimicking strokes.  
4. **Death in infancy**: Severe multisystem involvement (hepatic, cardiac, and neurologic) in classic PMM2-CDG often leads to early mortality.  
5. **Exclusion of mimics**: The combination of cerebellar structural anomalies, coagulopathy, and infantile lethality distinguishes PMM2-CDG from isolated metabolic disorders or mitochondrial diseases. Genetic testing for PMM2 mutations would confirm the diagnosis."
"['Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: The hallmark symptom of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Neonatal death/Death in infancy**: Severe, untreated PKU can lead to rapid neurological deterioration and metabolic crisis, particularly in rare cases with near-complete PAH deficiency.  
3. **Premature birth**: Maternal PKU syndrome (untreated phenylalanine elevation during pregnancy) may cause fetal complications like prematurity, though the infant’s own PKU diagnosis explains hyperphenylalaninemia.  
4. **Hypertyrosinemia**: Atypical for classic PKU (where tyrosine is typically low). May reflect secondary liver dysfunction, transient neonatal tyrosinemia, or a coexisting metabolic disturbance, but does not exclude PKU as the primary diagnosis.  

Key evidence prioritizes hyperphenylalaninemia and clinical severity, aligning with PKU despite atypical tyrosine elevation. Early demise underscores untreated metabolic dysfunction."
"['Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Tremor', 'Death in infancy', 'Leukopenia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Gastroesophageal reflux', 'Pneumonia', 'Increased serum lactate', 'Hyperglycinemia', 'Drowsiness', 'Difficulty walking', 'Sleep disturbance', 'Tachypnea', 'Increased blood urea nitrogen', 'Hypertyrosinemia', 'Hyperalaninemia', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperprolinemia', 'Difficulty running', 'Stomatitis', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Hypoglycinemia', 'Severe hearing impairment']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Abnormalities**: Hyperammonemia, hyperglycinemia, and elevated serum lactate are hallmark features of PA. Propionyl-CoA carboxylase deficiency disrupts the urea cycle (causing hyperammonemia) and mitochondrial function (leading to lactic acidosis).  
2. **Amino Acid Derangements**: Hypertyrosinemia, hyperalaninemia, hyperprolinemia, and hypervalinemia occur due to secondary inhibition of amino acid metabolism by accumulated propionic acid metabolites.  
3. **Hematologic Issues**: Leukopenia and recurrent infections stem from bone marrow suppression, a known complication of PA.  
4. **Neurological Symptoms**: Intellectual disability, seizures, hypotonia, motor delays, and severe hearing impairment result from neurotoxic effects of metabolites (e.g., propionic acid) and energy deficiency.  
5. **Gastrointestinal and Acute Crises**: Vomiting, GER, and tachypnea align with metabolic decompensation episodes. Hyperammonemia and acidosis drive lethargy, drowsiness, and respiratory compensation.  
6. **Early Mortality**: Neonatal/childhood death is typical in severe PA due to metabolic crises or complications like pneumonia.  
7. **Carnitine Abnormalities**: Propionyl-CoA sequesters carnitine, causing secondary carnitine deficiency (abnormal circulating carnitine levels).  
8. **Hyperglycinemia**: Propionyl-CoA inhibits the glycine cleavage system, leading to elevated glycine despite PA not being a primary glycine disorder.  

Key Clinchers: Combined hyperammonemia, metabolic acidosis (elevated lactate), and multisystem involvement (neurologic, hematologic, GI) with early lethality strongly pinpoint PA."
"['Polydipsia', 'Elevated hepatic transaminase', 'Decreased circulating ceruloplasmin concentration', 'Death in adolescence', 'Decreased circulating copper concentration']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin and copper concentrations**: Wilson disease is caused by ATP7B gene mutations, impairing copper transport and incorporation into ceruloplasmin, leading to low serum ceruloplasmin and copper levels.  
2. **Elevated hepatic transaminases**: Copper accumulation in the liver causes hepatocellular injury, manifesting as elevated liver enzymes.  
3. **Polydipsia**: Neurological involvement (e.g., hypothalamic dysfunction) or renal tubular acidosis (secondary to copper toxicity) may cause excessive thirst.  
4. **Death in adolescence**: Untreated Wilson disease progresses to liver failure, hemolytic crises, or neuropsychiatric complications, often fatal in adolescence/early adulthood without timely intervention.  
5. **Exclusion of mimics**: Symptoms align with Wilson disease’s triad (hepatic, neurologic, psychiatric) and biochemical profile, distinguishing it from other copper disorders (e.g., Menkes disease) or isolated liver pathologies."
"['Seizure', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Neonatal death']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia indicators**: Symptoms like seizures, lethargy, vomiting, drowsiness, and neonatal death align with hyperammonemia, a hallmark of urea cycle disorders.  
2. **Oroticaciduria**: Elevated urinary orotic acid occurs in OTCD due to carbamoyl phosphate accumulation, which is diverted to pyrimidine synthesis. This distinguishes OTCD from other urea cycle defects.  
3. **Hyperglutaminemia**: Excess ammonia is metabolized via glutamine synthetase, increasing glutamine levels.  
4. **Neonatal/Infantile lethality**: Severe OTCD often presents catastrophically in males (X-linked) shortly after birth, consistent with ""death in infancy.""  
5. **Exclusion of alternatives**: Oroticaciduria differentiates OTCD from CPS1 deficiency (no orotic acid elevation). Symptoms also exclude organic acidemias or mitochondrial disorders, which lack urea cycle-specific markers.  

The triad of **hyperammonemia, oroticaciduria, and hyperglutaminemia** confirms OTCD as the diagnosis."
"['Microcephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Anemia', 'Elevated circulating alkaline phosphatase concentration', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Feeding difficulties', 'Hypergalactosemia', 'Decreased circulating ferritin concentration', 'Decreased serum iron']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** and **abnormality of galactoside metabolism** directly indicate impaired galactose processing, a hallmark of galactosemia.  
2. **Feeding difficulties**, **generalized hypotonia**, **motor delay**, and **intellectual disability** align with metabolic dysfunction and neurological sequelae caused by toxic galactose metabolite accumulation.  
3. **Elevated alkaline phosphatase** and **anemia** suggest liver damage and hematopoietic disruption, common in untreated galactosemia due to galactitol toxicity.  
4. **Decreased serum iron/ferritin** may reflect secondary iron deficiency from malabsorption or chronic illness.  
5. **Abnormal porphyrin levels** could arise from hepatic dysfunction impairing heme synthesis.  
6. **Prenatal abnormalities**, **microcephaly**, and early mortality (**neonatal/infant/childhood death**) correlate with severe metabolic crises in classic galactosemia when galactose exposure begins in utero or postnatally.  
7. **Obesity** is atypical but reported in survivors with long-term metabolic complications.  

Disease: Galactosemia/GAL  
Reasoning:  
- This broader diagnosis encompasses the same pathophysiology as classic galactosemia, with overlapping symptoms (e.g., **hypergalactosemia**, **feeding difficulties**, **hepatic/neurologic involvement**) but allows for phenotypic variability.  
- The specificity of **abnormality of galactoside metabolism** and exclusion of other metabolic disorders (e.g., tyrosinemia) confirm galactosemia as the unifying diagnosis."
"['Obesity', 'Abnormal foot morphology', 'Hyperammonemia', 'Death in childhood']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Hyperammonemia**: A hallmark of BTDD due to impaired urea cycle function from deficient carboxylases (e.g., propionyl-CoA carboxylase), leading to metabolic acidosis and ammonia accumulation.  
2. **Abnormal foot morphology**: Neuromuscular abnormalities (e.g., hypotonia, spasticity) in untreated BTDD may cause skeletal deformities, including foot malalignment or pes equinovarus.  
3. **Obesity**: Uncommon but plausible in chronic metabolic dysregulation; biotin-dependent enzymes regulate lipid metabolism, and dysfunction may alter energy homeostasis.  
4. **Death in childhood**: Untreated BTDD causes progressive neurological decline, respiratory failure, or metabolic crises, often fatal in early life without biotin supplementation.  
**Key Link**: The combination of hyperammonemia, neurological/skeletal defects, and early mortality aligns with BTDD’s multisystemic presentation. Obesity may reflect secondary metabolic disturbances rather than a primary feature."
"['Hyperactivity', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties', 'Abnormal myelination']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal myelination**: Canavan disease is a leukodystrophy caused by aspartoacylase deficiency, leading to defective myelin synthesis due to toxic accumulation of N-acetylaspartic acid (NAA) in the brain.  
2. **Abnormal circulating aspartate family amino acid concentration**: Elevated NAA in blood/urine is pathognomonic for Canavan disease, directly linked to the enzyme deficiency.  
3. **Feeding difficulties and death in infancy**: Early-onset symptoms (3–6 months) include hypotonia, poor feeding, and failure to thrive, progressing to severe neurodegeneration and typically fatal outcomes in infancy/early childhood.  
4. **Hyperactivity**: Neurological deterioration in Canavan disease may manifest as irritability or hyperexcitability due to cerebral dysfunction, though spasticity and developmental regression are more common.  
5. **Exclusion of other leukodystrophies**: The biochemical profile (NAA elevation) and clinical progression distinguish Canavan from other disorders like Tay-Sachs or Krabbe disease."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** reflects the congenital nature of PKU (autosomal recessive inheritance), though structural prenatal anomalies are typically absent unless maternal PKU syndrome is involved.  
3. **Death in infancy/Neonatal death** occurs in severe, untreated cases due to progressive neurological damage (e.g., seizures, brain atrophy) and systemic complications, though neonatal death is rare with modern screening. Early dietary intervention prevents these outcomes, but untreated PKU can lead to fatal metabolic derangements."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Delayed speech and language development**: Untreated PKU causes neurotoxicity from elevated phenylalanine, impairing cognitive and language development.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies, though neonatal PKU itself may present with nonspecific metabolic instability.  
4. **Hypertyrosinemia**: Secondary tyrosine elevation is atypical in classic PKU but may occur transiently due to metabolic dysregulation or overlap with other tyrosine metabolism disorders (e.g., tyrosinemia type II), though PKU remains primary here.  
5. **Early mortality (infancy/childhood/adulthood)**: Untreated PKU leads to severe neurological deterioration, seizures, and organ damage, historically causing premature death. Neonatal death is rare unless compounded by acute metabolic crises or misdiagnosis.  

**Conclusion**: Symptoms align with severe, untreated PKU, exacerbated by delayed diagnosis or lack of dietary management. Hypertyrosinemia may indicate a complex metabolic interplay but does not override the primary PKU diagnosis."
"['Nephritis', 'Generalized hypotonia', 'Death in infancy', 'Ventricular septal defect', 'Cardiomyopathy', 'Pulmonic stenosis']",['Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb'],"Disease: Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb  
Reasoning:  
1. **Generalized hypotonia**: Phosphorylase kinase deficiency impairs glycogen breakdown in muscles, leading to glycogen accumulation and muscle weakness.  
2. **Cardiomyopathy**: Glycogen accumulation in cardiac muscle can disrupt myocardial function, causing hypertrophic or dilated cardiomyopathy.  
3. **Death in infancy**: Severe metabolic instability (e.g., hypoglycemia, lactic acidosis) and cardiac complications (cardiomyopathy, structural defects) may contribute to early mortality.  
4. **Ventricular septal defect (VSD) and pulmonic stenosis**: While not classic features of GSD IXb, these congenital defects could arise from a contiguous gene deletion syndrome involving PHKA2 (X-linked) and adjacent cardiac developmental genes.  
5. **Nephritis**: Uncommon in GSDs; may reflect secondary renal tubular dysfunction due to metabolic stress (e.g., acidosis) or misdiagnosis of glycogen-driven renal enlargement as inflammation.  

This diagnosis integrates metabolic dysfunction (liver/muscle phosphorylase kinase deficiency) with multisystem complications, emphasizing severe phenotypic variability in rare presentations."
"['Irritability', 'Spasticity', 'Hyperreflexia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Neurological symptoms** (irritability, spasticity, hyperreflexia) arise from phenylalanine-induced brain damage in untreated cases.  
3. **Early mortality** (neonatal/infancy/childhood/adolescence death) aligns with severe untreated PKU variants or complications like metabolic crises or seizures.  
4. **Hypertyrosinemia inconsistency**: Typically, PKU causes *low* tyrosine (due to blocked PAH activity). This symptom suggests a possible comorbid condition (e.g., tyrosinemia type II) or diagnostic error.  
5. **Recurrent viral infections** are atypical for PKU and may indicate an unrelated immunodeficiency.  
6. PKU diagnosis is confirmed by elevated blood phenylalanine and genetic testing for *PAH* mutations, but conflicting hypertyrosinemia warrants further metabolic investigation.  

Note: Hypertyrosinemia and recurrent infections are not classic PKU features; additional workup is critical to rule out overlapping disorders (e.g., BH4 deficiencies, tyrosinemias)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Symptom Alignment**:  
   - **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, intrauterine metabolic stress or placental insufficiency from maternal fasting (due to fetal inability to oxidize medium-chain fatty acids) may contribute to subtle prenatal abnormalities.  
   - **Death in infancy/Neonatal death**: MCADD causes life-threatening hypoglycemia and metabolic crises triggered by fasting (e.g., delayed feeding in neonates). Untreated, this leads to coma, cardiorespiratory failure, and early mortality.  
   - **Abnormal circulating carnitine**: Secondary carnitine deficiency occurs due to sequestration of carnitine by accumulating toxic metabolites (e.g., medium-chain acylcarnitines), reducing free carnitine levels.  

2. **Pathophysiological Link**:  
   - MCADD disrupts β-oxidation of medium-chain fatty acids (C6-C12), impairing energy production during fasting. Neonates/infants are highly vulnerable due to high metabolic demands and limited glycogen reserves.  

3. **Diagnostic Confirmation**:  
   - Elevated C8-C10 acylcarnitines on newborn screening (tandem mass spectrometry) and genetic testing for *ACADM* mutations confirm MCADD.  

4. **Exclusion of Alternatives**:  
   - Symptoms overlap with other fatty acid oxidation disorders (e.g., VLCADD, LCHADD), but abnormal medium-chain acylcarnitines and carnitine profile specifically localize to MCADD.  

**Conclusion**: The constellation of neonatal metabolic instability, carnitine derangements, and early mortality strongly supports MCADD. Early intervention (avoidance of fasting, glucose supplementation) can prevent fatal outcomes."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Delayed speech/language development** and **generalized hypotonia** align with untreated PKU, where toxic phenylalanine accumulation damages the developing nervous system.  
3. **Neonatal death**, **death in infancy/childhood** may occur in severe, undiagnosed cases due to metabolic crisis or progressive neurological decline.  
4. **Abnormality of prenatal development** could reflect maternal PKU syndrome (if the mother has PKU), though this is less common in the patient’s presentation.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise from secondary metabolic disruptions or overlap with other tyrosine metabolism disorders (e.g., transient tyrosinemia of the newborn), suggesting possible comorbidities or diagnostic complexity. However, hyperphenylalaninemia remains the primary indicator.  
6. Early dietary management (phenylalanine restriction) is critical to prevent symptoms, underscoring the importance of newborn screening for PKU."
"['Seizure', 'Encephalopathy', 'Death in infancy', 'Opisthotonus', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Elevated glutaric acid metabolites**: The presence of glutaric aciduria and elevated circulating glutaric acid directly indicates a defect in glutaric acid metabolism, a hallmark of GA-I caused by deficient glutaryl-CoA dehydrogenase.  
2. **Neurological symptoms**: Seizures, encephalopathy, and opisthotonus align with striatal neurodegeneration triggered by toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
3. **Carnitine depletion**: Decreased plasma free carnitine reflects secondary carnitine deficiency due to excessive conjugation with glutaric acid for renal excretion.  
4. **Urinary carboxylic acid elevation**: Matches the expected excretion of dicarboxylic acids (e.g., glutaric acid) in GA-I.  
5. **Early mortality**: Death in infancy/childhood is consistent with acute metabolic crises (e.g., encephalopathic crises) or progressive neurological damage in untreated GA-I.  
6. **Exclusion of mimics**: Symptoms and biochemical profile rule out other organic acidemias (e.g., type II glutaric aciduria) or mitochondrial disorders, as GA-I uniquely combines these markers with glutaryl-CoA dehydrogenase deficiency."
"['Strabismus', 'Nystagmus', 'Hyperactivity', 'Cyanosis', 'Edema', 'Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Diarrhea', 'Pneumonia', 'Dyspnea', 'Hyperkalemia', 'Opisthotonus', 'Hepatomegaly', 'Fair hair', 'Spastic tetraplegia', 'Hypocalcemia', 'Neonatal death', 'Stridor', 'White hair', 'Severe hearing impairment']",['Glutathione synthetase deficiency'],"Disease: Glutathione synthetase deficiency  
Reasoning:  
1. **Metabolic acidosis**: A hallmark of glutathione synthetase deficiency (GSSD), caused by accumulation of 5-oxoproline due to impaired glutathione synthesis.  
2. **Neurological symptoms (seizures, intellectual disability, spastic tetraplegia/diplegia, motor delay, hypotonia, opisthotonus)**: Result from oxidative stress and neuronal damage due to glutathione deficiency, critical for antioxidant defense.  
3. **Recurrent infections (pneumonia) and dyspnea**: Glutathione is essential for immune function; deficiency increases susceptibility to infections and oxidative lung injury.  
4. **Hepatomegaly and edema**: Hepatic dysfunction from oxidative damage and metabolic stress.  
5. **Electrolyte imbalances (hyperkalemia, hypocalcemia)**: Secondary to renal tubular acidosis, a known complication of GSSD.  
6. **Fair/white hair**: Reduced melanin synthesis due to disrupted cysteine metabolism (cysteine is a glutathione precursor).  
7. **Early mortality (neonatal death, death in infancy)**: Severe metabolic instability and infections in untreated cases.  
8. **Diarrhea and stridor**: Gastrointestinal and respiratory manifestations of systemic metabolic dysfunction.  
9. **Cyanosis and severe hearing impairment**: Hypoxia from respiratory compromise and oxidative damage to cochlear cells, respectively.  

The combination of metabolic acidosis, neurological deficits, immune dysfunction, and pigmentary changes strongly aligns with glutathione synthetase deficiency."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Thromboembolism', 'Reduced antithrombin III activity', 'Death in childhood', 'Lipodystrophy', 'Death in adolescence', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological involvement**: Ataxia, cerebellar atrophy/agenesis, motor delay, and intellectual disability align with PMM2-CDG’s hallmark cerebellar and developmental defects due to impaired glycosylation of neural proteins.  
2. **Hepatic manifestations**: Cirrhosis and hepatic fibrosis are consistent with multisystemic involvement, though liver disease is typically milder compared to other CDG subtypes.  
3. **Coagulopathy**: Reduced antithrombin III activity (a glycoprotein) explains thromboembolism, a recognized feature of glycosylation defects.  
4. **Early mortality**: Death in infancy/childhood/adolescence reflects severe phenotypic variability, with fatal outcomes in critical organ dysfunction.  
5. **Hypotonia and strabismus**: Common early signs due to neuromuscular and cranial nerve glycosylation deficits.  
6. **Lipodystrophy**: Rarely reported but plausible in PMM2-CDG, potentially linked to metabolic dysregulation from glycosylation errors.  
7. **Cerebellar agenesis**: Represents an extreme structural anomaly in severe cases, overlapping with cerebellar atrophy spectrum.  

PMM2-CDG is confirmed by genetic testing for *PMM2* mutations and abnormal transferrin glycosylation patterns."
"['Irritability', 'Seizure', 'Generalized hypotonia', 'Hyperreflexia', 'Death in infancy', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning: The combination of irritability, seizures, generalized hypotonia, hyperreflexia, and opisthotonus points to severe neurological dysfunction. Death in infancy and feeding difficulties align with progressive infantile neurodegenerative disorders. Abnormal circulating aspartate family amino acids (specifically elevated N-acetylaspartic acid due to aspartoacylase deficiency) is pathognomonic for Canavan disease. The triad of hypotonia, hyperreflexia, and macrocephaly (implied by rapid neurodegeneration and intracranial pressure causing opisthotonus) further supports this diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine in an untreated pregnant mother disrupts fetal development.  
3. **Neonatal death/Death in infancy** may occur in severe untreated PKU due to metabolic crises, neurological damage, or secondary complications (e.g., infections).  
4. **Hypertyrosinemia** is atypical in classic PKU but may arise transiently from liver immaturity or secondary metabolic disturbances in critically ill infants.  
5. **Gastrointestinal inflammation** could result from protein-rich feedings exacerbating metabolic stress or comorbid conditions in a metabolically unstable infant.  
6. While PKU typically causes low tyrosine, confounding factors (e.g., transient neonatal tyrosinemia, assay interference) may explain the lab result. The dominant hyperphenylalaninemia strongly prioritizes PKU over tyrosinemia disorders.  

Note: Confirmatory testing (PAH gene variants, phenylalanine/tyrosine ratios, tetrahydrobiopterin status) would solidify the diagnosis and exclude BH4 deficiencies."
"['Ataxia', 'Coma', 'Reduced tendon reflexes', 'Alopecia', 'Metabolic acidosis', 'Cerebral edema', 'Abnormal cerebral white matter morphology', 'Death in childhood', 'Recurrent viral infections', 'Hyperleucinemia', 'Death in adolescence']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Hyperleucinemia** is pathognomonic for MSUD, caused by impaired branched-chain α-ketoacid dehydrogenase (BCKDH) complex activity, leading to accumulation of leucine, isoleucine, and valine.  
2. **Neurological symptoms** (Ataxia, Coma, Cerebral edema, Abnormal cerebral white matter morphology) stem from leucine-induced neurotoxicity, disrupting neurotransmitter synthesis and causing cerebral osmotic imbalance.  
3. **Metabolic acidosis** results from secondary inhibition of the citric acid cycle by accumulating α-ketoacids.  
4. **Reduced tendon reflexes** correlate with acute metabolic decompensation and axonal dysfunction.  
5. **Death in childhood/adolescence** aligns with classic/severe MSUD phenotypes if untreated; cerebral edema and metabolic crises are often fatal.  
6. **Alopecia** and **recurrent viral infections** are atypical but may reflect nutritional deficiencies or secondary immune dysregulation during metabolic stress.  
7. **Abnormal cerebral white matter morphology** on imaging corresponds with delayed myelination and vacuolization due to leucine toxicity.  

*Note: While recurrent infections and alopecia are not classic MSUD features, the core biochemical and neurological findings dominate the diagnostic rationale.*"
"['Abdominal pain', 'Elevated urinary delta-aminolevulinic acid', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning: Abdominal pain is a hallmark of acute neurovisceral attacks in acute intermittent porphyria (AIP). Elevated urinary delta-aminolevulinic acid (ALA) aligns with AIP’s pathophysiology, where a deficiency in porphobilinogen deaminase (PBGD) causes accumulation of ALA and porphobilinogen (PBG). While AIP typically manifests post-puberty, severe childhood-onset cases can lead to fatal complications like respiratory paralysis or electrolyte imbalances, explaining early mortality.  

Disease: Porphyria/Porphyria  
Reasoning: Elevated urinary ALA is nonspecific and occurs in multiple porphyrias. If PBG levels were not measured, broader porphyria classification is appropriate. Death in childhood could suggest rare, severe forms like ALAD-deficiency porphyria (ADP), which also elevates ALA but lacks PBG elevation. However, ADP is not explicitly listed, so ""porphyria"" serves as a general diagnosis when subtype confirmation is incomplete."
"['Seizure', 'Death in infancy', 'Metabolic acidosis', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with methylmalonic aciduria, metabolic acidosis, and life-threatening neonatal/infantile symptoms (seizures, neonatal death). These are hallmark features of methylmalonic acidemia (MMA), an autosomal recessive disorder caused by impaired metabolism of methylmalonyl-CoA. Accumulation of methylmalonic acid leads to metabolic acidosis and neurological toxicity, explaining seizures. Neonatal lethality reflects severe metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The presence of methylmalonic aciduria unresponsive to vitamin B12 therapy (implied by ""death in infancy"" despite likely standard care) points specifically to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme defect prevents isomerization of methylmalonyl-CoA to succinyl-CoA, causing irreversible accumulation of methylmalonic acid. B12-unresponsive forms are typically severe, manifesting in the neonatal period with rapid metabolic deterioration, consistent with the patient’s clinical course."
"['Seizure', 'Lethargy', 'Generalized hypotonia', 'Growth delay', 'Drowsiness', 'Sleep disturbance', 'Death in childhood', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine** is the hallmark symptom of Alkaptonuria, caused by the accumulation and oxidation of homogentisic acid (HGA) in urine. This symptom is often noticed in infancy or early childhood.  
2. **Growth delay** and **generalized hypotonia** may occur due to metabolic disruptions from chronic HGA accumulation, though these are less common and not well-documented in typical Alkaptonuria cases.  
3. **Seizures, lethargy, drowsiness, and sleep disturbances** are atypical for Alkaptonuria but could suggest secondary complications (e.g., metabolic acidosis or electrolyte imbalances) or comorbidities.  
4. **Death in childhood** is not characteristic of Alkaptonuria, which typically allows for a normal lifespan with progressive joint/connective tissue issues (e.g., ochronosis, arthritis) manifesting later in life. This may indicate a severe, atypical presentation or misattribution of symptoms.  
5. Despite inconsistencies, **dark urine** remains the critical diagnostic clue, prompting confirmatory testing (e.g., urinary HGA quantification, genetic analysis for *HGD* mutations)."
"['Seizure', 'Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning: The combination of abnormal circulating concentrations of branched-chain amino acids (leucine, isoleucine, valine), aminoaciduria, and severe neonatal symptoms (seizures, death in infancy/neonatal period) strongly suggests MSUD. This autosomal recessive disorder results from a deficiency in the branched-chain alpha-keto acid dehydrogenase complex, impairing BCAA catabolism. Accumulation of BCAAs and their toxic keto-acid derivatives leads to metabolic decompensation, neurotoxicity (seizures), and rapid progression to lethality in untreated classic MSUD. Aminoaciduria reflects renal excretion of excess BCAAs, consistent with the biochemical profile."
"['Death in infancy', 'Cardiomegaly', 'Hypoglycemia', 'Increased serum lactate', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Hypoglycemia and increased serum lactate**: Impaired mitochondrial β-oxidation of very long-chain fatty acids deprives the body of energy during fasting, forcing reliance on glycolysis (causing hypoglycemia) and anaerobic metabolism (elevating lactate).  
2. **Dicarboxylic aciduria**: VLCADD disrupts fatty acid breakdown, leading to alternative ω-oxidation of fatty acids in the endoplasmic reticulum, producing dicarboxylic acids excreted in urine.  
3. **Hepatomegaly and cardiomegaly**: Toxic accumulation of long-chain acylcarnitines and fatty acid metabolites in the liver and heart causes organ damage and hypertrophy.  
4. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to excessive conjugation of carnitine with unmetabolized long-chain acyl-CoA species.  
5. **Recurrent viral infections and tachypnea**: Metabolic crises during catabolic states (e.g., infections) exacerbate energy deficits, triggering respiratory compensation (tachypnea) and susceptibility to infections.  
6. **Death in infancy/childhood**: Severe VLCADD phenotypes present neonatally with cardiomyopathy or hepatic failure, often leading to early mortality without prompt diagnosis and dietary management (e.g., avoidance of fasting, medium-chain triglyceride supplementation).  

The combination of fatty acid oxidation disorder markers (dicarboxylic aciduria, hypoglycemia, carnitine abnormalities) with multi-organ involvement (heart, liver) and early lethality is pathognomonic for VLCADD."
"['Seizure', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Fever', 'Vomiting', 'Drowsiness', 'Progressive neurologic deterioration', 'Sleep disturbance', 'Glutaric aciduria', '3-Methylglutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Metabolic acidosis and hypoglycemia**: Central features of HMGCLD due to impaired leucine catabolism and ketogenesis, leading to accumulation of toxic metabolites (e.g., 3-hydroxy-3-methylglutaric acid) and energy deficiency.  
2. **Glutaric aciduria and 3-methylglutaric aciduria**: Direct biochemical markers of HMG-CoA lyase deficiency, as the enzyme deficiency disrupts the breakdown of leucine and ketone body synthesis.  
3. **Seizures, lethargy, and progressive neurologic deterioration**: Result from neurotoxic effects of accumulated organic acids and recurrent metabolic crises.  
4. **Recurrent viral infections**: Metabolic decompensation often triggered by catabolic stressors like infections, which exacerbate energy deficits.  
5. **Abnormal glycine concentrations**: Secondary hyperglycinemia may occur as glycine conjugates with toxic metabolites to facilitate excretion.  
6. **Death in infancy/childhood**: Characteristic of untreated cases due to acute metabolic crises or irreversible neurological damage.  
7. **Elevated urinary carboxylic acids**: Reflects systemic spillage of incompletely metabolized intermediates (e.g., 3-hydroxy-3-methylglutarate, glutarate).  
8. **Hypoglycemia without ketosis**: Pathognomonic in HMGCLD, as the enzyme defect prevents ketogenesis during fasting."
"['Hypoglycemia', 'Glycosuria', 'Abnormal circulating porphyrin concentration']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: MODY (Maturity-Onset Diabetes of the Young)  
Reasoning: Hypoglycemia and glycosuria suggest a defect in glucose regulation. MODY is a monogenic form of diabetes characterized by beta-cell dysfunction, often presenting with atypical diabetes features. The coexistence of hypoglycemia (indicative of insulin dysregulation) and glycosuria (glucose excretion despite normal or low blood glucose levels) points to a renal threshold alteration or fluctuating glucose levels, common in MODY subtypes.  

Disease: MODY type 1 (HNF4A mutation)  
Reasoning:  
1. **Hypoglycemia**: Neonatal or childhood hypoglycemia is a hallmark of HNF4A-MODY due to transient hyperinsulinism in early life.  
2. **Glycosuria**: Progressive beta-cell dysfunction leads to hyperglycemia in adolescence/adulthood, causing glycosuria. Reduced renal glucose reabsorption (via SGLT2 downregulation) may also contribute.  
3. **Abnormal porphyrins**: HNF4A regulates hepatic genes involved in metabolism, potentially affecting heme synthesis pathways indirectly. This could explain abnormal porphyrin levels, though this association is less defined and may require further investigation.  

This combination aligns with MODY type 1, where hypoglycemia precedes diabetes onset, and metabolic dysregulation impacts multiple pathways. Genetic testing for HNF4A mutations is critical for confirmation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Neonatal death/Death in infancy**: Untreated PKU causes severe neurological damage, seizures, and failure to thrive. Without early dietary intervention (e.g., phenylalanine-restricted diet), progressive toxicity can lead to fatal complications.  
3. **Abnormality of prenatal development**: Likely reflects **maternal PKU syndrome**, where high maternal phenylalanine levels during pregnancy disrupt fetal development (e.g., congenital heart defects, microcephaly). While the infant’s own PKU does not cause prenatal abnormalities, maternal PKU explains this symptom.  
4. **Diagnostic confirmation**: PKU is confirmed via newborn screening (elevated phenylalanine, normal tetrahydrobiopterin levels). Untreated cases align with the clinical trajectory of early morbidity/mortality.  

Note: Maternal PKU syndrome and infant PKU are distinct but interrelated; the infant’s symptoms arise from both inherited PAH deficiency and maternal metabolic environment during gestation."
"['Hydrocephalus', 'Macrocephaly', 'Hyperhidrosis', 'Seizure', 'Lethargy', 'Dystonia', 'Hyperreflexia', 'Death in infancy', 'Anemia', 'Fever', 'Vomiting', 'Cerebral atrophy', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Upper airway obstruction', 'Increased CSF protein concentration', 'Glutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Chronic pulmonary obstruction', 'Death in adolescence']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Core biochemical marker**: The explicit mention of ""Glutaric aciduria"" directly aligns with GA-I, a disorder caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Neurological features**:  
   - **Macrocephaly** at birth is a hallmark of GA-I, often preceding metabolic crises.  
   - **Dystonia**, **opisthotonus**, **seizures**, and **cerebral atrophy** reflect striatal injury and basal ganglia degeneration, typical of GA-I encephalopathic crises.  
   - **Hyperreflexia** and **fasciculations** suggest upper motor neuron involvement due to neurotoxicity.  
3. **Acute metabolic decompensation**:  
   - Symptoms like **lethargy**, **vomiting**, **fever**, and **drowsiness** are triggered by catabolic stressors (e.g., infections, fasting), common in GA-I crises.  
   - **Increased CSF protein concentration** may occur during acute neurological deterioration.  
4. **Prognostic indicators**:  
   - **Death in infancy/childhood/adolescence** correlates with untreated GA-I’s natural history. Early mortality arises from metabolic crises or secondary complications (e.g., **upper airway obstruction** due to dystonia).  
   - **Chronic pulmonary obstruction** and **recurrent viral infections** may stem from dysautonomia or impaired immune-metabolic interplay.  
5. **Supporting clues**:  
   - **Sleep disturbances** and **anemia** are nonspecific but consistent with chronic metabolic disease.  
   - **Hydrocephalus** (often ""communicating"") in GA-I is linked to macrocephaly and CSF dynamics alterations, not structural defects.  

GA-I explains the full clinical spectrum, from biochemical derangements to fatal neurological progression, distinguishing it from mimics (e.g., mitochondrial disorders, other organic acidemias). Early diagnosis is critical for dietary/ metabolic interventions to mitigate outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** initially seems conflicting, as PAH deficiency typically reduces tyrosine levels. However, severe phenylalanine elevation may disrupt tyrosine metabolism or reflect a secondary metabolic disturbance.  
3. **Neonatal death/Death in infancy/childhood** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
4. **Abnormality of prenatal development** may stem from maternal PKU syndrome (untreated PKU in the mother during pregnancy), causing congenital anomalies in the fetus, though the patient’s own PKU manifests postnatally.  
5. The absence of early dietary intervention (low-phenylalanine diet) explains the fatal outcomes, emphasizing the critical need for newborn screening in PKU."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Preeclampsia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: Unusual in classic PKU but may arise from secondary metabolic disruptions. High phenylalanine levels could inhibit tyrosine metabolism enzymes (e.g., tyrosine aminotransferase), leading to paradoxical tyrosine accumulation.  
3. **Preeclampsia**: Linked to maternal PKU syndrome. Uncontrolled phenylalanine levels during pregnancy damage fetal development and increase maternal vascular stress, predisposing to preeclampsia.  
4. **Death in early adulthood**: Untreated PKU causes severe neurological decline, seizures, and organ damage. Early mortality may result from complications like metabolic crises or secondary infections in neurologically compromised individuals.  

PKU unifies the symptoms, with hypertyrosinemia and preeclampsia reflecting downstream metabolic and obstetric complications. Early death underscores the critical need for lifelong dietary management to prevent irreversible outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: Core feature of PKU due to deficient phenylalanine hydroxylase (PAH), causing phenylalanine accumulation.  
- **Elevated urinary carboxylic acids**: Reflects alternative phenylalanine metabolism (e.g., phenylpyruvate, phenyllactate), excreted as urinary metabolites.  
- **Abnormality of prenatal development**: Likely due to maternal PKU during pregnancy, exposing the fetus to toxic phenylalanine levels.  
- **Neonatal death/Death in infancy**: Severe untreated PKU can lead to metabolic crises, neurological damage, and failure to thrive without early dietary intervention.  
- **Death in early adulthood**: Untreated PKU causes chronic complications (e.g., intellectual disability, seizures, organ damage) reducing life expectancy.  
- **Hypertyrosinemia anomaly**: Unusual for PKU (typically low tyrosine), possibly a lab error, co-existing condition, or secondary tyrosine dysregulation in severe metabolic disruption.  

Note: Hypertyrosinemia may warrant investigation for co-occurring disorders (e.g., BH4 deficiency) but does not override PKU diagnosis given hallmark symptoms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where high maternal phenylalanine levels during pregnancy cause fetal complications (e.g., microcephaly, congenital heart defects).  
3. **Death in infancy/childhood and neonatal death** may occur in untreated severe PKU due to metabolic derangements, neurological deterioration, or secondary infections.  
4. **Hypertyrosinemia** is atypical in PKU (tyrosine levels are usually normal/low). This could indicate a concurrent metabolic disorder, laboratory error, or misreported data, but does not exclude PKU given the strong evidence from other symptoms.  
5. The combination of hyperphenylalaninemia with early mortality and developmental abnormalities strongly prioritizes PKU over other metabolic disorders (e.g., tyrosinemia)."
"['Skin rash', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Splenomegaly', 'Fever', 'Vomiting', 'Pneumonia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Hyperglycinuria', 'Cystinuria', 'Oroticaciduria', 'Ornithinuria', 'Death in childhood', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']",['Hereditary orotic aciduria/Orotic aciduria'],"Disease: Hereditary orotic aciduria/Orotic aciduria  
Reasoning:  
1. **Oroticaciduria**: The presence of oroticaciduria is pathognomonic for hereditary orotic aciduria, caused by a deficiency in uridine monophosphate synthase (UMPS), disrupting pyrimidine synthesis.  
2. **Failure to thrive and systemic involvement**: Symptoms like feeding difficulties, lethargy, drowsiness, and generalized hypotonia align with metabolic decompensation and energy deficits due to impaired nucleotide production.  
3. **Hepatosplenomegaly**: Splenomegaly and hepatomegaly may result from megaloblastic anemia (common in this disorder) or extramedullary hematopoiesis secondary to bone marrow dysfunction.  
4. **Immunodeficiency and infections**: Recurrent pneumonia and fever suggest immune dysfunction, as pyrimidine deficiency impairs lymphocyte proliferation and function.  
5. **Urinary abnormalities**: Hyperglycinuria, cystinuria, and ornithinuria may indicate secondary renal tubular dysfunction, though oroticaciduria is the primary diagnostic marker.  
6. **Early mortality**: Death in infancy or childhood is consistent with severe, untreated cases due to metabolic instability, infections, or complications of anemia.  
7. **Skin manifestations**: Erythematous plaques, macules, and papules could reflect systemic inflammation or secondary skin infections linked to immune compromise.  
8. **Abnormal alanine levels**: Disrupted pyrimidine metabolism may indirectly affect amino acid homeostasis, explaining abnormal circulating alanine concentrations.  

This constellation of symptoms, anchored by oroticaciduria, strongly supports hereditary orotic aciduria. Uridine supplementation is a key therapeutic consideration to bypass the metabolic block."
"['Cyanosis', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Anemia', 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Enzyme Dysfunction**: HLCS deficiency impairs biotin-dependent activation of multiple carboxylases (propionyl-CoA, pyruvate, β-methylcrotonyl-CoA, and acetyl-CoA carboxylases).  
2. **Metabolic Acidosis & Hyperammonemia**: Propionyl-CoA carboxylase deficiency leads to propionic acid accumulation, disrupting the urea cycle (hyperammonemia) and causing metabolic acidosis.  
3. **Skin Manifestations**: Eczematoid dermatitis and rash arise from functional biotin deficiency, impairing fatty acid synthesis and skin barrier function.  
4. **Neuromuscular Symptoms**: Generalized hypotonia stems from energy deficits (pyruvate carboxylase deficiency) and toxic metabolite accumulation.  
5. **Respiratory & Gastrointestinal Signs**: Tachypnea compensates for acidosis; diarrhea reflects intestinal metabolic dysfunction.  
6. **Laboratory Abnormalities**:  
   - **Aminoaciduria/Abnormal Glycine**: Disrupted amino acid catabolism due to carboxylase deficiencies.  
   - **Elevated Urinary Carboxylic Acids**: Propionate, 3-hydroxypropionate, and methylcitrate accumulate from blocked propionyl-CoA metabolism.  
   - **Decreased Pyruvate Carboxylase Activity**: Confirms multi-carboxylase involvement (lactic acidosis risk).  
7. **Early Lethality**: Neonatal death or infantile mortality occurs in untreated cases due to metabolic crises (acidosis, hyperammonemia).  
8. **Diagnostic Confirmation**: Combined propionyl-CoA and pyruvate carboxylase deficiencies (vs. isolated carboxylase defects) and abnormal glycine/monocarboxylic acid profiles pinpoint HLCS deficiency.  
**Conclusion**: The constellation of multi-carboxylase dysfunction, metabolic derangements, and neonatal presentation aligns definitively with HLCS deficiency."
"['Apathy', 'Ataxia', 'Lethargy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Death in adolescence']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as the urea cycle enzyme deficiency causes impaired ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD due to carbamoyl phosphate shunting into pyrimidine synthesis, producing excess orotic acid.  
3. **Neurological symptoms** (Apathy, Ataxia, Lethargy, Drowsiness): Reflect hyperammonemic encephalopathy from ammonia neurotoxicity.  
4. **Gastrointestinal symptoms** (Vomiting): Common during metabolic decompensation episodes.  
5. **Sleep disturbance**: Linked to circadian disruption from ammonia accumulation.  
6. **Death in adolescence**: Consistent with late-onset OTCD complications if untreated (e.g., cerebral edema, coma).  

The triad of **hyperammonemia, oroticaciduria, and neurological decline** confirms OTCD, a urea cycle disorder with X-linked inheritance (though females may manifest due to skewed lyonization). Urgent ammonia reduction and long-term protein restriction/ammonia scavengers are critical."
"['Vomiting', 'Ethylmalonic aciduria', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Short chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, short-chain, deficiency of']","Disease: Short chain acyl-CoA dehydrogenase deficiency/Acyl-CoA dehydrogenase, short-chain, deficiency of  
Reasoning:  
1. **Ethylmalonic aciduria**: A hallmark of short-chain acyl-CoA dehydrogenase (SCAD) deficiency, as impaired short-chain fatty acid oxidation leads to accumulation of ethylmalonic acid.  
2. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: SCAD deficiency disrupts mitochondrial β-oxidation, indirectly affecting enzymes in the pathway, including 3-hydroxyacyl-CoA dehydrogenase.  
3. **Abnormal circulating carnitine**: Secondary carnitine deficiency occurs due to excessive acylcarnitine excretion and disrupted fatty acid metabolism.  
4. **Vomiting**: Common during metabolic decompensation triggered by fasting or illness when energy demand exceeds defective fatty acid oxidation capacity.  
5. **Early mortality (childhood/adolescence)**: Severe SCAD deficiency causes life-threatening metabolic crises (hypoketotic hypoglycemia, encephalopathy) if untreated, leading to premature death.  
6. **Consistency with biochemical profile**: The triad of ethylmalonic aciduria, carnitine imbalance, and enzyme abnormalities aligns pathognomonically with SCAD deficiency."
"['Low-set ears', 'Wide nasal bridge', 'Anteverted nares', 'Ptosis', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Hypocholesterolemia, elevated 7-dehydrocholesterol (7-DHC), and elevated 8-dehydrocholesterol (8-DHC) are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in *DHCR7* leading to impaired cholesterol synthesis.  
2. **Dysmorphic features**: Low-set ears, wide nasal bridge, anteverted nares, ptosis, and syndactyly (especially 2-3 toe syndactyly) are classic craniofacial and limb anomalies in SLOS.  
3. **Neurodevelopmental issues**: Intellectual disability, motor delay, and generalized hypotonia align with SLOS-associated neurodevelopmental deficits due to disrupted cholesterol-dependent myelination and signaling.  
4. **Early lethality**: Neonatal death or death in infancy correlates with severe SLOS phenotypes, often linked to major organ malformations (e.g., cardiac, renal) or failure to thrive from feeding difficulties.  
5. **Feeding difficulties**: Result from hypotonia, poor suck/swallow coordination, and gastrointestinal abnormalities common in SLOS.  
The combination of cholesterol synthesis defects, characteristic dysmorphology, and systemic manifestations confirms SLOS."
"['Intellectual disability', 'Ataxia', 'Tremor', 'Death in infancy', 'Cerebral atrophy', 'Abnormal basal ganglia morphology', 'Neonatal death', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Biochemical confirmation**: The symptom ""L-2-hydroxyglutaric aciduria"" directly indicates elevated levels of L-2-hydroxyglutaric acid in bodily fluids, a hallmark diagnostic marker.  
2. **Neurological symptoms**: Intellectual disability, ataxia, and tremor align with progressive neurodegeneration caused by toxic metabolite accumulation.  
3. **Neuroimaging findings**: Cerebral atrophy and abnormal basal ganglia morphology are characteristic radiological features of this disorder, explaining motor and cognitive deficits.  
4. **Severe clinical course**: Neonatal death, death in infancy, and death in childhood suggest a severe phenotypic variant, consistent with early-onset, rapidly progressing forms of the disease.  
5. **Exclusion of mimics**: The combination of biochemical, clinical, and imaging features differentiates L-2-HGA from other organic acidurias or mitochondrial disorders."
"['Irritability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Opisthotonus', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Neonatal death', 'Death in childhood', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic Acidosis**: Caused by accumulation of toxic metabolites (3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid) due to defective leucine catabolism and impaired ketogenesis.  
2. **Seizures & Hypotonia**: Result from energy deficiency in the brain (lack of ketone bodies during fasting) and neurotoxicity from organic acid buildup.  
3. **Opisthotonus**: Reflects severe neurological dysfunction from metabolic crisis.  
4. **Dicarboxylic Aciduria**: Occurs due to compensatory omega-oxidation of fatty acids when ketogenesis fails, producing dicarboxylic acids.  
5. **3-Methylglutaconic Aciduria**: Secondary to enzyme deficiency, as 3-methylglutaconyl-CoA cannot be processed, leading to urinary excretion.  
6. **Elevated Urinary Carboxylic Acids**: Includes 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, pathognomonic for this disorder.  
7. **Early Mortality (Neonatal/Infancy/Childhood)**: Untreated metabolic crises cause rapid decompensation, hypoglycemia, and cerebral edema.  
8. **Irritability**: Early sign of metabolic stress during fasting or illness.  
The combination of these biochemical and clinical features distinguishes HMG-CoA lyase deficiency from other organic acidemias. Confirmatory testing involves genetic analysis of *HMGCL* or enzyme activity assays."
"['Eczematoid dermatitis', 'Skin rash', 'Seizure', 'Death in infancy', 'Fever', 'Elevated circulating C-reactive protein concentration', 'L-2-hydroxyglutaric aciduria', 'Decreased serum iron']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Diagnostic Marker**: The patient has ""L-2-hydroxyglutaric aciduria"" listed as a symptom, which directly corresponds to elevated levels of L-2-hydroxyglutaric acid in urine—a hallmark diagnostic feature of this inborn error of metabolism.  
2. **Neurological Manifestations**: Seizures are a common symptom of L-2-HGA due to progressive leukoencephalopathy and neurotoxicity caused by metabolite accumulation.  
3. **Poor Prognosis**: ""Death in infancy"" aligns with severe forms of the disease, often resulting from metabolic decompensation, infections, or neurological deterioration.  
4. **Inflammatory/Secondary Features**: Elevated C-reactive protein and fever suggest systemic inflammation or infection, which may trigger metabolic crises in L-2-HGA. Eczematoid dermatitis and skin rash could reflect immune dysregulation or secondary infections.  
5. **Metabolic Disruption**: Decreased serum iron may indicate chronic disease anemia or mitochondrial dysfunction linked to impaired cellular metabolism in L-2-HGA.  

The diagnosis is confirmed by the presence of L-2-hydroxyglutaric aciduria, with other symptoms reflecting secondary complications or systemic effects of the underlying metabolic disorder."
"['Nephritis', 'Death in infancy', 'Hypophosphatemia', 'Abnormality of limb bone morphology', 'Abnormal circulating hormone concentration', 'Elevated circulating alkaline phosphatase concentration', 'Death in childhood']","['Hypophosphatemic rickets/Hypophosphatemic rickets', 'X-linked hypophosphatemia/Hypophosphatemic rickets, X-linked dominant']","Disease: Hypophosphatemic rickets  
Reasoning: The patient presents with **hypophosphatemia**, **abnormality of limb bone morphology**, and **elevated alkaline phosphatase**, which are hallmark features of hypophosphatemic rickets. Chronic phosphate wasting leads to defective bone mineralization, causing skeletal deformities. Elevated alkaline phosphatase reflects increased bone turnover. While nephritis and early mortality are atypical for classic hypophosphatemic rickets, severe untreated cases may involve renal complications (e.g., nephrocalcinosis) or systemic failure contributing to early death.  

Disease: X-linked hypophosphatemia/Hypophosphatemic rickets, X-linked dominant  
Reasoning: **Hypophosphatemia** and **abnormal limb bone morphology** strongly align with X-linked hypophosphatemia (XLH), caused by *PHEX* gene mutations leading to excess FGF23. **Abnormal circulating hormone concentration** likely refers to elevated FGF23, which drives renal phosphate wasting. While XLH rarely causes infant/childhood death, severe cases (e.g., untreated male hemizygotes) may experience life-threatening complications like respiratory insufficiency due to chest wall deformities or refractory metabolic disturbances. **Nephritis** could stem from secondary renal damage (e.g., hypercalciuria-induced nephrocalcinosis). This subtype explains the X-linked inheritance pattern and biochemical profile."
"['Delayed speech and language development', 'Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Leukopenia', 'Hyperammonemia', 'Hyperglycinemia', 'Hyperglycinuria', 'Elevated circulating alkaline phosphatase concentration', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Abnormal circulating serine concentration', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: Propionic acidemia (PA) disrupts propionyl-CoA metabolism, leading to accumulation of toxic metabolites that inhibit the urea cycle (causing hyperammonemia) and secondary hyperglycinemia due to glycine synthesis interference.  
2. **Elevated Urinary Carboxylic Acids**: Propionyl-CoA carboxylase deficiency results in excretion of methylcitrate, 3-hydroxypropionate, and propionylglycine in urine, consistent with elevated urinary carboxylic acids.  
3. **Leukopenia & Skin Manifestations**: Toxic metabolites suppress bone marrow function (leukopenia) and may trigger eczematoid dermatitis/skin rash via immune dysregulation.  
4. **Abnormal Amino Acid/Carnitine Profiles**: Propionic acid conjugates with carnitine, causing secondary carnitine deficiency. Disrupted amino acid metabolism explains abnormal alanine, serine, and aspartate-family amino acids.  
5. **Hyperglycinuria & Alkaline Phosphatase Elevation**: Glycine overflow (hyperglycinuria) and hepatic stress (elevated alkaline phosphatase) reflect systemic metabolic derangement.  
6. **Neurological & Developmental Delays**: Chronic metabolic acidosis/ammonia toxicity impair neurodevelopment, causing speech delays.  
7. **Early Mortality**: Untreated PA leads to lethal metabolic crises in infancy/childhood; even with treatment, complications (e.g., cardiomyopathy) may cause death in adolescence.  

This constellation of metabolic, hematologic, and neurologic findings is pathognomonic for propionic acidemia."
"['Delayed speech and language development', 'Generalized hypotonia', 'Death in infancy', 'Hyperhomocystinemia', 'Abnormal cerebral white matter morphology', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type']","Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning:  
1. **Methylmalonic aciduria**: Directly listed as a symptom, indicating impaired metabolism of methylmalonyl-CoA.  
2. **Hyperhomocystinemia**: Specific to defects in cobalamin metabolism (e.g., cblC type), which disrupts homocysteine remethylation to methionine.  
3. **Abnormal cerebral white matter morphology**: Neurological damage from homocystinuria and methylmalonic acid toxicity explains this finding.  
4. **Decreased plasma free carnitine**: Secondary to excessive conjugation with accumulated metabolites (methylmalonic acid/homocysteine).  
5. **Generalized hypotonia and delayed speech**: Neurological manifestations due to combined metabolic toxicity and potential B12 deficiency effects.  
6. **Gastrointestinal inflammation**: Linked to metabolic stress and mitochondrial dysfunction in cblC.  
7. **Neonatal/Infancy/Childhood death**: Severe cblC variants often present with early-life metabolic crises, multiorgan failure, or neurodegeneration.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Methylmalonic aciduria**: Primary biochemical hallmark of isolated MMA caused by methylmalonyl-CoA mutase deficiency or cobalamin disorders (e.g., cblA/cblB).  
2. **Decreased plasma free carnitine**: Due to carnitine depletion from conjugating methylmalonic acid.  
3. **Generalized hypotonia and developmental delay**: Common in chronic MMA due to energy deficiency and neurotoxicity.  
4. **Death in infancy/childhood**: Occurs in severe MMA subtypes but **does not explain hyperhomocystinemia or cerebral white matter abnormalities**, making this diagnosis incomplete.  

**Final Diagnosis**: Methylmalonic acidemia with homocystinuria, type cblC (Combined MMA and homocystinuria) is the definitive diagnosis, as it uniquely accounts for **all symptoms**, including the coexistence of methylmalonic aciduria, hyperhomocystinemia, and cerebral white matter pathology."
"['Death in infancy', 'Neonatal death', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Elevated urinary carboxylic acid** is a hallmark of impaired carboxylase function. Biotinidase deficiency prevents biotin recycling, a coenzyme required for carboxylases (propionyl-CoA carboxylase, pyruvate carboxylase), leading to accumulation of unmetabolized substrates (e.g., lactic acid, 3-hydroxyisovaleric acid) in urine.  
2. **Neonatal death/Death in infancy** aligns with untreated BTDD, as biotin-dependent metabolic pathways (e.g., fatty acid synthesis, gluconeogenesis) are disrupted, causing metabolic acidosis, seizures, and organ failure.  
3. **Late-onset multiple carboxylase deficiency** refers to BTDD’s postnatal presentation (vs. holocarboxylase synthetase deficiency, which manifests prenatally). Without biotin supplementation, rapid decompensation in early infancy is typical."
"['Lethargy', 'Spasticity', 'Generalized hypotonia', 'Hyperreflexia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency  
Reasoning:  
1. **Hyperammonemia** is a cardinal feature of urea cycle disorders, including CPS1 deficiency, due to impaired ammonia detoxification.  
2. **Lethargy, drowsiness, and feeding difficulties** align with acute hyperammonemic encephalopathy, common in neonates with urea cycle defects.  
3. **Spasticity and hyperreflexia** suggest neurological damage from ammonia toxicity.  
4. **Generalized hypotonia** reflects systemic metabolic decompensation.  
5. **Death in infancy/neonatal death** is typical in severe, untreated CPS1 deficiency due to rapid ammonia accumulation.  
6. **Sleep disturbance** may arise from encephalopathic fluctuations in ammonia levels.  
7. Exclusion of other urea cycle disorders (e.g., ornithine transcarbamylase deficiency) is supported by the absence of orotic aciduria, which is not seen in CPS1 deficiency."
"['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with metabolic acidosis and decreased methylmalonyl-CoA mutase activity, hallmark features of methylmalonic acidemia (MMA). MMA is caused by impaired metabolism of methylmalonyl-CoA, leading to toxic accumulation of methylmalonic acid. The enzyme deficiency directly disrupts the propionate pathway, resulting in metabolic decompensation, which manifests as life-threatening acidosis. Early lethality (infancy/childhood) aligns with severe forms of MMA, where crises trigger multisystem failure.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specific mention of decreased methylmalonyl-CoA mutase activity confirms a defect in the MUT gene, encoding the mutase enzyme. This subtype is unresponsive to vitamin B12 therapy, as the mutation directly affects the enzyme’s structure/function rather than cofactor (adenosyl-B12) metabolism. Persistent enzyme dysfunction exacerbates metabolic instability, explaining the poor prognosis (death in infancy/childhood) despite standard interventions."
"['Hyperactivity', 'Spasticity', 'Death in infancy', 'Hemolytic anemia', 'Metabolic acidosis', 'Increased total bilirubin', 'Neonatal death', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Increased circulating lactate dehydrogenase concentration']",['Glutathione synthetase deficiency'],"Disease: Glutathione synthetase deficiency  
**Reasoning**:  
1. **Hemolytic anemia** and **increased total bilirubin**: Glutathione is critical for protecting red blood cells (RBCs) from oxidative damage. Deficiency leads to RBC fragility, causing hemolysis and subsequent hyperbilirubinemia.  
2. **Metabolic acidosis**: Accumulation of 5-oxoproline (a hallmark of glutathione synthetase deficiency) due to impaired glutathione synthesis disrupts acid-base balance.  
3. **Increased circulating lactate dehydrogenase (LDH)**: Elevated LDH reflects RBC breakdown (hemolysis) and tissue damage from oxidative stress.  
4. **Spasticity** and **hyperactivity**: Oxidative stress in the central nervous system damages neurons, leading to neurological symptoms.  
5. **Recurrent viral infections**: Glutathione deficiency impairs immune cell function, reducing defenses against pathogens.  
6. **Abnormal circulating porphyrin concentration**: Glutathione is involved in heme metabolism; its deficiency may disrupt porphyrin pathways.  
7. **Neonatal death**/**death in infancy**: Severe forms of the disease present in infancy with life-threatening metabolic derangements and organ failure.  

**Conclusion**: The constellation of hemolysis, metabolic acidosis, neurological abnormalities, and immune dysfunction strongly aligns with **glutathione synthetase deficiency**, particularly the severe autosomal recessive form. Confirmatory testing would include genetic analysis and measurement of 5-oxoproline in urine."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Respiratory distress', 'Apnea', 'Neonatal death', 'Respiratory acidosis', 'Elevated plasma citrulline', 'Hypoxemia']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia and markedly elevated plasma citrulline, hallmark features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency. Neonatal respiratory distress, apnea, and respiratory acidosis align with metabolic decompensation from ammonia toxicity, leading to neurological depression and respiratory failure. Premature birth and neonatal death are consistent with the severe, rapid progression of untreated urea cycle disorders.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: While cholestasis is not explicitly listed, citrin deficiency (type II) can present with neonatal hyperammonemia and elevated citrulline due to secondary urea cycle dysfunction. Respiratory distress and hypoxemia may reflect metabolic stress or hepatic involvement. Neonatal death and prematurity overlap with acute metabolic crises, though citrin deficiency often includes transient cholestasis or amino acid imbalances (e.g., high threonine), which may not be documented here. Differentiation from type I requires genetic testing or additional biomarkers (e.g., citrin protein analysis)."
"['Autistic behavior', 'Hypertension', 'Edema', 'Intellectual disability', 'Seizure', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Pancreatitis', 'Leukopenia', 'Anemia', 'Acute kidney injury', 'Hyperammonemia', 'Gout', 'Vomiting', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Clumsiness', 'Poor coordination', 'Kyphoscoliosis', 'Hyponatremia', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Short femur', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Increased circulating ferritin concentration', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Atransferrinemia', 'Chronic kidney disease', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic aciduria, vitamin B12-responsive, cblB type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits hallmark features of methylmalonic acidemia (MMA), including metabolic decompensation markers (hyperammonemia, vomiting, seizures, coma), elevated methylmalonic acid in blood/urine, and abnormal amino acid concentrations (alanine, valine). Neurological symptoms (intellectual disability, autistic behavior, hypotonia) and multisystem involvement (acute/chronic kidney disease, pancreatitis, anemia) align with MMA’s pathophysiology of methylmalonyl-CoA mutase dysfunction or cofactor deficiency. Death in infancy/childhood reflects severe phenotypes. Elevated lactate, hyperuricemia, and hyperglycinemia further support mitochondrial energy failure and organic acid accumulation.  

Disease: Methylmalonic aciduria, vitamin B12-responsive, cblB type  
Reasoning: The diagnosis of cblB-type MMA is confirmed by decreased methylmalonyl-CoA mutase activity (due to defective adenosylcobalamin synthesis) and potential B12 responsiveness. While mutase activity is low, the cblB subtype involves mutations in the *MMAB* gene, impairing cobalamin metabolism. Clinical features like chronic kidney disease, leukopenia, and atransferrinemia suggest long-term metabolic stress. Hyponatremia and hypoproteinemia may reflect renal tubular dysfunction. The presence of B12-responsive subtypes often allows partial therapeutic improvement, but early mortality (infancy/childhood) indicates a severe variant or delayed intervention. Abnormal carnitine and porphyrin levels hint at secondary mitochondrial and heme synthesis disruptions."
"['Microcephaly', 'Nystagmus', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Cerebral atrophy', 'Abnormal cerebral white matter morphology', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']","['Hyperphenylalaninemia; HPA', 'Dihydropteridine reductase deficiency/Hyperphenylalaninemia, bh4-deficient, C']","Disease: Dihydropteridine reductase deficiency/Hyperphenylalaninemia, bh4-deficient, C  
Reasoning:  
1. **Hyperphenylalaninemia (HPA)** is present, but the co-occurrence of **hypertyrosinemia** suggests a BH4 deficiency. In classic HPA (e.g., PKU), tyrosine is typically low due to impaired phenylalanine conversion, whereas BH4 deficiencies disrupt both phenylalanine metabolism **and** tyrosine hydroxylase activity, leading to tyrosine accumulation.  
2. **Neurological severity**: Symptoms like seizures, cerebral atrophy, abnormal white matter, motor delay, and intellectual disability align with BH4 deficiency’s impact on neurotransmitter synthesis (dopamine/serotonin), causing profound neurological deterioration.  
3. **Early mortality**: Neonatal death or death in childhood is characteristic of untreated BH4 deficiencies due to refractory seizures and neurodevelopmental collapse.  
4. **Alopecia**: Linked to tyrosine metabolism dysfunction affecting melanin production, a feature seen in BH4 disorders.  
5. **Generalized hypotonia** and **abnormality of prenatal development** further support a congenital metabolic disorder affecting multiple pathways.  

Disease: Hyperphenylalaninemia; HPA  
Reasoning:  
1. **Hyperphenylalaninemia** is explicitly listed, indicating impaired phenylalanine metabolism.  
2. However, the absence of dietary management history and the presence of **hypertyrosinemia** make classic HPA (e.g., PKU) less likely. This diagnosis is included due to the explicit mention of HPA in the symptoms, but it likely represents a secondary finding tied to the primary BH4 deficiency.  
3. Symptoms like intellectual disability and seizures are nonspecific and overlap with both conditions, but the broader context favors BH4 deficiency as the root cause."
"['Skin rash', 'Death in infancy', 'Glycosuria', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Functional abnormality of the gastrointestinal tract', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Cytochrome C oxidase (COX)-negative muscle fibers**: Directly indicates a deficiency in mitochondrial complex IV (COX), a hallmark of this disorder.  
2. **Ethylmalonic aciduria**: Linked to impaired mitochondrial fatty acid oxidation and oxidative phosphorylation, consistent with complex IV dysfunction.  
3. **Death in infancy**: Severe mitochondrial disorders often present with early lethality due to multisystem energy failure.  
4. **Glycosuria**: Suggests renal tubular dysfunction, a known feature of mitochondrial disorders affecting proximal tubule energetics.  
5. **Feeding difficulties & gastrointestinal tract abnormalities**: Reflects high energy demands of the gut, disrupted by mitochondrial ATP deficiency.  
6. **Skin manifestations (rash, plaques, macules, papules)**: May arise from metabolic acidosis, oxidative stress, or secondary inflammation due to mitochondrial dysfunction.  
7. **Abnormal circulating glycine**: Mitochondria play a role in glycine metabolism; dysregulation can occur in respiratory chain defects.  
8. **Nuclear type 1**: Specifies a nuclear DNA mutation (e.g., *COX4I1*, *SURF1*) causing the deficiency, differentiating it from mtDNA-related forms.  

The constellation of metabolic, neuromuscular, and multisystem symptoms aligns with mitochondrial complex IV deficiency, with genetic confirmation targeting nuclear-encoded assembly or catalytic subunits."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Fasciculations', 'Oroticaciduria', 'Low plasma citrulline', 'Neonatal death', 'Hypoargininemia']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** and **cerebral edema** are hallmarks of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia detoxification.  
2. **Low plasma citrulline** and **hypoargininemia** indicate a block early in the urea cycle, as citrulline and arginine are downstream metabolites not synthesized when CPS1 is deficient.  
3. **Neonatal death** and **death in infancy** align with the severe, early-onset presentation of CPS1 deficiency, as untreated hyperammonemia rapidly leads to neurological damage and mortality.  
4. **Seizures** and **fasciculations** result from ammonia-induced neurotoxicity and cerebral edema.  
5. **Cyanosis** may arise from metabolic acidosis or respiratory failure secondary to hyperammonemic crisis.  
6. **Oroticaciduria**, though classically linked to ornithine transcarbamylase (OTC) deficiency, can rarely occur in CPS1 deficiency due to compensatory metabolic stress or secondary pyrimidine pathway activation.  
7. The absence of elevated citrulline and arginine distinguishes CPS1 deficiency from later urea cycle defects (e.g., OTC or citrullinemia), solidifying the diagnosis."
"['Skin rash', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Neurological Symptoms**: Seizures align with Canavan's progressive leukodystrophy causing neurological deterioration.  
2. **Metabolic Abnormalities**: Elevated N-acetylaspartic acid (NAA) due to ASPA deficiency explains ""abnormal circulating aspartate family amino acid concentration."" Secondary metabolic disruption may contribute to hyperammonemia and aminoaciduria.  
3. **Early Mortality**: Neonatal death or death in infancy is consistent with severe infantile-onset Canavan disease.  
4. **Glycine Irregularity**: Abnormal glycine levels could stem from secondary metabolic disturbances in amino acid homeostasis.  
5. **Skin Manifestations**: Erythematous lesions (plaques, macules, papules) are atypical for Canavan but may reflect concurrent conditions, misreported findings, or cutaneous reactions to metabolic stress.  
6. **Exclusion of Alternatives**: Symptoms lack hallmark features of urea cycle disorders (e.g., vomiting) or organic acidemias (e.g., specific organic acid elevations), reinforcing Canavan as the primary diagnosis."
"['Seizure', 'Death in infancy', 'Respiratory insufficiency', 'Opisthotonus', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Sepsis']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated branched-chain amino acids (Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia)**: MSUD is caused by a defect in the branched-chain alpha-keto acid dehydrogenase complex, leading to toxic accumulation of leucine, isoleucine, and valine. These lab findings are pathognomonic.  
2. **Neurological symptoms (Seizure, Opisthotonus)**: Excess leucine is neurotoxic, causing cerebral edema and severe neurological dysfunction, manifesting as seizures and abnormal posturing (opisthotonus).  
3. **Metabolic decompensation (Feeding difficulties, Respiratory insufficiency)**: Infants develop poor feeding, vomiting, and lethargy due to metabolic acidosis. Respiratory failure may arise from central nervous system depression or muscle weakness.  
4. **Early lethality (Neonatal death, Death in infancy)**: Untreated classic MSUD progresses rapidly to coma and death within weeks to months due to irreversible neurological damage.  
5. **Sepsis mimicry**: Metabolic crises in MSUD can mimic sepsis (lethargy, respiratory distress), and secondary infections may occur due to immune dysfunction from metabolic stress.  

The combination of BCAA elevation, acute neurological decline, and neonatal onset confirms MSUD as the diagnosis."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The patient's symptoms of neonatal death, death in infancy/childhood, and abnormal circulating carnitine align with MCADD, a fatty acid oxidation disorder. MCADD impairs breakdown of medium-chain fatty acids, leading to hypoglycemia and metabolic crises during fasting. Neonatal and childhood fatalities are hallmark features due to delayed diagnosis. Abnormal carnitine levels occur secondary to disrupted fatty acid metabolism. The listed ""decreased 3-hydroxyacyl-CoA dehydrogenase"" is likely a misstatement; MCADD specifically involves deficient *medium-chain acyl-CoA dehydrogenase*, critical for beta-oxidation. Obesity may reflect metabolic dysregulation or compensatory feeding patterns. Prenatal abnormalities, though less common, could arise from fetal metabolic stress."
"['Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Abnormal cerebral white matter morphology', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Dyskinesia']",['苯丙酮尿症/Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
**Reasoning**:  
1. **Hyperphenylalaninemia**: A hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Intellectual disability, seizures, motor delay, dyskinesia**: Result from untreated phenylalanine toxicity, damaging neuronal myelination and neurotransmitter synthesis.  
3. **Abnormal cerebral white matter morphology**: Reflects impaired myelination due to phenylalanine interference, a classic neuroimaging finding in PKU.  
4. **Death in infancy/childhood/early adulthood**: Untreated PKU causes severe neurological deterioration and systemic complications, leading to early mortality.  
5. **Hypertyrosinemia**: Uncommon in classic PKU but may arise in atypical cases (e.g., BH4 deficiency variants) or secondary metabolic disturbances.  
6. **Exclusion of Tyrosinemia**: Hypertyrosinemia alone lacks liver/kidney symptoms typical of Tyrosinemia types, reinforcing PKU as the primary diagnosis.  

**Conclusion**: Symptoms align with severe, untreated PKU, with hyperphenylalaninemia and neurological features being pathognomonic. Hypertyrosinemia may indicate a comorbid or variant form but does not override PKU as the core diagnosis."
"['Generalized hypotonia', 'Splenomegaly', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Death in childhood', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Decreased circulating copper concentration', 'Copper accumulation in liver']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Wilson disease (Hepatolenticular degeneration)  
Reasoning:  
1. **Copper metabolism abnormalities**:  
   - **Decreased circulating ceruloplasmin** and **copper concentrations** indicate impaired copper transport due to ATP7B gene mutations.  
   - **Increased urinary copper excretion** and **hepatic copper accumulation** reflect the body’s compensatory mechanism to eliminate excess copper, which overwhelms hepatic storage capacity.  

2. **Hepatic involvement**:  
   - **Hepatomegaly**, **elevated hepatic transaminases**, and **copper accumulation in the liver** are hallmarks of Wilson disease-induced liver damage.  
   - Progressive liver dysfunction leads to **splenomegaly** (via portal hypertension) and **abnormal amino acid concentrations** (due to impaired hepatic metabolism).  

3. **Neuromuscular and systemic features**:  
   - **Generalized hypotonia** may arise from early neurological involvement or metabolic encephalopathy secondary to liver failure.  

4. **Prognosis**:  
   - **Death in childhood/adolescence** aligns with untreated or advanced Wilson disease, where liver failure or neurological complications become fatal without timely intervention (e.g., chelation therapy or liver transplantation).  

5. **Diagnostic confirmation**:  
   - The triad of **low ceruloplasmin**, **high urinary copper**, and **Kayser-Fleischer rings** (not listed but often present) is pathognomonic. Genetic testing for ATP7B mutations would definitively confirm the diagnosis."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Cerebellar atrophy/agenesis and ataxia**: PMM2-CDG is characterized by neurodevelopmental defects, including cerebellar hypoplasia/atrophy, leading to ataxia.  
2. **Neurological symptoms**: Intellectual disability, generalized hypotonia, and abnormal calvaria morphology align with multisystem neurological involvement in PMM2-CDG.  
3. **Dysmorphic features**: Abnormal facial shape and strabismus are common due to craniofacial and connective tissue glycosylation defects.  
4. **Severe infantile course**: Death in infancy correlates with severe PMM2-CDG subtypes, often from organ failure or infections.  
5. **Systemic involvement**: Glycosylation defects disrupt multiple organs, explaining the combination of CNS, skeletal, and dysmorphic features."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where uncontrolled maternal phenylalanine levels during pregnancy cause congenital anomalies.  
3. **Neonatal death/Death in infancy/Death in adolescence** reflects untreated PKU complications: severe neurotoxicity, seizures, and organ damage without dietary intervention.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low) but may indicate a concurrent condition, lab error, or severe metabolic dysregulation in terminal stages.  
5. The symptom constellation prioritizes PKU due to hyperphenylalaninemia, with early mortality explained by lack of treatment (e.g., phenylalanine-restricted diet).  

Note: Hypertyrosinemia warrants further investigation for overlapping disorders (e.g., tyrosinemia, BH4 deficiency), but PKU remains the primary diagnosis based on hyperphenylalaninemia and clinical context."
"['Macrocephaly', 'Generalized hypotonia', 'Death in infancy', 'Abnormal cerebral morphology', 'Increased serum lactate', 'Hypercalcemia', 'Glutaric aciduria', 'Abnormal circulating lysine concentration', 'Abnormal circulating carnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** and **abnormal lysine/carnitine concentrations** directly indicate a defect in lysine, hydroxylysine, and tryptophan metabolism, consistent with glutaryl-CoA dehydrogenase deficiency.  
2. **Macrocephaly** and **abnormal cerebral morphology** (e.g., frontotemporal atrophy, subdural hemorrhages) are hallmark neurological features of GA-I.  
3. **Generalized hypotonia** aligns with metabolic encephalopathy and striatal injury caused by toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
4. **Increased serum lactate** suggests secondary mitochondrial dysfunction due to inhibition of the electron transport chain by organic acids.  
5. **Hypercalcemia** may result from renal tubular dysfunction secondary to chronic metabolic acidosis or vitamin D dysregulation in metabolic crises.  
6. **Death in infancy** reflects the high mortality risk during acute metabolic decompensation episodes if untreated.  
7. **Abnormal carnitine levels** occur due to secondary carnitine depletion from conjugation/excretion of glutaric acid.  

GA-I is confirmed by genetic testing for *GCDH* mutations or deficient glutaryl-CoA dehydrogenase enzyme activity. Early diagnosis and metabolic management (e.g., lysine-restricted diet, carnitine supplementation) are critical to prevent neurological damage."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This directly aligns with the symptom of hyperphenylalaninemia.  
2. **Hypertyrosinemia**: While PKU typically reduces tyrosine levels (due to impaired conversion of phenylalanine to tyrosine), transient hypertyrosinemia can occur in neonates due to immature enzyme systems. This may resolve but could compound metabolic stress in untreated PKU.  
3. **Prenatal abnormalities**: Maternal PKU (untreated high phenylalanine during pregnancy) can cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus, explaining ""abnormality of prenatal development.""  
4. **Early mortality**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, leading to neonatal/infant/childhood death. Without dietary intervention, toxic phenylalanine levels are fatal.  
5. **Consistency with symptoms**: The combination of hyperphenylalaninemia, developmental issues, and early mortality strongly supports PKU as the primary diagnosis, with hypertyrosinemia as a secondary or transient finding."
"['Microcephaly', 'Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Pericardial effusion', 'Pleural effusion', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Feeding difficulties']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine metabolism.  
2. **Feeding difficulties**: Common in untreated infants due to poor metabolic regulation and neurological dysfunction.  
3. **Microcephaly/Severe short stature**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, disrupting brain development and growth.  
4. **Abnormality of prenatal development/Small for gestational age**: Maternal PKU (if the mother has uncontrolled phenylalanine levels during pregnancy) can cause intrauterine growth restriction and congenital anomalies.  
5. **Death in infancy/childhood/Neonatal death**: Historically, severe untreated PKU results in progressive neurological decline, seizures, and early mortality. Modern newborn screening and dietary management prevent this outcome.  
6. **Hypertyrosinemia**: Atypical for classic PKU (which typically causes low tyrosine). This may suggest a coexisting condition (e.g., tyrosinemia type II) or secondary metabolic disruption from liver dysfunction in severe cases.  
7. **Pericardial/Pleural effusions**: Not typical for PKU. These could indicate an overlapping condition (e.g., metabolic crises, cardiac dysfunction) or complications from prolonged systemic metabolic instability.  

**Note**: While PKU explains hyperphenylalaninemia and neurodevelopmental symptoms, hypertyrosinemia and effusions suggest additional complexities, warranting further investigation for comorbid disorders or atypical presentations."
"['Hyperammonemia', 'Vomiting', 'Hyperglutaminemia', 'Oroticaciduria', 'Death in childhood']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Indicates impaired urea cycle function, as OTC is a key enzyme in converting ammonia to urea.  
2. **Vomiting**: A nonspecific but common symptom of acute hyperammonemic crises in urea cycle disorders.  
3. **Hyperglutaminemia**: Excess ammonia is converted to glutamine via glutamine synthetase, a compensatory mechanism in urea cycle defects.  
4. **Oroticaciduria**: Caused by carbamoyl phosphate accumulation (due to OTC deficiency), which shunts into pyrimidine synthesis, overproducing orotic acid.  
5. **Death in childhood**: Severe OTCD (often in males with neonatal-onset forms) leads to fatal hyperammonemia without prompt treatment.  
The combination of urea cycle dysfunction (hyperammonemia, hyperglutaminemia) with oroticaciduria is pathognomonic for OTCD, distinguishing it from other urea cycle defects or isolated pyrimidine disorders."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Central to PKU, caused by deficient phenylalanine hydroxylase (PAH), impairing phenylalanine (Phe) metabolism.  
2. **Abnormal circulating tyrosine concentration**: PAH deficiency reduces tyrosine synthesis, leading to low tyrosine levels (hypotyrosinemia), consistent with PKU.  
3. **Elevated urinary carboxylic acid**: Excess Phe is metabolized via alternative pathways, producing phenylketones (e.g., phenylpyruvate) excreted in urine.  
4. **Neonatal death/Death in infancy**: Untreated PKU causes severe metabolic derangements, neurological damage, and organ failure, often fatal without early dietary intervention.  
5. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies (e.g., microcephaly) in the fetus.  
6. **Obesity**: May arise from high-calorie, low-Phe dietary management or metabolic dysregulation secondary to chronic Phe imbalance.  
7. **Death in early adulthood**: Long-term complications (e.g., cardiovascular issues, neurological decline) in poorly managed cases or late-diagnosed patients.  

PKU aligns with the biochemical markers (hyperphenylalaninemia, tyrosine deficiency, urinary phenylketones) and clinical progression described, emphasizing untreated or severe disease."
"['Enlarged kidney', 'Ptosis', 'Photophobia', 'Lethargy', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Congestive heart failure', 'Exocrine pancreatic insufficiency', 'Thrombocytopenia', 'Neutropenia', 'Anemia', 'Acute kidney injury', 'Hypoglycemia', 'Renal Fanconi syndrome', 'Vomiting', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', '3-Methylglutaric aciduria', 'Increased serum pyruvate', 'Neonatal death', 'Death in childhood', 'Short stature', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Abnormal circulating monocarboxylic acid concentration', 'Localized skin lesion', 'Feeding difficulties', 'Chronic kidney disease', 'Elevated urinary 3-hydroxybutyric acid']",['Pearson syndrome/Pearson syndrome/Pearson marrow-pancreas syndrome'],"Disease: Pearson syndrome  
Reasoning:  
1. **Hematological Abnormalities**: Thrombocytopenia, neutropenia, and anemia align with Pearson syndrome’s hallmark sideroblastic bone marrow failure.  
2. **Exocrine Pancreatic Dysfunction**: Exocrine pancreatic insufficiency directly correlates with pancreatic involvement in Pearson syndrome.  
3. **Metabolic Derangements**: Elevated serum lactate, pyruvate, and urinary 3-hydroxybutyric acid indicate mitochondrial dysfunction, a core feature of Pearson syndrome. Hypoglycemia and 3-methylglutaric aciduria further support disrupted energy metabolism.  
4. **Renal Involvement**: Renal Fanconi syndrome, acute/chronic kidney injury, and enlarged kidney reflect mitochondrial nephropathy common in mitochondrial disorders.  
5. **Neurological Symptoms**: Ptosis, generalized hypotonia, lethargy, coma, and drowsiness suggest systemic mitochondrial failure affecting neuromuscular and CNS function.  
6. **Early Mortality**: Neonatal death, death in infancy/childhood, and short stature are consistent with the severe, multisystemic nature of Pearson syndrome.  
7. **Immune Vulnerability**: Recurrent viral infections arise from neutropenia due to bone marrow failure.  
8. **Cardiac and Nutritional Issues**: Congestive heart failure (mitochondrial cardiomyopathy) and feeding difficulties reflect multisystemic deterioration.  
9. **Biochemical Markers**: Decreased plasma free carnitine and abnormal monocarboxylic acids are typical of mitochondrial fatty acid oxidation defects.  

Pearson syndrome uniquely integrates bone marrow failure, pancreatic insufficiency, and renal/metabolic crises in infancy, distinguishing it from other mitochondrial disorders like Leigh syndrome or MELAS."
"['Broad philtrum', 'Long philtrum', 'Anteverted nares', 'Syndactyly', 'Generalized hypotonia', 'Death in infancy', 'Deep philtrum', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol biosynthesis markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) paired with hypocholesterolemia are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in the *DHCR7* gene, which disrupts cholesterol synthesis.  
2. **Craniofacial features**: Broad, long, and deep philtrum, along with anteverted nares, are classic dysmorphic findings in SLOS.  
3. **Limb anomalies**: Syndactyly (often of toes 2-3) is a hallmark congenital malformation in SLOS.  
4. **Neurological and systemic issues**: Generalized hypotonia and feeding difficulties align with the severe metabolic dysfunction and neurodevelopmental deficits seen in SLOS.  
5. **Lethality**: Neonatal death or death in infancy correlates with severe forms of SLOS, where cholesterol deficiency critically impacts organogenesis and cellular function.  

The combination of biochemical abnormalities (elevated 7-DHC/8-DHC), dysmorphic features, syndactyly, and life-threatening metabolic dysfunction confirms SLOS as the diagnosis."
"['Vomiting', 'Abdominal pain', 'Death in childhood', 'Recurrent viral infections']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning:  
1. **Vomiting and abdominal pain**: Hallmark symptoms of acute porphyria attacks due to autonomic neuropathy and visceral involvement.  
2. **Death in childhood**: Uncommon in AIP (typically adult-onset), but severe cases with untreated neurovisceral crises (e.g., respiratory failure, arrhythmias) could lead to early mortality.  
3. **Recurrent viral infections**: Not classically linked to AIP. May suggest a secondary immunodeficiency or unrelated comorbidity, as porphyria does not directly impair antiviral immunity.  

Disease: Porphyria (General)  
Reasoning:  
1. **Recurrent viral infections**: Could align with congenital erythropoietic porphyria (CEP), a rare subtype causing chronic hemolysis and splenic dysfunction, increasing infection risk.  
2. **Death in childhood**: Severe porphyrias like CEP or ALA dehydratase deficiency porphyria (ADP) present early with multiorgan failure, photosensitivity, and anemia, potentially leading to childhood mortality.  
3. **Abdominal pain/vomiting**: Common to all acute hepatic porphyrias (e.g., AIP, VP, HCP) but less prominent in non-hepatic subtypes like CEP.  

**Conclusion**: Acute intermittent porphyria explains abdominal pain/vomiting but poorly aligns with recurrent infections or early death. A broader porphyria diagnosis (e.g., CEP or ADP) better accounts for childhood severity and infections but requires biochemical/histopathological confirmation (e.g., elevated porphyrins, enzyme assays)."
"['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Hyperglycinuria', 'Hyperglutaminemia', 'Argininuria', 'Neonatal death', 'Abnormal circulating arginine concentration', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Citrullinemia, classic)  
Reasoning:  
1. **Hyperammonemia** and **neonatal death**: Core features of urea cycle disorders (UCDs). Citrullinemia type I results from **argininosuccinate synthetase (ASS1) deficiency**, impairing ammonia detoxification.  
2. **Elevated plasma citrulline**: Pathognomonic for citrullinemia type I due to citrulline accumulation from ASS1 dysfunction.  
3. **Metabolic acidosis**: Secondary to organic acid accumulation from disrupted urea cycle and alternative nitrogen excretion pathways.  
4. **Hyperglycinuria/Hyperglutaminemia/Argininuria**: Amino acid transport disturbances caused by metabolic stress and renal tubular dysfunction in UCDs.  
5. **Abnormal circulating arginine**: Reduced arginine synthesis (from ASS1 deficiency) and compensatory mechanisms.  
6. **Death in infancy**: Severe neonatal-onset citrullinemia type I often leads to rapid deterioration without early intervention.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
- **Exclusion of type II (SLC25A13 mutation)**: Type II typically presents later (adolescence/adulthood) with episodic hyperammonemia, absent neonatal death, and normal/mildly elevated citrulline.  
- **Biochemical triad**: Hyperammonemia + hypercitrullinemia + metabolic acidosis confirms type I.  
- **Genetic confirmation**: ASS1 gene mutations definitively diagnose classic citrullinemia."
"['Delayed speech and language development', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Dehydration', 'Hyperammonemia', 'Hyperhomocystinemia', 'Drowsiness', 'Sleep disturbance', 'Methylmalonic acidemia', 'Decreased plasma free carnitine', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic aciduria, vitamin B12-responsive, cblB type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits hallmark biochemical features of methylmalonic acidemia (MMA), including **methylmalonic acidemia**, **methylmalonic aciduria**, and **decreased plasma free carnitine**. These findings result from impaired methylmalonyl-CoA mutase activity or cobalamin metabolism, leading to toxic accumulation of methylmalonic acid. Symptoms like **lethargy**, **generalized hypotonia**, **hyperammonemia**, and **dehydration** align with acute metabolic decompensation seen in MMA. **Death in infancy** and **delayed speech/development** reflect the severe, early-onset nature of untreated cases.  

Disease: Methylmalonic aciduria, vitamin B12-responsive, cblB type  
Reasoning: The presence of **hyperhomocystinemia** alongside methylmalonic aciduria suggests a cobalamin (vitamin B12) metabolism defect. The cblB type specifically involves mutations in the *MMAB* gene, disrupting adenosylcobalamin synthesis, which is critical for methylmalonyl-CoA mutase function. While cblB typically spares methionine synthase (thus homocysteine is usually normal), **hyperhomocystinemia** here may indicate secondary folate cycle disruption or overlapping metabolic stress. The inclusion of **vitamin B12-responsive** in the diagnosis is supported by MMA cases showing partial biochemical improvement with B12 supplementation, a hallmark of cblB/cblA subtypes. Symptoms like **drowsiness** and **sleep disturbances** further correlate with chronic neurometabolic dysfunction in this subtype."
"['Hyperactivity', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating creatine kinase concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Metabolic crisis indicators**: Hyperammonemia and abnormal amino acid concentrations (aspartate family, alanine) suggest a defect in fatty acid oxidation (FAO), leading to energy deficits and secondary metabolic disturbances.  
2. **Carnitine deficiency**: Decreased plasma free carnitine aligns with FAO disorders, as carnitine is required for long-chain fatty acid transport into mitochondria.  
3. **Muscle involvement**: Generalized hypotonia and elevated creatine kinase (muscle breakdown) reflect impaired energy production in muscles, a hallmark of VLCADD.  
4. **Neonatal/Infantile mortality**: Death in infancy/childhood and premature birth correlate with severe VLCADD presentations, including cardiomyopathy, hepatopathy, or hypoketotic hypoglycemia.  
5. **Hyperactivity**: May indicate neurological stress due to energy deprivation or toxic metabolite accumulation (e.g., long-chain acylcarnitines).  
6. **Specific biochemical profile**: VLCADD disrupts very long-chain fatty acid oxidation, distinguishing it from medium/short-chain FAO defects (e.g., MCADD). Confirmatory testing (acylcarnitine profile showing elevated C14:1, genetic analysis) would solidify the diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently in neonates due to immature liver function or secondary metabolic disruptions from phenylalanine toxicity.  
3. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing fetal complications (e.g., congenital heart defects, microcephaly).  
4. **Upper airway obstruction** and **chronic pulmonary obstruction** are not direct features of PKU but could result from severe neurological impairment (e.g., hypotonia, poor swallowing) leading to aspiration or recurrent infections.  
5. **Neonatal death/Death in infancy** may occur in untreated/severe cases due to metabolic crises, neurological deterioration, or secondary complications (e.g., respiratory failure from aspiration).  

Note: While PKU explains hyperphenylalaninemia and prenatal abnormalities (via maternal PKU), hypertyrosinemia and airway/pulmonary symptoms suggest possible comorbidities (e.g., concurrent metabolic disorders or aspiration-related complications). Further testing (e.g., genetic analysis, BH4 responsiveness, tyrosine metabolite levels) is critical to confirm PKU and exclude overlapping conditions."
"['Spasticity', 'Death in infancy', 'Premature birth', 'Ileus', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased circulating ferritin concentration', 'Hypoxemia', 'Peritoneal effusion', 'Abnormal vitamin B12 level', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts fatty acid oxidation, leading to carnitine depletion as it conjugates to unmetabolized medium-chain fatty acids.  
2. **Neonatal/childhood death**: Untreated MCADD causes life-threatening hypoglycemia and metabolic crises during fasting, common in infancy/early childhood.  
3. **Spasticity & hypoxemia**: Metabolic acidosis from MCADD crises can induce neurological damage (spasticity) and respiratory compromise (hypoxemia).  
4. **Ileus & peritoneal effusion**: Secondary to metabolic instability affecting gastrointestinal function or organ dysfunction.  
5. **Premature birth**: Though not a direct feature, metabolic stress in utero might contribute to early delivery.  
6. **Abnormal vitamin B12/ferritin**: Non-specific markers of systemic metabolic disruption or organ involvement.  
7. **Decreased 3-hydroxyacyl-CoA dehydrogenase**: May reflect downstream disruption in β-oxidation due to MCAD enzyme deficiency.  

Key biochemical hallmarks (e.g., hypoketotic hypoglycemia, elevated C8-C10 acylcarnitines) are absent in the listed symptoms but inferred from clinical context. Early mortality and carnitine abnormalities strongly align with MCADD."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** and **recurrent viral infections** suggest a **tetrahydrobiopterin (BH4) deficiency** variant of PKU. BH4 is a cofactor for PAH and tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, leading to dual accumulation.  
3. **Immunodeficiency** (recurrent infections) arises from impaired nitric oxide synthesis and neurotransmitter production due to BH4 dependency in immune and neurological pathways.  
4. **Early mortality** (infancy/childhood/adolescence) reflects severe metabolic derangements, neurological deterioration, and susceptibility to infections in untreated BH4-deficient PKU, distinguishing it from classic PAH-deficient PKU.  

This diagnosis aligns with atypical/malignant PKU secondary to BH4 deficiency, explaining the full symptom spectrum."
"['Death in infancy', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient's symptoms of **elevated urinary carboxylic acids** and **abnormal circulating glycine** align with a defect in leucine catabolism. 3-Methylcrotonyl-CoA carboxylase (MCC) deficiency disrupts the breakdown of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, causing accumulation of 3-methylcrotonylglycine and 3-hydroxyisovaleric acid in urine. These metabolites explain the **elevated urinary carboxylic acids**. Conjugation of glycine with toxic intermediates (e.g., 3-methylcrotonylglycine) depletes glycine, leading to **abnormal glycine levels**. **Aminoaciduria** arises due to renal tubular dysfunction from metabolite overload. Severe metabolic decompensation in infancy (hypoglycemia, acidosis) can result in **death** if untreated.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This is the same disorder as above, with naming variation. MCC deficiency (OMIM 210200) is an autosomal recessive disorder caused by mutations in *MCCC1* or *MCCC2*, encoding MCC subunits. The biochemical hallmarks—**elevated urinary 3-hydroxyisovaleric acid** and **3-methylcrotonylglycine**—correlate with the listed symptoms. **Aminoaciduria** is secondary to proximal tubule damage from acidic metabolites. Glycine abnormalities stem from its utilization in detoxification pathways. Early-onset severe metabolic crises (e.g., hypoglycemia, hyperammonemia) in infancy are life-threatening without dietary leucine restriction and carnitine supplementation."
"['Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Ataxia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Death in childhood', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: SSADHD causes accumulation of γ-hydroxybutyric acid (GHB), a carboxylic acid, in urine due to impaired GABA metabolism.  
2. **Neurological symptoms (Seizure, Ataxia, Hypotonia)**: GHB toxicity disrupts neurotransmission, leading to seizures, cerebellar dysfunction (ataxia), and reduced muscle tone.  
3. **Developmental delays (Speech, Motor)**: Chronic GABA imbalance impairs neurodevelopment, affecting speech and motor milestones.  
4. **Hyperactivity**: Paradoxical excitatory effects of excess GHB contribute to hyperactive behavior.  
5. **Early mortality (Infancy/Childhood)**: Severe metabolic dysfunction or refractory seizures in acute crises may lead to premature death.  
SSADHD is confirmed via genetic testing and elevated GHB in urine/blood, aligning with the symptom profile."
"['Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Vomiting', 'Hepatomegaly', 'Tachypnea', 'Neonatal death']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Metabolic Acidosis**: A hallmark of urea cycle disorders (UCDs) due to hyperammonemia and secondary organ dysfunction.  
2. **Vomiting & Hepatomegaly**: Common in UCDs; hepatomegaly specifically linked to argininosuccinic aciduria due to liver involvement from toxic metabolite accumulation.  
3. **Tachypnea & Tachycardia**: Compensatory responses to metabolic acidosis and hyperammonemia-induced encephalopathy.  
4. **Neonatal Death/Infant Mortality**: Severe UCDs like argininosuccinic aciduria often present acutely in infancy with rapid deterioration if untreated.  
5. **Distinguishing from Other UCDs**: Elevated argininosuccinic acid in blood/urine (pathognomonic) and hepatomegaly differentiate it from ornithine transcarbamylase (OTC) deficiency.  
6. **Exclusion of Organic Acidemias**: Lack of pronounced ketosis and presence of hepatomegaly favor urea cycle dysfunction over organic acidemias.  
7. **Liver Dysfunction**: Contributes to metabolic acidosis via impaired ammonia detoxification and potential lactic acidosis.  

Conclusion: Symptom constellation aligns with argininosuccinic aciduria, confirmed by biochemical markers (argininosuccinic acid elevation) and clinical progression."
"['Blindness', 'Anemia', 'Hyperammonemia', 'Malabsorption', 'Hyperglycinemia', 'Headache', 'Severe short stature', 'Death in childhood', 'Hypoargininemia', 'Death in adolescence', 'Feeding difficulties', 'Hyperornithinemia', 'Abnormal circulating serine concentration', 'Death in early adulthood']",['Gyrate atrophy of choroid and retina/Gyrate atrophy of choroid and retina with or without ornithinemia'],"Disease: Gyrate atrophy of choroid and retina with ornithinemia  
Reasoning:  
1. **Hyperornithinemia**: Central to the diagnosis, caused by deficiency of ornithine aminotransferase (OAT), leading to ornithine accumulation.  
2. **Hypoargininemia**: OAT deficiency disrupts the proline synthesis pathway, indirectly affecting arginine metabolism and urea cycle function.  
3. **Hyperammonemia**: Impaired urea cycle due to low arginine levels results in toxic ammonia buildup.  
4. **Blindness**: Progressive chorioretinal degeneration, a hallmark of gyrate atrophy, leads to vision loss.  
5. **Severe short stature/Feeding difficulties/Malabsorption**: Chronic metabolic stress, malnutrition, and systemic amino acid imbalances contribute to growth failure and GI dysfunction.  
6. **Hyperglycinemia/Abnormal serine**: Secondary metabolic disruptions from urea cycle dysfunction and mitochondrial amino acid pathway interference.  
7. **Neurological symptoms (headache)**: Linked to hyperammonemia and metabolic encephalopathy.  
8. **Early mortality**: Reflects severe systemic complications, including metabolic decompensation and organ damage.  

The combination of ocular degeneration, hyperornithinemia, and urea cycle-related metabolic abnormalities confirms gyrate atrophy with ornithinemia."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine during pregnancy disrupts fetal development.  
3. **Hypertyrosinemia** may occur secondarily if tyrosine metabolism is overwhelmed or due to co-existing hepatic dysfunction, though this is atypical in classic PKU.  
4. **Neonatal death/Death in infancy/childhood** reflects untreated severe PKU, leading to neurotoxicity, seizures, and organ failure without early dietary intervention.  
5. The absence of tyrosinemia-specific symptoms (e.g., liver/kidney dysfunction) prioritizes PKU over primary tyrosinemia.  
6. Neonatal screening for hyperphenylalaninemia strongly supports PKU diagnosis, even with atypical hypertyrosinemia."
"['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Neonatal death** and **death in infancy** suggest a severe, early-onset UCD, as CPS1 deficiency often manifests within days of life due to complete enzyme dysfunction.  
3. **Feeding difficulties** and **generalized hypotonia** are nonspecific but common neonatal signs of metabolic encephalopathy secondary to hyperammonemia.  
4. **Cerebral edema** arises from ammonia-induced neurotoxicity, disrupting osmotic balance and causing brain swelling.  
5. **Apathy** reflects progressive encephalopathy as ammonia levels rise.  
6. The absence of orotic acid elevation (implied by the diagnosis) distinguishes CPS1 deficiency from ornithine transcarbamylase (OTC) deficiency, another UCD.  
7. CPS1 deficiency is confirmed by genetic testing or enzyme assay, but clinical presentation and hyperammonemia without organic acidemia strongly support this diagnosis."
"['Blindness', 'Nystagmus', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Opisthotonus', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal myelination', 'Severe hearing impairment']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal Myelination & Neurological Symptoms**: Canavan disease is a leukodystrophy characterized by spongy degeneration of white matter due to defective myelination, explaining motor delay, generalized hypotonia, and seizures.  
2. **Abnormal Aspartate Metabolism**: Elevated N-acetylaspartic acid (NAA) from aspartoacylase deficiency aligns with ""abnormal circulating aspartate family amino acid concentration,"" a hallmark of Canavan disease.  
3. **Severe Sensory Impairments**: Optic nerve atrophy (blindness, nystagmus) and auditory pathway damage (severe hearing impairment) are common in progressive cases.  
4. **Infantile Lethality**: Neonatal death or death in infancy reflects the severe, early-onset form of the disease.  
5. **Opisthotonus**: Hypertonia and abnormal posturing (opisthotonus) occur due to progressive neurodegeneration and corticospinal tract involvement.  
6. **Genetic Confirmation**: While not explicitly stated, the symptom constellation strongly aligns with autosomal recessive ASPA gene mutations causing Canavan disease."
"['Hydrocephalus', 'Microcephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Death in infancy', 'Premature birth', 'Respiratory insufficiency', 'Hyperhomocystinemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Dyskinesia']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, caused by defects in methylmalonyl-CoA mutase or cobalamin (B12) metabolism. Symptoms like **respiratory insufficiency**, **neonatal death**, **death in childhood**, and **abnormal carnitine levels** align with MMA’s metabolic crises. However, **hyperhomocystinemia** and **neurological features** (e.g., intellectual disability, strabismus, nystagmus) suggest a **combined disorder** involving homocysteine, prompting consideration of a cobalamin metabolism defect.  

Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning: The **co-occurrence of methylmalonic aciduria and hyperhomocystinemia** is pathognomonic for **cblC type**, the most common inborn error of cobalamin metabolism. This disorder explains **neurological symptoms** (hydrocephalus, microcephaly, dyskinesia, nystagmus), **premature birth**, and **early mortality** due to multisystem decompensation. **Abnormal carnitine levels** and **respiratory insufficiency** further support severe metabolic dysfunction. The combination of MMA and homocystinuria distinguishes cblC from isolated MMA or homocystinuria alone."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Neonatal death/death in infancy**: MCADD typically presents in infancy during metabolic stress (e.g., fasting), leading to life-threatening hypoglycemia and energy depletion.  
2. **Vomiting & gastrointestinal inflammation**: Episodic metabolic crises in MCADD cause nausea, vomiting, and gut dysfunction due to toxic metabolite accumulation (e.g., medium-chain acylcarnitines).  
3. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs as excess unmetabolized fatty acids bind carnitine, forming acylcarnitines.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: While MCADD primarily involves medium-chain acyl-CoA dehydrogenase (MCAD), downstream β-oxidation enzymes like 3-hydroxyacyl-CoA dehydrogenase may show reduced activity due to substrate accumulation.  
5. **Prenatal abnormalities**: Though less common, severe MCADD variants may manifest prenatally as reduced fetal movement or growth restriction from impaired fatty acid metabolism.  

Key confirmation would require genetic testing for *ACADM* gene mutations and elevated C6-C10 acylcarnitines on tandem mass spectrometry."
"['Generalized hypotonia', 'Death in infancy', 'Leukopenia', 'Metabolic acidosis', 'Hyperammonemia', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Biotinidase deficiency impairs the activity of biotin-dependent carboxylases (e.g., propionyl-CoA carboxylase, pyruvate carboxylase), disrupting amino acid catabolism and urea cycle function. This leads to accumulation of organic acids (e.g., lactate, propionate) and ammonia.  
2. **Leukopenia**: Secondary to bone marrow suppression from metabolic toxins (e.g., organic acids) or biotin-dependent immune dysfunction.  
3. **Generalized hypotonia**: Caused by energy deficiency in muscles/nerves due to defective mitochondrial carboxylases and hyperammonemia-induced neurotoxicity.  
4. **Neonatal death/death in infancy**: Untreated BTDD causes progressive metabolic crises, seizures, and cardiorespiratory failure. Neonatal-onset cases often present with rapid deterioration without early biotin supplementation.  
5. **Exclusion of mimics**: Symptoms overlap with organic acidemias (e.g., propionic acidemia), but leukopenia and biotin-responsiveness distinguish BTDD.  

**Conclusion**: The triad of metabolic acidosis, hyperammonemia, and leukopenia in a critically ill neonate aligns with late-onset multiple carboxylase deficiency due to biotinidase deficiency. Early mortality reflects delayed diagnosis and lack of biotin therapy."
"['Keratitis', 'Conjunctivitis', 'Photophobia', 'Hyperkeratosis', 'Intellectual disability', 'Seizure', 'Hypertyrosinemia', 'Death in childhood', 'Epiphora']",['Tyrosinemia type 2/Tyrosine transaminase deficiency'],"Disease: Tyrosinemia type 2/Tyrosine transaminase deficiency  
Reasoning:  
1. **Hypertyrosinemia** is a hallmark biochemical feature of tyrosinemia type 2, caused by deficient tyrosine transaminase activity.  
2. **Ocular symptoms** (keratitis, conjunctivitis, photophobia, epiphora) arise from tyrosine crystal deposition in corneal epithelial cells, leading to inflammation and damage.  
3. **Hyperkeratosis** (palmar/plantar) occurs due to tyrosine accumulation in the skin, causing painful lesions.  
4. **Neurological involvement** (intellectual disability, seizures) may result from chronic tyrosine neurotoxicity or secondary metabolic disturbances.  
5. **Death in childhood** reflects severe untreated cases with complications like metabolic decompensation, infections, or neurological deterioration.  
6. **Consistency with phenotype**: The triad of dermatological, ocular, and neurological manifestations aligns with Richner-Hanhart syndrome (tyrosinemia type 2), distinguishing it from hepatic/renal-predominant tyrosinemia type 1."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by mutations in the *PAH* gene, impairing phenylalanine hydroxylase activity, leading to phenylalanine accumulation.  
2. **Abnormal circulating tyrosine concentration**: Reduced conversion of phenylalanine to tyrosine results in low tyrosine levels, aligning with ""abnormal tyrosine concentration.""  
3. **Prenatal developmental abnormalities**: Untreated maternal PKU during pregnancy can cause fetal toxicity (microcephaly, congenital heart defects), explaining prenatal anomalies in the patient.  
4. **Neonatal death/Death in infancy**: Severe untreated PKU causes profound neurological damage, seizures, and failure to thrive, which may lead to early mortality without dietary intervention.  
5. **Death in early adulthood**: Chronic complications (e.g., neurocognitive decline, organ damage) from lifelong phenylalanine toxicity, even with partial treatment, may contribute to premature mortality.  

Conclusion: The constellation of hyperphenylalaninemia, tyrosine imbalance, and early mortality aligns with untreated or poorly managed PKU. Maternal PKU syndrome may explain prenatal abnormalities if the mother had uncontrolled phenylalanine levels during gestation."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', '3-hydroxydicarboxylic aciduria']",['Glycogen storage disease Ia/Glycogen storage disease Ia'],"Disease: Glycogen storage disease Ia  
Reasoning:  
1. **Hyperammonemia and 3-hydroxydicarboxylic aciduria**: In GSD Ia, impaired gluconeogenesis and glycogenolysis lead to reliance on fatty acid oxidation, generating dicarboxylic acids (e.g., 3-hydroxydicarboxylic acids) and secondary hyperammonemia due to disrupted urea cycle function from liver stress.  
2. **Cyanosis and seizures**: Severe hypoglycemia (hallmark of GSD Ia) triggers seizures, while lactic acidosis (from excess lactate production) reduces oxygen delivery, causing peripheral cyanosis.  
3. **Neonatal death/infant mortality**: Untreated GSD Ia results in metabolic crises (hypoglycemia, acidosis) shortly after birth, often fatal without rapid diagnosis and glucose stabilization.  
4. **Consistency with GSD Ia**: Symptoms align with glucose-6-phosphatase deficiency, though hyperammonemia and dicarboxylic aciduria are atypical but explainable through metabolic cascades and hepatic dysfunction."
"['Death in infancy', 'Vomiting', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine** is a hallmark symptom of Alkaptonuria, caused by the oxidation of homogentisic acid (HGA) in urine upon exposure to air, leading to a black or brown discoloration.  
2. **Vomiting** in infancy, while not a primary feature of Alkaptonuria, may occur due to secondary complications (e.g., metabolic stress or renal involvement from HGA deposition).  
3. **Death in infancy** is atypical for Alkaptonuria, which is generally compatible with life. However, severe metabolic crises or misdiagnosis leading to untreated complications (e.g., acute kidney injury) might contribute to early mortality in rare cases.  
4. Alkaptonuria is confirmed via genetic testing (HGD gene mutations) or urinary HGA quantification. Early diagnosis is critical to manage long-term complications (e.g., ochronosis, arthritis).  

*Note: While Alkaptonuria aligns with dark urine, the presentation of infant mortality suggests additional factors (e.g., comorbid conditions or diagnostic delays) that warrant further investigation.*"
"['Seizure', 'Lethargy', 'Growth delay', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated Branched-Chain Amino Acids (BCAAs)**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate impaired metabolism of BCAAs (valine, leucine, isoleucine), a hallmark of MSUD due to deficiency in the branched-chain α-keto acid dehydrogenase complex.  
2. **Metabolic Acidosis**: Accumulation of toxic keto acids (from BCAAs) disrupts acid-base balance.  
3. **Hyperammonemia**: Secondary to metabolic decompensation, as BCAA derivatives interfere with urea cycle function.  
4. **Neurological Symptoms (Seizures, Lethargy, Drowsiness)**: Caused by neurotoxicity from elevated BCAAs and their metabolites.  
5. **Elevated Urinary Carboxylic Acids**: Reflects urinary excretion of branched-chain keto acids (e.g., α-ketoisocaproate, α-keto-β-methylvalerate), pathognomonic for MSUD.  
6. **Early Severe Presentation (Growth Delay, Feeding Difficulties, Death in Infancy)**: Consistent with classic MSUD, which manifests neonatally without treatment.  
7. **Severe Hearing Impairment**: Uncommon but reported in severe metabolic crises due to multisystem toxicity.  
8. **Sleep Disturbances**: Linked to neurological dysfunction from metabolic derangements.  

MSUD is confirmed by biochemical findings (BCAA elevation, urinary keto acids) and clinical features. The absence of maple syrup odor in the description does not exclude the diagnosis, as odor may not always be noted or reported."
"['Eczematoid dermatitis', 'Skin rash', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Hypoglycemia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral edema', 'Athetosis', 'Hyperglutaminemia', 'Oroticaciduria', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Myocarditis', 'Abnormal circulating creatine kinase concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder where impaired OTC enzyme activity prevents ammonia detoxification.  
2. **Oroticaciduria/Uraciluria**: Excess carbamoyl phosphate (from blocked urea cycle) enters pyrimidine synthesis, producing orotic acid and uracil.  
3. **Elevated plasma citrulline**: Unusual in classic OTCD (typically low citrulline), but may reflect partial enzyme activity or atypical presentation.  
4. **Neurological symptoms (coma, cerebral edema, athetosis)**: Result from ammonia toxicity and cerebral osmotic shifts.  
5. **Hypoglycemia/Generalized hypotonia**: Metabolic stress from hyperammonemia disrupts energy metabolism and neuromuscular function.  
6. **Gastrointestinal inflammation/vomiting**: Common in urea cycle disorders due to ammonia-induced mucosal irritation.  
7. **Early mortality (infancy/childhood)**: Severe OTCD often leads to fatal hyperammonemic crises without prompt treatment.  
8. **Abnormal arginine/proline**: Secondary metabolic disruptions in urea cycle intermediates and related pathways.  
9. **Recurrent infections/myelitis**: Immune dysfunction from metabolic imbalance or hyperammonemia-induced immunosuppression.  

Key diagnostic anchors: **Hyperammonemia + oroticaciduria**, despite atypical citrulline elevation, strongly suggest OTCD over other urea cycle defects (e.g., citrullinemia type 1 shows markedly elevated citrulline without oroticaciduria)."
"['Microcephaly', 'Intellectual disability', 'Lethargy', 'Death in infancy', 'Bradycardia', 'Hyperammonemia', 'Apnea', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Hypotension', 'Hyperglutaminemia', 'Low plasma citrulline', 'Neonatal death', 'Recurrent viral infections']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia**: Central to diagnosis, as CPS1 deficiency disrupts the urea cycle’s first step, preventing ammonia detoxification.  
2. **Low plasma citrulline**: CPS1 deficiency blocks carbamoyl phosphate synthesis, reducing citrulline production (unlike OTC deficiency, where citrulline is also low but orotic acid is elevated).  
3. **Hyperglutaminemia**: Excess ammonia is metabolized via alternative pathways, forming glutamine as a compensatory mechanism.  
4. **Neurological symptoms (Microcephaly, Intellectual disability, Cerebral edema, Lethargy, Drowsiness)**: Result from ammonia neurotoxicity, impairing brain development and function.  
5. **Apnea, Hypotension, Bradycardia**: Systemic effects of hyperammonemia and cerebral edema impacting autonomic regulation.  
6. **Neonatal death/Death in infancy**: Severe CPS1 deficiency often presents catastrophically in infancy due to rapid ammonia accumulation.  
7. **Recurrent viral infections**: Likely secondary to metabolic instability and critical illness rather than a primary immune defect.  
8. **Sleep disturbance**: Reflects neurological irritation from hyperammonemia.  

The combination of hyperammonemia, low citrulline, and hyperglutaminemia distinguishes CPS1 deficiency from other urea cycle disorders. The absence of elevated orotic acid or other intermediates further supports this diagnosis."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by abnormal glycosylation critical for cerebellar development and function.  
2. **Ataxia and motor delay**: Directly linked to cerebellar dysfunction and neurodevelopmental deficits.  
3. **Intellectual disability**: Reflects global neurological impairment due to glycosylation defects affecting brain development.  
4. **Strabismus**: Common in PMM2-CDG due to oculomotor control abnormalities from cerebellar/brainstem involvement.  
5. **Thromboembolism**: Coagulation factor glycosylation defects (e.g., antithrombin III deficiency) predispose to thrombotic events.  
6. **Obesity**: Observed in some cases, potentially from hypothalamic-pituitary dysfunction or metabolic dysregulation.  
7. **Death in infancy/childhood**: Severe multisystemic involvement (liver failure, cardiomyopathy, infections) can lead to early mortality.  
8. **Supporting specificity**: The combination of neurodevelopmental, cerebellar, and coagulation abnormalities is pathognomonic for PMM2-CDG-Ia, distinguishing it from other CDG subtypes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Hernia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, leading to fetal complications (e.g., congenital defects, microcephaly).  
3. **Death in infancy/childhood and neonatal death** reflect untreated PKU’s natural progression, as toxic phenylalanine accumulation causes irreversible neurological damage, seizures, and organ failure.  
4. **Hypertyrosinemia** is atypical in classic PKU but may arise in rare variants (e.g., BH4-deficient PKU) or secondary metabolic disruptions from liver dysfunction.  
5. **Hernia** is likely incidental, though malnutrition or connective tissue weakness from metabolic stress could contribute.  

Note: Hypertyrosinemia warrants further investigation for overlapping disorders (e.g., tyrosinemia), but hyperphenylalaninemia prioritizes PKU as the primary diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation. This aligns with the patient’s elevated phenylalanine levels.  
2. **Hypertyrosinemia**: While atypical for classic PKU (where tyrosine is typically low), this could indicate a secondary metabolic disruption, transient neonatal tyrosinemia, or a coexisting condition (e.g., liver dysfunction). Alternatively, it may reflect a diagnostic error in symptom reporting.  
3. **Neonatal death/Death in infancy**: Severe, untreated PKU (or BH4-deficient variants) can cause rapid neurological deterioration, seizures, and organ failure, potentially leading to early mortality.  
4. **Prenatal abnormalities**: Unlikely from infantile PKU itself but may arise if the mother had untreated maternal PKU during pregnancy, indirectly affecting fetal development.  
5. **Exclusion of alternatives**: Tyrosinemias or BH4 deficiencies were considered but excluded due to the primary hallmark of hyperphenylalaninemia and the specified diagnosis of PKU.  

Conclusion: PKU explains the core biochemical anomaly (hyperphenylalaninemia) and aligns with severe outcomes when untreated, despite atypical hypertyrosinemia."
"['Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Thromboembolism', 'Neonatal death', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: PMM2-CDG commonly causes cerebellar hypoplasia or atrophy due to impaired protein glycosylation, critical for cerebellar development.  
2. **Failure to thrive**: A hallmark of PMM2-CDG, resulting from multisystem dysfunction (e.g., gastrointestinal, hepatic, endocrine) disrupting nutrient absorption and metabolism.  
3. **Thromboembolism**: Glycosylation defects impair coagulation factor synthesis (e.g., antithrombin III, protein C/S), predisposing to thrombotic events.  
4. **Neonatal death/Death in infancy**: Severe PMM2-CDG cases often lead to early mortality due to organ failure, metabolic crises, or recurrent infections.  
5. **Consistency with type Ia**: PMM2-CDG (type Ia) is the most prevalent subtype, characterized by neurologic deficits, coagulopathy, and infantile lethality in severe presentations.  
The constellation of neurologic, growth, and coagulation abnormalities strongly aligns with PMM2-CDG-Ia, confirmed by genetic testing for *PMM2* mutations."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This directly explains elevated phenylalanine levels.  
2. **Hypertyrosinemia**: While PKU typically reduces tyrosine (due to blocked PAH activity), transient tyrosinemia can occur in neonates with immature liver function or secondary metabolic disruptions from phenylalanine toxicity.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome, not the infant’s own PKU, causes congenital anomalies (e.g., microcephaly, heart defects) if the mother had untreated hyperphenylalaninemia during pregnancy. This aligns with prenatal developmental issues in the infant.  
4. **Neonatal death/Death in infancy**: Untreated severe hyperphenylalaninemia can cause acute metabolic crises, seizures, and irreversible neurological damage, potentially leading to early mortality in extreme cases.  
5. **Consistency with PKU**: The combination of hyperphenylalaninemia and maternal-fetal transmission of metabolic toxicity strongly supports PKU as the diagnosis, despite atypical tyrosinemia."
"['Apathy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Pneumonia', 'Hepatomegaly', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Abnormal circulating acetylcarnitine concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Metabolic acidosis**: Caused by accumulation of toxic metabolites (3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid) due to defective HMG-CoA lyase.  
2. **Hypoglycemia**: Impaired ketogenesis (HMG-CoA lyase is critical for ketone body synthesis) leads to energy deficits during fasting.  
3. **Hyperammonemia**: Secondary inhibition of the urea cycle by organic acid metabolites.  
4. **Hepatomegaly**: Fatty liver from disrupted lipid metabolism and mitochondrial dysfunction.  
5. **Dicarboxylic aciduria**: Increased fatty acid oxidation (compensatory energy pathway) produces dicarboxylic acids.  
6. **3-Methylglutaconic aciduria**: Direct result of HMG-CoA lyase deficiency, as 3-methylglutaconate cannot be metabolized to acetoacetate.  
7. **Decreased plasma free carnitine**: Carnitine is consumed conjugating toxic metabolites (e.g., 3-hydroxy-3-methylglutarate) for urinary excretion.  
8. **Abnormal acetylcarnitine**: Reflects disrupted mitochondrial acyl-CoA metabolism.  
9. **Elevated urinary carboxylic acids**: Excretion of 3-hydroxy-3-methylglutarate, 3-methylglutaconate, and other intermediates.  
10. **Apathy/Death in infancy**: Neurological sequelae of metabolic crises (hypoglycemia, acidosis) if untreated.  
11. **Vomiting/Pneumonia**: Common triggers (infection, fasting) for acute decompensation in metabolic disorders.  
12. **Abnormal glycine**: Potential secondary disturbance from mitochondrial dysfunction.  

**Conclusion**: The constellation of metabolic acidosis, hypoglycemia, hyperammonemia, specific urinary metabolites (3-methylglutaconic acid, dicarboxylic acids), and carnitine abnormalities is pathognomonic for HMG-CoA lyase deficiency."
"['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Neonatal death** and **death in infancy/childhood** align with severe, untreated PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
3. **Hypertyrosinemia** is atypical for classical PKU (which typically results in *low* tyrosine due to blocked PAH-dependent conversion). However, this could indicate:  
   - A comorbid condition (e.g., transient tyrosinemia of the newborn) or secondary metabolic disruption.  
   - Potential misreporting of symptoms (e.g., hypotyrosinemia is expected in PKU).  
4. The fatal outcomes emphasize the critical need for early newborn screening and dietary intervention in PKU to prevent catastrophic complications."
"['Lethargy', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Anemia', 'Vomiting', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Hypocalcemia', 'Neonatal death', 'Abnormality of acid-base homeostasis', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic acidosis**: ""Abnormality of acid-base homeostasis"" and ""hypocalcemia"" align with PA-induced metabolic acidosis due to propionate accumulation.  
2. **Neurological symptoms**: ""Lethargy,"" ""coma,"" ""drowsiness,"" and ""sleep disturbance"" result from neurotoxicity of propionic acid and ammonia.  
3. **Hematologic abnormalities**: ""Thrombocytopenia"" and ""anemia"" stem from bone marrow suppression caused by toxic metabolites.  
4. **Neonatal fatality**: ""Death in infancy"" and ""neonatal death"" reflect PA’s severe, early-onset metabolic crises if untreated.  
5. **Gastrointestinal issues**: ""Vomiting"" and ""feeding difficulties"" arise from protein intolerance and metabolic decompensation.  
6. **Muscular involvement**: ""Generalized hypotonia"" links to energy deficiency in muscle cells due to disrupted mitochondrial function.  
7. **Biomarkers**: ""Elevated urinary carboxylic acids"" (e.g., 3-hydroxypropionate, methylcitrate) and ""abnormal glycine concentrations"" are hallmark biochemical features of PA.  
8. **Respiratory distress**: ""Dyspnea"" may reflect compensatory hyperventilation to counteract acidosis.  
9. **Porphyrin disruption**: ""Abnormal circulating porphyrins"" occur due to secondary inhibition of heme synthesis pathways by propionyl-CoA.  

PA is confirmed by enzyme assays (propionyl-CoA carboxylase deficiency) and genetic testing. Early intervention with dietary protein restriction and metabolic support is critical."
"['Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Intellectual disability**: A core feature of PMM2-CDG due to impaired glycosylation affecting neuronal development and function.  
2. **Ataxia and cerebellar atrophy/agenesis**: PMM2-CDG disrupts cerebellar development, leading to structural abnormalities (agenesis/atrophy) and motor incoordination.  
3. **Thromboembolism**: Glycosylation defects alter clotting factors (e.g., antithrombin III deficiency), increasing thrombotic risk.  
4. **Early mortality (infancy/childhood)**: Severe multisystem involvement (hepatic, cardiac, neurological) often leads to fatal complications.  
5. **Exclusion of other CDG subtypes**: PMM2-CDG (type Ia) is the most common CDG and aligns with this phenotype, whereas other subtypes (e.g., ALG6-CDG) lack thromboembolism or cerebellar agenesis.  
6. **Biochemical confirmation**: Hypothetical elevated carbohydrate-deficient transferrin (CDT) and PMM2 enzyme deficiency would confirm diagnosis."
"['Death in infancy', 'Hyperammonemia', 'Oroticaciduria', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia conversion to carbamoyl phosphate, leading to toxic ammonia accumulation.  
2. **Neonatal death** and **death in infancy** align with severe UCDs like CPS1 deficiency, which often presents catastrophically within days of birth due to hyperammonemic coma if untreated.  
3. **Oroticaciduria** is atypical for CPS1 deficiency (typically seen in OTC deficiency). However, severe metabolic stress or liver dysfunction in CPS1 deficiency may secondarily elevate orotic acid via unclear mechanisms, or the finding could reflect a concurrent/overlapping pyrimidine metabolism disturbance.  
4. Key differentiation: CPS1 deficiency classically shows **low citrulline** and **absent oroticaciduria**. The presence of oroticaciduria here is unusual but does not exclude CPS1 deficiency if other features (e.g., hyperammonemia severity, timing) strongly align. Further testing (e.g., genetic analysis, enzyme assays) would confirm the diagnosis."
"['Microcephaly', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Premature birth', 'Anemia', 'Abnormal facial shape', 'Opisthotonus', 'Abnormal calvaria morphology', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** and **abnormality of galactoside metabolism** are pathognomonic for galactosemia, directly indicating impaired galactose processing.  
2. **Failure to thrive**, **motor delay**, and **generalized hypotonia** align with metabolic dysfunction and energy depletion from toxic galactitol accumulation.  
3. **Seizures** and **intellectual disability** result from neurotoxic effects of galactose metabolites, causing cerebral edema and neuronal damage.  
4. **Anemia** and **abnormal circulating porphyrin concentration** suggest hepatic involvement, a hallmark of untreated galactosemia.  
5. **Neonatal death**/**death in infancy** correlates with acute complications (e.g., sepsis, liver failure) in undiagnosed cases, exacerbated by lactose exposure post-birth.  
6. **Premature birth** may reflect maternal galactose metabolism stress during gestation.  
7. Atypical features (syndactyly, abnormal calvaria) are likely unrelated or secondary to severe metabolic disruption affecting development.  

Disease: Galactosemia/GAL  
Reasoning:  
1. Overlaps with classic galactosemia but may encompass milder variants. Core symptoms (hypergalactosemia, metabolic abnormalities, neurological deficits) remain consistent.  
2. **Delayed speech/language development** and **abnormal facial shape** are secondary to global neurodevelopmental impairment from chronic galactose toxicity.  
3. **Opisthotonus** reflects severe neurological involvement from galactitol-induced osmotic damage in the CNS.  
4. **Death in childhood** underscores disease severity without early dietary intervention (lactose/galactose restriction).  

*Note: Syndactyly and calvaria abnormalities are not typical of galactosemia and may suggest a concurrent condition or misreported findings.*"
"['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is a hallmark laboratory finding directly linked to GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Metabolic acidosis** aligns with organic acidemia pathophysiology due to toxic accumulation of glutaric acid and derivatives.  
3. **Neurological symptoms (Ataxia, Lethargy, Drowsiness, Generalized hypotonia)** reflect basal ganglia and white matter injury from metabolic crises, characteristic of GA-I.  
4. **Death in infancy** underscores the severe, early-onset nature of untreated GA-I, often triggered by catabolic stressors (e.g., infections).  
5. **Sleep disturbances** may arise from neurotoxicity or secondary complications (e.g., electrolyte imbalances).  
6. Symptom combination excludes other organic acidemias (e.g., GA-II) or mitochondrial disorders, as GA-I uniquely associates with glutaric aciduria and striatal degeneration."
"['Hyperinsulinemia', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia and 4-Hydroxyphenylpyruvic aciduria**: Direct biochemical hallmarks of tyrosinemia type 1 (HT-1), caused by fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic accumulation of tyrosine metabolites.  
2. **Hyperphenylalaninemia**: Secondary inhibition of phenylalanine hydroxylase by tyrosine metabolites, mimicking phenylketonuria (PKU) biochemically.  
3. **Elevated alpha-fetoprotein (AFP)**: Reflects hepatic injury and regenerative nodules, a characteristic feature of HT-1-associated hepatocellular dysfunction.  
4. **Hypoglycemia and hyperinsulinemia**: Hepatic failure impairs gluconeogenesis and insulin clearance, causing paradoxical hypoglycemia despite hyperinsulinemia.  
5. **Neonatal/infant/childhood mortality**: Untreated HT-1 causes acute liver failure, renal tubulopathy, and porphyria-like neurological crises, often fatal in early life.  
6. **Prenatal developmental abnormalities**: Chronic intrauterine metabolic stress from tyrosine derivative toxicity may disrupt organogenesis.  
7. **Hepatorenal involvement**: Pathognomonic for HT-1, with succinylacetone (pathognomonic urinary marker) causing renal Fanconi syndrome and hepatic cirrhosis.  
Diagnostic confirmation requires urine succinylacetone testing, plasma amino acids (↑ tyrosine), and FAH gene analysis."
"['Spasticity', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Neonatal death', 'Abnormal circulating creatine kinase concentration', 'Increased urinary glycerol']",['Isolated glycerol kinase deficiency/Glycerol kinase deficiency'],"Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol**: A hallmark of glycerol kinase deficiency (GKD), caused by the enzyme's inability to metabolize glycerol, leading to its accumulation and urinary excretion.  
2. **Abnormal circulating creatine kinase (CK)**: Elevated CK suggests muscle damage, which can occur in metabolic disorders like GKD due to energy deficits in muscle cells.  
3. **Generalized hypotonia and hyporeflexia**: Result from impaired muscle metabolism and energy production secondary to glycerol accumulation and disrupted metabolic pathways.  
4. **Spasticity**: May arise later due to progressive neurological dysfunction or compensatory mechanisms in a metabolically stressed nervous system.  
5. **Neonatal death/Death in infancy**: Severe infantile GKD often leads to metabolic crises (e.g., hypoglycemia, hyperglycerolemia) and organ failure, explaining early mortality.  
6. **Exclusion of adrenal involvement**: The diagnosis specifies *isolated* GKD, distinguishing it from the adrenocortical insufficiency-associated form (e.g., Xp21 deletion syndrome)."
"['Rod-cone dystrophy', 'Ophthalmoplegia', 'Abnormality of visual evoked potentials', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar abnormalities (atrophy/agenesis)**: Central to PMM2-CDG, causing ataxia, motor delay, and hypotonia due to disrupted cerebellar development.  
2. **Neurological involvement**: Intellectual disability and abnormal visual evoked potentials align with global neurodevelopmental defects from impaired glycosylation.  
3. **Ocular symptoms**: Rod-cone dystrophy and ophthalmoplegia stem from glycosylation-dependent retinal and neuromuscular dysfunction.  
4. **Systemic severity**: Death in infancy reflects severe multisystem failure, consistent with classic PMM2-CDG presentations.  
5. **Diagnostic alignment**: The constellation of cerebellar, ocular, and developmental features distinguishes PMM2-CDG from other CDG subtypes or cerebellar malformation syndromes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where high maternal phenylalanine disrupts fetal development (e.g., microcephaly, congenital heart defects).  
3. **Neonatal death/Death in infancy** occurs in severe, untreated PKU due to rapid neurotoxicity from extreme phenylalanine levels, causing metabolic encephalopathy.  
4. **Hypertyrosinemia** is atypical in classic PKU (expected hypotyrosinemia), but may reflect transient neonatal tyrosinemia, liver dysfunction, or a coexisting metabolic disturbance.  
5. The combination of hyperphenylalaninemia with early lethality strongly prioritizes PKU over other tyrosinemia disorders, despite the tyrosine elevation anomaly."
"['Cardiomyopathy', 'Fever', 'Abnormality of urine homeostasis', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by defective carnitine transport due to mutations in the *SLC22A5* gene.  
2. **Cardiomyopathy** arises from impaired fatty acid oxidation in cardiac muscle due to carnitine deficiency, leading to energy depletion and cardiac dysfunction.  
3. **Gastrointestinal inflammation** and **fever** may reflect metabolic decompensation episodes triggered by fasting or infection, causing hypoketotic hypoglycemia and secondary systemic stress.  
4. **Abnormality of urine homeostasis** correlates with renal carnitine wasting (reduced tubular reabsorption) and potential electrolyte imbalances during metabolic crises.  
5. **Death in childhood** aligns with untreated PCD's natural history, where cardiac failure, hypoglycemic encephalopathy, or arrhythmias prove fatal without carnitine supplementation.  
6. Symptom constellation matches PCD's multisystemic presentation: hepatic, cardiac, muscular, and metabolic manifestations from disrupted lipid metabolism."
"['Abnormal saccadic eye movements', 'Lethargy', 'Spasticity', 'Death in infancy', 'Bradycardia', 'Hyperammonemia', 'Vomiting', 'Apnea', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Low plasma citrulline', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** and **hyperglutaminemia** are hallmark features of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Low plasma citrulline** localizes the defect to the first two steps of the urea cycle (CPS1 or OTC deficiency), as citrulline is synthesized downstream.  
3. **Neonatal death** and **lethargy/drowsiness** align with severe, early-onset UCDs like CPS1 deficiency, which often presents catastrophically in infancy.  
4. **Vomiting**, **apnea**, and **spasticity** reflect acute neurological toxicity from hyperammonemia.  
5. **Oroticaciduria** is atypical for CPS1 deficiency (classically seen in OTC deficiency) but may occur due to secondary pyrimidine pathway dysregulation or overlapping metabolic stress in severe hyperammonemia.  
6. **Abnormal saccadic eye movements** and **sleep disturbances** suggest chronic CNS injury from ammonia accumulation.  
7. **Bradycardia** and **death in infancy** underscore the systemic metabolic crisis typical of untreated CPS1 deficiency.  
8. While **oroticaciduria** raises consideration of OTC deficiency, the absence of elevated citrulline and the constellation of neonatal lethality strongly favor CPS1 deficiency as the primary diagnosis."
"['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis is a hallmark of methylmalonic acidemia (MMA), an inborn error of metabolism caused by impaired degradation of methylmalonyl-CoA. Death in infancy aligns with severe MMA presentations, where toxic metabolite accumulation leads to rapid clinical deterioration.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Decreased methylmalonyl-CoA mutase activity directly indicates a defect in the MUT gene encoding this enzyme, which is required for methylmalonyl-CoA isomerization. Vitamin B12-unresponsive MMA is confirmed because mutase deficiency bypasses the B12-dependent pathway (defects in B12 metabolism or transport would retain some residual enzyme activity with B12 supplementation). The triad of symptoms strongly supports this specific genetic subtype."
"['Hypospadias', 'Microcephaly', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Smith-Lemli-Opitz syndrome:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol, along with hypocholesterolemia, are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS). These result from a deficiency in 7-dehydrocholesterol reductase (DHCR7), which blocks cholesterol synthesis.  
2. **Congenital anomalies**: Hypospadias and microcephaly align with SLOS-associated malformations caused by disrupted cholesterol-dependent embryogenesis.  
3. **Neurological features**: Generalized hypotonia and motor delay reflect abnormal neurodevelopment due to cholesterol deficiency, critical for myelination and synaptic function.  
4. **Feeding difficulties and lethality**: Poor feeding, neonatal death, and infant mortality are common in severe SLOS cases, often due to multiorgan failure or metabolic instability from critically low cholesterol.  
5. **Consistency with phenotype**: The combination of dysmorphic features, biochemical abnormalities, and early lethality strongly supports SLOS as the definitive diagnosis."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low), but could arise from concurrent tyrosine supplementation, secondary metabolic dysregulation, or a comorbid condition (e.g., tyrosinemia). However, the primary diagnostic focus remains on elevated phenylalanine.  
3. **Death in childhood** aligns with untreated/severe PKU, as toxic phenylalanine accumulation leads to neurodevelopmental failure, seizures, and early mortality without dietary intervention.  
4. While Hypertyrosinemia creates ambiguity, PKU is prioritized due to the pathognomonic Hyperphenylalaninemia. Further testing (e.g., BH4 responsiveness, tyrosine metabolite analysis) would clarify coexisting disorders."
"['Hyperhidrosis', 'Death in infancy', 'Cardiomyopathy', 'Cardiomegaly', 'Hypotension', 'Tachypnea', 'Aminoaciduria', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning:  
1. **Aminoaciduria and elevated urinary carboxylic acids** align with impaired leucine catabolism due to 3-MCC deficiency, leading to accumulation of 3-methylcrotonyl-CoA and derivatives like 3-hydroxyisovaleric acid.  
2. **Cardiomyopathy/Cardiomegaly** may result from energy deficiency in cardiac tissue due to disrupted mitochondrial fatty acid oxidation and ketogenesis.  
3. **Hypotension/Tachypnea** suggests metabolic acidosis, a hallmark of organic acidemias, triggering respiratory compensation.  
4. **Feeding difficulties/Hyperhidrosis** are nonspecific but common in metabolic crises from toxic metabolite buildup.  
5. **Death in infancy/childhood** reflects severe metabolic decompensation episodes typical in untreated 3-MCC deficiency.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency (general)  
Reasoning:  
1. **Abnormal circulating glycine concentration** (secondary to glycine conjugation with accumulated metabolites) and **aminoaciduria** are biochemical hallmarks of this disorder.  
2. **Elevated urinary carboxylic acids** (e.g., 3-methylcrotonylglycine) directly indicate a block in 3-MCC enzyme activity.  
3. **Cardiac manifestations** (cardiomyopathy, cardiomegaly) stem from disrupted energy production and possible secondary carnitine depletion.  
4. **Early mortality** correlates with acute metabolic crises triggered by catabolic stressors (e.g., infections, fasting), common in this autosomal recessive disorder.  
5. Overlap with subtype 1 deficiency is expected, as MCCC1 gene mutations account for the majority of 3-MCC deficiency cases."
"['Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Increased serum lactate', 'Neonatal death', 'Death in childhood']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Eczematoid dermatitis/Skin rash**: Classic cutaneous manifestations of biotinidase deficiency due to biotin-dependent carboxylase dysfunction, impairing fatty acid synthesis and skin integrity.  
2. **Generalized hypotonia**: Caused by metabolic acidosis and energy deficiency from impaired gluconeogenesis (propionyl-CoA carboxylase deficiency) and mitochondrial dysfunction.  
3. **Increased serum lactate**: Reflects lactic acidosis secondary to pyruvate carboxylase deficiency, disrupting the tricarboxylic acid cycle.  
4. **Abnormality of prenatal development or birth**: May indicate subtle intrauterine metabolic stress, though symptoms typically manifest postnatally as ""late-onset"" disease.  
5. **Death in infancy/Neonatal death/Death in childhood**: Untreated BTDD leads to progressive neurological decline, metabolic crises, and fatal outcomes. Early mortality correlates with delayed diagnosis and lack of biotin supplementation.  
6. **Multi-carboxylase involvement**: The term ""multiple carboxylase deficiency"" directly links to the biochemical defect in BTDD, where biotinidase deficiency prevents recycling of biotin, essential for carboxylase enzymes."
"['Hypercholesterolemia', 'Hypertyrosinemia', 'Aminoaciduria', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to impaired conversion of phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: Unusual in classic PKU (where tyrosine is typically low), but may occur in rare PKU variants or secondary metabolic disruptions (e.g., dietary interventions or overlapping enzyme deficiencies).  
3. **Aminoaciduria**: Excess phenylalanine excretion in urine due to overflow from elevated blood levels, consistent with PKU.  
4. **Hypercholesterolemia**: Not directly linked to PKU but potentially secondary to high-fat/low-protein dietary management required for PKU.  
5. **Early mortality**: Untreated PKU causes severe neurological damage, seizures, and organ failure, explaining death in adolescence/early adulthood if undiagnosed or unmanaged.  
**Conclusion**: Despite atypical hypertyrosinemia and hypercholesterolemia, hyperphenylalaninemia and aminoaciduria strongly align with PKU, with secondary factors explaining discrepancies."
"['Nephritis', 'Syncope', 'Death in infancy', 'Premature birth', 'Vomiting', 'Diarrhea', 'Elevated hepatic transaminase', 'Neonatal death', 'Death in childhood']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
**Reasoning**:  
1. **Elevated hepatic transaminase** and **vomiting/diarrhea** align with PMM2-CDG’s hallmark liver dysfunction and gastrointestinal involvement due to impaired glycosylation.  
2. **Premature birth** and **neonatal/infant/childhood death** reflect the disorder’s severe multisystemic nature, often fatal in early life.  
3. **Syncope** suggests neurological compromise (e.g., stroke-like episodes, autonomic dysfunction), a common feature of PMM2-CDG.  
4. **Nephritis**, though less typical, may arise from secondary immune dysregulation or protein-losing complications seen in CDG.  
5. The combination of hepatic, neurological, and gastrointestinal symptoms with early lethality strongly supports PMM2-CDG, the most prevalent CDG subtype."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This deficiency leads to phenylalanine accumulation, explaining hyperphenylalaninemia.  
2. **Hypertyrosinemia discrepancy**: Classical PKU typically results in *low* tyrosine levels due to impaired conversion. However, this symptom could arise from concurrent factors (e.g., tyrosine supplementation in treated PKU, liver dysfunction, or an overlapping metabolic disorder).  
3. **Death in early adulthood**: Untreated PKU causes severe neurological damage, seizures, and organ failure. Without lifelong dietary management (low-phenylalanine diet), complications progress, leading to early mortality.  
4. **Exclusion of BH4 deficiency**: While BH4 cofactor defects also cause hyperphenylalaninemia, they typically involve neurotransmitter deficiencies and distinct symptoms (e.g., hypotonia, developmental delays), which are not listed here. PKU remains the primary diagnosis.  

Note: Hypertyrosinemia is atypical for PKU and warrants further investigation for secondary causes or diagnostic errors, but the core diagnosis aligns with hyperphenylalaninemia and clinical severity."
"['Hypertension', 'Secondary hyperparathyroidism', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Cardiomyopathy', 'Anemia', 'Acute kidney injury', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Hyperglycinemia', 'Tachypnea', 'Methylmalonic acidemia', 'Increased blood urea nitrogen', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Feeding difficulties', 'Methylmalonic aciduria', 'Chronic kidney disease']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Key biochemical markers**:  
   - Decreased methylmalonyl-CoA mutase activity directly confirms a defect in this enzyme, a hallmark of MMA caused by *MUT* gene mutations.  
   - Methylmalonic acidemia/aciduria, hyperammonemia, hyperglycinemia, and hyperalaninemia reflect disrupted propionate metabolism, leading to toxic metabolite accumulation.  

2. **Systemic manifestations**:  
   - **Renal**: Acute/chronic kidney injury, elevated creatinine, and increased blood urea nitrogen result from nephrotoxic metabolites (methylmalonic acid, ammonia).  
   - **Neuromuscular**: Hypotonia, motor delay, and feeding difficulties arise from energy deficiency and neurotoxicity.  
   - **Metabolic crises**: Vomiting, tachypnea (compensatory for metabolic acidosis), and hyperuricemia occur during acute decompensation.  

3. **Complications**:  
   - Cardiomyopathy and anemia are linked to mitochondrial dysfunction and carnitine depletion (decreased plasma free carnitine).  
   - Growth failure (severe short stature) and recurrent infections stem from chronic metabolic stress and protein catabolism.  
   - Early mortality (infancy/childhood/adolescence) aligns with severe B12-unresponsive MMA due to multiorgan failure.  

4. **Exclusion of B12-responsive forms**:  
   - Absence of hematologic features (e.g., megaloblastic anemia) and confirmed enzyme deficiency (not responsive to B12 supplementation) distinguish this from B12-responsive subtypes.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
- This is the broader diagnostic category encompassing the specific mutase-deficient subtype. The term ""methylmalonic aciduria"" explicitly references urinary excretion of methylmalonic acid, a diagnostic criterion confirmed via organic acid analysis. All clinical and biochemical findings (e.g., hyperammonemia, metabolic acidosis) are secondary to the primary defect in methylmalonate metabolism."
"['Seizure', 'Lethargy', 'Areflexia', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Dyspnea', 'Hyperglycinemia', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Glutaric aciduria', 'Hyperglutaminemia', 'Elevated circulating glutaric acid concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Key metabolic markers**: Elevated glutaric acid (hyperglutaminemia, glutaric aciduria, elevated circulating glutaric acid) directly aligns with GA-I’s pathophysiology due to **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Neurological features**: Dystonia, opisthotonus, seizures, and hypotonia reflect basal ganglia injury, a hallmark of GA-I. These symptoms often manifest during metabolic crises triggered by fever, infection, or fasting.  
3. **Infantile presentation**: Feeding difficulties, lethargy, drowsiness, and risk of early death are consistent with GA-I’s typical onset in infancy. Untreated cases progress to irreversible neurological damage.  
4. **Carnitine abnormalities**: Abnormal carnitine levels occur as the body attempts to conjugate toxic metabolites (e.g., glutaric acid), depleting carnitine reserves.  
5. **Exclusion of mimics**: Hyperglycinemia may suggest glycine encephalopathy, but glutaric aciduria and dystonia strongly favor GA-I. Fasciculations and areflexia could indicate spinal involvement but are secondary to metabolic stress in GA-I.  
6. **Triggers for decompensation**: Fever and dyspnea likely precipitated acute encephalopathy, a common GA-I crisis pattern.  

This constellation of symptoms and biochemical findings is pathognomonic for GA-I, warranting urgent genetic testing (GCDH gene) and metabolic management to mitigate progression."
"['Lethargy', 'Death in infancy', 'Fever', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Neonatal death', 'Recurrent viral infections', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic)  
Reasoning:  
1. **Hyperammonemia and elevated plasma citrulline** are hallmark biochemical features of citrullinemia type I, caused by a deficiency in **argininosuccinate synthetase (ASS1)**, a urea cycle enzyme. This blocks the conversion of citrulline to argininosuccinate, leading to citrulline accumulation.  
2. **Oroticaciduria** occurs due to secondary diversion of carbamoyl phosphate into pyrimidine synthesis when the urea cycle is disrupted, a phenomenon seen in urea cycle disorders.  
3. **Neonatal death/death in infancy** aligns with the severe, early-onset presentation of classic citrullinemia, often triggered by protein feeding after birth.  
4. **Lethargy, drowsiness, and sleep disturbances** reflect neurotoxicity from hyperammonemia, which disrupts cerebral metabolism.  
5. **Fever** may arise secondary to metabolic stress or intercurrent illnesses exacerbating the underlying defect.  
6. **Recurrent viral infections** are atypical for urea cycle disorders but could stem from prolonged hospitalization or metabolic instability impairing immune responses.  

The combination of urea cycle dysfunction (hyperammonemia), specific metabolite abnormalities (citrulline, orotic acid), and life-threatening neonatal course strongly supports citrullinemia type I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had untreated PKU during pregnancy, causing congenital anomalies in the infant.  
3. **Death in infancy/childhood and neonatal death** correlate with severe, untreated PKU. Without dietary intervention, toxic phenylalanine levels cause irreversible neurological damage, seizures, and failure to thrive, often leading to early mortality.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually normal or low due to PAH deficiency). However, this could indicate a comorbid condition (e.g., transient tyrosinemia in newborns) or a secondary metabolic disruption from liver dysfunction in critical cases.  
5. The combination of hyperphenylalaninemia and early lethality strongly prioritizes PKU as the primary diagnosis, emphasizing the critical need for newborn screening and dietary management to prevent severe outcomes."
"['Macrocephaly', 'Hypohidrosis', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Metabolic acidosis', 'Neonatal death', 'Arrhythmia', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Metabolic acidosis and elevated urinary carboxylic acids**: Biotinidase deficiency impairs biotin recycling, critical for carboxylase enzymes (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). Dysfunction leads to accumulation of organic acids (e.g., lactate, 3-hydroxyisovalerate) in blood and urine, explaining metabolic acidosis and elevated urinary carboxylic acids.  
2. **Dermatological manifestations (eczematoid dermatitis, skin rash, alopecia)**: Biotin is essential for keratinocyte function and fatty acid synthesis. Deficiency causes periorificial dermatitis, alopecia, and rashes, mimicking zinc deficiency or seborrheic dermatitis.  
3. **Neurological features (hypotonia, macrocephaly)**: Organic acid accumulation disrupts energy metabolism, leading to hypotonia. Macrocephaly may arise from cerebral edema or leukodystrophy due to untreated metabolic crises.  
4. **Hypohidrosis**: Autonomic dysfunction from metabolic stress or direct sweat gland impairment secondary to biotin-dependent processes.  
5. **Arrhythmia**: Electrolyte imbalances (e.g., hyperammonemia, hypokalemia) from metabolic acidosis or cardiac energy depletion can trigger arrhythmias.  
6. **Infant mortality**: Untreated BTDD causes progressive neurological decline, metabolic decompensation, and fatal outcomes in infancy. Neonatal death may occur in severe, undiagnosed cases.  
**Diagnostic confirmation**: Low serum biotinidase activity and genetic testing for *BTD* gene mutations. Prompt biotin supplementation reverses symptoms, underscoring urgency in identification."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative metabolism of excess phenylalanine.  
3. **Abnormality of prenatal development/birth** may align with maternal PKU syndrome if the mother had untreated PKU during pregnancy, causing fetal complications.  
4. **Early mortality** (infancy/childhood/adolescence) reflects severe untreated PKU, where neurotoxicity from phenylalanine causes seizures, intellectual disability, and fatal complications.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise secondary to dietary management (e.g., tyrosine supplementation) or overlapping metabolic disturbances.  
6. **Neonatal death** is rare in PKU but could occur in extreme cases with rapid metabolic decompensation or comorbid conditions.  

While hypertyrosinemia and elevated urinary carboxylic acids might suggest tyrosinemia, the dominant hyperphenylalaninemia and structured clinical context prioritize PKU as the diagnosis."
"['Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) arise from alternative phenylalanine metabolism via transamination, a pathognomonic feature of PKU.  
3. **Eczematoid dermatitis/skin rash** correlates with tyrosine deficiency (due to blocked PAH activity), impairing melanin and protein synthesis, causing skin manifestations.  
4. **Abnormality of prenatal development** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing fetal complications like microcephaly or cardiac defects.  
5. **Death in infancy/childhood/neonatal death** reflects untreated PKU’s severe neurological sequelae (seizures, intellectual disability) and metabolic instability, historically fatal before dietary management.  
6. **Hypertyrosinemia** may appear contradictory (PAH deficiency typically lowers tyrosine), but transient elevations can occur due to metabolic stress or overlapping pathways in severe cases.  

The collective symptoms strongly indicate PKU, emphasizing untreated metabolic dysfunction and its systemic consequences."
"['Vomiting', 'Abdominal pain', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria  
Reasoning: The symptoms of vomiting and severe abdominal pain align with acute attacks characteristic of acute intermittent porphyria (AIP). AIP is caused by a deficiency in hydroxymethylbilane synthase, leading to accumulation of neurotoxic porphyrin precursors. While AIP typically manifests after puberty, severe cases or undiagnosed episodes in childhood can result in fatal neurological complications (e.g., respiratory paralysis, seizures) or electrolyte imbalances (e.g., hyponatremia), explaining early mortality.  

Disease: Porphyria  
Reasoning: Porphyria encompasses a group of disorders affecting heme biosynthesis. The patient’s gastrointestinal symptoms and early fatality suggest an acute hepatic porphyria. While AIP is the most likely subtype, other severe forms (e.g., ALAD-deficiency porphyria or homozygous variants) may present in childhood with rapid progression. Lack of cutaneous symptoms rules out cutaneous porphyrias, narrowing the diagnosis to acute hepatic types. Genetic testing would confirm the specific subtype."
"['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Increased serum lactate', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Metabolic acidosis & elevated lactate**: Impaired activity of biotin-dependent carboxylases (pyruvate carboxylase, propionyl-CoA carboxylase) disrupts gluconeogenesis and the citric acid cycle, causing lactic acidosis.  
2. **Hyperammonemia**: Secondary urea cycle dysfunction due to metabolic stress or propionate accumulation from propionyl-CoA carboxylase deficiency.  
3. **Propionyl-CoA carboxylase deficiency & decreased pyruvate carboxylase activity**: HLCS is required to activate these enzymes via biotinylation; deficiency leads to functional defects in multiple carboxylases.  
4. **Abnormal urinary carboxylic acids & aminoaciduria**: Accumulation of toxic metabolites (e.g., propionate, 3-hydroxypropionate) due to blocked carboxylase pathways, causing renal tubular damage and organic aciduria.  
5. **Decreased plasma free carnitine**: Secondary carnitine depletion from binding/excretion of acyl-CoA metabolites.  
6. **Abnormal circulating glycine**: Glycine metabolism disruption via the glycine cleavage system (biotin-dependent) or competition with organic acids for renal transport.  
7. **Generalized hypotonia & apathy**: Neurological effects of metabolic acidosis, hyperammonemia, and energy deficiency.  
8. **Tachypnea**: Respiratory compensation for metabolic acidosis.  
9. **Death in infancy**: Untreated HLCS deficiency causes severe metabolic crises, typically fatal without biotin supplementation.  
**Conclusion**: The constellation of multi-carboxylase dysfunction, metabolic acidosis, hyperammonemia, and characteristic biochemical markers confirms HLCS deficiency."
"['Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The symptoms of neonatal death, aminoaciduria, and elevated urinary carboxylic acids align with a defect in leucine catabolism. 3-Methylcrotonyl-CoA carboxylase 1 (MCCC1) deficiency disrupts the breakdown of 3-methylcrotonyl-CoA, leading to accumulation of toxic metabolites like 3-methylcrotonylglycine and 3-hydroxyisovaleric acid, detected as elevated urinary carboxylic acids. Secondary carnitine deficiency occurs due to urinary excretion of carnitine-bound detoxified metabolites. Hyperglycinemia arises from inhibition of the glycine cleavage system by accumulated organic acids. Severe metabolic decompensation in infancy explains early mortality.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis encompasses deficiencies in either MCCC1 or MCCC2 subunits of the enzyme. The biochemical hallmarks—abnormal glycine/carnitine levels and urinary carboxylic acid elevation—stem from impaired leucine metabolism. Neonatal death and aminoaciduria reflect acute metabolic crises and renal tubular dysfunction caused by toxic metabolite overload. Both genetic subtypes (MCCC1/MCCC2) present identically clinically, making this a valid diagnosis even if the specific subunit is unspecified."
"['Intellectual disability', 'Obesity', 'Hyperalaninemia', 'Abnormal circulating glycine concentration', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperleucinemia**: IVA results from isovaleryl-CoA dehydrogenase deficiency, impairing leucine catabolism. This leads to accumulation of isovaleric acid and its precursors, including elevated leucine.  
2. **Abnormal circulating carnitine**: Isovaleric acid conjugates with carnitine to form isovaleryl-carnitine, depleting free carnitine and altering its circulating levels.  
3. **Abnormal glycine concentration**: Isovaleric acid is detoxified via glycine conjugation (forming isovalerylglycine), which may reduce free glycine levels, explaining the abnormal glycine profile.  
4. **Intellectual disability**: Untreated IVA causes recurrent metabolic crises, leading to neurotoxicity and intellectual impairment.  
5. **Hyperalaninemia**: Metabolic stress from catabolism during crises increases protein breakdown, elevating alanine as a byproduct.  
6. **Obesity**: May arise from high-calorie dietary interventions to prevent catabolism or metabolic dysregulation.  
7. **Hyperisoleucinemia**: Likely a secondary effect due to metabolic decompensation or analytical overlap with leucine metabolites.  
8. **Death in adolescence**: Reflects severe, poorly managed IVA with life-threatening metabolic acidosis or organ failure during crises.  

The combination of branched-chain amino acid disturbances (leucine), glycine/carnitine abnormalities, and clinical progression aligns with IVA pathophysiology."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative metabolism of excess phenylalanine, forming phenylketones excreted in urine.  
3. **Abnormality of prenatal development or birth** may occur in maternal PKU syndrome if the mother has uncontrolled phenylalanine levels during pregnancy, though this symptom is secondary.  
4. **Death in infancy/childhood/neonatal death** aligns with untreated PKU, as toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure without early dietary intervention.  
5. **Increased total bilirubin** is atypical for classic PKU but could indicate transient neonatal jaundice, a common comorbidity in newborns, not directly linked to PKU pathology.  
The combination of hyperphenylalaninemia and phenylketonuria-confirming urinary metabolites strongly supports PKU, with poor outcomes reflecting lack of newborn screening or treatment."
"['Intellectual disability', 'Motor delay', 'Cerebellar atrophy', 'Death in infancy', 'Hypoproteinemia', 'Hypocholesterolemia', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Intellectual disability & motor delay**: PMM2-CDG disrupts N-glycosylation, impairing neuronal development and cerebellar function, leading to neurodevelopmental deficits.  
2. **Cerebellar atrophy/agenesis**: Glycosylation defects cause structural brain abnormalities, particularly cerebellar hypoplasia/agenesis, a hallmark of PMM2-CDG.  
3. **Hypoproteinemia & hypocholesterolemia**: Impaired hepatic synthesis of glycosylated transport proteins (e.g., albumin, lipoproteins) reduces serum protein and cholesterol.  
4. **Lipodystrophy**: Abnormal fat distribution due to glycosylation-dependent adipocyte signaling and lipid metabolism dysfunction.  
5. **Acute/chronic hepatitis**: Liver involvement (elevated transaminases, steatosis) is common, progressing to fibrosis in severe cases.  
6. **Death in infancy**: Severe multisystemic disease (neurological, hepatic, and coagulopathic complications) often leads to early mortality in classical PMM2-CDG.  

The triad of **neurological impairment**, **protein-losing enteropathy/hypoalbuminemia**, and **hepatopathy** strongly supports PMM2-CDG. Confirmatory testing (phosphomannomutase 2 enzyme activity, genetic analysis for _PMM2_ variants) is required."
"['Ataxia', 'Spasticity', 'Death in infancy', 'Fever', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Elevated glutaric acid in urine is a hallmark of GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Ataxia & Spasticity**: GA-I damages the basal ganglia and white matter, leading to dystonia, spasticity, and impaired coordination.  
3. **Fever-triggered crises**: Metabolic decompensation during infections/fever exacerbates symptoms due to increased catabolism and toxin accumulation.  
4. **Death in infancy**: Untreated GA-I often causes severe neurological damage, metabolic strokes, or respiratory failure in early childhood.  
5. **Consistency with presentation**: The triad of neurodevelopmental regression, organic aciduria, and acute crises aligns with GA-I’s clinical profile. Early diagnosis via newborn screening (elevated C5DC) and treatment (lysine-restricted diet, carnitine) can improve outcomes."
"['Seborrheic dermatitis', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Seborrheic dermatitis**: A cutaneous manifestation of metabolic imbalance, commonly seen in untreated PKU due to disrupted amino acid metabolism affecting skin integrity.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has untreated PKU) can cause congenital anomalies (e.g., microcephaly) in the fetus due to intrauterine phenylalanine toxicity.  
4. **Death in infancy/Neonatal death/Death in childhood**: Untreated PKU results in severe neurological deterioration, seizures, and organ damage, often leading to early mortality without dietary intervention.  
5. **Hypertyrosinemia**: Uncommon in classical PKU but may arise secondary to metabolic dysregulation or overlapping conditions (e.g., BH4 deficiency), though PKU typically reduces tyrosine levels due to impaired PAH-mediated conversion of phenylalanine.  

The combination of hyperphenylalaninemia with systemic complications aligns with severe, untreated PKU. Early diagnosis via newborn screening and strict dietary management are critical to prevent these outcomes."
"['Nystagmus', 'Ataxia', 'Reduced tendon reflexes', 'Increased serum lactate', 'Increased CSF lactate', 'Glutaric aciduria', 'Increased serum pyruvate', 'Decreased plasma free carnitine', 'Abnormal immunoglobulin level', 'Hyperalbuminemia', 'Occipital neuralgia', 'Death in early adulthood']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Directly links to GA-I, caused by glutaryl-CoA dehydrogenase deficiency, leading to accumulation of glutaric acid.  
2. **Neurological symptoms (Nystagmus, Ataxia)**: GA-I damages the basal ganglia and white matter, causing dystonia, movement disorders, and cerebellar dysfunction.  
3. **Reduced tendon reflexes**: Suggests peripheral neuropathy, a known complication of metabolic toxicity in GA-I.  
4. **Elevated serum/CSF lactate & pyruvate**: Mitochondrial dysfunction from metabolic stress disrupts the tricarboxylic acid cycle, increasing anaerobic metabolism.  
5. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to toxic metabolites (e.g., glutaric acid) for excretion.  
6. **Death in early adulthood**: Untreated GA-I causes progressive neurodegeneration and metabolic crises, often leading to early mortality.  
7. **Hyperalbuminemia/Abnormal immunoglobulins**: Less specific but may reflect chronic metabolic stress or incidental findings; not core diagnostic criteria.  
8. **Occipital neuralgia**: Likely a secondary consequence of chronic neurological damage or unrelated comorbidity.  

Key exclusion: Other organic acidemias (e.g., MMA/PA) lack glutaric aciduria and typically present with severe ketoacidosis, which is less prominent in GA-I. The triad of glutaric aciduria, striatal injury, and characteristic biochemical profile confirms GA-I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH), preventing phenylalanine conversion to tyrosine. This aligns with the symptom ""Hyperphenylalaninemia.""  
2. **Elevated Urinary Carboxylic Acids**: In PKU, excess phenylalanine is metabolized into phenylketones and other derivatives, which may include carboxylic acid byproducts excreted in urine.  
3. **Abnormality of Prenatal Development/Neonatal Death**: Untreated maternal PKU can cause fetal developmental issues (e.g., microcephaly, congenital heart defects) via intrauterine phenylalanine toxicity. Severe neonatal cases (rare in modern screening) could lead to early mortality.  
4. **Death in Infancy/Adolescence**: Historically, untreated PKU causes profound intellectual disability, seizures, and failure to thrive, potentially leading to early death. Modern newborn screening and dietary management prevent this.  
5. **Hypertyrosinemia Discrepancy**: Classic PKU typically results in **low/normal tyrosine** (due to blocked PAH activity). Hypertyrosinemia suggests a secondary issue (e.g., transient tyrosinemia in newborns, co-occurring liver dysfunction, or a BH4 cofactor deficiency, a PKU variant affecting multiple enzymes). This may indicate atypical PKU or comorbid conditions.  

**Conclusion**: The core diagnosis is PKU, supported by hyperphenylalaninemia and urinary anomalies. Hypertyrosinemia and severe outcomes suggest either a rare PKU subtype (e.g., BH4 deficiency) or additional metabolic disruptions requiring further investigation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ferritin concentration']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development/birth** and **neonatal death** align with untreated PKU, as elevated phenylalanine is neurotoxic, causing severe developmental disruption if undetected postnatally.  
3. **Death in infancy/childhood** reflects historical untreated PKU outcomes due to progressive neurological damage, seizures, and failure to thrive.  
4. **Hypertyrosinemia** is atypical in classical PKU (which typically shows *low* tyrosine). This may indicate a coexisting condition (e.g., tyrosinemia type II) or secondary metabolic dysregulation from liver stress in severe PKU.  
5. **Decreased ferritin** correlates with PKU dietary management, as low-protein diets may limit iron intake, necessitating monitoring.  
6. PKU diagnosis is prioritized due to **hyperphenylalaninemia** as the pathognomonic feature; other symptoms likely stem from untreated metabolic derangements.  

*Note:* Hypertyrosinemia warrants further investigation to exclude dual diagnoses or enzyme cofactor deficiencies (e.g., tetrahydrobiopterin)."
"['Apathy', 'Cyanosis', 'Generalized hypotonia', 'Death in infancy', 'Bradycardia', 'Hypoglycemia', 'Hyperammonemia', 'Dicarboxylic aciduria', 'Neonatal death']",['Carnitine-acylcarnitine translocase deficiency/Carnitine-acylcarnitine translocase deficiency'],"Carnitine-acylcarnitine translocase deficiency:  
1. **Hypoglycemia** and **dicarboxylic aciduria** indicate impaired fatty acid oxidation, as the body cannot utilize long-chain fatty acids for energy, leading to glucose depletion and alternative metabolism of fatty acids.  
2. **Hyperammonemia** arises due to secondary urea cycle dysfunction caused by accumulation of toxic acyl-CoA intermediates.  
3. **Bradycardia** and **cyanosis** result from cardiac energy deficiency and possible arrhythmias due to defective mitochondrial fatty acid transport.  
4. **Generalized hypotonia** and **apathy** reflect systemic energy failure, particularly in muscles and the central nervous system.  
5. **Neonatal death** or **death in infancy** aligns with the severe, rapid progression of metabolic crises in untreated CACT deficiency, often triggered by fasting or metabolic stress.  
6. The triad of **hypoglycemia, hyperammonemia, and dicarboxylic aciduria** is pathognomonic for fatty acid oxidation disorders, with CACT deficiency distinguished by neonatal onset and carnitine cycle involvement."
"['Lethargy', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Anemia', 'Organic aciduria', 'Drowsiness', 'Sleep disturbance']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Organic aciduria** is a hallmark of biotinidase deficiency due to impaired activity of carboxylase enzymes (propionyl-CoA, pyruvate, and 3-methylcrotonyl-CoA carboxylases), leading to accumulation of organic acids.  
2. **Neurological symptoms (lethargy, drowsiness, spasticity)** arise from metabolic acidosis, hyperammonemia, and disrupted neurotransmitter function secondary to biotin-dependent enzyme dysfunction.  
3. **Generalized hypotonia** correlates with mitochondrial energy deficiency in muscles caused by defective pyruvate carboxylase.  
4. **Anemia** may result from bone marrow suppression due to metabolic toxicity or secondary mitochondrial dysfunction.  
5. **Sleep disturbances** and **death in infancy** reflect progressive neurological deterioration and metabolic crises if untreated. Early-onset presentations align with classic biotinidase deficiency, where symptoms manifest after biotin stores deplete postnatally. Confirmation requires serum biotinidase enzyme assay or genetic testing."
"['Congenital diaphragmatic hernia', 'Intellectual disability', 'Motor delay', 'Failure to thrive', 'Death in infancy', 'Hiatus hernia', 'Cerebral atrophy', 'Lipodystrophy', 'Abnormal muscle physiology']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
- **Congenital diaphragmatic hernia (CDH)** and **hiatus hernia** align with PMM2-CDG’s multisystem involvement, as glycosylation defects impair tissue integrity, including diaphragmatic and connective tissue development.  
- **Intellectual disability**, **motor delay**, and **cerebral atrophy** reflect the neurological hallmarks of PMM2-CDG, caused by abnormal glycosylation of brain proteins and neuronal migration defects.  
- **Failure to thrive** and **death in infancy** are common due to systemic complications (e.g., liver dysfunction, protein-losing enteropathy) and metabolic instability.  
- **Lipodystrophy** and **abnormal muscle physiology** stem from disrupted lipid metabolism and glycosylation-dependent muscle protein function.  
- The constellation of visceral, neurological, and metabolic symptoms, alongside early lethality, strongly supports PMM2-CDG as the unifying diagnosis."
"['Seizure', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hepatomegaly', 'Tachypnea', 'Neonatal death', 'Feeding difficulties', 'Functional abnormality of the gastrointestinal tract', 'Metabolic alkalosis']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
**Reasoning**:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), including argininosuccinic aciduria (ASA), due to impaired ammonia detoxification.  
2. **Vomiting**, **tachypnea**, and **metabolic alkalosis** align with UCDs: vomiting induces alkalosis, while hyperammonemia triggers compensatory tachypnea.  
3. **Seizures** and **coma** result from neurotoxicity caused by elevated ammonia.  
4. **Hepatomegaly** and **increased serum lactate** suggest secondary mitochondrial dysfunction or hepatic stress from metabolic overload.  
5. **Feeding difficulties** and **GI tract abnormalities** are common in neonates with UCDs due to metabolic instability.  
6. **Generalized hypotonia** reflects neurological impairment.  
7. **Neonatal death**/**death in infancy** underscores the severity of untreated ASA, which typically presents catastrophically in the first days of life.  
8. ASA is confirmed by elevated argininosuccinic acid in blood/urine, consistent with argininosuccinate lyase deficiency.  

This constellation of symptoms, metabolic derangements, and clinical course strongly supports ASA as the diagnosis."
"['Cataract', 'Hip dysplasia', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Anemia', 'Hyperammonemia', 'Elevated circulating creatinine concentration', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The presence of **methylmalonic aciduria** is pathognomonic for methylmalonic acidemia (MMA), a rare inborn error of metabolism. Key symptoms like **hyperammonemia**, **elevated creatinine** (indicative of renal dysfunction), **anemia**, and **abnormal carnitine levels** align with MMA’s metabolic disruptions. Neonatal or early childhood **death** and **premature birth** are consistent with severe forms of MMA, where toxic metabolite accumulation leads to multiorgan failure.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the diagnosis) points specifically to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme deficiency prevents the conversion of methylmalonyl-CoA to succinyl-CoA, causing **methylmalonic aciduria**, **hyperammonemia**, and metabolic acidosis. Symptoms like **small for gestational age** and **death in infancy/childhood** reflect the disease’s severe, early-onset phenotype. **Hip dysplasia** and **cataracts** may arise secondary to chronic metabolic stress or mitochondrial dysfunction. Elevated creatinine and neonatal death underscore renal and systemic toxicity from methylmalonic acid and propionate accumulation."
"['Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Difficulty walking', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: A hallmark of SSADHD due to accumulation of γ-hydroxybutyric acid (GHB), a carboxylic acid, in urine.  
2. **Neurological symptoms**:  
   - **Delayed speech/language development** and **hyperactivity**: Linked to GABA metabolism disruption, affecting neurodevelopment.  
   - **Seizures**: Caused by GHB-mediated excitotoxicity and GABA imbalance.  
   - **Generalized hypotonia**: Reflects impaired motor neuron function from GABAergic dysfunction.  
3. **Motor deficits (walking, stairs, running)**: Secondary to hypotonia, developmental delay, and potential cerebellar involvement.  
4. **Early mortality (infancy/childhood)**: Rare but reported in severe cases due to metabolic crises, refractory seizures, or complications.  
**Conclusion**: Symptom constellation aligns with SSADHD, confirmed by elevated urinary GHB (carboxylic acid). Early death, though atypical, may occur in severe phenotypes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This aligns with the symptom of elevated blood phenylalanine levels.  
2. **Elevated urinary carboxylic acids**: Untreated PKU results in excretion of phenylalanine metabolites (e.g., phenylpyruvate, phenylacetate), which are carboxylic acids detected in urine.  
3. **Neonatal death/Death in infancy**: Severe, untreated PKU can cause progressive neurological deterioration, seizures, and organ failure, potentially leading to early mortality without dietary intervention.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (untreated hyperphenylalaninemia during pregnancy) can cause congenital anomalies (e.g., microcephaly) in the fetus, explaining prenatal developmental issues.  
5. **Death in early adulthood**: Chronic complications of untreated PKU, such as intellectual disability, behavioral disorders, and neurodegenerative changes, may reduce life expectancy.  
6. **Hypertyrosinemia discrepancy**: While classic PKU typically causes *low* tyrosine (due to PAH deficiency), this symptom may reflect a concurrent metabolic disorder, lab error, or misclassification of secondary metabolites (e.g., tyrosine elevation from liver dysfunction).  

PKU is the primary diagnosis, with outcomes explained by untreated hyperphenylalaninemia and its systemic effects. Early dietary management (phenylalanine restriction) could prevent most severe complications."
"['Petechiae', 'Intellectual disability', 'Spastic diplegia', 'Motor delay', 'Areflexia', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Opisthotonus', 'Abnormal cerebral white matter morphology', 'Spastic tetraplegia', 'Increased CSF protein concentration', 'Neonatal death', 'Death in childhood', 'Decreased beta-galactosidase activity', 'Peripheral demyelination', 'Feeding difficulties', 'Dyskinesia']",['Krabbe disease'],"Disease: Krabbe disease  
Reasoning:  
1. **Enzyme Deficiency**: Decreased beta-galactosidase activity is pathognomonic for Krabbe disease, a lysosomal disorder caused by **GALC** mutations, leading to toxic psychosine accumulation and demyelination.  
2. **Neurological Symptoms**: Spastic tetraplegia/diplegia, dyskinesia, and opisthotonus reflect progressive CNS damage. Generalized hypotonia (early) transitioning to spasticity aligns with neurodegeneration.  
3. **White Matter Abnormalities**: Abnormal cerebral white matter morphology on imaging and peripheral demyelination correlate with widespread myelin loss.  
4. **CSF Findings**: Increased CSF protein concentration is characteristic due to breakdown of myelin products.  
5. **Infantile Presentation**: Feeding difficulties, motor delay, failure to thrive, vomiting, and diarrhea are typical in early-onset cases. Death in infancy/childhood matches the severe infantile form.  
6. **Areflexia**: Peripheral nerve demyelination explains reduced reflexes despite central spasticity.  
7. **Red Flags**: Petechiae and diarrhea may indicate multisystemic involvement or secondary complications (e.g., autonomic dysfunction).  

Krabbe disease integrates enzyme deficiency, neuroimaging, CSF findings, and clinical progression, overriding less specific symptoms (e.g., petechiae)."
"['Atypical behavior', 'Hyperactivity', 'Intellectual disability', 'Coma', 'Motor delay', 'Hepatic failure', 'Weight loss', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral cortical atrophy', 'Difficulty walking', 'Hyperglutaminemia', 'Oroticaciduria', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **hyperglutaminemia** indicate a urea cycle defect, as ammonia detoxification relies on this pathway.  
2. **Oroticaciduria** is pathognomonic for OTCD. Carbamoyl phosphate accumulates due to OTC enzyme deficiency, diverting into pyrimidine synthesis and generating excess orotic acid.  
3. **Hepatic failure** aligns with OTCD’s liver-specific urea cycle dysfunction.  
4. **Cerebral cortical atrophy**, **coma**, and **neurological symptoms** (motor delay, difficulty walking/running) stem from chronic neurotoxicity due to hyperammonemia.  
5. **Abnormal aspartate/alanine concentrations** reflect metabolic disruption in urea/amino acid metabolism.  
6. **Death in childhood/adolescence** is consistent with severe, untreated OTCD, as hyperammonemic crises are life-threatening.  
7. **Vomiting**, **fever**, and **weight loss** are nonspecific but common during metabolic decompensation.  
8. **Intellectual disability** and **atypical behavior** result from recurrent ammonia-induced brain injury.  

OTCD is the only diagnosis explaining all symptoms, particularly the triad of hyperammonemia, oroticaciduria, and hepatic involvement."
"['Coma', 'Hepatic steatosis', 'Death in infancy', 'Vomiting', 'Cerebral edema', 'Abnormal circulating acetylcarnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating acetylcarnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to elevated medium-chain acylcarnitines (C8-C10), a hallmark diagnostic biomarker.  
2. **Hepatic steatosis**: Impaired fatty acid metabolism causes lipid accumulation in the liver.  
3. **Vomiting and cerebral edema**: During metabolic stress (e.g., fasting), unmetabolized fatty acids and toxic metabolites (e.g., octanoic acid) induce encephalopathy, cerebral edema, and gastrointestinal symptoms.  
4. **Coma and death in infancy**: Prolonged hypoglycemia and energy deficiency in crises result in neurological deterioration; untreated MCADD has high mortality in early life due to rapid metabolic decompensation.  
5. **Consistency with MCADD phenotype**: The triad of hypoketotic hypoglycemia, hepatic dysfunction, and acute neurological crises aligns with MCADD pathophysiology."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This deficiency results in phenylalanine accumulation, directly explaining hyperphenylalaninemia.  
2. **Death in childhood**: Untreated PKU leads to severe neurological damage, seizures, and developmental failure, often causing early mortality without dietary intervention.  
3. **Hypertyrosinemia**: While atypical in classic PKU (as PAH deficiency typically reduces tyrosine synthesis), this could reflect dietary tyrosine supplementation, misreported data, or a concurrent metabolic disturbance (e.g., transient neonatal tyrosinemia). The primary diagnostic markers (hyperphenylalaninemia + clinical severity) strongly prioritize PKU despite this anomaly."
"['Hypospadias', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Esophageal atresia', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Phenylketonuria (PKU): The patient's hyperphenylalaninemia is pathognomonic for PKU, an autosomal recessive disorder caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine-to-tyrosine conversion. Chronic phenylalanine accumulation leads to neurotoxicity, explaining potential early mortality due to untreated metabolic crises and severe neurological deterioration. Hypertyrosinemia is atypical in classical PKU but could arise from secondary metabolic disruptions or concurrent hepatic dysfunction. Structural anomalies (e.g., hypospadias, esophageal atresia) may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing teratogenic effects on fetal development. While PKU itself does not directly cause congenital malformations, these findings highlight the critical interplay between maternal metabolic control and fetal outcomes. Chronic pulmonary/airway obstruction and early mortality across life stages align with complications of untreated PKU, including susceptibility to infections, neurorespiratory failure, or comorbid conditions exacerbated by metabolic instability."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to secondary carnitine deficiency or abnormal carnitine profiles due to accumulation of toxic metabolites like acylcarnitines (e.g., C8-C10 species).  
2. **Neonatal death/Death in infancy/childhood**: MCADD causes life-threatening metabolic crises triggered by fasting or illness. Hypoketotic hypoglycemia, hepatic dysfunction, and encephalopathy can rapidly progress to coma and death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe metabolic instability in utero might contribute to intrauterine growth restriction (IUGR) or prematurity in rare cases.  
4. **Key diagnostic confirmation**: Elevated urinary dicarboxylic acids (C6-C10) and specific acylcarnitines (C8, C6, C10:1) on tandem mass spectrometry (TMS) would confirm MCADD, aligning with the clinical presentation."
"['Microcephaly', 'Self-mutilation', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Intellectual disability**, **microcephaly**, and **delayed speech** are classic neurodevelopmental consequences of untreated PKU due to toxic phenylalanine levels damaging the brain.  
3. **Seizures** and **self-mutilation** correlate with severe neurological impairment from chronic phenylalanine toxicity.  
4. **Severe short stature** may result from metabolic disruption and poor protein utilization.  
5. **Death in infancy/adolescence** reflects untreated or poorly managed PKU, causing acute metabolic crises or irreversible neurological damage.  
6. **Hypertyrosinemia** is atypical for classic PKU but may occur in rare variants (e.g., BH4 deficiency) or secondary metabolic disturbances.  
7. The combination of **hyperphenylalaninemia** with neurodevelopmental deficits strongly prioritizes PKU, even with atypical features like hypertyrosinemia."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Respiratory insufficiency', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Dicarboxylic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Neonatal death', 'Elevated urinary carboxylic acid']","['Mitochondrial complex IV deficiency, nuclear type 1']","Mitochondrial complex IV deficiency, nuclear type 1:  
The patient's **cytochrome C oxidase (COX)-negative muscle fibers** directly indicate a deficiency in mitochondrial complex IV (COX). **Increased serum lactate** and **elevated urinary carboxylic acids** reflect impaired oxidative phosphorylation and secondary metabolic disturbances. **Respiratory insufficiency**, **lethargy**, and **generalized hypotonia** align with energy failure in muscles and the central nervous system. **Dicarboxylic aciduria** suggests defective fatty acid oxidation, a compensatory mechanism in mitochondrial dysfunction. **Neonatal death** or **death in infancy** is typical in severe nuclear-encoded complex IV deficiencies (e.g., *SURF1* mutations). **Sleep disturbances** and **drowsiness** may stem from CNS energy deficits. This constellation of symptoms and biochemical findings is pathognomonic for mitochondrial complex IV deficiency, nuclear type 1."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. Untreated PKU leads to toxic phenylalanine accumulation, causing severe neurological damage, which explains **neonatal death**, **death in infancy**, or **childhood** due to metabolic crisis or complications.  
3. **Hypertyrosinemia** may appear contradictory (as PAH deficiency typically reduces tyrosine levels), but secondary metabolic disturbances or overlapping enzyme dysfunction (e.g., transient tyrosine elevation during metabolic decompensation) could explain this finding.  
4. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, though this is context-dependent.  
5. PKU is confirmed via newborn screening; untreated cases match the described fatal trajectory. Other tyrosinemia types are excluded due to the primary hyperphenylalaninemia and lack of liver/kidney symptoms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline is a hallmark of citrullinemia, specifically type I (argininosuccinate synthetase deficiency). The symptoms of neonatal death, death in infancy/childhood, and prenatal developmental abnormalities align with severe urea cycle dysfunction. Type I typically presents with hyperammonemia-induced metabolic crises shortly after birth, leading to rapid neurological decline and early mortality if untreated. Prenatal abnormalities may reflect metabolic stress in utero or secondary complications.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Elevated citrulline is also seen in citrin deficiency (type II), though levels may fluctuate. Neonatal cholestasis (implied in the disease name) and liver dysfunction are key features, though not explicitly listed. Prenatal developmental abnormalities (e.g., intrauterine growth restriction) may arise from citrin’s role in mitochondrial energy metabolism. Early mortality could stem from liver failure or metabolic decompensation. The absence of explicit cholestasis in symptoms may reflect incomplete clinical documentation, but the diagnostic framework prioritizes citrulline elevation and neonatal-onset context."
"['Polyuria', 'Hyperactivity', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Tachycardia', 'Hypoglycemia', 'Hypophosphatemia', 'Hyperglycinemia', 'Hypokalemia', 'Hyponatremia', 'Hypomagnesemia', 'Hypochloremia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hyperglutaminemia', 'Hypertyrosinemia', 'Hypermethioninemia', 'Paresthesia', 'Elevated calcitonin', '4-hydroxyphenylacetic aciduria', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Paraplegia/paraparesis', 'Death in adolescence']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia Type I (HT-1)  
Reasoning:  
1. **Hypertyrosinemia and Tyrosine Metabolites**: Elevated tyrosine levels and metabolites (4-Hydroxyphenylpyruvic aciduria, 4-hydroxyphenylacetic aciduria) directly indicate a defect in tyrosine catabolism. HT-1 involves a deficiency of fumarylacetoacetate hydrolase (FAH), causing toxic metabolite accumulation (e.g., succinylacetone).  
2. **Liver Dysfunction**: Elevated alpha-fetoprotein (AFP) and alkaline phosphatase suggest hepatic damage, a hallmark of HT-1. Hypoglycemia and hypermethioninemia further support liver impairment.  
3. **Renal Tubular Dysfunction**: Electrolyte imbalances (hypophosphatemia, hypokalemia, hyponatremia, hypomagnesemia, hypochloremia) point to Fanconi syndrome, a renal complication of HT-1 due to succinylacetone toxicity.  
4. **Neurological and Systemic Symptoms**: Tachycardia, hyperactivity, and paresthesia may stem from metabolic crises or electrolyte disturbances. Generalized hypotonia aligns with systemic metabolic dysfunction.  
5. **Early Mortality**: Neonatal death, death in infancy/childhood/adolescence reflects the severe, progressive nature of untreated HT-1, often due to liver failure or neurological crises.  
6. **Prenatal/Developal Abnormalities**: Congenital enzyme deficiency explains prenatal growth issues and multisystemic involvement.  
7. **Biochemical Markers**: Elevated calcitonin and hyperglycinemia are less specific but may occur secondary to metabolic stress.  

**Conclusion**: The constellation of tyrosine metabolism derangements, liver/krenal pathology, and early lethality confirm Tyrosinemia Type I."
"['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Intellectual disability, delayed speech/motor development** align with untreated PKU, as excess phenylalanine disrupts myelination and neurotransmitter synthesis, damaging the central nervous system.  
3. **Hypertyrosinemia** may initially seem contradictory (PAH deficiency typically reduces tyrosine), but secondary tyrosine supplementation in PKU management or coexisting hepatic dysfunction could elevate levels.  
4. **Abnormal circulating porphyrin** might reflect secondary metabolic stress or liver involvement, though not a classic PKU feature.  
5. **Early mortality** (infancy/childhood/adolescence) suggests severe, untreated PKU with complications like seizures, neurodegeneration, or infections due to compromised immunity.  
6. While some symptoms (e.g., porphyrin abnormalities) are atypical, they may arise from systemic metabolic derangements or comorbidities. PKU remains the primary diagnosis due to the central role of hyperphenylalaninemia and its neurodevelopmental consequences."
"['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Obesity', 'Large for gestational age', 'Death in infancy', 'Abnormal cerebral morphology', 'Neonatal death', 'Death in childhood', 'Abnormal circulating lysine concentration', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key biochemical marker**: The presence of **L-2-hydroxyglutaric aciduria** directly indicates a defect in the metabolism of L-2-hydroxyglutarate, typically due to mutations in the *L2HGDH* gene, which encodes the enzyme L-2-hydroxyglutarate dehydrogenase.  
2. **Neurological and developmental symptoms**: **Macrocephaly**, **delayed speech**, **intellectual disability**, and **seizures** align with the progressive neurodegenerative features of L-2-HGA, caused by toxic accumulation of L-2-hydroxyglutarate in the central nervous system.  
3. **Abnormal cerebral morphology**: MRI findings (e.g., leukoencephalopathy, subcortical cysts, or basal ganglia abnormalities) are hallmark features of this disorder.  
4. **Metabolic derangement**: **Abnormal circulating lysine concentration** reflects disrupted lysine metabolism, a pathway linked to L-2-HGA.  
5. **Early mortality**: **Death in infancy/childhood** and **neonatal death** suggest severe forms of the disease, often due to metabolic decompensation or refractory seizures.  
6. **Large for gestational age (LGA)**: While less common, LGA may occur in metabolic disorders due to prenatal metabolic dysregulation.  
7. **Obesity**: May arise secondary to mitochondrial dysfunction or disrupted energy metabolism associated with the disease.  

**Conclusion**: The combination of neurodevelopmental regression, characteristic biochemical findings (L-2-hydroxyglutaric aciduria), cerebral abnormalities, and metabolic disturbances confirms the diagnosis of **L-2-hydroxyglutaric aciduria**."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Death in adolescence', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Elevated plasma citrulline and hyperammonemia are hallmark biochemical features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency. This disrupts the urea cycle, leading to ammonia accumulation. Neonatal death, death in infancy/childhood, and hypotonia align with acute neonatal-onset presentations of classic citrullinemia, where rapid ammonia toxicity causes severe neurological compromise. Motor and speech delays reflect chronic neurodevelopmental damage from recurrent hyperammonemia. Obesity may arise from metabolic dysregulation or dietary management strategies. Prenatal abnormalities (e.g., intrauterine growth restriction) and early mortality underscore the disease’s severity.  

Disease: Citrullinemia  
Reasoning: This term broadly encompasses urea cycle disorders with citrulline accumulation. The patient’s elevated citrulline, hyperammonemia, and life-threatening neonatal/childhood course are consistent with the general diagnosis. However, the specificity of neonatal death and classic biochemical profile narrows it further to type I. The inclusion of “abnormality of prenatal development” supports a congenital metabolic disorder like citrullinemia, where intrauterine ammonia exposure may affect fetal development."
"['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Intellectual disability**, **delayed speech/language development**, and **motor delay** align with untreated PKU, as elevated phenylalanine disrupts neurotransmitter synthesis and myelination.  
3. **Severe short stature** may result from chronic malnutrition due to restrictive dietary management or secondary metabolic disturbances.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low/normal). This may suggest a concurrent metabolic disorder, lab artifact, or a rare PKU variant with secondary tyrosine dysregulation.  
5. **Death in infancy/childhood** is uncommon in isolated PKU but could occur in severe, untreated cases with catastrophic neurological complications or misdiagnosis (e.g., confusion with BH4 deficiency, which has overlapping hyperphenylalaninemia but worse prognosis).  

Note: While PKU explains hyperphenylalaninemia and neurodevelopmental delays, the presence of hypertyrosinemia and early mortality warrants further investigation for comorbid conditions (e.g., tyrosinemia, BH4 deficiency) or diagnostic errors."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** may reflect untreated maternal PKU during pregnancy (maternal PKU syndrome), where high maternal phenylalanine levels disrupt fetal development (e.g., microcephaly, congenital heart defects). However, if the *infant* has PKU, prenatal abnormalities are unlikely unless compounded by maternal metabolic dysregulation.  
3. **Neonatal death/Death in infancy** aligns with severe, untreated PKU variants (e.g., classic PKU with near-complete PAH deficiency). Without early dietary intervention, hyperphenylalaninemia causes irreversible neurological damage, seizures, and failure to thrive, potentially leading to fatal complications (e.g., infections, metabolic crises) within infancy.  
4. PKU is identified via newborn screening; undiagnosed cases in unscreened populations may explain rapid progression to fatal outcomes.  

Conclusion: The combination of hyperphenylalaninemia with early mortality strongly supports PKU, emphasizing the critical need for prompt diagnosis and lifelong phenylalanine-restricted diets to prevent severe outcomes."
"['Seborrheic dermatitis', 'Death in infancy', 'Increased serum lactate', 'Fair hair', 'Brittle hair', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'White hair', 'Death in adolescence']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Metabolic abnormalities**: Increased serum lactate and hyperalaninemia indicate mitochondrial dysfunction and impaired amino acid metabolism, consistent with biotin-dependent carboxylase deficiencies (e.g., pyruvate carboxylase, propionyl-CoA carboxylase).  
2. **Dermatological features**: Seborrheic dermatitis and hair abnormalities (brittle, fair/white hair) result from biotin’s critical role in keratin synthesis and epidermal integrity.  
3. **Early mortality**: Neonatal/childhood death aligns with untreated BTDD’s progressive metabolic crises (acidosis, hyperammonemia) and neurologic deterioration.  
4. **Diagnostic confirmation**: BTDD specifically disrupts biotin recycling, causing secondary multiple carboxylase deficiency. Symptoms resolve with biotin supplementation, underscoring the enzyme deficiency as the root cause."
"['Hypertelorism', 'Low-set ears', 'Wide nasal bridge', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Excessive salivation', 'Neonatal death', 'Abnormal circulating acetylcarnitine concentration', 'Severe hearing impairment', 'Abnormal circulating creatine kinase concentration']",['Carnitine palmitoyl transferase 1A deficiency/Carnitine palmitoyltransferase I deficiency'],"Disease: Carnitine palmitoyl transferase 1A deficiency/Carnitine palmitoyltransferase I deficiency  
Reasoning:  
1. **Metabolic Abnormalities**: The patient’s abnormal circulating acetylcarnitine and creatine kinase concentrations strongly suggest a fatty acid oxidation disorder. CPT1A deficiency disrupts mitochondrial long-chain fatty acid transport, leading to accumulation of specific acylcarnitines (e.g., C16, C18:1) and secondary carnitine depletion, which may explain the abnormal acetylcarnitine profile. Elevated creatine kinase indicates muscle damage, consistent with metabolic crises.  
2. **Prenatal/Neonatal Severity**: ""Abnormality of prenatal development or birth,"" ""neonatal death,"" and ""death in infancy"" align with severe CPT1A deficiency, which can cause intrauterine metabolic stress, hypoglycemia, and lethal neonatal hepatic failure.  
3. **Neurological Manifestations**: Intellectual disability and motor delay result from recurrent hypoglycemic episodes and energy deficiency in the brain during critical developmental periods.  
4. **Dysmorphic Features**: Hypertelorism, low-set ears, and wide nasal bridge may reflect disrupted prenatal growth due to chronic metabolic instability, rather than primary structural anomalies.  
5. **Supporting Symptoms**: Excessive salivation (dysphagia/neurologic dysfunction) and severe hearing impairment (energy deficiency affecting cochlear function) are rare but plausible secondary effects of systemic metabolic dysfunction.  

**Note**: While craniofacial dysmorphism is atypical in CPT1A deficiency, the combination of metabolic lab findings, neonatal fatality, and neurological deficits provides a stronger diagnostic anchor, with dysmorphic features likely stemming from prenatal metabolic compromise."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), leading to toxic accumulation of phenylalanine.  
2. **Delayed speech and language development**: Untreated PKU results in neurotoxic effects of elevated phenylalanine, impairing brain development and cognitive/linguistic function.  
3. **Abnormality of prenatal development or birth**: Maternal PKU (untreated during pregnancy) can cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus due to intrauterine phenylalanine toxicity.  
4. **Neonatal death/Death in infancy/childhood**: Severe untreated PKU causes progressive neurodegeneration, seizures, and failure to thrive, historically leading to early mortality before dietary management became standard.  
5. **Hypertyrosinemia**: While PKU typically reduces tyrosine levels (due to blocked PAH-mediated conversion), transient hypertyrosinemia may occur in critically ill infants with hepatic dysfunction or secondary metabolic disturbances, or as a lab artifact. This symptom is atypical but does not exclude PKU as the primary diagnosis.  

**Note**: The diagnosis assumes classic PKU, with hypertyrosinemia requiring further investigation for coexisting conditions (e.g., tyrosinemia type II) or confounding factors. Confirmatory testing (PAH gene analysis, phenylalanine/tyrosine ratios) is critical."
"['Seizure', 'Spasticity', 'Death in infancy', 'Hyperammonemia', 'Increased serum lactate', 'Tachypnea', 'Oroticaciduria', 'Neonatal death', 'Elevated circulating acylcarnitine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Core feature of urea cycle disorders like OTCD, caused by impaired ammonia detoxification due to deficient OTC enzyme.  
2. **Oroticaciduria**: Pathognomonic for OTCD; accumulation of carbamoyl phosphate shunts into pyrimidine synthesis, increasing orotic acid excretion.  
3. **Elevated serum lactate**: Secondary to mitochondrial dysfunction from hyperammonemia or respiratory chain inhibition.  
4. **Tachypnea**: Compensatory response to metabolic acidosis induced by hyperammonemia and lactic acidosis.  
5. **Seizures/Spasticity**: Neurotoxicity from ammonia crossing the blood-brain barrier, causing cerebral edema and neuronal excitation.  
6. **Elevated acylcarnitines**: May reflect secondary carnitine depletion or metabolic stress disrupting fatty acid oxidation.  
7. **Neonatal death/Death in infancy**: Severe OTCD typically presents catastrophically in males (X-linked) shortly after birth due to hyperammonemic crisis if untreated.  

The constellation of hyperammonemia, oroticaciduria, and neonatal demise strongly prioritizes OTCD over other urea cycle disorders or metabolic diseases."
"['Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Recurrent viral infections', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid and glutaric aciduria**: Direct biochemical markers of glutaryl-CoA dehydrogenase deficiency, which disrupts lysine and tryptophan metabolism.  
2. **Generalized hypotonia and feeding difficulties**: Common early signs of metabolic decompensation due to toxic metabolite accumulation.  
3. **Athetosis**: Reflects basal ganglia injury (e.g., striatal necrosis) from acute encephalopathic crises triggered by metabolic stressors like infections or fasting.  
4. **Death in infancy**: Untreated GA-I leads to irreversible neurological damage or fatal metabolic crises.  
5. **Recurrent viral infections**: Likely act as triggers for metabolic decompensation rather than indicating primary immune dysfunction.  
6. **Consistency with GA-I phenotype**: Macrocephaly, movement disorders, and episodic crises align with classic GA-I presentation, though immune dysfunction is not a core feature."
"['Death in infancy', 'Hyperammonemia', 'Oroticaciduria', 'Short stature']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: OTCD disrupts the urea cycle, impairing ammonia detoxification. This leads to toxic ammonia accumulation, a hallmark of urea cycle disorders.  
2. **Oroticaciduria**: The enzyme deficiency causes carbamoyl phosphate to divert into pyrimidine synthesis, overproducing orotic acid, which is excreted in urine.  
3. **Death in infancy**: Severe neonatal-onset OTCD often results in life-threatening hyperammonemic crises without prompt treatment.  
4. **Short stature**: Chronic metabolic stress and recurrent hyperammonemia impair growth and development over time.  
OTCD aligns uniquely with this symptom cluster, distinguishing it from other urea cycle defects (e.g., citrullinemia) through the presence of oroticaciduria."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: VLCADD disrupts mitochondrial β-oxidation of very long-chain fatty acids, leading to secondary carnitine deficiency due to increased acyl-carnitine excretion and reduced reabsorption.  
2. **Neonatal death/Death in infancy**: Severe VLCADD presents in infancy with hypoketotic hypoglycemia, cardiomyopathy, or hepatic encephalopathy during metabolic stress (e.g., fasting), often progressing to fatal metabolic crises.  
3. **Abnormality of prenatal development**: Severe cases may cause intrauterine growth restriction or structural anomalies (e.g., hypertrophic cardiomyopathy) due to impaired energy production during fetal development.  
4. **Key biochemical link**: Elevated C14:1 acylcarnitine on newborn screening supports VLCADD diagnosis, aligning with the observed carnitine abnormality and clinical outcomes.  

The combination of metabolic instability, carnitine dysregulation, and early lethality strongly aligns with the severe neonatal form of VLCADD."
"['Hyperactivity', 'Lethargy', 'Coma', 'Encephalopathy', 'Abnormal cerebellum morphology', 'Dystonia', 'Tachycardia', 'Acute kidney injury', 'Fever', 'Leukocytosis', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Abnormality of extrapyramidal motor function', 'Hyperkalemia', 'Drowsiness', 'Sleep disturbance', 'Elevated hepatic transaminase', 'Hypernatremia', 'Death in childhood', 'Fatigue', 'Chronic kidney disease', 'Dyskinesia']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Hyperammonemia** and **encephalopathy**: Hallmark features of urea cycle disorders (UCDs). Citrullinemia type I (argininosuccinate synthetase deficiency) disrupts the urea cycle, leading to ammonia accumulation, neurotoxicity, and cerebral edema.  
2. **Neurological symptoms** (lethargy, coma, dystonia, dyskinesia, extrapyramidal abnormalities): Result from ammonia-induced neuronal damage, particularly in the basal ganglia and cerebellum, explaining **abnormal cerebral/cerebellar morphology**.  
3. **Acute/chronic kidney injury** and **hyperkalemia**: Metabolic acidosis and dehydration during hyperammonemic crises impair renal function. Chronic hyperammonemia may also cause tubular injury.  
4. **Elevated hepatic transaminases**: Secondary to metabolic stress or liver involvement in ammonia detoxification.  
5. **Hypernatremia**: Often due to dehydration during acute crises or inappropriate fluid management.  
6. **Death in childhood**: Untreated neonatal-onset citrullinemia type I is fatal within days to weeks without urgent ammonia-lowering therapy (e.g., dialysis).  
7. **Supporting features**: Leukocytosis and fever (inflammatory response to metabolic crisis), sleep disturbances, and fatigue (neurological dysfunction).  

Disease: Citrullinemia  
Reasoning:  
- This is the Chinese term for Citrullinemia type I. The reasoning aligns identically with the above, as it refers to the same disorder. The symptoms collectively match the classic presentation of this autosomal recessive urea cycle defect."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Fever', 'Diarrhea', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating aspartate family amino acid concentration', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: The hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia**: Secondary elevation of tyrosine may occur due to competitive inhibition of tyrosine metabolism by excess phenylalanine or dietary protein restrictions.  
3. **Delayed speech/development**: Untreated PKU results in neurotoxic effects of phenylalanine, impairing cognitive and language development.  
4. **Abnormal prenatal development/Neonatal death**: Severe PAH deficiency can manifest prenatally; untreated cases may lead to metabolic instability and early mortality.  
5. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) may appear in urine as alternative degradation products.  
6. **Recurrent infections/Diarrhea/Fever**: Possible secondary to dietary management (low-protein diets affecting immune function) or metabolic stress.  
7. **Abnormal aspartate family amino acids**: Disruption in amino acid metabolism pathways due to phenylalanine excess may indirectly alter aspartate-related metabolites.  

*Note:* While some symptoms (e.g., recurrent infections) are atypical for classic PKU, they may reflect complications of severe/prolonged metabolic derangement or comorbidities. Confirmatory testing (PAH gene variants, phenylalanine levels, neonatal screening results) is critical."
"['Low-set ears', 'Anteverted nares', 'Ptosis', 'Delayed speech and language development', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'High, narrow palate', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Polydactyly', 'Elevated 7-dehydrocholesterol']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) paired with hypocholesterolemia are pathognomonic for SLOS, caused by DHCR7 mutations disrupting cholesterol synthesis.  
2. **Craniofacial features**: Low-set ears, anteverted nares, ptosis, and high/narrow palate align with SLOS-associated dysmorphisms.  
3. **Limb anomalies**: Syndactyly (often 2nd-3rd toes) and polydactyly are hallmark findings in SLOS.  
4. **Neurodevelopmental delays**: Intellectual disability, motor/speech delays, and hyperactivity reflect impaired cholesterol-dependent neurodevelopment.  
5. **Severe prognosis**: Neonatal death, infant/childhood mortality, and multisystem involvement indicate a severe SLOS phenotype (e.g., type II).  
6. **Exclusion of mimics**: No features suggesting other polydactyly-associated syndromes (e.g., Bardet-Biedl, Meckel-Gruber), and biochemical findings uniquely point to SLOS."
"['Macrocephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Death in infancy', 'Hyperammonemia', 'Opisthotonus', 'Hepatomegaly', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Elevated plasma citrulline', 'Uraciluria']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Hyperammonemia** and **elevated plasma citrulline** are hallmark biochemical features of argininosuccinic aciduria (ASA), a urea cycle disorder caused by argininosuccinate lyase deficiency.  
2. **Aminoaciduria** (including **uraciluria**) and **abnormal circulating arginine/proline concentrations** reflect disrupted urea cycle metabolism and secondary effects on amino acid transport.  
3. **Neurological symptoms** (ataxia, opisthotonus, intellectual disability, motor/speech delays) result from chronic hyperammonemia and toxic metabolite accumulation.  
4. **Hepatomegaly** and **neonatal/childhood death** align with acute metabolic crises and multi-organ failure in severe ASA.  
5. **Prenatal abnormalities** and **macrocephaly** may stem from intrauterine ammonia toxicity or metabolic dysregulation.  
6. **Elevated citrulline** specifically differentiates ASA from other urea cycle defects (e.g., ornithine transcarbamylase deficiency), while **arginine/proline abnormalities** correlate with ASA’s unique biochemical profile."
"['Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Hypertyrosinemia**: Uncommon in classic PKU but may occur secondary to metabolic dysregulation or dietary mismanagement (e.g., unbalanced tyrosine intake).  
3. **Neonatal death/Death in infancy/adolescence**: Untreated PKU can cause severe neurological damage, seizures, and organ failure, potentially leading to early mortality without strict dietary intervention.  
4. **Obesity**: May arise from excessive calorie intake in low-phenylalanine diets or metabolic imbalances from prolonged poor disease control.  
5. **Exclusion of alternatives**: Tyrosinemia or other aminoacidurias were considered but ruled out due to the prominence of hyperphenylalaninemia and alignment with PKU pathophysiology.  

Note: Hypertyrosinemia and early death suggest atypical severity or comorbidities, but PKU remains the primary diagnosis based on hyperphenylalaninemia."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria  
Reasoning:  
1. **Hyperphenylalaninemia** is the defining biochemical feature of PKU, caused by mutations in the *PAH* gene, leading to impaired phenylalanine metabolism.  
2. **Abnormality of prenatal development or birth** may occur in maternal PKU syndrome, where elevated phenylalanine levels during pregnancy cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus. If the patient is the affected infant, this could reflect intrauterine growth restriction due to metabolic dysregulation.  
3. **Neonatal death/Death in infancy**: Untreated PKU does not typically cause death in the neonatal period, but severe variants (e.g., BH4-deficient PKU) or complications like metabolic crises/sepsis in undiagnosed cases may lead to early mortality.  
4. **Death in early adulthood**: Chronic untreated hyperphenylalaninemia results in irreversible neurological damage, seizures, and systemic complications (e.g., osteoporosis, cardiomyopathy), which may contribute to premature death if dietary management is absent.  

The constellation of symptoms aligns with a severe, untreated PKU phenotype, exacerbated by lack of newborn screening or therapy, progressing from infancy to adulthood with fatal outcomes."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Death in infancy/childhood/adolescence**: Untreated PKU leads to severe neurological damage, seizures, and failure to thrive, often resulting in early mortality without dietary intervention.  
3. **Elevated urinary carboxylic acids**: Phenylalanine derivatives like phenylpyruvate and phenyllactate (classic phenylketones) may be detected as urinary carboxylic acids.  

**Inconsistencies/Additional Considerations**:  
- **Hypertyrosinemia**: Not typical in PKU (tyrosine levels are usually low/normal). Suggests possible comorbid tyrosinemia or BH4 deficiency (a PKU variant).  
- **Recurrent viral infections**: Unrelated to classic PKU; may indicate immune dysfunction from malnutrition or a secondary disorder.  
- **Abnormal porphyrins/decreased ferritin**: Could reflect hepatic dysfunction or nutritional deficiencies due to restricted diets in PKU management.  

While PKU explains hyperphenylalaninemia and early mortality, hypertyrosinemia and immune issues warrant investigation for overlapping metabolic disorders (e.g., BH4 deficiency) or comorbidities."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Spasticity', 'Death in infancy', 'Hyperammonemia', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia & Abnormality of galactoside metabolism**: Directly indicate impaired galactose metabolism, a hallmark of galactosemia.  
2. **Feeding difficulties & Spasticity**: Common in infants with galactosemia due to toxin accumulation (e.g., galactitol) affecting the liver, brain, and kidneys.  
3. **Hyperammonemia & Abnormal amino acid concentrations**: Caused by liver dysfunction from toxic metabolite buildup (galactose-1-phosphate), disrupting urea cycle and amino acid metabolism.  
4. **Prolonged PTT**: Results from coagulopathy secondary to liver damage.  
5. **Neonatal/Infancy/Childhood death**: Untreated classic galactosemia leads to sepsis, liver failure, or neurological complications, often fatal early in life.  
6. **Prenatal developmental abnormality**: May reflect intrauterine toxicity from maternal galactose exposure in severe cases.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning:  
- Overlaps with classic galactosemia but emphasizes the broader category. Key symptoms (hypergalactosemia, liver dysfunction, metabolic abnormalities) align with galactosemia subtypes. Early mortality and hyperammonemia reinforce the diagnosis.  
- Differentiation: Classic galactosemia (GALT deficiency) is the most severe form, explaining the fatal trajectory, while ""galactosemia"" may encompass other enzymatic defects (e.g., GALK1, GALE), though the symptom severity here points to GALT deficiency."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Hepatomegaly', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating creatine kinase concentration', 'Preeclampsia']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by defective carnitine transport due to mutations in the *SLC22A5* gene.  
2. **Hyperammonemia** and **hepatomegaly** arise from impaired fatty acid oxidation, leading to toxic metabolite accumulation and hepatic dysfunction.  
3. **Increased total bilirubin** reflects secondary liver injury from metabolic stress.  
4. **Abnormal circulating aspartate/alanine concentrations** suggest disrupted amino acid metabolism due to energy crisis in hepatocytes.  
5. **Elevated creatine kinase** indicates muscle damage from insufficient energy production in skeletal/cardiac muscle.  
6. **Gastrointestinal inflammation** may result from mitochondrial dysfunction in enterocytes.  
7. **Premature birth** and **preeclampsia** are maternal-fetal complications linked to placental insufficiency in maternal PCD.  
8. **Infancy/childhood mortality** correlates with untreated metabolic crises (hypoketotic hypoglycemia, cardiomyopathy) characteristic of PCD.  
9. Neonatal presentations align with the classic severe phenotype of early-onset PCD.  

The constellation of metabolic derangements, organ dysfunction, and carnitine deficiency strongly supports this diagnosis over urea cycle disorders or mitochondrial fatty acid oxidation defects."
"['Death in infancy', 'Premature birth', 'Hypertriglyceridemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Premature birth** and early mortality (**neonatal death, death in infancy/childhood**) align with MCADD, a fatty acid oxidation disorder causing metabolic crises triggered by fasting, often fatal if undiagnosed.  
2. **Hypertriglyceridemia** arises due to impaired mitochondrial β-oxidation of medium-chain fatty acids, leading to alternative lipid metabolism pathways and triglyceride accumulation.  
3. **Abnormal circulating carnitine concentration** (secondary carnitine deficiency) occurs as excess unmetabolized medium-chain acyl-CoA intermediates bind carnitine, promoting its urinary excretion.  
4. MCADD typically presents with hypoglycemia, lethargy, and vomiting during metabolic stress (e.g., fasting), progressing to seizures, coma, or death—consistent with the fatal outcomes described.  
5. Ruled out long-chain fatty acid oxidation disorders (e.g., VLCADD) due to absence of cardiomyopathy/muscle weakness, which are less prominent in MCADD."
"['Coma', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Hyperammonemia', 'Respiratory distress', 'Cerebral edema', 'Fasciculations', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating citrulline concentration']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic Citrullinemia)  
Reasoning:  
1. **Hyperammonemia** and **metabolic acidosis** are hallmark features of urea cycle disorders (UCDs). Citrullinemia type I results from **argininosuccinate synthetase (ASS) deficiency**, disrupting the urea cycle.  
2. **Abnormal circulating citrulline concentration** (severely elevated) directly reflects the enzyme defect, as citrulline cannot be converted to argininosuccinate.  
3. **Abnormal glutamine** (elevated) and **aspartate family amino acids** (disrupted) align with urea cycle dysfunction, as glutamine acts as an ammonia buffer.  
4. **Cerebral edema** and **coma** are secondary to ammonia neurotoxicity. **Respiratory distress** may arise from ammonia-induced central hyperventilation or metabolic acidosis compensation.  
5. **Generalized hypotonia**, **hyporeflexia**, and **fasciculations** reflect acute neurological injury from hyperammonemia.  
6. **Neonatal death** and **death in infancy** are typical in untreated classic citrullinemia due to rapid ammonia accumulation and multiorgan failure.  
7. **Prolonged PTT** and **increased bilirubin** suggest hepatic dysfunction, a known complication of UCDs.  
8. **Tachycardia** and **metabolic acidosis** correlate with systemic metabolic decompensation.  

The absence of liver-specific markers (e.g., citrin deficiency in type II) and the neonatal presentation confirm **Citrullinemia type I**."
"['Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Death in childhood', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency (SSADH deficiency)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: SSADH deficiency disrupts GABA metabolism, leading to accumulation of gamma-hydroxybutyric acid (GHB), a carboxylic acid excreted in urine.  
2. **Neurodevelopmental symptoms**: Delayed speech, hyperactivity, and intellectual disability align with GABAergic dysfunction, as GABA is critical for neuronal regulation and brain development.  
3. **Early mortality**: Severe cases may involve life-threatening complications (e.g., seizures, respiratory failure, or neuroregressive crises) contributing to death in childhood/adolescence.  
4. **Metabolic confirmation**: The triad of neurobehavioral abnormalities, elevated urinary GHB, and genetic testing confirms SSADH deficiency, distinguishing it from other organic acidurias."
"['Polycystic ovaries', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Hypertyrosinemia', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood', 'Pustule']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Skin rash** and **eczematoid dermatitis** align with PKU’s dermatologic manifestations due to metabolite accumulation and impaired skin barrier function.  
3. **Gastrointestinal inflammation**, **vomiting**, and **diarrhea** may reflect dietary protein intolerance or metabolic stress from phenylalanine toxicity.  
4. **Generalized hypotonia** and **obesity** correlate with untreated PKU’s neurologic sequelae and restrictive dietary management (high-carbohydrate diets).  
5. **Recurrent viral infections** could stem from secondary immune dysfunction due to chronic metabolic imbalance.  
6. **Death in infancy/childhood/adolescence/early adulthood** reflects untreated PKU’s natural history, involving severe neurodegeneration, organ failure, or complications like seizures.  
7. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or coexisting metabolic stressors.  
8. **Polycystic ovaries** and **pustules** are less specific but may arise from hormonal disruptions or inflammatory responses linked to chronic metabolic derangement.  

Note: While some symptoms (e.g., hypertyrosinemia) suggest overlap with tyrosinemia or BH4 deficiency, the definitive diagnosis of PKU is prioritized due to **hyperphenylalaninemia** as the central finding. Early fatality timelines emphasize untreated/severe disease progression."
"['Obesity', 'Abdominal pain', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning:  
1. **Abdominal pain** is a hallmark symptom of acute intermittent porphyria (AIP), caused by neurovisceral attacks due to accumulation of porphyrin precursors.  
2. **Death in childhood** aligns with severe, undiagnosed AIP cases, where acute attacks can lead to respiratory failure, seizures, or cardiac arrhythmias.  
3. **Obesity** is atypical for AIP but may reflect metabolic comorbidities, misreported ascites, or steroid use (e.g., during treatment).  
4. AIP typically manifests post-puberty but can occur earlier; childhood mortality suggests a severe genetic variant or delayed diagnosis.  

Disease: Porphyria/Porphyria  
Reasoning:  
1. The term broadly encompasses porphyria disorders, including hepatic (e.g., AIP) or erythropoietic types.  
2. **Abdominal pain** and **death in childhood** could indicate a severe subtype (e.g., congenital erythropoietic porphyria), though cutaneous symptoms would typically dominate.  
3. **Obesity** remains incongruent with classical porphyria phenotypes but may reflect secondary factors (e.g., limited mobility from chronic illness).  
4. Generalized classification allows for atypical presentations but lacks specificity compared to AIP.  

**Conclusion**: Acute intermittent porphyria is the most precise diagnosis, while ""porphyria"" serves as a broader category. Obesity likely represents a confounding factor or comorbidity."
"['Cerebellar atrophy', 'Generalized hypotonia', 'Tachycardia', 'Cardiac arrest', 'Skeletal muscle atrophy', 'Death in childhood', 'Recurrent viral infections', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Cerebellar agenesis', 'Increased urinary glycerol']",['Isolated glycerol kinase deficiency/Glycerol kinase deficiency'],"Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol** is pathognomonic for glycerol kinase deficiency (GKD), as the enzyme deficiency prevents glycerol metabolism, leading to its urinary excretion.  
2. **Skeletal muscle atrophy** and **generalized hypotonia** align with impaired energy production due to disrupted glycerol utilization in muscle tissue.  
3. **Aplasia/Hypoplasia of extremity musculature** suggests developmental metabolic dysfunction affecting muscle formation.  
4. **Cardiac arrest** and **tachycardia** may result from metabolic crises or cardiomyopathy secondary to energy deficits in cardiac tissue.  
5. **Recurrent viral infections** could reflect episodic metabolic decompensation weakening immune resilience.  
6. **Death in childhood** correlates with severe metabolic instability or cardiac complications in untreated GKD.  
7. **Cerebellar atrophy/agenesis** is atypical for isolated GKD but may represent a phenotypic variant or comorbid condition, though the primary diagnosis is anchored by urinary glycerol elevation and metabolic features."
"['Acne', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia**: Uncommon in classic PKU but may occur in atypical variants or secondary metabolic disruptions (e.g., tyrosine supplementation or overlapping enzyme deficiencies).  
3. **Neonatal death/Death in infancy/Death in adolescence**: Untreated PKU causes severe neurological damage, seizures, and organ failure, leading to early mortality in unscreened or unmanaged cases.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies, though this symptom is atypical for infantile PKU.  
5. **Acne**: May arise from tyrosine metabolism imbalances or secondary skin effects of chronic metabolic stress.  
6. **Diagnostic alignment**: While hypertyrosinemia and prenatal abnormalities are atypical, hyperphenylalaninemia and the mortality pattern strongly suggest PKU with severe complications from delayed diagnosis/treatment."
"['Coma', 'Death in infancy', 'Premature birth', 'Metabolic acidosis', 'Hypoglycemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Death in adolescence', 'Hypoxemia']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia and metabolic acidosis**: MCADD impairs mitochondrial β-oxidation of medium-chain fatty acids, leading to insufficient ketone production during fasting. This results in hypoglycemia (due to reliance on glucose without alternative energy sources) and metabolic acidosis (from accumulating toxic metabolites like medium-chain acylcarnitines).  
2. **Decreased plasma free carnitine**: Unmetabolized medium-chain acyl-CoA intermediates bind to carnitine, forming acylcarnitines that accumulate and deplete free carnitine.  
3. **Life-threatening crises and early mortality**: Prolonged fasting or metabolic stress (e.g., infections) triggers acute decompensation, causing coma, hypoxemia (secondary to respiratory failure), and multi-organ dysfunction. Untreated cases often result in neonatal death or death in infancy/childhood/adolescence.  
4. **Gastrointestinal inflammation**: May arise during metabolic crises due to tissue hypoxia or direct toxicity from metabolites.  
5. **Premature birth**: Not a primary feature of MCADD but may reflect prenatal stress or comorbid factors contributing to early presentation.  

The constellation of hypoglycemia, metabolic acidosis, carnitine deficiency, and catastrophic outcomes aligns pathognomonically with MCADD, a disorder of fatty acid oxidation. Confirmatory testing would include plasma acylcarnitine profile (elevated C6-C10 species) and genetic analysis of *ACADM* gene variants."
"['Hyperammonemia', 'Hyperglycinemia', 'Hyperalaninemia', 'Decreased plasma free carnitine']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia/Propionic acidemia  
Reasoning:  
1. **Hyperammonemia**: Propionic acidemia disrupts the urea cycle due to accumulation of propionyl-CoA and its derivatives, impairing ammonia detoxification.  
2. **Hyperglycinemia**: Propionyl-CoA inhibits glycine cleavage enzyme activity, reducing glycine catabolism and elevating glycine levels.  
3. **Hyperalaninemia**: Secondary mitochondrial dysfunction and metabolic stress increase protein catabolism, releasing alanine as a byproduct.  
4. **Decreased plasma free carnitine**: Excess propionyl-CoA conjugates with carnitine (forming propionylcarnitine), depleting free carnitine reserves.  
5. **Pathogenic mechanism**: Biallelic mutations in *PCCA* or *PCCB* genes cause propionyl-CoA carboxylase deficiency, blocking valine, isoleucine, methionine, and odd-chain fatty acid metabolism. This results in toxic metabolite accumulation and secondary biochemical disturbances."
"['Cryptorchidism', 'Self-mutilation', 'Delayed speech and language development', 'Cyanosis', 'Abnormality of skin pigmentation', 'Abnormality of prenatal development or birth', 'Seizure', 'Death in infancy', 'Dehydration', 'Fever', 'Hyperkalemia', 'Hypokalemia', 'Hyponatremia', 'Neonatal death', 'Death in childhood', 'Pigmentation of the sclera', 'Severe hearing impairment', 'Elevated circulating 17-hydroxyprogesterone concentration']","['21-hydroxylase deficiency; 21-OHD/Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency/Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency']","Disease: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency  
Reasoning:  
1. **Elevated 17-hydroxyprogesterone (17-OHP)**: This is the hallmark biochemical marker of 21-hydroxylase deficiency (21-OHD), as the enzyme defect blocks cortisol synthesis, causing precursor accumulation.  
2. **Salt-wasting features**: Hyponatremia, hyperkalemia, dehydration, and neonatal/childhood death align with aldosterone deficiency, leading to electrolyte imbalances and adrenal crises.  
3. **Skin/scleral pigmentation**: Elevated ACTH (due to cortisol deficiency) stimulates melanocytes, causing hyperpigmentation.  
4. **Cryptorchidism and prenatal abnormalities**: Androgen imbalances in utero may disrupt genital development in males, though ambiguous genitalia (more typical in females) is absent here.  
5. **Seizures and developmental delays**: Likely secondary to recurrent metabolic derangements (e.g., hyponatremia, hypoglycemia) during adrenal crises.  
6. **Fever, cyanosis, death**: Reflect acute adrenal insufficiency crises, which can cause hypovolemic shock and multi-organ failure if untreated.  
7. **Hypokalemia discrepancy**: May represent transient fluctuations or misclassification; hyperkalemia is pathognomonic for salt-wasting 21-OHD.  
8. **Severe hearing impairment**: Uncommon in 21-OHD but could indicate a coincidental finding or atypical presentation.  

Other symptoms (e.g., self-mutilation) are atypical for 21-OHD and may suggest comorbidities, but the biochemical and cardinal clinical features strongly confirm the diagnosis."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, along with **metabolic acidosis** caused by toxic accumulation of methylmalonic acid. **Seizures** and **generalized hypotonia** align with neurological complications of MMA. **Neonatal death** and **death in infancy** reflect the severe, early-onset nature of the disease due to metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The lack of response to vitamin B12 (implied by the absence of hematologic abnormalities and rapid progression) points to a **mutase deficiency subtype**. This subtype is caused by mutations in the *MUT* gene, leading to dysfunctional methylmalonyl-CoA mutase. The severity of symptoms (e.g., **neonatal death**) and metabolic instability are characteristic of this variant, which typically does not improve with B12 supplementation."
"['Macrocephaly', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** is a hallmark biochemical feature of GA-I, directly indicating a defect in glutaryl-CoA dehydrogenase, which disrupts lysine and tryptophan metabolism.  
2. **Macrocephaly** often presents in infancy due to abnormal accumulation of neurotoxic metabolites (glutaric acid, 3-hydroxyglutaric acid), causing frontotemporal atrophy.  
3. **Dystonia and dyskinesia** arise from striatal neurodegeneration, typically triggered by acute metabolic crises during infections or fever (aligned with **fever**, **vomiting**, and **diarrhea**).  
4. **Lethargy**, **drowsiness**, and **generalized hypotonia** reflect acute encephalopathic crises caused by metabolic acidosis and energy depletion in the brain.  
5. **Hyperhidrosis** and **sleep disturbance** are linked to autonomic nervous system dysfunction secondary to metabolic stress.  
6. **Dyspnea** may occur during metabolic decompensation due to respiratory compensation for acidosis or muscle weakness.  
7. **Death in infancy** underscores the severity of untreated GA-I, as crises lead to irreversible neurological damage or metabolic collapse.  
The combination of neurodevelopmental, metabolic, and autonomic symptoms, alongside biochemical evidence (glutaric aciduria), confirms GA-I."
"['Hydrocephalus', 'High forehead', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Cerebral atrophy', 'Athetosis', 'Glutaric aciduria', 'Death in childhood']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity.  
2. **Neurological symptoms (Spasticity, Athetosis, Cerebral atrophy)**: Accumulation of glutaric acid and 3-hydroxyglutaric acid damages the basal ganglia and white matter, leading to dystonia, movement disorders, and progressive neurodegeneration.  
3. **Macrocephaly/High forehead**: Often presents in infancy due to transient subdural hemorrhages or pseudohydrocephalus secondary to brain atrophy.  
4. **Generalized hypotonia**: Early manifestation before metabolic crises or neurological deterioration.  
5. **Death in infancy/childhood**: Severe metabolic decompensation (e.g., during infections) or irreversible brain injury in untreated cases.  
6. **Cerebral atrophy**: Chronic neurotoxicity from toxic metabolites results in progressive loss of brain tissue.  
The combination of characteristic organic aciduria, striatal injury patterns, and clinical progression aligns definitively with GA-I."
"['Hyperactivity', 'Hypertrichosis', 'Intellectual disability', 'Spasticity', 'Coma', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Pneumonia', 'Oroticaciduria', 'Ornithinuria', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating glutamine concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties', 'Hyperornithinemia', 'Uraciluria', 'Hypoammonemia', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: The patient exhibits **elevated plasma citrulline**, a hallmark of citrullinemia, caused by defects in the urea cycle. Key symptoms like **hyperammonemia** (ammonia accumulation), **oroticaciduria**, and **uraciluria** indicate a urea cycle disruption, as excess carbamoyl phosphate is diverted to pyrimidine synthesis. **Intellectual disability**, **spasticity**, and **coma** align with neurotoxicity from hyperammonemia. **Feeding difficulties** and **neonatal death** are consistent with severe neonatal-onset forms. Abnormal amino acid concentrations (**glutamine**, **arginine**) further reflect urea cycle dysfunction.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia type I (argininosuccinate synthetase deficiency) is confirmed by **elevated citrulline** and **hyperornithinemia**. **Acute/chronic hepatitis** and **hypertrichosis** suggest liver involvement, common in type I. **Recurrent infections** and **pneumonia** may stem from metabolic instability impairing immunity. **Death in infancy/childhood** correlates with the severe prognosis of untreated type I. **Oroticaciduria** and **ornithinuria** directly link to urea cycle blockage, while **hypoammonemia** (if confirmed) could indicate late-stage liver failure. The biochemical triad of citrullinemia (high citrulline, orotic aciduria, hyperammonemia) and early lethality solidify this diagnosis."
"['Vomiting', 'Migraine', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Low plasma citrulline', 'Death in childhood', 'Death in adolescence', 'Uraciluria', 'Decreased circulating ferritin concentration', 'Abnormal vitamin B12 level']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Urea Cycle Dysregulation**: OTCD disrupts the urea cycle, impairing ammonia detoxification. While hyperammonemia is not explicitly listed, symptoms like vomiting and migraines align with episodic ammonia toxicity.  
2. **Hyperglutaminemia**: Excess ammonia drives glutamine synthesis via glutamine synthetase, explaining elevated glutamine levels.  
3. **Oroticaciduria/Uraciluria**: Urea cycle blockage shunts carbamoyl phosphate into pyrimidine synthesis, overproducing orotic acid and uracil, excreted in urine.  
4. **Low Plasma Citrulline**: OTCD prevents carbamoyl phosphate and ornithine from forming citrulline, reducing its plasma levels.  
5. **Hyperalaninemia**: Alternative nitrogen disposal via alanine transamination elevates alanine.  
6. **Secondary Metabolic Abnormalities**: Decreased ferritin and abnormal B12 may reflect liver dysfunction or metabolic stress from chronic hyperammonemia.  
7. **Early Mortality**: Untreated OTCD causes lethal hyperammonemic crises, consistent with death in childhood/adolescence.  
**Key Differentiators**: Oroticaciduria and low citrulline distinguish OTCD from other urea cycle disorders (e.g., citrullinemia, where citrulline is elevated)."
"['Macrocephaly', 'Cystic hygroma', 'Death in infancy', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria and elevated glutaric acid**: These are hallmark biochemical findings of GA-I, caused by a deficiency in glutaryl-CoA dehydrogenase (GCDH), disrupting lysine and tryptophan metabolism.  
2. **Macrocephaly**: A common early feature of GA-I, often due to frontotemporal atrophy or enlarged subdural spaces, creating the appearance of an enlarged head.  
3. **Death in infancy**: Untreated GA-I leads to acute metabolic crises (triggered by infections or fasting), resulting in striatal necrosis, dystonia, and severe neurological deterioration, which can be fatal in early childhood.  
4. **Cystic hygroma**: While not a typical feature of GA-I, it may represent a coincidental finding or a prenatal manifestation of fluid accumulation due to altered metabolic stress.  
5. **Exclusion of alternatives**: Glutaric acidemia type II (GA-II) presents with different metabolic profiles (e.g., multiple acyl-CoA dehydrogenase deficiency), and other macrocephaly-associated disorders (e.g., Sotos syndrome) lack the biochemical markers seen here.  

The combination of macrocephaly, glutaric aciduria, and metabolic derangement strongly supports GA-I as the primary diagnosis."
"['Spastic diplegia', 'Death in infancy', 'Cerebral cortical atrophy', 'Opisthotonus', 'Athetosis', 'Spastic tetraplegia', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Elevated glutaric acid & Glutaric aciduria**: Direct biochemical markers of GA-I due to deficient glutaryl-CoA dehydrogenase enzyme activity, impairing lysine and tryptophan metabolism.  
2. **Decreased plasma free carnitine**: Secondary carnitine depletion occurs as carnitine binds to accumulating glutaric acid, forming glutarylcarnitine for excretion.  
3. **Cerebral cortical atrophy**: Neurotoxic effects of glutaric acid and its derivatives (e.g., 3-hydroxyglutaric acid) cause striatal and cortical neuronal damage.  
4. **Spastic diplegia/tetraplegia, Opisthotonus, Athetosis**: Result from basal ganglia and corticospinal tract injury, characteristic of GA-I-associated encephalopathic crises.  
5. **Death in infancy**: Untreated GA-I leads to acute metabolic decompensation (often triggered by infections), severe neurological damage, and early mortality.  
The triad of macrocephaly (not listed here but common), striatal necrosis, and organic acidemia strongly supports GA-I. Early-onset neurological deterioration with specific biochemical abnormalities confirms the diagnosis."
"['Seizure', 'Death in infancy', 'Hypoglycemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormality of acid-base homeostasis', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency  
Reasoning:  
1. **Hypoglycemia & Seizures**: Impaired ketogenesis due to HMG-CoA lyase deficiency prevents energy production during fasting, leading to hypoglycemia and subsequent seizures.  
2. **Hepatomegaly & Elevated Transaminases**: Toxic accumulation of metabolites (e.g., 3-hydroxy-3-methylglutaric acid) causes hepatic stress and mitochondrial dysfunction.  
3. **Dicarboxylic Aciduria**: Secondary to defective fatty acid β-oxidation, prompting ω-oxidation of fatty acids as an alternative pathway.  
4. **3-Methylglutaric Aciduria**: Direct consequence of blocked leucine catabolism at the HMG-CoA lyase step, causing buildup of upstream metabolites.  
5. **Acid-Base Homeostasis Abnormality**: Metabolic acidosis from excess organic acids (e.g., 3-hydroxy-3-methylglutaric acid) overwhelms buffering systems.  
6. **Decreased Plasma Free Carnitine**: Organic acids bind carnitine, forming acylcarnitines excreted in urine, depleting free carnitine reserves.  
7. **Elevated Urinary Carboxylic Acids**: Reflects systemic excretion of toxic intermediates (3-hydroxy-3-methylglutaric, 3-methylglutaric, and dicarboxylic acids).  
8. **Death in Infancy**: Untreated episodes of metabolic decompensation (hypoglycemia, acidosis) lead to fatal outcomes early in life.  

The constellation of findings aligns pathognomonically with HMG-CoA lyase deficiency, a leucine catabolism and ketogenesis disorder."
"['Macrocephaly', 'Seizure', 'Death in infancy', 'Anemia', 'Fever', 'Glutaric aciduria', 'Death in childhood']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and related metabolites.  
2. **Macrocephaly**: A hallmark of GA-I, often presenting prenatally or in early infancy due to abnormal brain development or fluid accumulation (e.g., subdural hygromas).  
3. **Seizures**: Result from metabolic crises triggered by catabolic stressors (e.g., fever, infection), causing acute neurotoxicity from accumulating metabolites.  
4. **Death in infancy/childhood**: Untreated GA-I leads to severe encephalopathic crises, irreversible striatal damage, and early mortality without dietary and metabolic management.  
5. **Anemia**: May arise secondary to metabolic disturbances or bone marrow suppression during acute illness.  
6. **Fever**: Often precipitates metabolic decompensation, exacerbating glutaric acid and 3-hydroxyglutaric acid accumulation, worsening neurological symptoms.  
The combination of macrocephaly, metabolic acidosis (implied by glutaric aciduria), and neurological deterioration aligns pathognomonically with GA-I."
"['Seizure', 'Death in infancy', 'Neonatal death', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning: The combination of seizures, neonatal death or death in infancy, and elevated urinary carboxylic acids strongly suggests a severe inborn error of branched-chain amino acid (BCAA) metabolism. MSUD is caused by deficient activity of the branched-chain α-keto acid dehydrogenase complex, leading to accumulation of leucine, isoleucine, valine, and their corresponding α-keto acids (branched-chain carboxylic acids) in bodily fluids. Elevated urinary carboxylic acids reflect this biochemical signature. Neonatal presentation with metabolic decompensation (e.g., seizures, encephalopathy) and rapid progression to lethality without intervention aligns with the classic form of MSUD. Early diagnosis via newborn screening or urinary organic acid analysis is critical, as delayed treatment results in irreversible neurological damage or death."
"['Generalized hypotonia', 'Death in infancy', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia', 'Decreased circulating ferritin concentration', 'Acute hepatitis', 'Chronic hepatitis']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** and **abnormality of galactoside metabolism** directly indicate impaired galactose processing, a hallmark of galactosemia.  
2. **Elevated hepatic transaminases**, **increased bilirubin**, and **acute/chronic hepatitis** reflect severe liver injury caused by toxic accumulation of galactose metabolites (e.g., galactitol).  
3. **Prolonged partial thromboplastin time** and **neonatal death** stem from liver dysfunction impairing clotting factor synthesis and multisystem failure.  
4. **Generalized hypotonia** and **abnormal aspartate/alanine concentrations** suggest secondary metabolic disturbances from hepatic damage and mitochondrial dysfunction.  
5. **Decreased ferritin** may arise from disrupted iron metabolism due to hepatic injury.  
6. **Neonatal presentation** aligns with classic galactosemia (GALT deficiency), where symptoms manifest upon lactose exposure from breast milk/formula.  
7. Exclusion of other disorders (e.g., tyrosinemia) is supported by specific galactose-related abnormalities and the provided diagnostic list."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with untreated maternal PKU, where high phenylalanine levels during pregnancy cause fetal developmental issues.  
3. **Death in infancy/Neonatal death/Death in childhood** reflects severe untreated PKU, leading to neurotoxicity, seizures, and metabolic crises without early dietary intervention.  
4. **Hypertyrosinemia** initially seems contradictory (classic PKU typically shows *low* tyrosine), but may indicate:  
   - Coexisting tyrosinemia type II/III (unlikely without specific hepatic/ocular symptoms),  
   - Secondary tyrosine elevation due to liver dysfunction or metabolic stress in critical illness,  
   - A rare PKU variant with atypical tyrosine dynamics (e.g., partial PAH activity with compensatory pathways).  
5. PKU remains the primary diagnosis due to **hyperphenylalaninemia** and clinical progression, with hypertyrosinemia requiring further investigation for comorbidities or metabolic complexities."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
- **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by a deficiency in phenylalanine hydroxylase (PAH), which prevents the conversion of phenylalanine to tyrosine.  
- **Hypertyrosinemia**: While classic PKU typically results in **low or normal tyrosine levels** (due to blocked PAH activity), hypertyrosinemia here may indicate a secondary metabolic disruption, transient neonatal tyrosinemia, or overlap with another condition (e.g., maternal PKU syndrome or BH4 deficiency).  
- **Abnormality of prenatal development**: Maternal PKU during pregnancy can cause fetal developmental defects (e.g., microcephaly, congenital heart defects) due to phenylalanine toxicity, even if the infant itself has PKU.  
- **Neonatal death/Death in infancy**: Untreated severe PKU or BH4-deficient forms (malignant PKU) can lead to rapid neurological deterioration, seizures, and metabolic crises, resulting in early mortality.  
- **Conflict resolution**: The combination of hyperphenylalaninemia and hypertyrosinemia suggests possible comorbid tyrosinemia type II (genetically distinct) or transient tyrosinemia of the newborn. However, PKU remains the primary diagnosis due to the dominant hyperphenylalaninemia and clinical alignment with severe phenotypes. Early newborn screening and dietary management are critical to prevent fatal outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD is an autosomal recessive disorder affecting fatty acid oxidation, which can lead to intrauterine stress and developmental issues due to energy deficiency.  
2. **Neonatal/Infancy/Childhood death**: Untreated MCADD causes life-threatening hypoglycemia and metabolic crises during fasting, often fatal in early life without prompt diagnosis and management.  
3. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to accumulation of toxic medium-chain acylcarnitines, which bind free carnitine, reducing its availability for fatty acid transport.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misinterpretation or mislabelling of enzyme testing. MCADD directly involves *medium-chain acyl-CoA dehydrogenase (MCAD)* deficiency, not 3-hydroxyacyl-CoA dehydrogenase. This discrepancy may stem from overlapping terminology or assay cross-reactivity in biochemical profiling.  

The constellation of early mortality, metabolic instability, and carnitine abnormalities strongly aligns with MCADD, a common fatty acid oxidation defect. Confirmatory testing would include genetic analysis of *ACADM* gene mutations and acylcarnitine profile showing elevated C6-C10 species."
"['Hypertension', 'Increased circulating renin level', 'Generalized hypotonia', 'Failure to thrive', 'Obesity', 'Death in infancy', 'Vomiting', 'Hyperkalemia', 'Hyponatremia', 'Decreased circulating renin level', 'Neonatal death', 'Death in childhood', 'Decreased circulating cortisol level', 'Feeding difficulties', 'Elevated circulating 17-hydroxyprogesterone concentration']","['21-hydroxylase deficiency; 21-OHD/Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency/Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency']","Disease: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency  
Reasoning:  
1. **Elevated 17-hydroxyprogesterone (17-OHP)**: A hallmark of 21-hydroxylase deficiency (21-OHD), as the enzyme defect prevents conversion of 17-OHP to cortisol, causing precursor accumulation.  
2. **Decreased cortisol**: Impaired cortisol synthesis due to the 21-hydroxylase enzyme deficiency, triggering compensatory adrenal hyperplasia via increased ACTH.  
3. **Salt-wasting features (hyponatremia, hyperkalemia)**: Aldosterone synthesis is also disrupted, leading to renal sodium loss, potassium retention, and hypovolemia. This explains vomiting, feeding difficulties, and failure to thrive.  
4. **Hypotonia and dehydration**: Secondary to electrolyte imbalances and hypovolemia from salt wasting.  
5. **Increased renin (if prioritized over decreased renin)**: Expected in salt-wasting 21-OHD due to hypovolemia-driven RAAS activation. ""Decreased renin"" in the symptom list may reflect testing variability or late-stage adrenal failure.  
6. **Neonatal/childhood mortality**: Untreated salt-wasting crises cause severe dehydration, shock, and death in infancy or early childhood without prompt diagnosis and glucocorticoid/mineralocorticoid replacement.  
7. **Obesity discrepancy**: Atypical for classic 21-OHD but may reflect fluid retention misinterpretation, comorbid factors, or misreported data.  
8. **Hypertension paradox**: Unusual in salt-wasting 21-OHD (typically hypotensive). Possible confounding factors (e.g., acute stress, measurement error) or overlapping conditions.  

**Conclusion**: Elevated 17-OHP, cortisol deficiency, and salt-wasting features confirm classic 21-OHD. Conflicting renin/hypertension data require clinical correlation but do not override diagnostic biochemical markers."
"['Generalized hypotonia', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Generalized hypotonia** aligns with Canavan disease, a leukodystrophy causing progressive brain tissue degeneration and impaired motor function.  
2. **Death in infancy** is consistent with the severe, rapidly progressive nature of Canavan disease, often fatal by early childhood.  
3. **Abnormal circulating aspartate family amino acid concentration** directly links to the disease’s hallmark biochemical defect: aspartoacylase deficiency, leading to elevated N-acetylaspartic acid (NAA) in blood/urine.  
4. Confirmatory evidence includes genetic testing for ASPA gene mutations and neuroimaging showing leukodystrophy (e.g., diffuse white matter degeneration).  
5. Exclusion of other leukodystrophies (e.g., Tay-Sachs, Krabbe) or amino acid metabolism disorders (e.g., citrullinemia) via clinical and biochemical differentiation."
"['Cryptorchidism', 'Hypospadias', 'Microcephaly', 'Pointed chin', 'Short chin', 'Anteverted nares', 'Torticollis', 'Strabismus', 'Hypermetropia', 'Syndactyly', 'Intellectual disability', 'Hyporeflexia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Bradycardia', 'Apnea', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Polydactyly', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol metabolism abnormalities**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol, along with hypocholesterolemia, are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS) due to defective 7-dehydrocholesterol reductase.  
2. **Craniofacial and physical features**: Microcephaly, pointed/short chin, anteverted nares, syndactyly (classic 2–3 toe fusion), and polydactyly align with SLOS-associated congenital anomalies.  
3. **Urogenital abnormalities**: Cryptorchidism and hypospadias are common in SLOS.  
4. **Neurodevelopmental issues**: Intellectual disability, motor delay, generalized hypotonia, and hyporeflexia reflect impaired nervous system development linked to cholesterol deficiency.  
5. **Perinatal complications**: Premature birth, feeding difficulties, apnea, bradycardia, and early mortality (neonatal/childhood death) correlate with severe SLOS phenotypes.  
6. **Ocular and musculoskeletal findings**: Strabismus, hypermetropia, and torticollis are consistent with SLOS.  
7. **Immunological vulnerability**: Recurrent viral infections may stem from cholesterol-dependent immune dysfunction.  
8. **Biochemical confirmation**: Elevated 7- and 8-dehydrocholesterol levels confirm the diagnosis, distinguishing SLOS from other syndromic disorders with overlapping features."
"['Irritability', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Aminoaciduria', 'Abnormal circulating pyrimidine concentration', 'Decreased plasma free carnitine', 'Hyperprolinemia', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Death in early adulthood']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, as the urea cycle enzyme deficiency prevents ammonia detoxification.  
2. **Oroticaciduria & Uraciluria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate diverts to pyrimidine synthesis, overproducing orotic acid and uracil.  
3. **Hyperglutaminemia**: Excess ammonia is converted to glutamine as an alternative detoxification pathway.  
4. **Elevated plasma citrulline**: Uncommon in classic OTCD but may occur in partial deficiencies or compensatory mechanisms, though typically low. This could reflect atypical presentation or overlapping metabolic stress.  
5. **Aminoaciduria/Hyperalaninemia/Hyperprolinemia**: Secondary to generalized amino acid overflow from impaired urea cycle function.  
6. **Metabolic acidosis**: Likely due to secondary organic acid accumulation or renal tubular dysfunction from ammonia toxicity.  
7. **Decreased plasma carnitine**: Carnitine depletion from increased acylcarnitine formation during metabolic crises.  
8. **Early mortality**: Aligns with severe urea cycle defects; untreated hyperammonemia leads to neurological damage and death.  

The triad of **hyperammonemia, oroticaciduria, and uraciluria** is diagnostic for OTCD, overriding atypical citrulline elevation. Other amino acid abnormalities and clinical outcomes further support this diagnosis."
"['Failure to thrive', 'Death in infancy', 'Hepatomegaly', 'Elevated hepatic transaminase', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Aminoaciduria', '4-hydroxyphenylacetic aciduria', 'Prolonged partial thromboplastin time', 'Hyperphenylalaninemia', 'Abnormal circulating alanine concentration', 'Acute hepatitis', 'Chronic hepatitis']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Tyrosinemia, type I: The patient presents with hepatomegaly, elevated hepatic transaminases, and acute/chronic hepatitis, indicating severe liver dysfunction. Hypertyrosinemia, hypermethioninemia, and hyperphenylalaninemia directly reflect impaired tyrosine metabolism due to fumarylacetoacetate hydrolase (FAH) deficiency. The accumulation of toxic metabolites (4-hydroxyphenylpyruvate, 4-hydroxyphenylacetate) in urine (4-Hydroxyphenylpyruvic aciduria, 4-hydroxyphenylacetic aciduria) confirms a block in the tyrosine degradation pathway. Prolonged partial thromboplastin time suggests secondary coagulopathy from hepatic synthetic failure. Aminoaciduria and abnormal alanine levels indicate renal tubular damage, consistent with the hepatorenal phenotype. Early-onset liver failure (""death in infancy"" and ""failure to thrive"") is pathognomonic for untreated Tyrosinemia type I. The biochemical and clinical triad (liver disease, renal dysfunction, neurological crises) aligns exclusively with this diagnosis."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Abnormal cerebral morphology', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability & abnormal cerebral morphology**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting myelination and neurotransmitter synthesis, causing brain damage.  
3. **Hypertyrosinemia**: Secondary tyrosine elevation may occur due to metabolic dysregulation in PKU or overlapping enzyme deficiencies (e.g., transient tyrosinemia in neonates).  
4. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) are excreted as urinary carboxylic acids.  
5. **Neonatal/infant death or death in adolescence**: Severe untreated PKU causes progressive neurodegeneration, seizures, and multisystem failure; early mortality reflects delayed diagnosis or poor dietary compliance.  
6. **Obesity**: A complication of PKU management due to high-carbohydrate/low-protein diets required to restrict phenylalanine intake.  
7. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) causes fetal developmental defects, though this overlaps less with neonatal PKU presentation.  

PKU is the unifying diagnosis, with most symptoms explained by phenylalanine toxicity or dietary management challenges."
"['Cerebellar atrophy', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy**: PMM2-CDG is characterized by progressive neurological deterioration. Cerebellar atrophy is a hallmark of the disease due to disrupted glycosylation, impairing cerebellar development and function.  
2. **Death in childhood**: PMM2-CDG type Ia is a severe, multisystem disorder. Mortality in early life is common due to complications such as liver failure, infections, or severe neurological decline.  
3. **Cerebellar agenesis**: While ""agenesis"" implies complete absence (rare in PMM2-CDG), severe cerebellar hypoplasia (underdevelopment) is frequently reported. This may reflect variability in phenotypic terminology or extreme cerebellar malformation secondary to glycosylation defects.  
4. **Consistency with PMM2-CDG**: The triad of cerebellar structural anomalies, early lethality, and systemic involvement aligns with PMM2-CDG’s clinical spectrum. Confirmatory testing (e.g., phosphomannomutase activity, genetic analysis for *PMM2* mutations) would solidify the diagnosis."
"['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Fever', 'Abnormal cerebral morphology', 'Severe hearing impairment', 'L-2-hydroxyglutaric aciduria', 'L-2-hydroxyglutaric acidemia']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key biochemical markers**: The presence of ""L-2-hydroxyglutaric aciduria"" and ""L-2-hydroxyglutaric acidemia"" in the symptom list directly indicates a defect in L-2-hydroxyglutarate dehydrogenase, leading to toxic accumulation of L-2-hydroxyglutaric acid in urine and blood.  
2. **Neurological manifestations**: Macrocephaly, delayed speech, intellectual disability, seizures, and abnormal cerebral morphology align with this disorder’s characteristic progressive encephalopathy and leukoencephalopathy.  
3. **Severe systemic involvement**: Severe hearing impairment and death in infancy suggest advanced disease progression, often due to metabolic crises, neurodegeneration, or complications like status epilepticus.  
4. **Supporting features**: Fever may reflect metabolic decompensation during intercurrent illnesses, exacerbating neurological symptoms.  
5. **Exclusion of mimics**: The combination of biochemical findings, neurodevelopmental regression, and cerebral abnormalities rules out other organic acidurias or leukodystrophies.  

The diagnosis is confirmed by genetic testing (e.g., _L2HGDH_ mutations) and consistent biochemical/neuroimaging findings."
"['Delayed speech and language development', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Opisthotonus', 'Neonatal death', 'Death in childhood', 'D-2-hydroxyglutaric aciduria']",['D-2-Hydroxyglutaric aciduria 1'],"Disease: D-2-Hydroxyglutaric Aciduria 1  
Reasoning:  
1. **Biochemical Marker**: The presence of **D-2-hydroxyglutaric aciduria** is a hallmark of D-2-Hydroxyglutaric Aciduria (D-2-HGA), specifically linking to this metabolic disorder.  
2. **Neurological Symptoms**:  
   - **Seizures** and **opisthotonus** indicate severe neurological dysfunction, consistent with cerebral accumulation of toxic metabolites (D-2-hydroxyglutarate) disrupting energy metabolism.  
   - **Generalized hypotonia** aligns with diffuse neurometabolic impairment affecting muscle tone regulation.  
3. **Developmental Delays**: **Delayed speech and language development** reflects chronic neurodevelopmental deficits caused by progressive metabolic encephalopathy.  
4. **Early Mortality**: **Neonatal death**, **death in infancy**, or **death in childhood** are seen in severe D-2-HGA type 1 cases due to metabolic crises, intractable seizures, or neurodegenerative progression.  
5. **Genetic Confirmation**: D-2-HGA type 1 is caused by mutations in *D2HGDH*, leading to impaired enzyme activity and metabolite accumulation. While phenotypic severity varies, the combination of biochemical findings and clinical features confirms the diagnosis.  

This structured analysis integrates biochemical, clinical, and genetic evidence to pinpoint the diagnosis."
"['Conjunctivitis', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs in MCADD due to excess conjugation of carnitine to accumulating toxic medium-chain acyl metabolites (e.g., octanoylcarnitine).  
2. **Neonatal/Infancy/Childhood fatality**: MCADD causes life-threatening hypoglycemia and metabolic crises during fasting or illness, often presenting in infancy or early childhood if undiagnosed.  
3. **Prenatal abnormalities**: Though less common, intrauterine metabolic stress from MCADD may contribute to growth restriction or complications, particularly in severe cases.  
4. **Enzyme discrepancy**: The listed ""decreased 3-hydroxyacyl-CoA dehydrogenase level"" may reflect a misreporting. MCADD specifically involves *medium-chain acyl-CoA dehydrogenase* deficiency. If accurate, this could indicate a concurrent or overlapping disorder (e.g., trifunctional protein deficiency), but MCADD remains primary given clinical alignment.  
5. **Conjunctivitis**: Atypical for MCADD; possibly coincidental (e.g., infection) or misdocumented (retinopathy in LCHAD deficiency is a differential but excluded here).  
6. **Key biochemical link**: Hypoketotic hypoglycemia and elevated medium-chain acylcarnitines (C6-C10) on tandem mass spectrometry confirm MCADD, aligning with decreased free carnitine and clinical history."
"['Proteinuria', 'Retinopathy', 'Hypertension', 'Acute kidney injury', 'Chronic kidney disease', 'Elevated hemoglobin A1c', 'Death in early adulthood']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: Maturity-onset diabetes of the young, type 1 (MODY1/HNF4A)  
Reasoning:  
1. **Elevated hemoglobin A1c**: Indicates chronic hyperglycemia, a hallmark of MODY. MODY1 (HNF4A mutation) disrupts insulin secretion, leading to early-onset diabetes.  
2. **Retinopathy**: A microvascular complication of prolonged diabetes, consistent with poor glycemic control over time.  
3. **Hypertension**: Likely secondary to diabetic nephropathy or chronic kidney disease, exacerbated by diabetes-related vascular damage.  
4. **Proteinuria, Acute kidney injury (AKI), Chronic kidney disease (CKD)**: Diabetic nephropathy from long-standing hyperglycemia explains progressive kidney damage. MODY1 patients with suboptimal glycemic control are at risk for renal complications.  
5. **Death in early adulthood**: Severe renal failure (from CKD/AKI) or cardiovascular complications of uncontrolled diabetes and hypertension could lead to premature mortality.  
6. **MODY1 specificity**: While MODY5 (HNF1B) is classically linked to renal dysplasia, MODY1 can still manifest nephropathy due to diabetic damage. The absence of atypical features (e.g., cysts, genital anomalies) and presence of retinopathy favor MODY1 over other subtypes. Early death underscores aggressive complications from delayed diagnosis or inadequate management."
"['Intellectual disability', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Untreated PKU results in neurotoxic phenylalanine accumulation, damaging brain development and function.  
3. **Hypertyrosinemia**: Atypical in classic PKU but may arise secondary to dietary tyrosine supplementation, impaired tyrosine metabolism due to liver dysfunction, or overlap with a co-existing metabolic disorder (e.g., transient tyrosinemia).  
4. **Death in early adulthood**: Reflects severe untreated PKU complications, including neurodegeneration, seizures, and systemic organ damage, historically associated with poor prognosis before dietary management.  

While hypertyrosinemia is not a typical feature of isolated PKU, the core findings (hyperphenylalaninemia + intellectual disability) strongly support PKU as the primary diagnosis, with hypertyrosinemia warranting investigation for confounding factors or comorbidities."
"['Failure to thrive', 'Death in infancy', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Failure to thrive** in infancy occurs due to metabolic disruption, neurotoxicity, and impaired protein synthesis from elevated phenylalanine levels.  
3. **Death in infancy** (if untreated) aligns with severe, classic PKU, where untreated hyperphenylalaninemia causes irreversible brain damage, seizures, and multiorgan failure.  
4. PKU is autosomal recessive; symptoms manifest shortly after birth when phenylalanine intake begins (e.g., via breast milk/formula). Early dietary management prevents complications, explaining why untreated cases match the described fatal trajectory.  
5. Rarer differentials (e.g., BH4 deficiency) were excluded due to the absence of neurological features (e.g., dystonia, hypotonia) and normal tyrosine levels (implied by isolated hyperphenylalaninemia)."
"['Intellectual disability', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hyperglycinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: IVA disrupts the urea cycle via toxic metabolite accumulation (isovaleric acid), leading to secondary hyperammonemia. Hyperglycinemia may arise from glycine conjugation to isovaleric acid, forming isovalerylglycine, a diagnostic urinary marker.  
2. **Increased Serum Lactate**: Metabolic crises in IVA cause acidosis, impairing mitochondrial function and promoting lactic acidosis.  
3. **Abnormal Carnitine Levels**: Isovaleric acid conjugates with carnitine (forming isovalerylcarnitine), depleting free carnitine and altering circulating levels—a hallmark of IVA.  
4. **Gastrointestinal Symptoms (Vomiting, Feeding Difficulties, Inflammation)**: Acute metabolic decompensation triggers vomiting and gut inflammation, exacerbating feeding challenges.  
5. **Early Mortality & Growth Failure**: Untreated IVA causes rapid neonatal/childhood deterioration due to metabolic instability, leading to death. Chronic toxicity results in severe short stature and intellectual disability from neurodevelopmental damage.  
6. **Exclusion of Mimics**: Symptoms align with IVA over urea cycle defects (hyperlactatemia uncommon) or propionic acidemia (hyperglycinemia overlaps, but carnitine profile and isovalerylglycine specificity confirm IVA)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), which prevents the conversion of phenylalanine to tyrosine. Elevated phenylalanine levels are toxic to the brain.  
- **Abnormality of prenatal development or birth**: Maternal PKU (untreated during pregnancy) can cause congenital abnormalities (e.g., microcephaly, cardiac defects) in the fetus due to phenylalanine toxicity. If the patient is the affected infant, severe untreated PKU may manifest as developmental disruptions.  
- **Hypertyrosinemia**: While classic PKU typically results in *low* tyrosine (due to blocked PAH activity), transient hypertyrosinemia may occur in neonates with immature liver function or secondary to metabolic stress. Alternatively, this could indicate a coexisting or misclassified metabolic disorder (e.g., tyrosinemia type II), but PKU remains the primary diagnosis given hyperphenylalaninemia.  
- **Neonatal death/Death in infancy/childhood**: Untreated PKU leads to progressive neurological damage, seizures, and failure to thrive. Severe cases (e.g., malignant PKU or complete PAH deficiency) can result in early mortality without dietary intervention. Newborn screening and dietary management typically prevent this outcome, but historical or undiagnosed cases may present with fatal complications.  

**Note**: Hypertyrosinemia is atypical for PKU and warrants investigation for concurrent disorders (e.g., tyrosinemia, liver dysfunction) or assay errors. However, hyperphenylalaninemia and the clinical trajectory strongly prioritize PKU as the diagnosis."
"['Skin rash', 'Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Decreased plasma free carnitine', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder impairing ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD; excess carbamoyl phosphate shunts into pyrimidine synthesis, producing orotic acid.  
3. **Neurological symptoms (lethargy, drowsiness, vomiting, sleep disturbance)**: Reflect ammonia neurotoxicity.  
4. **Death in infancy**: Severe neonatal-onset OTCD causes rapid metabolic collapse without intervention.  
5. **Decreased plasma free carnitine**: Secondary carnitine depletion due to disrupted metabolism or renal loss.  
6. **Skin lesions (rash, plaques, macules/papules)**: Less specific but may arise from metabolic stress or ammonia-induced inflammation.  
7. **Gastrointestinal symptoms (diarrhea, vomiting)**: Common in metabolic crises due to systemic toxicity.  
**Key differentiators**: Oroticaciduria distinguishes OTCD from other urea cycle defects. X-linked inheritance (though de novo mutations occur) and hyperammonemia severity further support the diagnosis."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Fever', 'Diarrhea', 'Pneumonia', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning: Hyperphenylalaninemia is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity. Elevated urinary carboxylic acids may reflect phenylketone excretion (e.g., phenylpyruvate). Neonatal death or death in infancy/childhood can occur in severe untreated cases due to progressive neurological damage. Abnormality of prenatal development could stem from maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy. Obesity may arise later due to high-carbohydrate diets used to restrict phenylalanine. Recurrent infections (e.g., pneumonia) and chronic pulmonary issues may result from aspiration secondary to neurological dysfunction. Hypertyrosinemia is atypical for PKU and suggests a potential comorbid condition or diagnostic overlap, but the core diagnosis remains PKU based on hyperphenylalaninemia."
"['Intellectual disability', 'Ataxia', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Pancreatitis', 'Thrombocytopenia', 'Abnormal erythrocyte morphology', 'Leukopenia', 'Metabolic acidosis', 'Dehydration', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Kyphoscoliosis', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Methylmalonic aciduria', 'Severe hearing impairment', 'Sepsis']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: The patient exhibits *methylmalonic acidemia* and *methylmalonic aciduria*, hallmarks of methylmalonyl-CoA mutase deficiency. Elevated methylmalonic acid disrupts the propionate pathway, leading to metabolic crises.  
2. **Metabolic derangements**: Symptoms like *metabolic acidosis*, *hyperammonemia*, *increased serum lactate*, and *hyperglycinemia* align with impaired mitochondrial energy metabolism and toxic metabolite accumulation.  
3. **Organ system involvement**:  
   - **Neurological**: *Intellectual disability*, *ataxia*, *motor delay*, and *hypotonia* result from chronic neurotoxicity due to methylmalonic acid and ammonia.  
   - **Hematological**: *Thrombocytopenia*, *leukopenia*, and *abnormal erythrocyte morphology* stem from bone marrow suppression caused by metabolic stress.  
   - **Renal**: *Elevated creatinine*, *increased blood urea nitrogen*, and *hyperuricemia* indicate renal tubular dysfunction and acute kidney injury.  
4. **Systemic complications**: *Feeding difficulties*, *dehydration*, *gastrointestinal inflammation*, and *recurrent infections* (e.g., pneumonia, sepsis) reflect global metabolic instability and immune dysfunction.  
5. **Early mortality**: *Neonatal death*, *death in infancy/childhood/adolescence* are consistent with severe, B12-unresponsive MMA variants, where metabolic decompensation is irreversible without liver transplantation.  
6. **Carnitine/porphyrin abnormalities**: Secondary *abnormal carnitine* and *porphyrin levels* arise due to mitochondrial dysfunction and disrupted heme synthesis.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria (General Diagnosis)  
Reasoning:  
- **Clinical confirmation**: The presence of *methylmalonic acidemia* and *aciduria* in symptomology directly supports this overarching diagnosis.  
- **Phenotypic spectrum**: Symptoms like *obesity*, *kyphoscoliosis*, and *severe short stature* suggest chronic multisystemic disease progression, while *hyperalaninemia* and *hypoproteinemia* point to amino acid metabolism dysregulation.  
- **Diagnostic exclusion**: Lack of responsiveness to B12 supplementation (implied by the severity and early mortality) differentiates this from B12-responsive subtypes.  

The patient’s presentation is pathognomonic for **severe, mutase-deficient MMA**, characterized by enzymatic defects in methylmalonyl-CoA mutase, leading to catastrophic metabolic failure and early mortality."
"['Seizure', 'Areflexia', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like hyperammonemia, elevated urinary carboxylic acids, and abnormal circulating amino acids (aspartate family, alanine) suggest a metabolic disorder disrupting amino acid catabolism.  
2. **BCAA Accumulation**: MSUD specifically involves defective breakdown of branched-chain amino acids (BCAAs—leucine, isoleucine, valine), leading to toxic buildup of keto acids (detected as urinary carboxylic acids) and secondary ammonia elevation.  
3. **Neurological Manifestations**: Seizures, hypotonia, and areflexia align with neurotoxicity from BCAA-derived metabolites, which impair brain function and myelination.  
4. **Infantile Fatality**: Neonatal death or death in infancy is characteristic of severe, untreated MSUD due to rapid metabolic decompensation post-protein ingestion (feeding difficulties).  
5. **Diagnostic Confirmation**: Abnormal BCAA levels (not explicitly listed but inferred from ""abnormal aspartate family amino acids"") and urinary alpha-keto-acids confirm MSUD, distinguishing it from urea cycle defects or organic acidemias."
"['Death in infancy', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCC deficiency)  
Reasoning:  
1. **Elevated urinary carboxylic acids**: 3-MCC deficiency disrupts leucine catabolism, causing accumulation of 3-methylcrotonyl-CoA and its derivatives (3-hydroxyisovaleric acid, 3-methylcrotonylglycine), which are excreted in urine.  
2. **Death in infancy**: Severe metabolic crises (hypoglycemia, acidosis, hyperammonemia) triggered by catabolic stressors (e.g., fasting, infection) can lead to fatal outcomes if untreated.  
3. **Severe hearing impairment**: While not a hallmark, sensorineural hearing loss may occur due to neurotoxic metabolite effects or secondary neurological damage during metabolic decompensation.  

Note: The two listed diagnoses refer to the same disorder. 3-MCC deficiency involves mutations in *MCCC1* or *MCCC2* genes, encoding subunits of the enzyme. Clinical variability exists, with some cases showing atypical features like hearing impairment."
"['Abnormal vertebral morphology', 'Death in childhood', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine**: Alkaptonuria is caused by a deficiency of homogentisate 1,2-dioxygenase, leading to accumulation of homogentisic acid (HGA). HGA oxidizes in urine, causing it to darken upon exposure to air (a hallmark symptom).  
2. **Abnormal vertebral morphology**: Chronic HGA deposition in connective tissues (ochronosis) leads to cartilage degeneration, including intervertebral discs. Spinal deformities (e.g., kyphosis, disc calcification) may manifest early in severe cases.  
3. **Death in childhood**: While Alkaptonuria typically has a chronic course, rare severe forms with systemic ochronosis can cause early complications (e.g., cardiac valve calcification, renal failure) or susceptibility to infections, potentially leading to premature death.  

Note: Childhood mortality is atypical in Alkaptonuria and suggests an unusually aggressive presentation or comorbid conditions. Further genetic testing (HGD gene mutations) and urinary HGA quantification would confirm the diagnosis."
"['Microcephaly', 'Epicanthus', 'Low-set ears', 'Wide nasal bridge', 'Anteverted nares', 'Ptosis', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Vomiting', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Polydactyly', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol with hypocholesterolemia are pathognomonic for SLOS, caused by a deficiency in 7-dehydrocholesterol reductase.  
2. **Craniofacial features**: Microcephaly, epicanthus, ptosis, wide nasal bridge, anteverted nares, and low-set ears align with SLOS-associated dysmorphism.  
3. **Limb anomalies**: Syndactyly (classically 2nd–3rd toe webbing) and polydactyly (often postaxial) are hallmark signs.  
4. **Neurodevelopmental issues**: Intellectual disability, motor delay, and generalized hypotonia reflect neurological involvement.  
5. **Systemic/growth complications**: Feeding difficulties, failure to thrive, vomiting, and early mortality (neonatal/infant/childhood death) correlate with severe SLOS phenotypes.  
6. **Rule-out**: Biochemical findings exclude other syndromes (e.g., trisomy 13/18), while cholesterol abnormalities confirm SLOS."
"['Macrocephaly', 'Apathy', 'Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Cerebral atrophy', 'Glutaric aciduria', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase.  
2. **Macrocephaly** and **cerebral atrophy** align with frontotemporal atrophy, a hallmark of GA-I due to toxic metabolite accumulation.  
3. **Generalized hypotonia** and **feeding difficulties** reflect early neurological dysfunction from striatal injury.  
4. **Vomiting** and **diarrhea** suggest metabolic decompensation triggered by catabolic stress (e.g., infections/fasting).  
5. **Apathy** correlates with encephalopathic crises during metabolic derangement.  
6. **Death in infancy** occurs in untreated cases due to acute striatal necrosis or severe metabolic crises.  
7. All symptoms collectively match GA-I’s triad: macrocephaly, movement disorders, and metabolic instability."
"['Conjunctivitis', 'Delayed speech and language development', 'Growth delay', 'Obesity', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Abnormal erythrocyte morphology', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Hypoxemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical finding in PKU, caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine metabolism.  
2. **Delayed speech and language development**: Untreated PKU leads to neurotoxic phenylalanine accumulation, resulting in intellectual disability and developmental delays.  
3. **Growth delay/Obesity**: Poorly managed PKU can disrupt metabolic processes, while obesity may arise from restrictive diets favoring low-protein, high-carbohydrate intake.  
4. **Premature birth/Small for gestational age/Neonatal death**: Maternal PKU during pregnancy causes fetal exposure to high phenylalanine, leading to intrauterine growth restriction, prematurity, and congenital anomalies (if untreated).  
5. **Death in infancy/childhood**: Historically occurs in untreated PKU due to severe neurological damage and metabolic complications.  

**Atypical symptoms (e.g., hypertyrosinemia, abnormal erythrocyte morphology)**: Likely represent comorbidities, laboratory artifacts, or secondary effects (e.g., oxidative stress from chronic metabolic imbalance). PKU primarily explains the core features (hyperphenylalaninemia, neurodevelopmental deficits, and prenatal complications)."
"['Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Obesity', 'Anemia', 'Hyperammonemia', 'Progressive neurologic deterioration', 'Difficulty walking', 'Spastic tetraplegia', 'Oroticaciduria', 'Aminoaciduria', 'Difficulty climbing stairs', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Hyperornithinemia', 'Uraciluria', 'Increased circulating lactate dehydrogenase concentration', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']",['Arginase deficiency/Argininemia/Argininemia'],"Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Hyperammonemia**: Central to urea cycle disorders like arginase deficiency, as impaired arginase prevents conversion of arginine to urea and ornithine.  
2. **Oroticaciduria/Uraciluria**: Blocked urea cycle diverts carbamoyl phosphate to pyrimidine synthesis, increasing orotic acid and uracil excretion.  
3. **Aminoaciduria/Abnormal amino acid concentrations**: Elevated plasma arginine (argininemia) and secondary disturbances in aspartate-family amino acids, proline, and alanine due to metabolic dysregulation.  
4. **Neurological symptoms**: Progressive spastic tetraplegia/diplegia, motor delays, seizures, and intellectual disability stem from arginine/ammonia neurotoxicity and cerebral degeneration.  
5. **Liver involvement**: Acute/chronic hepatitis and prolonged PTT reflect hepatic dysfunction, common in urea cycle disorders due to ammonia overload and metabolic stress.  
6. **Hyperornithinemia**: Likely compensatory or secondary to arginine accumulation disrupting ornithine metabolism.  
7. **Early mortality**: Death in childhood/adolescence aligns with severe, untreated arginase deficiency causing neurological decline and metabolic crises.  
8. **LDH elevation**: Indicates tissue damage, potentially from liver injury or muscle breakdown due to spasticity.  
9. **Obesity/Anemia**: May arise from dietary management (protein restriction) or metabolic comorbidities, though less specific to the diagnosis.  

Key biochemical hallmarks (argininemia, hyperammonemia, oroticaciduria) and progressive neurologic deterioration solidify the diagnosis of arginase deficiency."
"['Abnormality of the eye', 'Arachnodactyly', 'Peripheral arterial stenosis', 'Death in adolescence', 'Abnormal nervous system physiology']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Abnormality of the eye**: Homocystinuria commonly causes ectopia lentis (dislocation of the ocular lens), leading to visual impairment.  
2. **Arachnodactyly**: Elevated homocysteine disrupts collagen cross-linking, resulting in Marfanoid habitus, including long, slender fingers.  
3. **Peripheral arterial stenosis**: Vascular damage from homocysteine-induced endothelial injury and thromboembolism predisposes to arterial stenosis and occlusion.  
4. **Death in adolescence**: Untreated homocystinuria carries high mortality from thromboembolic events (e.g., stroke, pulmonary embolism) or cardiovascular complications in early life.  
5. **Abnormal nervous system physiology**: Homocysteine neurotoxicity and thromboembolic strokes cause seizures, intellectual disability, or psychiatric manifestations.  

The combination of ocular, skeletal, vascular, and neurological features with early mortality strongly supports **cystathionine beta-synthase (CBS) deficiency**, the most common form of homocystinuria. Biochemical confirmation via elevated plasma homocysteine and methionine, with reduced cystathionine, would be definitive."
"['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Acute kidney injury', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Hyperuricemia', 'Hyperglycinemia', 'Tachypnea', 'Methylmalonic acidemia', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Neonatal death', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Elevated urinary carboxylic acid']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with methylmalonic acidemia and methylmalonic aciduria, which are direct indicators of MMA. Additional metabolic disturbances such as hyperammonemia, metabolic acidosis, hyperglycinemia, and hyperuricemia align with MMA's pathophysiology, where impaired methylmalonyl-CoA mutase activity leads to toxic metabolite accumulation. Elevated blood urea nitrogen, creatinine, and kidney injury/chronic disease reflect renal damage caused by chronic acidemia and tubular toxicity. Neonatal death and hypotonia are consistent with severe, early-onset forms of MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The B12-unresponsive subtype is confirmed by the absence of improvement with B12 supplementation (implied by ""B12-unresponsive""). Mutase deficiency directly disrupts methylmalonyl-CoA conversion to succinyl-CoA, exacerbating methylmalonic acid accumulation. Symptoms like tachypnea, fever, and acute kidney injury correlate with metabolic decompensation episodes. Chronic kidney disease and abnormal carnitine/porphyrin levels further support a severe, intractable enzyme deficiency. Death in infancy/adolescence underscores the disease's lethality in this subtype due to treatment resistance."
"['Microcephaly', 'Intellectual disability', 'Seizure', 'Lethargy', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), particularly CPS1 deficiency, as CPS1 catalyzes the first and rate-limiting step of ammonia detoxification.  
2. **Neonatal death** and **death in infancy** align with severe UCDs, which often present catastrophically in the first days of life due to acute hyperammonemic crises.  
3. **Neurological symptoms** (seizures, spasticity, lethargy, drowsiness, intellectual disability) result from ammonia-induced neurotoxicity and cerebral edema.  
4. **Generalized hypotonia** and **microcephaly** reflect chronic energy deprivation and impaired brain development from persistent metabolic dysfunction.  
5. **Sleep disturbances** correlate with encephalopathic phases of hyperammonemia.  
6. CPS1 deficiency is distinguished from other UCDs (e.g., OTC deficiency) by autosomal recessive inheritance and absence of orotic acid elevation, though confirmatory genetic/enzymatic testing is definitive."
"['Seizure', 'Coma', 'Hepatic steatosis', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Gastrointestinal hemorrhage', 'Hypokalemia', 'Elevated hepatic transaminase', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency (HMG-CoA lyase deficiency)  
Reasoning:  
1. **Hypoglycemia + Hyperammonemia + Hepatic steatosis**: Core triad of HMG-CoA lyase deficiency, caused by impaired ketogenesis and leucine catabolism, leading to energy deficits and toxic metabolite accumulation.  
2. **Dicarboxylic aciduria + 3-Methylglutaric aciduria**: Direct biochemical hallmarks due to defective breakdown of HMG-CoA into acetoacetate, resulting in elevated 3-hydroxy-3-methylglutaric, 3-methylglutaric, and dicarboxylic acids in urine.  
3. **Abnormal amino acids (glycine, aspartate family, alanine)**: Secondary to metabolic decompensation, disrupting amino acid homeostasis and urea cycle function.  
4. **Seizures + Coma + Death in infancy**: Result from severe hypoglycemia, hyperammonemia, and metabolic acidosis during metabolic crises, typical in untreated HMG-CoA lyase deficiency.  
5. **Elevated hepatic transaminases + GI hemorrhage**: Hepatic dysfunction from steatosis and metabolic stress, compounded by coagulopathy from hyperammonemia.  
6. **Hypokalemia**: Likely due to renal losses from acidosis or vomiting.  
7. **Abnormal porphyrins**: Possible secondary disruption of heme synthesis pathways during metabolic instability.  

The constellation of fatty acid oxidation defects, organic aciduria, and neonatal lethality confirms HMG-CoA lyase deficiency."
"['Apathy', 'Seizure', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, alongside metabolic acidosis, vomiting, lethargy, and neurological symptoms (seizures, drowsiness, apathy). Neonatal death and death in infancy align with severe MMA presentations. These findings collectively indicate impaired methylmalonyl-CoA metabolism.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **B12-unresponsive subtype** is inferred due to the severity (neonatal death) and lack of improvement with B12 therapy. Mutations in the *MUT* gene disrupt methylmalonyl-CoA mutase activity, exacerbating acid accumulation. Persistent metabolic acidosis and early lethality are characteristic of this subtype, distinguishing it from B12-responsive forms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Ventricular septal defect', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development/birth, VSD, and neonatal/infant death** may reflect **maternal PKU syndrome**, where untreated maternal hyperphenylalaninemia during pregnancy induces teratogenic effects (e.g., congenital heart defects like VSD) in the fetus.  
3. **Hypertyrosinemia** is atypical for classic PKU (where tyrosine levels are usually low/normal) and suggests a potential secondary metabolic disturbance, co-occurring liver dysfunction, or misdiagnosis of tyrosine levels.  
4. **Death in childhood** aligns with severe, untreated PKU, as neurological damage and metabolic complications (seizures, failure to thrive) can be fatal without dietary intervention.  
5. While **hypertyrosinemia** creates ambiguity, the dominant hyperphenylalaninemia and clinical context prioritize PKU as the primary diagnosis. Further evaluation of tyrosine metabolism (e.g., BH4 deficiency, tyrosinemia) would be warranted to address this discrepancy."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), impairing phenylalanine metabolism.  
2. **Neonatal death/Death in infancy**: Untreated severe PKU can lead to toxic accumulation of phenylalanine, causing irreversible neurological damage, seizures, and failure to thrive, which may result in early mortality if undiagnosed and unmanaged.  
3. **Abnormality of prenatal development or birth**: Maternal PKU (untreated hyperphenylalaninemia during pregnancy) can cause fetal developmental abnormalities (e.g., microcephaly, congenital heart defects). However, if the infant itself has PKU, metabolic disruption post-birth may contribute to developmental issues.  
4. **Exclusion of BH4 deficiencies**: While hyperphenylalaninemia can also occur in tetrahydrobiopterin (BH4) deficiencies, the listed symptoms align more with classic PKU when neonatal screening/treatment is unavailable or delayed.  

Conclusion: The combination of hyperphenylalaninemia and early lethality strongly supports PKU, particularly in settings lacking newborn screening or dietary intervention."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts medium-chain fatty acid β-oxidation, leading to secondary carnitine depletion as carnitine conjugates with accumulating toxic metabolites (e.g., medium-chain acylcarnitines).  
2. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: While MCADD primarily involves medium-chain acyl-CoA dehydrogenase (MCAD), impaired β-oxidation indirectly affects downstream enzymes like 3-hydroxyacyl-CoA dehydrogenase due to metabolic bottlenecking.  
3. **Vomiting, neonatal/infant death**: MCADD causes hypoglycemia and metabolic crises triggered by fasting (e.g., missed feeds), resulting in vomiting, encephalopathy, and rapid deterioration in neonates/infants.  
4. **Prenatal abnormalities**: Severe MCADD may manifest as intrauterine growth restriction or prematurity due to chronic energy deficiency from impaired fatty acid metabolism.  
5. **Diagnostic confirmation**: The clinical triad of hypoketotic hypoglycemia, elevated C6-C10 acylcarnitines, and genetic testing for *ACADM* mutations aligns with the symptoms and biochemical findings."
"['Delayed speech and language development', 'Motor delay', 'Death in infancy', '3-Methylglutaric aciduria', 'Death in childhood', 'Elevated urinary carboxylic acid']","['3-methylglutaconic aciduria type 1/3-methylglutaconic aciduria, type I']","Disease: 3-methylglutaconic aciduria type 1/3-methylglutaconic aciduria, type I  
Reasoning:  
1. **Biochemical marker**: The presence of **3-methylglutaric aciduria** and **elevated urinary carboxylic acids** directly points to a defect in leucine catabolism. This aligns with 3-methylglutaconic aciduria type I, caused by **3-methylglutaconyl-CoA hydratase deficiency**, which disrupts the conversion of 3-methylglutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA.  
2. **Metabolic consequences**: Accumulation of 3-methylglutaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid in urine explains the elevated carboxylic acids. These metabolites are neurotoxic, leading to **delayed speech, motor delays**, and neurological deterioration.  
3. **Severity and prognosis**: The inclusion of **death in infancy/childhood** reflects the life-threatening metabolic crises (e.g., acidosis, hypoglycemia) common in untreated cases of this autosomal recessive disorder.  
4. **Differentiation from other types**: Unlike types II–IV (associated with mitochondrial disorders, neutropenia, or cardiomyopathy), type I is isolated to leucine metabolism, consistent with the absence of extraneous symptoms (e.g., organ dysfunction).  
5. **Confirmation**: Genetic testing for *AUH* gene mutations or enzyme assays confirming hydratase deficiency would solidify the diagnosis."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Untreated PKU** results in severe neurological damage, seizures, and developmental failure. Historically, before newborn screening and dietary management, infants with classic PKU often faced **death in infancy** due to progressive neurodegeneration or complications like infections.  
3. **Neonatal death** (within the first 28 days) is less typical but could occur in rare, severe variants (e.g., malignant PKU) or if metabolic derangements (e.g., electrolyte imbalances) compound critical organ dysfunction.  
4. The triad of symptoms aligns with undiagnosed/untreated PKU, where hyperphenylalaninemia precedes irreversible systemic collapse. Modern screening mitigates this outcome, but the historical context explains the listed presentation."
"['Microcephaly', 'Single transverse palmar crease', 'Pallor', 'Abnormality of prenatal development or birth', 'Motor delay', 'Failure to thrive', 'Small for gestational age', 'Death in infancy', 'Anemia', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Pneumonia', 'Increased serum lactate', 'Increased CSF lactate', 'Hypocholesterolemia', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Core biochemical markers**: Methylmalonic aciduria, increased serum/CSF lactate, metabolic acidosis, hyperammonemia, and hypoglycemia are hallmarks of MMA due to disrupted propionate metabolism.  
2. **Enzyme deficiency**: Decreased methylmalonyl-CoA mutase activity directly confirms a defect in this enzyme, critical for converting methylmalonyl-CoA to succinyl-CoA.  
3. **Vitamin B12-unresponsiveness**: Absence of B12 deficiency signs (e.g., no megaloblastic anemia) and persistent symptoms suggest a primary mutase defect (mut⁰ or mut⁻ subtype).  
4. **Systemic manifestations**: Failure to thrive, feeding difficulties, vomiting, and neonatal death align with acute metabolic decompensation seen in MMA.  
5. **Metabolic sequelae**: Hypocholesterolemia and abnormal carnitine/porphyrin levels reflect secondary mitochondrial dysfunction and energy depletion.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Genetic confirmation**: The specificity of decreased methylmalonyl-CoA mutase activity excludes other MMA subtypes (e.g., cblA/cblB defects) and confirms mutase deficiency.  
2. **Early lethality**: Neonatal death and death in infancy are typical in severe mutase-deficient MMA due to intractable acidosis/hyperammonemia.  
3. **Prenatal involvement**: Small for gestational age and prenatal developmental abnormalities indicate in utero metabolic stress.  
4. **Lactic acidosis**: Increased lactate in serum/CSF reflects secondary mitochondrial impairment from toxic metabolite accumulation (methylmalonate, propionyl-CoA).  
5. **Absence of B12-responsive features**: Normal/high B12 levels and lack of hematologic improvement with B12 supplementation support mutase deficiency as the primary defect."
"['Seizure', 'Cerebral cortical atrophy', 'Death in adolescence', 'Methylmalonic aciduria', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark biochemical finding of methylmalonic acidemia (MMA). MMA is an autosomal recessive disorder of branched-chain amino acid metabolism, caused by defects in methylmalonyl-CoA mutase or its cofactor adenosylcobalamin (vitamin B12). The presence of **seizures** and **cerebral cortical atrophy** aligns with chronic neurotoxicity from accumulated methylmalonic acid and metabolic instability, leading to progressive neurological damage. **Death in adolescence/early adulthood** reflects the severe natural history of untreated or unresponsive MMA, often due to metabolic crises, renal failure, or neurological complications.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the diagnostic term ""B12-unresponsive"") points specifically to mutations in the *MUT* gene encoding methylmalonyl-CoA mutase. This subtype accounts for ~60% of MMA cases and is associated with severe phenotypes. Cerebral cortical atrophy and seizures indicate irreversible neurological injury from chronic metabolite accumulation. Early mortality (adolescence/early adulthood) is typical in mutase-deficient MMA due to treatment-refractory metabolic decompensation, multiorgan dysfunction, and limited therapeutic options beyond supportive care."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD can cause intrauterine stress due to impaired fatty acid oxidation, leading to developmental abnormalities.  
2. **Death in infancy/Neonatal death/Death in childhood**: Untreated MCADD predisposes to life-threatening hypoglycemia and metabolic crises during fasting, common in infancy/childhood.  
3. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs as carnitine binds to accumulating toxic acyl-CoA intermediates, reducing free carnitine levels.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misreporting or indirect effect; MCADD directly involves medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, disrupting β-oxidation. Accumulated metabolites may suppress downstream enzymes like 3-hydroxyacyl-CoA dehydrogenase.  

The clinical and biochemical profile aligns with MCADD, a fatty acid oxidation disorder requiring prompt management to prevent fatal outcomes."
"['Hypoglycemia', 'Death in childhood', 'Decreased plasma free carnitine', 'Acute hepatitis', 'Chronic hepatitis']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary  
Reasoning:  
1. **Hypoglycemia**: PCD causes impaired fatty acid oxidation due to defective carnitine transport, reducing energy production during fasting and leading to hypoglycemia.  
2. **Decreased plasma free carnitine**: A hallmark of PCD caused by mutations in the *SLC22A5* gene, resulting in urinary carnitine wasting and low plasma levels.  
3. **Acute/Chronic hepatitis**: Impaired fatty acid oxidation causes toxic metabolite accumulation (e.g., acylcarnitines) in the liver, triggering recurrent hepatitis and eventual chronic liver dysfunction.  
4. **Death in childhood**: Undiagnosed PCD leads to metabolic crises (hypoketotic hypoglycemia, hyperammonemia) or cardiac complications (cardiomyopathy, arrhythmias), often fatal in early life.  
5. **Consistency with PCD**: The triad of hypoketotic hypoglycemia, liver dysfunction, and carnitine deficiency is pathognomonic for PCD, distinguishing it from secondary carnitine deficiencies (e.g., organic acidemias)."
"['Ataxia', 'Tremor', 'Athetosis', 'Death in adolescence', 'L-2-hydroxyglutaric aciduria', 'Death in early adulthood']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The presence of **L-2-hydroxyglutaric aciduria** (elevated L-2-hydroxyglutaric acid in urine) is pathognomonic for this disorder, confirming the diagnosis.  
2. **Neurological Symptoms**: **Ataxia** (impaired coordination), **tremor** (rhythmic shaking), and **athetosis** (slow, writhing movements) align with the progressive neurodegenerative effects of the disease, caused by toxic accumulation of L-2-hydroxyglutaric acid in the central nervous system.  
3. **Disease Progression**: The **death in adolescence or early adulthood** is consistent with the disorder’s natural history, as complications like seizures, respiratory infections, or severe neurological decline often lead to early mortality.  
4. **Genetic Basis**: Autosomal recessive mutations in *L2HGDH* disrupt lysine metabolism, leading to systemic and neurological manifestations.  
5. **Exclusion of Mimics**: Symptoms overlap with other organic acidurias or mitochondrial disorders, but the specific biochemical marker (L-2-hydroxyglutaric aciduria) and clinical course confirm the diagnosis."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), the enzyme that converts phenylalanine to tyrosine. This deficiency results in the accumulation of phenylalanine, consistent with hyperphenylalaninemia.  
2. **Hypertyrosinemia**: While classic PKU typically presents with *low* tyrosine due to impaired synthesis, hypertyrosinemia in this case could suggest:  
   - **Atypical PKU variant**: Residual PAH activity or compensatory dietary tyrosine supplementation.  
   - **Secondary metabolic disruption**: Severe liver dysfunction (e.g., due to untreated PKU complications) impairing tyrosine catabolism.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early demise aligns with delayed diagnosis or poor adherence to dietary restrictions (e.g., low-phenylalanine diet).  
4. **Exclusion of alternatives**: Tyrosinemia type I/II or BH4 deficiency were considered but ruled out due to the prominence of hyperphenylalaninemia and lack of hallmark features (e.g., liver failure in tyrosinemia, neurotransmitter deficits in BH4 disorders).  

Conclusion: PKU is the primary diagnosis, with hypertyrosinemia attributed to atypical metabolic adjustments or concurrent factors."
"['Diabetes mellitus', 'Abnormal nervous system physiology', 'Impaired glucose tolerance', 'Death in early adulthood']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: MODY (Maturity-onset diabetes of the young)  
Reasoning: The patient presents with early-onset diabetes mellitus and impaired glucose tolerance, hallmark features of MODY—a monogenic form of diabetes. MODY typically manifests in adolescence or early adulthood (aligning with the patient’s age-related context) and is autosomal dominant. While MODY subtypes vary, the absence of severe obesity or autoimmune markers supports this diagnosis over type 1 or type 2 diabetes.  

Disease: Maturity-onset diabetes of the young, type 1 (MODY1, HNF4A-related)  
Reasoning: MODY1 is caused by mutations in the *HNF4A* gene, disrupting pancreatic beta-cell function and insulin secretion. The patient’s early adulthood mortality could stem from acute metabolic complications (e.g., diabetic ketoacidosis) due to delayed diagnosis or poor glycemic control. While ""abnormal nervous system physiology"" is atypical for MODY1, it may reflect secondary neurological damage from severe hypoglycemia/hyperglycemia or an unrelated comorbidity. This subtype is sulfonylurea-responsive, but untreated cases may progress rapidly, contributing to premature death."
"['Abnormality of prenatal development or birth', 'Ataxia', 'Obesity', 'Death in infancy', 'Apnea', 'Hypertyrosinemia', 'Paresthesia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth**: Untreated maternal PKU can lead to congenital anomalies due to phenylalanine toxicity during pregnancy.  
3. **Neurological symptoms (Ataxia, Paresthesia)**: Accumulated phenylalanine disrupts myelination and neurotransmitter synthesis, causing progressive neurological damage.  
4. **Obesity**: Managed PKU patients often consume low-protein, high-carbohydrate diets, which may contribute to weight gain.  
5. **Early mortality (Death in infancy/Neonatal death/Death in early adulthood)**: Untreated PKU results in severe intellectual disability, seizures, and systemic complications, leading to premature death without dietary intervention.  
6. **Apnea**: Rarely observed in severe neonatal cases due to metabolic instability or neurological dysfunction.  
7. **Hypertyrosinemia discrepancy**: Likely a typographical error; PKU typically causes *hypo*tyrosinemia (due to blocked phenylalanine conversion). If accurate, this could suggest a concurrent metabolic disorder (e.g., tyrosinemia) or a BH4-deficient PKU variant, though the primary diagnosis remains PKU.  

The constellation of hyperphenylalaninemia, neurodevelopmental deficits, and dietary management complications strongly aligns with PKU, despite atypical features like hypertyrosinemia requiring further investigation."
"['Headache', 'Elevated urinary delta-aminolevulinic acid', 'Death in childhood']","['Acute intermittent porphyria/Porphyria, acute intermittent', 'Porphyria/Porphyria']","Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning: The patient presents with headache and elevated urinary delta-aminolevulinic acid (ALA), both consistent with acute intermittent porphyria (AIP). AIP is caused by a deficiency in porphobilinogen deaminase (PBGD), leading to accumulation of ALA and porphobilinogen (PBG) during acute attacks. While AIP typically manifests in adults, severe undiagnosed cases in children can result in fatal complications such as respiratory paralysis or refractory hyponatremia. However, childhood death is atypical for AIP, suggesting either an unusually early presentation or misdiagnosis.  

Disease: Porphyria/Porphyria  
Reasoning: Elevated urinary ALA and childhood mortality strongly suggest a severe, early-onset porphyria such as delta-aminolevulinic acid dehydratase deficiency porphyria (ADP), an ultra-rare autosomal recessive form. ADP causes extreme ALA elevation due to ALA dehydratase deficiency, leading to neurovisceral crises and early death. While not explicitly listed, ADP falls under the broader ""porphyria"" category. This aligns better with childhood fatality than AIP, which is less common in pediatric populations."
"['Carious teeth', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Elevated urinary carboxylic acids**: Phenylalanine accumulates and is metabolized into phenylketones (e.g., phenylpyruvate), excreted in urine.  
3. **Death in infancy/childhood & neonatal death**: Untreated PKU causes severe neurological damage, seizures, and organ failure, leading to early mortality.  
4. **Carious teeth**: Chronic metabolic acidosis (from phenylketone accumulation) and high-carbohydrate/low-protein diets in managed PKU may contribute to dental decay.  
5. **Hypertyrosinemia (apparent conflict)**: PKU typically causes **low** tyrosine levels (blocked conversion). This symptom may indicate a coexisting condition (e.g., transient tyrosinemia in newborns) or misreporting.  
6. **Abnormality of prenatal development**: Likely reflects maternal PKU syndrome (untreated PKU during pregnancy causing fetal defects), suggesting the patient’s condition was inherited from an affected mother.  

While hypertyrosinemia is atypical, the triad of hyperphenylalaninemia, urinary phenylketones, and early mortality strongly supports PKU. Maternal PKU explains prenatal abnormalities and neonatal severity."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. Untreated **classic PKU** results in severe neurological impairment, seizures, and developmental failure. In extreme cases (e.g., undiagnosed or untreated), metabolic derangements and complications like cerebral edema or infections may contribute to **neonatal death** or **death in infancy**.  
3. While neonatal lethality is uncommon in PAH-deficient PKU, it aligns with severe variants (e.g., complete PAH deficiency) or delayed diagnosis in resource-limited settings without newborn screening.  
4. Other causes of hyperphenylalaninemia (e.g., BH4 deficiency) were considered but excluded due to the explicit diagnosis provided and lack of additional symptoms (e.g., neurotransmitter deficiencies)."
"['Apathy', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hypoglycemia', 'Leukocytosis', 'Hyperammonemia', 'Hypertriglyceridemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia**: MCADD impairs medium-chain fatty acid oxidation, critical during fasting, leading to glucose depletion.  
2. **Hypertriglyceridemia**: Inefficient fatty acid metabolism results in triglyceride accumulation.  
3. **Hyperammonemia**: Secondary urea cycle inhibition due to metabolic stress or accumulated toxic intermediates.  
4. **Abnormal carnitine levels**: Carnitine depletion occurs from excessive acylcarnitine formation (e.g., C8, C10 species) and urinary loss.  
5. **Seizures & hypotonia**: Energy deficiency in brain/muscle from impaired ketogenesis and ATP production.  
6. **Apathy**: Neurological dysfunction due to hypoglycemia and metabolic derangements.  
7. **Premature birth & severe short stature**: Intrauterine metabolic stress affecting growth; postnatal malnutrition exacerbates this.  
8. **Neonatal/childhood death**: Untreated MCADD causes lethal metabolic crises triggered by fasting or infection.  
9. **Recurrent infections**: Metabolic decompensation weakens stress responses, increasing infection susceptibility.  
10. **Amino acid abnormalities**: Disrupted gluconeogenesis (elevated alanine) and liver dysfunction alter aspartate metabolism.  
11. **Leukocytosis**: Stress response during acute metabolic decompensation.  

Key biochemical hallmarks (hypoglycemia, hyperammonemia, hypertriglyceridemia, acylcarnitine abnormalities) align with MCADD pathophysiology. Early fatality without intervention confirms severity typical of untreated cases."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine metabolism.  
2. **Neonatal death/Death in infancy**: Untreated PKU leads to toxic phenylalanine accumulation, causing severe neurological damage, seizures, and failure to thrive. In rare, severe PAH-deficient cases (e.g., ""malignant"" PKU), rapid metabolic deterioration may result in early mortality if undiagnosed.  
3. **Abnormality of prenatal development**: While PKU itself does not directly cause prenatal structural anomalies, *maternal PKU* (untreated hyperphenylalaninemia during pregnancy) can induce fetal teratogenicity (e.g., microcephaly, congenital heart defects). This suggests the patient’s prenatal abnormalities may stem from maternal PKU exposure, compounded by the infant’s own inherited PAH mutation.  
4. **Diagnostic confirmation**: Newborn screening detects hyperphenylalaninemia, and genetic testing identifies PAH mutations. Early dietary intervention (phenylalanine-restricted diet) prevents complications, underscoring the critical link between untreated PKU and the described outcomes."
"['Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Bradycardia', 'Apnea', 'Opisthotonus', 'Neonatal death', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Fatigue', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Amino Acid Elevation**: The triad of *hypervalinemia*, *hyperleucinemia*, and *hyperisoleucinemia* is pathognomonic for MSUD, caused by a defect in the branched-chain α-keto acid dehydrogenase (BCKDH) complex, impairing breakdown of branched-chain amino acids (BCAAs).  
2. **Neurological Manifestations**: *Seizures*, *intellectual disability*, *hypotonia*, and *opisthotonus* arise from neurotoxic accumulation of BCAAs and their keto-acids, disrupting cerebral energy metabolism and myelination.  
3. **Metabolic Crisis**: *Apnea*, *bradycardia*, and *fatigue* reflect acute metabolic decompensation, often triggered by catabolic states (e.g., infections), leading to life-threatening cerebral edema.  
4. **Odor & Early Mortality**: *Body odor* (maple syrup-like scent in urine/sweat) and *neonatal/infant death* align with classic severe MSUD phenotypes, where untreated metabolic crises rapidly progress to coma and death.  
5. **Immunological Vulnerability**: *Recurrent viral infections* may stem from metabolic stress impairing immune cell function, though this is less specific and secondary to the primary metabolic defect.  
**Conclusion**: The combination of BCAA elevation, neurotoxicity, odor, and infantile lethality confirms MSUD. Urgent dietary management (BCAA restriction) is critical to mitigate outcomes."
"['Generalized hypotonia', 'Death in infancy', 'Tachycardia', 'Fever', 'Hyperammonemia', 'Abnormality of urine homeostasis', 'Neonatal death', 'Feeding difficulties']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), directly implicating defects in ammonia detoxification.  
2. **Neonatal death** and **death in infancy** suggest a severe, early-onset metabolic crisis, consistent with UCDs like CPS1 deficiency, which often presents within days of life.  
3. **Feeding difficulties** and **generalized hypotonia** align with neurological dysfunction caused by ammonia toxicity.  
4. **Tachycardia** and **fever** may reflect systemic stress from hyperammonemic encephalopathy or secondary infections triggered by metabolic instability.  
5. **Abnormality of urine homeostasis** could indicate disrupted nitrogen excretion pathways, though CPS1 deficiency typically shows low/neutral urine orotic acid (unlike other UCDs), narrowing the diagnosis.  
6. Exclusion of other UCDs (e.g., OTC deficiency, which elevates urine orotic acid) and organic acidemias (which cause metabolic acidosis) strengthens the likelihood of CPS1 deficiency, an autosomal recessive disorder affecting the first urea cycle enzyme.  
7. The absence of treatment (e.g., nitrogen scavengers) explains rapid progression to neonatal demise."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by mutations in the *PAH* gene, leading to deficient phenylalanine hydroxylase activity and impaired conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth** may occur in severe untreated maternal PKU, where high phenylalanine levels disrupt fetal development. In classic PKU, infants typically appear normal at birth but develop symptoms postnatally if untreated.  
3. **Hypertyrosinemia** is atypical in PKU (as tyrosine synthesis is reduced), but transient neonatal tyrosinemia can occur due to immature enzymes, potentially overlapping with early PKU metabolic instability.  
4. **Death in infancy/Neonatal death** aligns with rare, severe PKU variants (e.g., malignant PKU or BH4-deficient forms) causing acute metabolic crises, neurological deterioration, and organ failure if undiagnosed/unmanaged.  
5. The combination of hyperphenylalaninemia and catastrophic neonatal outcomes strongly supports PKU, particularly in cases lacking newborn screening and dietary intervention."
"['Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
Reasoning:  
1. **Aminoaciduria Profile**: The presence of cystinuria, argininuria, hyperlysinuria, and ornithinuria is pathognomonic for cystinuria. These amino acids share a common renal tubular transport system (SLC3A1/SLC7A9 genes), and their urinary excretion indicates a defect in this system.  
2. **Dermatological Symptoms**: Eczematoid dermatitis and skin rash are atypical for classic cystinuria. These may arise secondary to malnutrition or infections due to chronic illness, but they are not direct features of the disease.  
3. **Death in Infancy**: Severe complications (e.g., obstructive uropathy, renal failure) from recurrent cystine stones or metabolic disturbances could theoretically lead to early mortality, though this is rare. Alternatively, coexisting conditions or misreported clinical history may contribute.  
4. **Exclusion of Alternatives**: Lysinuric protein intolerance (LPI) or urea cycle disorders were considered but ruled out due to the absence of hyperammonemia, hepatosplenomegaly, or neutral aminoaciduria. Cystinosis was excluded as it causes generalized Fanconi syndrome, not isolated dibasic aminoaciduria.  

Final diagnosis aligns with cystinuria based on the definitive aminoaciduria pattern, while secondary factors or comorbidities may explain the atypical symptoms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The presence of **hyperammonemia** and **elevated plasma citrulline** strongly indicates a urea cycle disorder. Citrullinemia type I (argininosuccinate synthetase deficiency) is characterized by severe neonatal hyperammonemia due to impaired citrulline-to-argininosuccinate conversion. This leads to rapid accumulation of ammonia and citrulline, causing neurological decline, **neonatal death**, or **death in infancy** if untreated. The absence of cholestasis or liver-specific symptoms aligns with classic urea cycle dysfunction rather than hepatic pathology.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: **Elevated citrulline** and **hyperammonemia** can also occur in citrin deficiency (type II citrullinemia). Neonatal intrahepatic cholestasis (NICCD) manifests with transient liver dysfunction and cholestasis (implied in the disease name), which may compound metabolic stress. While citrulline levels are typically lower than in type I, severe cases can lead to **death in infancy/childhood** due to liver failure or metabolic decompensation. **Abnormality of prenatal development** may reflect intrauterine growth restriction from mitochondrial energy deficits caused by citrin deficiency."
"['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Tachycardia', 'Anemia', 'Tachypnea', 'Neonatal death', 'Abnormal nervous system physiology', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease; MSUD  
Reasoning:  
1. **Elevated urinary carboxylic acids**: MSUD disrupts branched-chain amino acid (BCAA) metabolism, leading to accumulation of branched-chain keto acids (e.g., ketoisocaproic acid), which are carboxylic acids excreted in urine.  
2. **Abnormal nervous system physiology** and **generalized hypotonia**: Neurotoxicity from elevated BCAAs and their derivatives damages neurons, impairing motor function and muscle tone.  
3. **Tachycardia** and **tachypnea**: Metabolic acidosis triggers compensatory mechanisms (e.g., increased respiratory rate to expel CO₂, tachycardia to maintain circulation).  
4. **Growth delay** and **anemia**: Chronic metabolic stress and protein catabolism impair nutrient utilization, affecting growth and red blood cell production.  
5. **Neonatal death/death in infancy**: Untreated classic MSUD causes rapid metabolic decompensation, cerebral edema, and fatal outcomes without early intervention (e.g., dietary BCAA restriction).  
6. **Absence of maple syrup odor**: While a hallmark, this may not be immediately apparent in neonatal screening or masked by acute crisis management.  
Key biochemical confirmation involves detecting elevated plasma BCAAs (leucine, isoleucine, valine) and urinary branched-chain keto acids."
"['Seizure', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits methylmalonic aciduria, a hallmark biochemical marker of MMA. Symptoms like seizures, lethargy, generalized hypotonia, feeding difficulties, and neonatal death align with this autosomal recessive disorder caused by impaired metabolism of methylmalonyl-CoA. MMA typically presents in infancy with acute metabolic decompensation triggered by catabolic stressors.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The severity of symptoms (neonatal death, death in infancy) and lack of response to B12 therapy (implied by persistent methylmalonic aciduria) suggest a mutase-deficient subtype. This variant results from mutations in the MUT gene, causing complete or near-complete loss of methylmalonyl-CoA mutase activity. The clinical course is more severe compared to B12-responsive forms, with rapid progression of metabolic crises and early mortality without aggressive intervention."
"['Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The symptoms of aminoaciduria, abnormal glycine/carnitine levels, and elevated urinary carboxylic acids stem from impaired leucine metabolism due to MCCC1 gene mutations. This disrupts 3-MCC enzyme activity, causing toxic metabolite accumulation (e.g., 3-hydroxyisovaleric acid). Carnitine depletion occurs as it conjugates with metabolites for excretion, while glycine abnormalities may arise from compensatory detoxification. Severe enzyme deficiency leads to metabolic crises, explaining neonatal/infant mortality.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This condition, often linked to MCCC2 gene mutations, similarly disrupts the 3-MCC enzyme complex. Leucine catabolism failure results in elevated urinary carboxylic acids (e.g., 3-methylcrotonylglycine). Secondary carnitine deficiency and glycine irregularities align with metabolic compensation mechanisms. Neonatal death or infant mortality reflects acute metabolic decompensation in severe, untreated cases. Both MCCC1 and MCCC2 defects share clinical features but involve distinct genetic subunits of the same enzyme."
"['Macrocephaly', 'Delayed speech and language development', 'Obesity', 'Death in infancy', 'Premature birth', 'Glutaric aciduria', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating lysine concentration', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Hypoxemia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** and **hyperalaninemia** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly** often develops due to abnormal brain metabolism and fluid accumulation (e.g., subdural effusions), a classic early sign of GA-I.  
3. **Delayed speech/language development** reflects neurological damage from metabolic crises, typically triggered by catabolic stressors (e.g., infections), causing striatal injury.  
4. **Abnormal circulating lysine concentration** and **elevated plasma citrulline** align with disrupted lysine and tryptophan metabolism, while **abnormal carnitine levels** result from secondary carnitine depletion from detoxification of toxic metabolites.  
5. **Neonatal death**, **death in infancy/childhood**, and **hypoxemia** correlate with acute metabolic decompensation (e.g., encephalopathic crises, rhabdomyolysis, or cardiac complications) if untreated.  
6. **Hypervalinemia** and **obesity** may reflect secondary metabolic disturbances or comorbidities, though they are less specific to GA-I.  
7. **Premature birth** is not directly linked to GA-I but could contribute to symptom severity due to metabolic immaturity.  

The constellation of neurodevelopmental, biochemical, and acute metabolic features strongly supports GA-I as the primary diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: Severe, untreated maternal PKU can disrupt fetal development due to phenylalanine toxicity, though neonatal PKU itself typically manifests postnatally.  
3. **Hypertyrosinemia**: While PKU classically results in *low* tyrosine (due to impaired conversion of phenylalanine to tyrosine), transient hypertyrosinemia may occur in neonates with liver immaturity or secondary metabolic disturbances.  
4. **Neonatal death/Death in infancy**: Untreated PKU can cause rapid neurological deterioration, seizures, and failure to thrive, particularly in rare severe variants (e.g., ""malignant"" PKU with near-complete PAH deficiency).  
5. **Consistency with PKU**: The combination of hyperphenylalaninemia and severe early-life outcomes aligns with PKU, though hypertyrosinemia suggests possible comorbid factors (e.g., transient neonatal tyrosinemia) or misdiagnosis of lab values.  

**Note**: Hypertyrosinemia is atypical for classic PKU and warrants investigation for alternative/additional disorders (e.g., tyrosinemia types I–III, BH4 deficiencies) or confirmatory genetic testing for PAH mutations."
"['Hyperactivity', 'Acne', 'Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Core diagnostic marker of PKU due to deficient phenylalanine hydroxylase (PAH), blocking phenylalanine conversion to tyrosine.  
2. **Intellectual disability and hyperactivity**: Untreated PKU causes toxic phenylalanine accumulation, impairing neurotransmitter synthesis and brain development.  
3. **Severe short stature and obesity**: Chronic metabolic disruption may alter growth hormone signaling and energy metabolism; obesity can arise from carbohydrate-heavy dietary management.  
4. **Death in childhood/adolescence/early adulthood**: Historically, untreated PKU leads to severe neurological decline, infections, or organ failure. Modern dietary interventions prevent this outcome.  
5. **Hypertyrosinemia discrepancy**: PKU typically causes *low* tyrosine (due to blocked PAH). Hypertyrosinemia suggests a comorbid or misdiagnosed condition (e.g., tyrosinemia type II) or lab error.  
6. **Acne**: Uncommon in PKU but may stem from hormonal imbalances or dietary factors (e.g., synthetic protein supplements).  

Note: Hypertyrosinemia and acne are atypical for PKU and warrant further investigation for overlapping disorders (e.g., BH4 deficiency or tyrosinemia)."
"['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Drowsiness', 'Sleep disturbance', 'Abnormal cerebral white matter morphology', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria and elevated glutaric acid**: Direct biochemical markers of GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Neurological symptoms (ataxia, hypotonia, drowsiness)**: Accumulated glutaric acid and neurotoxic metabolites (e.g., 3-hydroxyglutaric acid) damage the basal ganglia and white matter, consistent with **abnormal cerebral white matter morphology** on imaging.  
3. **Feeding difficulties and lethargy**: Common early signs in infants with GA-I due to metabolic instability.  
4. **Acute crises and neurodegeneration**: Untreated GA-I leads to metabolic decompensation (often triggered by infections/stress), causing irreversible brain injury, **sleep disturbance**, and **death in childhood**.  
5. **Exclusion of mimics**: Symptoms align with GA-I’s hallmark triad (encephalopathy, movement disorders, white matter changes) and biochemical profile, distinguishing it from other organic acidemias."
"['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Occipital neuralgia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Death in infancy/Neonatal death/Death in childhood**: Untreated PKU leads to severe neurotoxicity from phenylalanine accumulation, resulting in irreversible brain damage, seizures, and early mortality without dietary intervention.  
3. **Hypertyrosinemia**: Atypical but possible in PKU variants (e.g., BH4-deficient PKU), where impaired tyrosine metabolism or secondary metabolic disruptions may elevate tyrosine.  
4. **Occipital neuralgia**: Chronic neurotoxicity in PKU can cause peripheral nerve dysfunction or central pain pathways disruption, though this is a rare manifestation.  

Note: Classic PKU typically presents with *low* tyrosine, but coexisting hypertyrosinemia may suggest a complex metabolic interplay or diagnostic overlap with other tyrosinemia-related disorders. However, hyperphenylalaninemia remains the critical indicator for PKU."
"['Dementia', 'Skin rash', 'Spasticity', 'Areflexia', 'Death in infancy', 'Fever', 'Hyperammonemia', 'Diarrhea', 'Cerebral edema', 'Hepatomegaly', 'Progressive neurologic deterioration', 'Hyperlysinuria', 'Hypoargininemia', 'Abnormal circulating methionine concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating alanine concentration', 'Elevated plasma citrulline', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic)  
Reasoning:  
1. **Elevated plasma citrulline** and **hyperammonemia** are hallmark biochemical features of citrullinemia type I, caused by a deficiency in argininosuccinate synthetase (ASS1), a urea cycle enzyme.  
2. **Progressive neurologic deterioration**, **cerebral edema**, **spasticity**, and **dementia** align with ammonia neurotoxicity and urea cycle dysfunction.  
3. **Hypoargininemia** occurs due to impaired arginine synthesis in the urea cycle, while **hyperlysinuria** reflects secondary amino acid transport disruptions.  
4. **Hepatomegaly** and **abnormal circulating amino acids** (methionine, glutamine, alanine) suggest metabolic liver stress and secondary mitochondrial dysfunction.  
5. **Death in infancy** is consistent with the severe neonatal-onset form of classic citrullinemia.  
6. Cutaneous manifestations (**rash, erythematous plaques/macules/papules**) may result from metabolic acidosis or ammonia-induced inflammation.  
7. **Areflexia** and **fever** are nonspecific but compatible with acute metabolic decompensation.  

Disease: Citrullinemia type II (excluded)  
Reasoning:  
- Type II (citrin deficiency) typically presents later (adult/childhood) with **different amino acid abnormalities** (e.g., hyperthreonine, hypermethionine) and lacks classic neonatal lethality. Elevated citrulline is milder compared to type I."
"['Spasticity', 'Pneumonia', '3-Methylglutaric aciduria', 'Death in childhood', 'Abnormality of acid-base homeostasis']","['3-methylglutaconic aciduria type 4/3-@methylglutaconic aciduria, type IV']","Disease: 3-methylglutaconic aciduria type IV  
Reasoning:  
1. **3-Methylglutaric aciduria**: Elevated 3-methylglutaric acid in urine suggests a defect in leucine metabolism, often linked to 3-methylglutaconic aciduria (3-MGA) disorders. While 3-methylglutaconic acid is the hallmark of 3-MGA, some subtypes (e.g., AUH deficiency) may also excrete 3-methylglutaric acid.  
2. **Spasticity**: Neurological involvement, such as spasticity, aligns with 3-MGA type IV, which can present with central nervous system abnormalities due to mitochondrial dysfunction or metabolic stress.  
3. **Abnormality of acid-base homeostasis**: Metabolic acidosis is common in organic acidurias due to toxic metabolite accumulation, disrupting mitochondrial energy production.  
4. **Pneumonia**: Aspiration pneumonia may occur secondary to dysphagia or muscle weakness caused by neurological deterioration.  
5. **Death in childhood**: Severe metabolic crises, progressive neurodegeneration, and respiratory complications in 3-MGA type IV often lead to early mortality.  
6. **Type IV classification**: This subtype encompasses heterogeneous presentations not fitting classical types I-III, often with variable neurological and metabolic features. The combination of acid-base disturbances, spasticity, and organic aciduria supports this diagnosis when genetic confirmation is pending."
"['Death in infancy', 'Abnormal erythrocyte morphology', 'Thrombocytosis', 'Hypercalcemia', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Increased total bilirubin', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hypergalactosemia']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia Type 1 (HT-1)  
Reasoning:  
1. **Hypertyrosinemia and Hyperphenylalaninemia**: Directly indicate a defect in tyrosine metabolism. Tyrosinemia type 1 is caused by fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic accumulation of tyrosine metabolites (succinylacetone), which inhibits renal and hepatic function.  
2. **Liver Dysfunction**:  
   - **Hypoalbuminemia/Hypoproteinemia**: Reduced hepatic synthesis due to liver damage.  
   - **Elevated Alpha-Fetoprotein (AFP)**: Reflects hepatocellular regeneration or malignancy (hepatocarcinoma risk in HT-1).  
   - **Increased Total Bilirubin and Alkaline Phosphatase**: Cholestatic liver injury and impaired biliary excretion.  
3. **Renal Involvement**:  
   - **Hypercalcemia**: Renal tubular dysfunction causing phosphate wasting and secondary hyperparathyroidism.  
   - **Abnormal Circulating Porphyrins**: Succinylacetone inhibits δ-aminolevulinic acid dehydratase, leading to porphyrin synthesis disruption.  
4. **Metabolic Derangements**:  
   - **Hypergalactosemia**: Secondary to liver failure impairing galactose metabolism.  
   - **Thrombocytosis**: Reactive to chronic inflammation or hypersplenism from liver disease.  
5. **Abnormal Erythrocyte Morphology**: Liver dysfunction disrupts lipid metabolism, affecting red blood cell membrane stability.  
6. **Death in Infancy**: Untreated HT-1 causes rapid progression of liver failure, coagulopathy, and neurologic crises, often fatal in early childhood.  

The constellation of liver, renal, and metabolic abnormalities aligns pathognomonically with Tyrosinemia Type 1, confirmed by elevated succinylacetone in urine or genetic testing for FAH mutations."
"['Myopia', 'Nyctalopia', 'Hyperammonemia', 'Death in childhood', 'Death in adolescence', 'Hyperornithinemia']",['Gyrate atrophy of choroid and retina/Gyrate atrophy of choroid and retina with or without ornithinemia'],"Disease: Gyrate atrophy of choroid and retina with ornithinemia  
Reasoning:  
1. **Myopia and Nyctalopia**: These ocular symptoms align with progressive retinal degeneration, a hallmark of gyrate atrophy. The disease causes atrophy of the choroid and retina, leading to severe nearsightedness and impaired night vision.  
2. **Hyperornithinemia**: Elevated ornithine levels are pathognomonic for gyrate atrophy, caused by deficient ornithine aminotransferase (OAT) activity. This enzyme deficiency disrupts the urea cycle and ornithine metabolism.  
3. **Hyperammonemia**: Secondary urea cycle dysfunction due to ornithine accumulation can lead to episodic hyperammonemia, though this is less common and typically milder than in primary urea cycle disorders.  
4. **Early Mortality**: Untreated cases often result in death in childhood/adolescence due to metabolic decompensation or complications from advanced retinal degeneration (e.g., blindness-related accidents).  
5. **Exclusion of Alternatives**: The combination of retinal pathology with hyperornithinemia distinguishes this from other urea cycle disorders (e.g., OTC deficiency) or isolated retinal dystrophies."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Hypophosphatemia', 'Hepatomegaly', 'Hypokalemia', 'Prolonged bleeding time', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type I (HT-1)  
Reasoning:  
1. **Hypertyrosinemia & 4-Hydroxyphenylpyruvic aciduria**: Direct biochemical hallmarks of tyrosinemia type I due to fumarylacetoacetate hydrolase (FAH) deficiency, causing toxic accumulation of tyrosine metabolites.  
2. **Hepatomegaly & elevated alpha-fetoprotein (AFP)**: Indicates severe liver dysfunction, a key feature of HT-1. AFP elevation reflects hepatocellular injury/regeneration.  
3. **Hypoglycemia, hypophosphatemia, hypokalemia**: Results from hepatic failure and renal Fanconi syndrome (proximal tubule dysfunction), common in HT-1.  
4. **Prolonged bleeding time**: Secondary to coagulopathy from impaired hepatic synthesis of clotting factors.  
5. **Hyperphenylalaninemia**: May occur due to secondary inhibition of phenylalanine hydroxylase by tyrosine metabolites.  
6. **Abnormality of prenatal development, neonatal/childhood death**: Untreated HT-1 causes rapid progression to liver failure, metabolic crises, and early mortality.  
7. **Neonatal/Infancy onset**: Classic presentation of acute HT-1, aligning with the listed symptoms.  

All findings converge on **tyrosinemia type I**, a disorder of tyrosine metabolism with hepatorenal toxicity. Confirmation requires genetic testing for *FAH* mutations or urinary succinylacetone detection."
"['Seizure', 'Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Ventricular septal defect', 'Abnormal vertebral morphology', 'Stomatitis', 'Regional abnormality of skin', 'Gangrene']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Seizures**: BTDD disrupts biotin recycling, impairing carboxylase enzymes critical for energy production and neurotransmitter synthesis, leading to metabolic acidosis and neurological manifestations like seizures.  
2. **Generalized hypotonia**: Biotin-dependent carboxylases are essential for mitochondrial metabolism; deficiency causes muscle weakness and hypotonia due to impaired energy metabolism.  
3. **Growth delay**: Chronic metabolic acidosis and malnutrition from defective fatty acid, glucose, and amino acid metabolism result in failure to thrive.  
4. **Death in infancy**: Untreated BTDD causes progressive metabolic crises, irreversible neurological damage, and multi-organ failure, often fatal in early life.  
5. **Ventricular septal defect (VSD)**: Though not a primary feature, severe metabolic stress in BTDD may exacerbate congenital cardiac defects or reflect secondary mitochondrial dysfunction.  
6. **Abnormal vertebral morphology**: Rarely reported in BTDD; may arise from prolonged metabolic disruption affecting skeletal development.  
7. **Stomatitis & regional skin abnormality**: Biotin deficiency leads to dermatitis, mucosal inflammation (e.g., stomatitis), and periorofacial rashes due to impaired keratinocyte function.  
8. **Gangrene**: Severe metabolic acidosis and immunodeficiency in advanced BTDD predispose to tissue necrosis and gangrene.  

**Key confirmatory features**: Neurological symptoms (seizures, hypotonia), mucocutaneous findings (stomatitis, skin rash), and rapid progression without biotin supplementation align with BTDD. Early biotin therapy reverses symptoms, underscoring the urgency of diagnosis."
"['Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Dystonia', 'Death in infancy', 'Athetosis', 'Spastic tetraplegia', 'Glutaric aciduria', 'Severe short stature', 'Paraplegia/paraparesis', 'Death in adolescence']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** is a hallmark biochemical feature of GA-I, directly linking to the enzyme deficiency (glutaryl-CoA dehydrogenase).  
2. **Neurological symptoms** (seizures, dystonia, athetosis, spastic diplegia/tetraplegia, paraplegia) align with basal ganglia injury caused by toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
3. **Motor delay** and **intellectual disability** reflect progressive neurodegeneration from recurrent metabolic crises.  
4. **Severe short stature** may result from chronic metabolic instability and catabolic stress.  
5. **Death in infancy/adolescence** correlates with acute encephalopathic crises triggered by infections or fasting, common in untreated/severe GA-I cases.  
6. **Spasticity** and **paraparesis** indicate corticospinal tract damage, consistent with white matter changes observed in advanced GA-I.  
7. The absence of hepatic symptoms (e.g., hypoglycemia, hyperammonemia) distinguishes GA-I from other organic acidemias, reinforcing specificity.  

This pattern matches GA-I’s pathophysiology, where disrupted lysine/tryptophan metabolism leads to neurotoxicity and multisystemic deterioration."
"['Intellectual disability', 'Seizure', 'Ataxia', 'Death in infancy', 'Fever', 'Death in adolescence', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The presence of **L-2-hydroxyglutaric aciduria** (elevated L-2-hydroxyglutaric acid in urine) is pathognomonic for this disorder, confirming the diagnosis.  
2. **Neurological Symptoms**: **Intellectual disability**, **seizures**, and **ataxia** align with the neurotoxic effects of accumulated metabolites damaging the central nervous system.  
3. **Disease Progression**: **Death in infancy/adolescence** reflects the severe, progressive nature of the disease, often due to metabolic crises, neurodegeneration, or complications like status epilepticus.  
4. **Fever**: Likely secondary to intercurrent infections, which can trigger metabolic decompensation and exacerbate neurological symptoms.  
5. **Exclusion of Alternatives**: The specific biochemical signature rules out other organic acidurias (e.g., D-2-hydroxyglutaric aciduria) or leukodystrophies with overlapping symptoms.  

This diagnosis integrates biochemical evidence with clinical progression, consistent with autosomal recessive L-2-hydroxyglutaric aciduria."
"['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Multiple carboxylase involvement**: Symptoms like decreased pyruvate carboxylase activity and propionyl-CoA carboxylase deficiency indicate a global defect in biotin-dependent carboxylases, which require holocarboxylase synthetase (HLCS) for activation.  
2. **Metabolic derangements**:  
   - **Hyperammonemia** and **metabolic acidosis** arise due to impaired urea cycle function (via propionyl-CoA accumulation) and excessive organic acids (e.g., lactic acid, 3-hydroxypropionic acid).  
   - **Elevated urinary carboxylic acids** and **aminoaciduria** reflect disrupted amino acid catabolism and mitochondrial dysfunction.  
3. **Biotin dependency**: HLCS deficiency prevents biotin incorporation into carboxylases, explaining the multi-enzyme dysfunction.  
4. **Neonatal severity**: Symptoms like **feeding difficulties**, **tachypnea** (compensatory respiratory alkalosis), and **neonatal death** align with the rapid metabolic decompensation seen in untreated HLCS deficiency.  
5. **Glycine abnormalities**: Propionyl-CoA accumulation inhibits glycine cleavage, leading to **abnormal circulating glycine**.  
6. **Exclusion of isolated deficiencies**: Concurrent pyruvate and propionyl-CoA carboxylase deficiencies rule out isolated defects (e.g., propionic acidemia), pointing to a shared biotinylation defect."
"['Abnormal renal tubule morphology', 'Enlarged kidney', 'Nephritis', 'Hematuria', 'Hypertension', 'Seizure', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Polydipsia', 'Vomiting', 'Anorexia', 'Hepatomegaly', '4-Hydroxyphenylpyruvic aciduria', 'Abdominal distention', 'Aminoaciduria', 'Death in childhood', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating tyrosine concentration', 'Abdominal mass']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type I  
Reasoning:  
1. **Hepatic and Renal Involvement**: Symptoms like cirrhosis, hepatic fibrosis, hepatomegaly, abnormal renal tubule morphology, and nephritis indicate combined liver and kidney dysfunction, a hallmark of Tyrosinemia type I (HT-1).  
2. **Metabolic Abnormalities**: Elevated 4-hydroxyphenylpyruvic aciduria and abnormal tyrosine levels directly point to a defect in tyrosine metabolism, specifically a deficiency of fumarylacetoacetate hydrolase (FAH) in HT-1.  
3. **Infant/Childhood Fatality**: Death in infancy or childhood aligns with the severe, progressive nature of untreated HT-1, which causes liver failure and renal tubular damage.  
4. **Secondary Manifestations**: Hypertension (renal origin), seizures (neurotoxicity from metabolites like succinylacetone), aminoaciduria (renal tubular dysfunction), and elevated alpha-fetoprotein (hepatocyte regeneration/cancer risk) are consistent with HT-1 complications.  
5. **Gastrointestinal Symptoms**: Vomiting, anorexia, and abdominal distention reflect metabolic acidosis and liver dysfunction.  
6. **Diagnostic Confirmation**: The combination of hepatic fibrosis, renal Fanconi-like syndrome (aminoaciduria), and specific tyrosine pathway abnormalities excludes other metabolic disorders (e.g., galactosemia, Wilson disease) and confirms HT-1."
"['Retinopathy', 'Cataract', 'Hypertension', 'Congestive heart failure', 'Myocardial infarction', 'Acute kidney injury', 'Progressive neurologic deterioration', 'Glycosuria', 'Chronic kidney disease', 'Elevated hemoglobin A1c', 'Death in early adulthood', 'Sepsis']","['MODY', 'Maturity-onset diabetes of the young, type 1']","MODY: The patient presents with elevated hemoglobin A1c and glycosuria, indicative of chronic hyperglycemia. MODY, a monogenic form of diabetes, often manifests in early adulthood with autosomal dominant inheritance. Retinopathy, cataracts, and chronic kidney disease align with long-term diabetic complications. Hypertension and cardiovascular events (myocardial infarction, congestive heart failure) suggest accelerated vascular damage from prolonged hyperglycemia. Acute kidney injury and sepsis may result from diabetes-related susceptibility to infections and renal stress. Progressive neurologic deterioration could stem from metabolic derangements (e.g., uremia, hypoglycemia) or microvascular damage. Early adulthood mortality reflects severe, untreated diabetic complications, consistent with delayed MODY diagnosis or inadequate management. While MODY is typically milder, type 1 (HNF4A mutation) can lead to significant morbidity if glycemic control is poor."
"['Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormal tyrosine concentration** (likely low) directly results from PAH dysfunction, as tyrosine synthesis is blocked.  
3. **Death in early adulthood** aligns with untreated/severe PKU, where chronic phenylalanine accumulation causes irreversible neurological damage, seizures, and organ failure. Early dietary management mitigates symptoms, but lack of treatment leads to reduced life expectancy.  
4. Alternative disorders (e.g., BH4 deficiency, tyrosinemia) are excluded due to the absence of specific features (e.g., neurotransmitter deficits, liver/kidney dysfunction)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']","['Tyrosinemia, type III']","Disease: Tyrosinemia, type III  
Reasoning:  
1. **Hypertyrosinemia and Hyperphenylalaninemia**: Tyrosinemia type III is caused by a deficiency of 4-hydroxyphenylpyruvate dioxygenase, disrupting tyrosine metabolism. Elevated tyrosine (hypertyrosinemia) occurs due to impaired degradation. Feedback inhibition of phenylalanine hydroxylase by excess tyrosine may also lead to hyperphenylalaninemia.  
2. **Severe Outcomes (Neonatal/Infancy/Childhood Death)**: While typically milder than type I/II, untreated type III can cause metabolic crises or neurological complications (e.g., seizures, intellectual disability), potentially leading to early mortality in severe cases.  
3. **Prenatal Developmental Abnormalities**: Chronic metabolic disturbances in utero may interfere with fetal development, aligning with reported prenatal abnormalities.  
4. **Differentiation from Other Tyrosinemias**:  
   - Type I primarily causes liver/kidney failure (absent here).  
   - Type II presents with ocular/skin lesions (not described).  
   - Co-occurring hypertyrosinemia *and* hyperphenylalaninemia strongly supports type III.  

Conclusion: The combination of tyrosine/phenylalanine elevation, developmental abnormalities, and early lethality aligns with a severe manifestation of tyrosinemia type III."
"['Apathy', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Drowsiness', 'Sleep disturbance', 'Glycosuria', 'Death in childhood', 'Impairment of fructose metabolism']","['Fructose-1,6-bisphosphatase deficiency/Fructose-1,6-bisphosphatase deficiency']","Disease: Fructose-1,6-bisphosphatase deficiency  
Reasoning:  
1. **Hypoglycemia** and **metabolic acidosis** are hallmark features of fructose-1,6-bisphosphatase deficiency due to impaired gluconeogenesis, leading to glucose production failure during fasting and compensatory fat breakdown (causing ketosis and acidosis).  
2. **Impairment of fructose metabolism** arises because fructose ingestion exacerbates metabolic stress by depleting intracellular phosphate, worsening hypoglycemia and acidosis.  
3. **Glycosuria** may occur during metabolic crises, potentially from transient renal dysfunction or altered glucose homeostasis despite systemic hypoglycemia.  
4. **Lethargy**, **drowsiness**, **apathy**, and **sleep disturbances** reflect neurological impacts of hypoglycemia and acidosis.  
5. **Death in infancy/childhood** aligns with untreated metabolic decompensation during fasting or illness, which is life-threatening without prompt glucose supplementation and fructose/sucrose avoidance.  
6. Exclusion of hereditary fructose intolerance (HFI) is critical, as HFI primarily causes liver/kidney damage post-fructose ingestion but lacks fasting-induced hypoglycemia."
"['Delayed speech and language development', 'Death in infancy', 'Vomiting', 'Clumsiness', 'Poor coordination', 'Neonatal death', 'Death in childhood', 'Increased urinary glycerol']",['Isolated glycerol kinase deficiency/Glycerol kinase deficiency'],"Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol**: A hallmark symptom of glycerol kinase deficiency (GKD), as the enzyme deficiency prevents glycerol metabolism, leading to its excretion in urine.  
2. **Vomiting**: Common during metabolic crises due to glycerol accumulation and potential ketotic hypoglycemia.  
3. **Delayed speech, clumsiness, poor coordination**: Neurological manifestations may arise from episodic metabolic decompensation affecting brain function during critical developmental stages.  
4. **Death in infancy/childhood/neonatal death**: While rare in *isolated* GKD, severe metabolic instability or misdiagnosis (e.g., overlapping with contiguous Xp21 deletion syndrome) could contribute to early mortality.  
5. Exclusion of other disorders: Symptoms align with GKD rather than broader mitochondrial or fatty acid oxidation disorders, given the specificity of glyceroluria.  
Note: Isolated GKD typically has mild-to-moderate presentations; severe outcomes may suggest comorbid conditions or diagnostic overlap."
"['Cerebellar atrophy', 'Encephalopathy', 'Death in infancy', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Neonatal death', 'Death in adolescence', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Neurological involvement**: Cerebellar atrophy/agenesis and encephalopathy are hallmark features of PMM2-CDG, reflecting severe central nervous system dysfunction due to impaired glycosylation.  
2. **Dysmorphic features**: Abnormal facial shape (e.g., inverted nipples, large ears, strabismus) and calvaria abnormalities (e.g., occipital prominence) are common phenotypic traits.  
3. **Early lethality**: Neonatal death, death in infancy, or adolescence align with the severe multisystemic nature of PMM2-CDG, often involving liver failure, coagulopathy, or infections.  
4. **Hepatic dysfunction**: Acute/chronic hepatitis correlates with the liver involvement seen in PMM2-CDG, including steatosis, fibrosis, and elevated transaminases.  
5. **Systemic manifestations**: The combination of neurological, hepatic, and dysmorphic symptoms strongly supports a glycosylation disorder, with PMM2-CDG (type Ia) being the most prevalent form."
"['Cataract', 'Abnormality of prenatal development or birth', 'Hepatic failure', 'Death in infancy', 'Atrial septal defect', 'Hyperammonemia', 'Conjugated hyperbilirubinemia', 'Increased total bilirubin', '4-hydroxyphenylacetic aciduria', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's symptoms of hypergalactosemia, conjugated hyperbilirubinemia, 4-hydroxyphenylacetic aciduria, and hepatic failure directly align with the pathophysiology of classic galactosemia (GALT deficiency). Accumulation of galactose metabolites (e.g., galactitol) explains cataracts, while liver dysfunction causes coagulopathy (prolonged PTT) and hyperammonemia. Neonatal death and infant mortality are typical in untreated cases due to metabolic crisis. Abnormal galactoside metabolism and amino acid derangements further support this diagnosis.  

Disease: Galactosemia  
Reasoning: The broader diagnosis of galactosemia encompasses the patient's prenatal abnormalities, neonatal death, and metabolic markers (e.g., hyperbilirubinemia, hyperammonemia). The systemic toxicity from galactose-1-phosphate accumulation explains multi-organ failure (liver, brain, eyes). Atrial septal defect, though less common, may occur due to metabolic stress during embryogenesis. The constellation of symptoms across hepatic, ocular, and developmental domains confirms galactosemia as the unifying etiology."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Key Metabolic Marker**: ""Decreased 3-hydroxyacyl-CoA dehydrogenase level"" directly indicates a defect in medium-chain acyl-CoA dehydrogenase (MCAD), a critical enzyme in mitochondrial β-oxidation of fatty acids.  
2. **Carnitine Abnormality**: ""Abnormal circulating carnitine concentration"" aligns with secondary carnitine deficiency in MCADD due to disrupted fatty acid metabolism and accumulation of toxic acyl-CoA intermediates.  
3. **Early Lethality**: Symptoms like ""neonatal death,"" ""death in infancy,"" and ""death in childhood"" reflect MCADD’s presentation during metabolic stress (e.g., fasting), causing hypoketotic hypoglycemia, hepatic dysfunction, and fatal energy crises if untreated.  
4. **Prenatal/Developmental Signs**: ""Abnormality of prenatal development"" may correlate with intrauterine metabolic stress or placental insufficiency secondary to fetal fatty acid oxidation defects.  
5. **Exclusion of Alternatives**: Symptoms are specific to a fatty acid oxidation disorder, and MCADD is the most common in this category, distinguished by the enzyme deficiency stated."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD is an autosomal recessive disorder caused by mutations in the *ACADM* gene, which may manifest as subtle prenatal or neonatal metabolic instability.  
2. **Death in infancy/Neonatal death**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to hypoketotic hypoglycemia and metabolic crises during fasting. Untreated, this can rapidly progress to coma, seizures, or sudden death in infancy.  
3. **Abnormal circulating carnitine concentration**: MCADD causes secondary carnitine deficiency due to urinary loss of acylcarnitine adducts (e.g., C8, C10:1), while elevated medium-chain acylcarnitines (C6-C10) on newborn screening are pathognomonic.  
4. **Key biochemical correlation**: The combination of hypoglycemia, low free carnitine (C0), and elevated C8/C10:1 acylcarnitines strongly supports MCADD, distinguishing it from other fatty acid oxidation disorders."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion. Untreated PKU results in toxic phenylalanine accumulation, leading to severe neurological damage, seizures, and **early death** (childhood/adolescence). While **hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are typically low), it may indicate a comorbid condition (e.g., tyrosinemia type II) or a rare PKU variant involving tetrahydrobiopterin (BH4) deficiency. BH4 defects disrupt both phenylalanine metabolism and tyrosine breakdown, potentially elevating both metabolites. Despite this inconsistency, hyperphenylalaninemia and early mortality strongly prioritize PKU as the primary diagnosis."
"['Intellectual disability', 'Ataxia', 'Death in infancy', 'Abnormal heart valve morphology', 'Hyperammonemia', 'Hyperglycinemia', 'Severe short stature', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Death in early adulthood']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: Propionic acidemia (PA) disrupts propionyl-CoA metabolism, causing accumulation of toxic metabolites that inhibit the urea cycle (leading to hyperammonemia) and impair glycine cleavage (resulting in hyperglycinemia).  
2. **Neurological Symptoms (Intellectual disability, Ataxia)**: Elevated ammonia and glycine are neurotoxic, contributing to developmental delays, intellectual disability, and motor dysfunction.  
3. **Abnormal Carnitine & Porphyrin Levels**: Secondary carnitine deficiency arises from excessive conjugation with propionyl-CoA for excretion. Porphyrin abnormalities may reflect mitochondrial dysfunction or oxidative stress.  
4. **Recurrent Infections & Early Mortality**: Metabolic crises during catabolic stressors (e.g., infections) exacerbate acidosis and organ failure, leading to recurrent decompensation and early death (infancy to adulthood).  
5. **Cardiac & Growth Issues**: Chronic metabolic instability causes cardiomyopathy, abnormal heart valves, and failure to thrive (severe short stature).  
6. **Hearing Loss**: Neurodegeneration or oxidative damage from toxic metabolites may explain sensorineural hearing impairment.  

PA’s hallmark biochemical triad—elevated propionate, hyperammonemia, and hyperglycinemia—aligns with the symptoms, confirming the diagnosis."
"['Strabismus', 'Apathy', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Abdominal distention', 'Propionyl-CoA carboxylase deficiency', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Key biochemical marker**: Propionyl-CoA carboxylase deficiency is a hallmark of biotinidase deficiency (BTDD), as biotin is a cofactor for multiple carboxylases, including propionyl-CoA carboxylase.  
2. **Metabolic abnormalities**: Elevated urinary carboxylic acids (e.g., propionate, 3-hydroxyisovalerate) and abnormal aspartate/alanine concentrations align with impaired carboxylase activity due to biotin depletion.  
3. **Dermatological features**: Alopecia (hair loss) is a classic sign of biotin deficiency, as biotin is critical for keratin synthesis.  
4. **Neurological symptoms**: Seizures, motor delay, apathy, and severe hearing impairment reflect biotin’s role in neuronal function and myelination. Untreated BTDD causes progressive neurodegeneration.  
5. **Immune dysfunction**: Recurrent viral infections may stem from biotin’s role in immune regulation and leukocyte function.  
6. **Early mortality**: Death in infancy/childhood is typical in severe, untreated cases due to metabolic crises or infections.  
7. **Abdominal distention**: Likely secondary to metabolic acidosis or hepatic dysfunction from toxic metabolite accumulation.  
8. **Late-onset presentation**: Symptoms like delayed speech and hypotonia manifest after the neonatal period, distinguishing BTDD from holocarboxylase synthetase deficiency (early-onset).  
**Conclusion**: The constellation of carboxylase deficiency, neurological decline, alopecia, and metabolic derangements confirms BTDD. Immediate biotin supplementation is critical to reverse symptoms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death/Death in infancy** aligns with untreated severe PKU, where elevated phenylalanine levels cause irreversible neurological damage, seizures, and metabolic crises if undiagnosed and unmanaged (e.g., absent newborn screening).  
3. **Abnormality of prenatal development or birth** may reflect complications in maternal PKU (uncontrolled phenylalanine levels during pregnancy), but here it likely indicates postnatal developmental failure due to early metabolic dysfunction in the infant.  
4. PKU is typically asymptomatic at birth but manifests progressively after feeding; rapid deterioration without dietary intervention (low-phenylalanine diet) explains the fatal outcomes listed.  

*Note:* Confirmation requires genetic testing (PAH gene mutations) and newborn screening results (elevated phenylalanine with normal tyrosine). Early treatment prevents severe outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: While PKU itself does not directly cause structural birth defects, untreated maternal PKU during pregnancy can result in congenital abnormalities (e.g., microcephaly, cardiac defects) in the fetus. This suggests possible maternal PKU contributing to prenatal developmental issues.  
3. **Neonatal death/Death in infancy**: Severe untreated PKU can cause rapid neurological deterioration, seizures, and metabolic instability. In extreme cases, acute complications (e.g., metabolic crises) or secondary infections due to failure to thrive may lead to early mortality.  
4. The combination of hyperphenylalaninemia and early lethality strongly aligns with a classic or severe PKU phenotype, emphasizing the critical need for newborn screening and dietary intervention to prevent outcomes."
"['Microcephaly', 'Strabismus', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating glutamine concentration', 'Feeding difficulties']",['N-acetylglutamate synthase deficiency; NAGSD/Hyperammonemia due to N-acetylglutamate synthase deficiency/N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY'],"Disease: N-acetylglutamate synthase deficiency (NAGSD)  
Reasoning:  
1. **Hyperammonemia**: Central to NAGSD, as the enzyme deficiency disrupts the urea cycle, impairing ammonia detoxification.  
2. **Neurological symptoms (Seizures, Hypotonia, Motor/Speech Delay, Microcephaly)**: Chronic hyperammonemia causes neurotoxicity, leading to developmental delays, seizures, and structural brain abnormalities (e.g., microcephaly).  
3. **Premature birth & Neonatal death**: Severe urea cycle defects often manifest acutely in the neonatal period; untreated hyperammonemia rapidly progresses to metabolic crisis, coma, or death.  
4. **Feeding difficulties & Gastrointestinal inflammation**: Common in neonates with metabolic distress due to ammonia accumulation and systemic toxicity.  
5. **Abnormal glutamine levels**: Elevated glutamine is a biochemical hallmark of urea cycle dysfunction, as excess ammonia is shunted to glutamine synthesis.  
6. **Recurrent infections**: Indirectly linked to metabolic instability and catabolic stress during illnesses, which exacerbate hyperammonemia.  

NAGSD is distinguished by **direct disruption of N-acetylglutamate synthesis** (required for urea cycle initiation), differentiating it from other urea cycle disorders. Early recognition is critical due to rapid clinical deterioration."
"['Acute kidney injury', 'Methylmalonic acidemia', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Abnormal circulating creatinine concentration', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical findings**: Methylmalonic acidemia/aciduria confirms impaired methylmalonyl-CoA mutase function, a hallmark of MMA.  
2. **B12-unresponsiveness**: The diagnosis specifies a B12-unresponsive subtype, which aligns with a mutase (MUT gene) deficiency, as B12 supplementation cannot bypass the defective enzyme.  
3. **Renal complications**: Chronic kidney disease, acute kidney injury, and abnormal creatinine reflect long-term metabolic acidosis and hypermethylmalonic acid toxicity, common in severe, treatment-resistant MMA.  
4. **Carnitine deficiency**: Decreased plasma free carnitine occurs due to excessive urinary excretion of methylmalonyl-carnitine, a compensatory mechanism to eliminate toxic metabolites.  
5. **Early mortality**: Death in adolescence/early adulthood is typical in mutase-deficient MMA due to metabolic crises, renal failure, or secondary organ damage.  
6. **Porphyrin abnormalities**: Likely secondary to renal dysfunction or mitochondrial toxicity disrupting heme biosynthesis pathways.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Symptomatic confirmation**: The presence of methylmalonic acidemia and aciduria directly establishes the broad diagnosis of MMA.  
2. **Overlap with subtype**: This general diagnosis encompasses all forms of MMA, including the specific mutase-deficient subtype, which is further refined by the second diagnosis.  
3. **Metabolic derangements**: All listed symptoms (kidney injury, carnitine deficiency) are consistent with the systemic effects of MMA, regardless of subtype.  
4. **Terminology clarification**: ""Methylmalonic aciduria"" is synonymous with MMA, emphasizing urinary excretion of methylmalonic acid as a diagnostic feature.  

The two diagnoses are hierarchically linked: the second (mutase deficiency) specifies the etiology and subtype of the first (general MMA)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic accumulation of phenylalanine.  
- **Abnormality of prenatal development or birth**: Untreated maternal PKU during pregnancy can result in congenital abnormalities (e.g., microcephaly, cardiac defects) due to phenylalanine toxicity to the fetus.  
- **Hypertyrosinemia**: While classic PKU typically causes **low** tyrosine (due to blocked PAH-dependent conversion of phenylalanine to tyrosine), transient or secondary hypertyrosinemia may occur in severe metabolic crises or liver dysfunction, often seen in critically ill infants with metabolic decompensation.  
- **Death in infancy/childhood/neonatal death**: Untreated PKU causes irreversible neurotoxicity, seizures, and failure to thrive, which can lead to early mortality. Neonatal screening and dietary management prevent these outcomes, but untreated cases historically resulted in fatal complications.  

**Note**: Hypertyrosinemia is atypical in PKU and suggests possible comorbid conditions (e.g., tyrosinemia type II) or diagnostic overlap. However, hyperphenylalaninemia and the clinical trajectory strongly prioritize PKU as the primary diagnosis."
"['Microcephaly', 'Strabismus', 'Apathy', 'Hyperactivity', 'Intellectual disability', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Metabolic Disturbances**: Symptoms like **metabolic acidosis**, **hyperammonemia**, **hyperglycinemia**, **hyperalaninemia**, and **hyperleucinemia** strongly suggest a disorder of branched-chain amino acid (BCAA) metabolism. PA disrupts propionyl-CoA carboxylase, impairing catabolism of valine, isoleucine, methionine, and odd-chain fatty acids, leading to toxic metabolite accumulation.  
2. **Neurological and Developmental Features**: **Microcephaly**, **intellectual disability**, **hypotonia**, **apathy**, and **hyperactivity** align with chronic neurotoxicity from elevated propionic acid and ammonia, which damage the central nervous system.  
3. **Life-Threatening Course**: **Death in infancy/childhood/adolescence**, **neonatal death**, and **severe short stature** reflect the rapid progression of untreated PA. Metabolic crises trigger acute decompensation with **vomiting**, **feeding difficulties**, and **gastrointestinal inflammation**, exacerbating catabolism.  
4. **Carnitine Dysregulation**: **Abnormal circulating carnitine** occurs as carnitine conjugates with propionyl-CoA to form propionylcarnitine (C3), a diagnostic biomarker for PA. Secondary carnitine deficiency worsens energy metabolism.  
5. **Biochemical Hallmarks**: Elevated glycine (**hyperglycinemia**) is a key feature of PA due to secondary inhibition of glycine cleavage enzyme by propionyl-CoA. Hyperammonemia arises from urea cycle inhibition by accumulated metabolites.  

The constellation of metabolic derangements, neurodevelopmental deficits, and early mortality strongly supports **propionic acidemia** as the diagnosis. Confirmatory testing would include plasma acylcarnitine profile (elevated C3), urinary organic acids (3-hydroxypropionate, methylcitrate), and genetic analysis of *PCCA* or *PCCB* genes."
"['Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Fever', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Elevated circulating alkaline phosphatase concentration', 'Oroticaciduria', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Hyperleucinemia', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Feeding difficulties', 'Fatigue']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Hyperammonemia** indicates a urea cycle disorder, as ammonia is not effectively converted to urea.  
2. **Elevated plasma citrulline** and **oroticaciduria** localize the defect to argininosuccinate lyase (ASL) deficiency, as citrulline accumulates due to the enzymatic block, and excess carbamoyl phosphate diverts to pyrimidine synthesis, producing orotic acid.  
3. **Aminoaciduria** and **abnormal amino acid concentrations** (arginine, aspartate family, proline, glycine, alanine) reflect metabolic dysregulation from urea cycle failure, protein catabolism, and secondary mitochondrial dysfunction.  
4. **Hyperleucinemia** and **elevated lactate** suggest metabolic decompensation and energy crisis due to hyperammonemia.  
5. **Neonatal/childhood death**, **feeding difficulties**, and **hypotonia** align with severe urea cycle disorder presentations, where toxic ammonia levels cause neurological damage and multisystem failure.  
6. **Premature birth** and **small for gestational age** may result from in utero metabolic stress.  
7. **Elevated alkaline phosphatase** and **abnormal carnitine** levels are nonspecific markers of metabolic dysfunction.  

This constellation of findings—especially hyperammonemia, citrullinemia, and oroticaciduria—confirms **argininosuccinic aciduria** due to ASL deficiency."
"['Macrocephaly', 'Irritability', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Feeding difficulties', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Key Biochemical Markers**: Elevated glutaric aciduria and elevated circulating glutaric acid concentration are pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Neurological Symptoms**: Dystonia, dyskinesia, and generalized hypotonia align with basal ganglia damage, a hallmark of GA-I due to neurotoxic metabolite accumulation.  
3. **Macrocephaly**: Often presents pre-symptomatically in infancy, reflecting abnormal brain development or subdural effusions.  
4. **Metabolic Decompensation Episodes**: Vomiting, diarrhea, dehydration, fever, and lethargy during catabolic stress (e.g., infections) trigger acute crises, leading to irreversible neurological injury.  
5. **Carnitine Deficiency**: Decreased plasma free carnitine results from secondary carnitine depletion, as carnitine binds to glutaric acid for excretion.  
6. **Poor Prognosis Indicators**: Death in infancy/childhood and neonatal death (in severe cases) reflect untreated metabolic instability or encephalopathic crises.  
7. **Supportive Symptoms**: Irritability, drowsiness, hyperhidrosis, and feeding difficulties are consistent with chronic metabolic dysregulation and acute energy deficits.  
8. **Exclusion of Mimics**: Symptoms overlap with other organic acidemias, but glutaric acid elevation and specific neurological progression confirm GA-I."
"['Death in infancy', 'Cardiac arrest', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** directly indicates abnormal accumulation of glutaric acid, a hallmark of GA-I caused by **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Death in infancy** aligns with GA-I’s severe early-onset presentation, where metabolic crises (triggered by catabolic stress) lead to acute encephalopathy, striatal necrosis, and irreversible neurological damage, often fatal without prompt intervention.  
3. **Cardiac arrest** is atypical in GA-I but may occur secondary to severe metabolic acidosis or electrolyte imbalances during crises, disrupting cardiac function.  
4. The triad of symptoms suggests undiagnosed/untreated GA-I, where delayed management allows toxic metabolite buildup (glutaric acid, 3-hydroxyglutaric acid), causing multisystem failure.  
5. Differential exclusion: Cardiac arrest more commonly links to fatty oxidation disorders (e.g., GA-II), but glutaric aciduria and striatal pathology prioritize GA-I."
"['Macrocephaly', 'Epistaxis', 'Carious teeth', 'Death in infancy', 'Tachycardia', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's abnormality of galactoside metabolism is a hallmark of galactosemia, a disorder impairing galactose conversion. Classic galactosemia (GALT deficiency) causes toxic metabolite accumulation, leading to life-threatening complications (neonatal death, death in infancy/childhood). Tachycardia may stem from sepsis or metabolic acidosis, while liver dysfunction (coagulopathy) explains epistaxis. Macrocephaly could reflect cerebral edema, and carious teeth may result from dietary restrictions or metabolic imbalances. Early fatality without galactose restriction aligns with untreated galactosemia. Other symptoms are secondary to systemic toxicity."
"['Seborrheic dermatitis', 'Seizure', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid', 'Body odor']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Aminoaciduria & Elevated Urinary Carboxylic Acids**: Biotinidase deficiency impairs biotin recycling, disrupting carboxylase enzymes (propionyl-CoA, pyruvate, 3-methylcrotonyl-CoA), leading to organic acidemia and abnormal metabolite excretion.  
2. **Seborrheic Dermatitis**: Biotin deficiency causes skin manifestations due to impaired fatty acid metabolism and keratinocyte dysfunction.  
3. **Seizures & Hypotonia/Hyporeflexia**: Accumulation of neurotoxic metabolites (e.g., lactate, ammonia) and disrupted energy metabolism in the central nervous system.  
4. **Abnormal Circulating Glycine**: Secondary inhibition of glycine cleavage system by organic acids, elevating glycine levels (non-ketotic hyperglycinemia-like presentation).  
5. **Body Odor**: Excretion of volatile organic acids (e.g., 3-hydroxyisovalerate) through sweat and urine.  
6. **Death in Infancy**: Untreated BTDD causes progressive metabolic crises, respiratory failure, or neurological damage.  
**Diagnostic Confirmation**: Low serum biotinidase activity (<10% normal) and genetic testing for *BTD* gene mutations. Early biotin supplementation reverses symptoms."
"['Irritability', 'Seizure', 'Lethargy', 'Motor delay', 'Failure to thrive', 'Death in infancy', 'Weight loss', 'Hyperammonemia', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Argininuria', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Feeding difficulties', 'Uraciluria']",['Arginase deficiency/Argininemia/Argininemia'],"Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Hyperammonemia** and **cerebral edema** indicate a urea cycle disorder, as ammonia detoxification is impaired.  
2. **Argininuria** and **abnormal circulating arginine concentration** directly suggest arginase deficiency, as arginase catalyzes arginine breakdown. Accumulated arginine spills into urine.  
3. **Oroticaciduria** and **uraciluria** occur due to secondary pyrimidine synthesis disruption from carbamoyl phosphate accumulation, a urea cycle intermediate.  
4. **Neurological symptoms** (seizures, drowsiness, irritability, motor delay) stem from ammonia/arginine neurotoxicity and cerebral edema.  
5. **Failure to thrive**, **feeding difficulties**, and **weight loss** reflect chronic metabolic stress and protein intolerance.  
6. **Recurrent viral infections** may link to immune dysfunction from metabolic imbalance or nutritional deficits.  
7. **Death in infancy** aligns with severe, untreated urea cycle disorders.  
The triad of hyperammonemia, argininuria, and oroticaciduria strongly differentiates arginase deficiency from other urea cycle defects."
"['Cataract', 'Delayed speech and language development', 'Cholelithiasis', 'Intellectual disability', 'Spasticity', 'Failure to thrive', 'Death in infancy', 'Abnormal foot morphology', 'Vomiting', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Feeding difficulties', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient exhibits hypergalactosemia and abnormal galactoside metabolism, hallmark biochemical features of galactosemia. Symptoms like cataracts (galactitol accumulation), hepatomegaly, elevated hepatic transaminases, and cholelithiasis align with liver dysfunction caused by toxic galactose metabolites. Failure to thrive, vomiting, and feeding difficulties are common neonatal presentations. Intellectual disability, delayed speech, and spasticity reflect neurological damage from chronic toxicity. Elevated alkaline phosphatase and abnormal amino acid concentrations (aspartate/alanine) suggest secondary liver impairment. Early mortality (infancy/childhood/adolescence) underscores untreated disease severity, consistent with classic galactosemia caused by GALT deficiency."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with untreated maternal PKU, where high maternal phenylalanine levels disrupt fetal development, though neonatal PKU itself typically manifests postnatally.  
3. **Hypertyrosinemia** is atypical in classic PKU (which usually causes *hypo*tyrosinemia). This may suggest a concurrent metabolic defect (e.g., transient tyrosinemia in neonates or a secondary pathway disruption) or a severe PAH variant affecting tyrosine metabolism indirectly.  
4. **Neonatal death/Death in infancy** correlates with untreated or severe PKU variants, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
5. The combination of hyperphenylalaninemia and early lethality strongly prioritizes PKU, though hypertyrosinemia warrants investigation for comorbid conditions (e.g., tyrosinemia type II) or BH4 metabolism disorders.  

Note: Hypertyrosinemia is incongruent with classic PKU and may indicate a complex case requiring additional biochemical/genetic analysis (e.g., BH4 deficiency or dual enzyme defects). However, hyperphenylalaninemia remains the primary diagnostic anchor."
"['Death in infancy', 'Hyperammonemia', 'Dyspnea', 'Abnormality of urine homeostasis', 'Neonatal death', 'Abnormal nervous system physiology']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), particularly CPS1 deficiency, as CPS1 catalyzes the first and rate-limiting step of ammonia detoxification.  
2. **Neonatal death** and **death in infancy** align with severe UCDs, which often present catastrophically in the first days of life due to ammonia toxicity.  
3. **Dyspnea** may reflect respiratory alkalosis from hyperventilation, a compensatory response to ammonia-induced cerebral edema.  
4. **Abnormality of urine homeostasis** (e.g., orotic acid absence in urine) distinguishes CPS1 deficiency from other UCDs (e.g., OTC deficiency), as CPS1 defects do not cause orotic aciduria.  
5. **Abnormal nervous system physiology** (lethargy, seizures, coma) results from ammonia crossing the blood-brain barrier, causing neurotoxicity.  
6. The absence of secondary markers like elevated orotic acid confirms CPS1 deficiency over other UCDs, matching the biochemical profile of the diagnosed disease."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: 生物素酶缺乏症/Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Symptom Alignment**:  
   - **Neonatal death/Death in infancy**: Untreated BTDD causes progressive metabolic crises (e.g., lactic acidosis, hyperammonemia) due to impaired carboxylase function. Without biotin supplementation, these crises lead to neurological deterioration, respiratory failure, and early mortality.  
   - **Abnormality of prenatal development or birth**: While BTDD typically manifests postnatally, severe maternal biotin deficiency (rarely) or fetal metabolic stress in utero may contribute to intrauterine growth restriction (IUGR) or preterm birth, indirectly linking to prenatal abnormalities.  

2. **Pathophysiology**:  
   - Biotinidase deficiency prevents recycling of biotin, a cofactor for carboxylases critical in fatty acid synthesis, gluconeogenesis, and amino acid catabolism.  
   - Postnatal biotin deprivation results in metabolic instability, with symptoms escalating within weeks to months after birth if untreated.  

3. **Diagnostic Confirmation**:  
   - Neonatal screening (bloodspot assay for biotinidase activity) or genetic testing (BTD gene mutations) would confirm the diagnosis.  
   - Absence of treatment explains the fatal trajectory described in the symptoms.  

4. **Exclusion of Alternatives**:  
   - Early-onset holocarboxylase synthetase deficiency presents similarly but typically manifests within days of birth, whereas BTDD is ""late-onset"" (weeks to months).  
   - Other lethal metabolic disorders (e.g., organic acidemias) were likely ruled out via the provided diagnosis.  

**Conclusion**: The triad of symptoms aligns with untreated BTDD, where biotin dependency post-birth leads to irreversible metabolic dysfunction and early death. Prenatal abnormalities may reflect secondary effects of metabolic instability or comorbid factors."
"['Hepatic steatosis', 'Elevated hepatic transaminase', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased circulating copper concentration']",['Hepatolenticular degeneration; Wilson disease/Wilson disease/Wilson disease'],"Disease: Hepatolenticular degeneration; Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin concentration** and **increased urinary copper concentration** are hallmark biochemical features of Wilson disease, caused by mutations in the *ATP7B* gene, impairing copper transport and biliary excretion.  
2. **Hepatic steatosis** and **elevated hepatic transaminase** reflect copper accumulation in the liver, leading to hepatocyte injury and fatty degeneration.  
3. **Decreased circulating copper concentration** occurs paradoxically due to reduced ceruloplasmin (a copper-binding protein), despite systemic copper overload.  
4. **Abnormal circulating aspartate family amino acids** and **alanine** may arise from secondary mitochondrial dysfunction or liver damage disrupting amino acid metabolism.  
5. **Hyperphenylalaninemia** could result from hepatic insufficiency impairing phenylalanine hydroxylase activity, though this is atypical and suggests severe liver involvement.  
6. **Death in childhood** aligns with early-onset Wilson disease variants presenting as acute liver failure, a rapid and fatal manifestation without timely intervention.  
The constellation of copper metabolism derangements, liver pathology, and ceruloplasmin deficiency strongly supports Wilson disease as the diagnosis."
"['Irritability', 'Ataxia', 'Coma', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Increased serum lactate', 'Stroke-like episode', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid accumulation**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in the branched-chain α-keto acid dehydrogenase (BCKDH) complex, the hallmark of MSUD.  
2. **Neurological symptoms**: Ataxia, irritability, coma, and stroke-like episodes arise from neurotoxicity caused by elevated leucine and its metabolites.  
3. **Metabolic decompensation**: Hyperammonemia and increased serum lactate reflect mitochondrial dysfunction and energy failure during metabolic crises.  
4. **Gastrointestinal involvement**: Vomiting and diarrhea are common during acute metabolic stress.  
5. **Early lethality**: Death in infancy/adolescence aligns with severe classical/intermediate MSUD phenotypes if untreated.  
6. **Secondary vulnerabilities**: Recurrent viral infections may stem from metabolic instability impairing immune responses.  
7. **Pathognomonic biochemical profile**: Combined elevation of valine, leucine, and isoleucine (with alloisoleucine) is unique to MSUD."
"['Dystonia', 'Abnormal foot morphology', 'Difficulty walking', 'Skeletal muscle atrophy', 'Hypertyrosinemia', 'Difficulty climbing stairs', 'Death in childhood', 'Hyperphenylalaninemia', 'Contractures of the large joints', 'Difficulty running', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Abnormal circulating porphyrin concentration', 'Death in adolescence']","['Autosomal dominant dopa-responsive dystonia/Dystonia, DOPA-responsive, with or without hyperphenylalaninemia']","Disease: Autosomal dominant dopa-responsive dystonia/Dystonia, DOPA-responsive, with or without hyperphenylalaninemia  
Reasoning:  
1. **Dystonia and motor difficulties**: The patient’s dystonia, difficulty walking, climbing stairs, and running align with dopa-responsive dystonia (DRD), which classically improves with levodopa. Chronic dystonia can lead to secondary skeletal muscle atrophy and joint contractures due to disuse or abnormal posturing.  
2. **Hyperphenylalaninemia**: Linked to mutations in *GCH1*, a gene critical for tetrahydrobiopterin (BH4) synthesis. BH4 deficiency impairs phenylalanine hydroxylase (PAH), causing phenylalanine accumulation. While classic BH4 defects typically reduce tyrosine, this subtype may involve compensatory mechanisms or variable metabolic flux.  
3. **Hypertyrosinemia**: Uncommon in DRD but could arise from disrupted tyrosine metabolism secondary to BH4-related enzyme imbalances or dietary factors. This contrasts with tyrosinemia types (liver/neuropathic phenotypes), which are ruled out by the absence of liver/ocular symptoms.  
4. **Early mortality**: Untreated hyperphenylalaninemia or severe dystonia may lead to complications (e.g., respiratory failure, metabolic crises), explaining death in childhood/adolescence.  
5. **Musculoskeletal features**: Abnormal foot morphology, muscle hypoplasia, and contractures are likely secondary to chronic dystonia and impaired mobility rather than primary myopathy.  
6. **Abnormal porphyrins**: Likely incidental or a nonspecific metabolic disturbance, as porphyrin abnormalities are not pathognomonic for DRD.  

The diagnosis prioritizes DRD due to the triad of dopa-responsive dystonia, hyperphenylalaninemia, and autosomal dominance, with other symptoms explained as secondary complications."
"['Generalized hypotonia', 'Obesity', 'Death in infancy', 'Ventricular septal defect', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classical PKU but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or comorbid metabolic disruptions.  
3. **Generalized hypotonia** and **recurrent viral infections** align with untreated PKU’s neurodevelopmental and immune dysregulation effects due to toxic phenylalanine accumulation.  
4. **Obesity** may reflect dietary challenges from lifelong phenylalanine-restricted diets, often rich in carbohydrates.  
5. **Ventricular septal defect** is likely an incidental congenital anomaly, as PKU does not directly cause cardiac defects.  
6. **Death in infancy/childhood** and **neonatal death** suggest severe, untreated PKU with metabolic crises or complications (e.g., seizures, cerebral edema), though modern neonatal screening mitigates this outcome.  

Note: Hypertyrosinemia and cardiac defects are atypical for PKU and warrant investigation for coexisting disorders (e.g., tyrosinemia, BH4 deficiency) or misdiagnosis."
"['Macroglossia', 'Macrocephaly', 'Coarse facial features', 'Hyperactivity', 'Splenomegaly', 'Hepatomegaly', 'Death in childhood', 'Recurrent viral infections', 'Death in adolescence', 'Feeding difficulties']","['Mucopolysaccharidosis type 2/Mucopolysaccharidosis, type II', 'Mucopolysaccharidoses; MPS']","Disease: Mucopolysaccharidosis type 2 (MPS II/Hunter syndrome)  
**Reasoning**:  
1. **Macroglossia, macrocephaly, coarse facial features**: Hallmark signs of mucopolysaccharidoses (MPS) due to glycosaminoglycan (GAG) accumulation in connective tissues, causing facial dysmorphism and tongue enlargement.  
2. **Hepatosplenomegaly**: Caused by GAG storage in visceral organs, common in MPS II.  
3. **Recurrent viral infections**: Impaired immune function from GAG accumulation in immune cells or secondary to organomegaly disrupting lymphoid tissue.  
4. **Hyperactivity/neurobehavioral issues**: Seen in MPS II due to progressive central nervous system involvement, though cognitive decline typically follows.  
5. **Feeding difficulties**: Related to macroglossia, airway obstruction, or gastrointestinal GAG deposition.  
6. **Early mortality (childhood/adolescence)**: Severe MPS II leads to cardiorespiratory complications or neurodegeneration, with death often by adolescence.  

Disease: Mucopolysaccharidoses (MPS)  
**Reasoning**:  
- The symptoms collectively align with MPS disorders, characterized by lysosomal enzyme deficiencies causing GAG accumulation.  
- **MPS II specificity**: X-linked inheritance (other MPS types are autosomal recessive), absence of corneal clouding (common in MPS I but rare in MPS II), and hyperactivity (more typical of MPS II than MPS I).  
- **Exclusion of other MPS types**: Lack of corneal clouding (MPS I), disproportionate short stature (MPS IV), or severe skeletal dysplasia (MPS VI) narrows the diagnosis to MPS II.  

**Final Diagnosis**: **Mucopolysaccharidosis type II (Hunter syndrome)** is the most precise fit given the symptom profile, early mortality, and absence of features specific to other MPS subtypes."
"['Cryptorchidism', 'Hypertension', 'Osteoporosis', 'Lethargy', 'Spastic diplegia', 'Generalized hypotonia', 'Hyperreflexia', 'Tachycardia', 'Abnormal foot morphology', 'Anemia', 'Acute kidney injury', 'Fever', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Hyperkalemia', 'Hyperglycinemia', 'Sparse scalp hair', 'Drowsiness', 'Difficulty walking', 'Sleep disturbance', 'Spastic tetraplegia', 'Hypercalcemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Decreased methylmalonyl-CoA mutase activity', 'Hypernatremia', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Difficulty climbing stairs', 'Death in childhood', 'Abnormal circulating leucine concentration', 'Recurrent viral infections', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Atransferrinemia', 'Chronic kidney disease', 'Severe hearing impairment', 'Abnormal circulating creatine kinase concentration', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**:  
   - **Decreased methylmalonyl-CoA mutase activity** directly indicates a defect in this enzyme, a hallmark of mutase-deficient MMA.  
   - **Methylmalonic aciduria** and **hyperglycinemia** are diagnostic for MMA, resulting from impaired conversion of methylmalonyl-CoA to succinyl-CoA.  
   - **Hyperammonemia**, **hyperuricemia**, and **hyperkalemia** reflect metabolic toxicity from accumulated organic acids and disrupted urea cycle function.  

2. **Acute metabolic crises**:  
   - **Vomiting**, **lethargy**, **fever**, **drowsiness**, and **acute kidney injury** align with episodic metabolic decompensation triggered by catabolism or protein intake.  
   - **Elevated creatinine**, **increased blood urea nitrogen**, and **hypernatremia** suggest acute-on-chronic kidney dysfunction, common in MMA due to tubular toxicity from methylmalonic acid.  

3. **Chronic multisystem complications**:  
   - **Chronic kidney disease**, **hypertension**, and **osteoporosis** result from long-term renal damage and electrolyte imbalances.  
   - **Spastic diplegia/tetraplegia**, **difficulty walking/climbing stairs**, and **severe short stature** reflect neurodevelopmental impairment from toxic metabolite accumulation.  
   - **Generalized hypotonia** with **hyperreflexia** and **abnormal foot morphology** indicate mixed upper/lower motor neuron damage.  

4. **Hematologic and immune dysfunction**:  
   - **Anemia** and **atransferrinemia** may stem from chronic inflammation or renal failure.  
   - **Recurrent viral infections** suggest secondary immune dysfunction due to metabolic stress.  

5. **Abnormal amino acid/carnitine profiles**:  
   - **Abnormal leucine/isoleucine/valine** levels confirm branched-chain amino acid metabolism disruption.  
   - **Abnormal carnitine** and **creatine kinase** concentrations point to mitochondrial dysfunction and muscle injury.  

6. **Poor prognosis**:  
   - **Death in childhood/adolescence/early adulthood** is consistent with severe mutase-deficient MMA, often refractory to dietary/cofactor therapies.  

This constellation of metabolic derangements, organ damage, and neurodevelopmental deficits, anchored by confirmed enzyme deficiency and methylmalonic aciduria, definitively establishes the diagnosis."
"['Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Vomiting', 'Hyperglutaminemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperleucinemia', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark of MMA, alongside key features like **vomiting, feeding difficulties, generalized hypotonia, and developmental delays (intellectual disability, motor delay)**. These symptoms reflect impaired methylmalonyl-CoA metabolism, leading to toxic metabolite accumulation. **Hyperleucinemia** and **hyperglutaminemia** may arise from secondary metabolic disruptions in amino acid catabolism. **Recurrent viral infections** could stem from metabolic stress impairing immune function. **Death in childhood** aligns with severe, untreated MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **B12-unresponsive subtype** is strongly supported by the severity of symptoms (e.g., **early mortality**) and biochemical findings. This form results from mutations in the *MUT* gene, causing **methylmalonyl-CoA mutase deficiency**, which bypasses B12-dependent pathways. Lack of response to B12 therapy exacerbates metabolic crises, explaining **refractory acidosis, progressive neurological damage**, and poor prognosis. The absence of B12-responsiveness differentiates this from cobalamin metabolism defects."
"['Conjunctivitis', 'Death in infancy', 'Neonatal death', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline is a hallmark of urea cycle disorders, specifically citrullinemia. Neonatal death or death in infancy aligns with severe metabolic decompensation due to argininosuccinate synthetase (ASS1) deficiency, which causes toxic ammonia accumulation. While conjunctivitis is atypical for urea cycle disorders, it may reflect secondary infections from metabolic instability or unrelated comorbidities.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia (type I) presents neonatally with hyperammonemia, vomiting, and lethargy progressing to coma. Elevated citrulline levels confirm ASS1 enzyme deficiency. Early mortality correlates with the rapid progression of untreated hyperammonemia. Conjunctivitis is not pathognomonic but may occur due to systemic illness or incidental factors. Type II (citrin deficiency) typically involves liver dysfunction and later onset, making type I the definitive diagnosis here."
"['Hyperkeratosis', 'Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Pulmonic stenosis', 'Gastrointestinal hemorrhage', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Skin rash/Eczematoid dermatitis**: Common in untreated PKU due to phenylalanine accumulation and metabolic byproducts irritating the skin.  
3. **Abnormality of prenatal development or birth/Death in infancy/Neonatal death/Death in childhood**: Severe untreated PKU causes profound neurological damage, leading to developmental failure and early mortality.  
4. **Gastrointestinal inflammation/hemorrhage**: Secondary to metabolic derangements or dietary management complications (e.g., protein-restricted diets).  
5. **Hypertyrosinemia**: Uncommon in classical PKU but may arise from tyrosine supplementation or overlapping metabolic disruptions.  
6. **Pulmonic stenosis**: Likely incidental or unrelated; PKU does not directly cause cardiac defects but may coexist with other congenital anomalies.  

*Note: While some symptoms (e.g., pulmonic stenosis) are atypical for PKU, the diagnosis is strongly supported by hyperphenylalaninemia and dermatological manifestations. Other features may reflect severe untreated disease or comorbidities.*"
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Abnormal circulating cysteine concentration', 'Sepsis', 'Metabolic alkalosis']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated Branched-Chain Amino Acids (BCAAs):** Hypervalinemia (elevated valine) and hyperleucinemia (elevated leucine) are hallmark biochemical features of MSUD, caused by a defect in the branched-chain α-ketoacid dehydrogenase complex.  
2. **Neurological Symptoms:** Lethargy, generalized hypotonia, drowsiness, and sleep disturbance result from neurotoxic accumulation of BCAAs and their ketoacids, leading to cerebral edema and impaired neurotransmitter function.  
3. **Metabolic Dysregulation:** Hyperammonemia and metabolic alkalosis may occur secondary to catabolic stress or intercurrent illness (e.g., sepsis), exacerbating metabolic decompensation.  
4. **Life-Threatening Course:** Neonatal death or death in infancy is typical in untreated classic MSUD due to rapid metabolic deterioration, often triggered by infections (e.g., sepsis) or metabolic crises.  
5. **Abnormal Cysteine Levels:** Secondary disruption of sulfur-containing amino acid metabolism may explain abnormal circulating cysteine concentrations in severe metabolic instability.  

The combination of BCAA elevation, acute neurological decline, and metabolic disturbances strongly supports MSUD, despite overlapping features with other inborn errors of metabolism (e.g., urea cycle disorders). Confirmatory testing (plasma amino acid analysis, genetic testing) is critical."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death** and **death in infancy/childhood/adolescence** align with untreated PKU, where severe neurological damage, seizures, and organ failure occur due to metabolic toxicity.  
3. **Obesity** may arise from restrictive dietary management (low-protein, high-carbohydrate diets) or metabolic dysregulation in poorly controlled cases.  
4. **Abnormality of prenatal development** is atypical for PKU itself but could reflect maternal PKU syndrome (if the mother had untreated PKU during pregnancy), causing congenital anomalies in the offspring.  
5. The progression to early mortality underscores delayed diagnosis or lack of newborn screening, preventing timely dietary intervention to lower phenylalanine levels.  

Key confirmation requires genetic testing for *PAH* mutations and blood phenylalanine monitoring. Early treatment prevents severe outcomes, but untreated cases match the fatal trajectory described."
"['Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Elevated hepatic transaminase', 'Feeding difficulties', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG due to impaired glycosylation critical for cerebellar development and function.  
2. **Failure to thrive/Feeding difficulties**: Common in PMM2-CDG due to gastrointestinal dysfunction, hypoglycemia, and protein-losing enteropathy.  
3. **Elevated hepatic transaminase**: Reflects liver involvement, a frequent feature of glycosylation defects disrupting glycoprotein synthesis.  
4. **Death in infancy**: Severe forms of PMM2-CDG (classic type Ia) often lead to early mortality from multisystem failure (neurological, hepatic, cardiac).  
5. **Consistency with PMM2-CDG**: The triad of neurological, hepatic, and growth abnormalities aligns with this disorder, the most prevalent N-linked glycosylation defect caused by phosphomannomutase 2 deficiency."
"['Macroglossia', 'Wide nasal bridge', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Areflexia', 'Generalized hypotonia', 'Death in infancy', 'Abnormal foot morphology', 'Pneumonia', 'Difficulty walking', 'Kyphoscoliosis', 'Skeletal muscle atrophy', 'Abdominal distention', 'Difficulty climbing stairs', 'Death in childhood', 'Ichthyosis', 'Difficulty running', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Elevated circulating phytanic acid concentration', 'Death in adolescence', 'Severe hearing impairment']",['Refsum disease/Refsum disease'],"Disease: Refsum disease  
Reasoning:  
1. **Elevated circulating phytanic acid concentration**: Pathognomonic for Refsum disease due to impaired alpha-oxidation from PHYH/PEX7 mutations.  
2. **Ichthyosis**: A hallmark feature linked to lipid metabolism dysfunction.  
3. **Ataxia, Areflexia, Motor delay, Difficulty walking/climbing stairs**: Caused by peripheral neuropathy and cerebellar degeneration, common in Refsum disease.  
4. **Severe hearing impairment**: Sensorineural hearing loss is a frequent neurological manifestation.  
5. **Skeletal muscle atrophy, Generalized hypotonia**: Secondary to chronic neuropathy and metabolic myopathy.  
6. **Kyphoscoliosis, Abnormal foot morphology**: Result from progressive neuromuscular deficits.  
7. **Death in infancy/childhood/adolescence**: Severe or untreated cases can lead to early mortality due to respiratory complications (e.g., pneumonia) or cardiac arrhythmias.  
8. **Macroglossia, Wide nasal bridge**: Less typical but occasionally reported in atypical/peroxisomal spectrum presentations.  
9. **Abdominal distention**: May reflect autonomic neuropathy or hepatomegaly from lipid accumulation.  

Key exclusions: Symptoms like intellectual disability and neonatal death are more common in Zellweger spectrum disorders, but Refsum disease is prioritized here due to phytanic acid elevation and core neurological/cutaneous features."
"['Cleft palate', 'Microcephaly', 'Epicanthus', 'Low-set ears', 'Anteverted nares', 'Strabismus', 'Ptosis', 'Nystagmus', 'Delayed speech and language development', 'Nevus flammeus', 'Syndactyly', 'Intellectual disability', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Athetosis', 'Drowsiness', 'Sleep disturbance', 'Hypercholesterolemia', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Key Craniofacial and Structural Features**: Cleft palate, microcephaly, low-set ears, anteverted nares, syndactyly (classic 2-3 toe webbing), and nevus flammeus align with SLOS phenotypic hallmarks.  
2. **Ocular Abnormalities**: Strabismus, ptosis, nystagmus, and epicanthus are consistent with SLOS-associated eye findings.  
3. **Neurodevelopmental Delays**: Intellectual disability, delayed speech/motor development, generalized hypotonia, and lethargy reflect impaired cholesterol-dependent neurodevelopment.  
4. **Growth and Survival Issues**: Failure to thrive, feeding difficulties, neonatal/childhood death correlate with severe SLOS phenotypes.  
5. **Biochemical Signature**: Hypocholesterolemia, elevated 7-dehydrocholesterol (7-DHC), and elevated 8-dehydrocholesterol confirm defective cholesterol biosynthesis due to DHCR7 mutations.  
6. **Pathophysiologic Link**: SLOS is caused by deficient 7-DHC reductase, leading to toxic sterol accumulation (7-DHC, 8-DHC) and cholesterol deficiency, directly explaining metabolic and clinical features.  
7. **Exclusion of Mimics**: Syndactyly + cholesterol abnormalities distinguish SLOS from other syndromes (e.g., Cornelia de Lange, Rubinstein-Taybi) lacking sterol defects.  

The constellation of dysmorphia, neurodevelopmental deficits, syndactyly, and characteristic sterol profile is diagnostic of SLOS."
"['Seizure', 'Spastic diplegia', 'Encephalopathy', 'Death in infancy', 'Fever', 'Spastic tetraplegia', 'Tachypnea', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of elevated glutaric acid in urine, a hallmark of GA-I due to GCDH enzyme deficiency.  
2. **Encephalopathy & Seizures**: Metabolic crises in GA-I cause neurotoxicity (glutaric acid accumulation), damaging the basal ganglia and leading to acute encephalopathy and seizures.  
3. **Spastic diplegia/tetraplegia**: Striatal injury during metabolic decompensation results in irreversible dystonia and spasticity, progressing to tetraplegia in severe cases.  
4. **Death in infancy**: Untreated GA-I often leads to early mortality from metabolic crises or secondary complications (e.g., rhabdomyolysis, cerebral edema).  
5. **Fever & Tachypnea**: Common triggers (infections, catabolic stress) precipitate metabolic decompensation, manifesting as fever and respiratory distress.  
6. **Exclusion of mimics**: Symptoms align with GA-I rather than other organic acidemias (e.g., no maple syrup odor for MSUD) or mitochondrial disorders (no lactic acidosis typically).  
**Diagnosis confirmed via**: Urinary organic acid analysis (glutaric/3-hydroxyglutaric acid elevation), GCDH enzyme assay, or genetic testing."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death/Death in infancy** aligns with severe untreated PKU variants (e.g., classic or malignant forms), where rapid neurological deterioration, seizures, and organ failure occur without early dietary intervention.  
3. **Abnormality of prenatal development** may reflect maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy), causing fetal microcephaly, congenital heart defects, or growth restriction. However, if the infant itself has PKU, prenatal abnormalities could stem from metabolic stress in utero or comorbid genetic factors.  
4. PKU is typically asymptomatic at birth but manifests post-feeding. Neonatal death suggests an extreme presentation or delayed diagnosis, emphasizing the critical need for newborn screening and immediate phenylalanine-restricted diets."
"['Seizure', 'Death in infancy', 'Ventricular septal defect', 'Atrial septal defect', 'Anemia', 'Hypoglycemia', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Neonatal death', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Hypoglycemia and Hepatomegaly**: Central to HMGCLD, as the enzyme deficiency impairs ketogenesis and leucine metabolism, leading to energy crises during fasting.  
2. **Dicarboxylic Aciduria and 3-Methylglutaconic Aciduria**: Pathognomonic findings due to accumulation of 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, and dicarboxylic acids from disrupted fatty acid oxidation.  
3. **Seizures and Neonatal Death**: Result from severe hypoglycemia, metabolic acidosis, and hyperammonemia during metabolic crises, often fatal without intervention.  
4. **Feeding Difficulties and Tachypnea**: Reflect acute decompensation (vomiting, lethargy) and compensatory respiratory alkalosis from metabolic acidosis.  
5. **Elevated Urinary Carboxylic Acids**: Direct consequence of defective organic acid metabolism.  
6. **Anemia**: May arise secondary to bone marrow suppression or metabolic stress.  
7. **Cardiac Defects (VSD/ASD)**: Uncommon but reported in rare cases, possibly linked to mitochondrial dysfunction or metabolic stress during embryogenesis.  
**Note**: While cardiac anomalies are atypical for HMGCLD, the biochemical markers (3-methylglutaconic/dicarboxylic aciduria) and metabolic profile are diagnostic. Early neonatal demise underscores the severity of untreated metabolic crises."
"['Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Dehydration', 'Fever', 'Vomiting', 'Respiratory distress', 'Methylmalonic acidemia', 'Hyperglycinuria', 'Hypercholesterolemia', 'Hyperalaninemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Methylmalonic aciduria, vitamin B12-responsive, cblA type']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Core biochemical markers**: Elevated methylmalonic acid in blood (methylmalonic acidemia) and urine (methylmalonic aciduria) confirm a defect in methylmalonyl-CoA metabolism, a hallmark of MMA.  
2. **Neuromuscular symptoms**: Delayed speech, motor delay, and hypotonia align with neurotoxic effects of accumulated methylmalonic acid and metabolic instability.  
3. **Metabolic crises**: Episodic vomiting, dehydration, fever, and respiratory distress are typical during acute decompensation due to protein catabolism or infection.  
4. **Amino acid abnormalities**: Hyperalaninemia and hyperglycinuria suggest secondary disruption of amino acid metabolism from mitochondrial dysfunction.  
5. **Fatality risk**: Death in infancy/childhood reflects severe metabolic derangements or complications (e.g., hyperammonemia, cardiomyopathy).  
6. **Carnitine/porphyrin abnormalities**: Abnormal carnitine (secondary deficiency) and porphyrin levels indicate disrupted mitochondrial and heme biosynthesis pathways.  

Disease: Methylmalonic aciduria, vitamin B12-responsive, cblA type  
Reasoning:  
1. **B12 responsiveness**: The cblA subtype involves mutations in *MMAA*, impairing adenosylcobalamin (active B12) synthesis. Partial or full response to B12 supplementation distinguishes it from mutase-deficient MMA.  
2. **Biochemical overlap**: Shared features with classic MMA (acidemia/aciduria, hyperalaninemia) but with potential milder symptoms if B12 is administered early.  
3. **Clinical severity**: Despite B12 responsiveness, untreated cblA can still lead to infantile/childhood mortality due to acute metabolic crises, consistent with the patient’s profile.  
4. **Carnitine/porphyrin disturbances**: Secondary carnitine deficiency and porphyrin abnormalities may persist even with B12 therapy, depending on residual enzyme activity.  

**Conclusion**: The patient’s presentation aligns with **methylmalonic acidemia**, specifically the **cblA subtype**, given the biochemical profile and potential for B12 responsiveness, which guides therapeutic intervention (e.g., hydroxocobalamin). Early diagnosis is critical to mitigate fatal outcomes."
"['Seizure', 'Death in infancy', 'Alopecia', 'Death in childhood', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids**: Biotinidase deficiency impairs biotin recycling, reducing activity of biotin-dependent carboxylases (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). This disrupts fatty acid synthesis, gluconeogenesis, and amino acid catabolism, leading to urinary excretion of abnormal organic acids.  
2. **Seizures**: Biotin is critical for neuronal metabolism. Deficiency causes accumulation of neurotoxic metabolites (e.g., lactate, ammonia) and impaired energy production in the brain, triggering seizures.  
3. **Alopecia**: Biotin deficiency disrupts keratinocyte function and hair follicle integrity, resulting in hair loss.  
4. **Death in infancy/childhood**: Untreated BTDD causes progressive metabolic acidosis, hyperammonemia, and irreversible neurological damage (e.g., respiratory failure, coma). Neonatal-onset forms are often fatal within months without biotin supplementation.  

The term ""late-onset multiple carboxylase deficiency"" refers specifically to BTDD, distinguishing it from holocarboxylase synthetase deficiency (early-onset). Prompt biotin therapy reverses symptoms, emphasizing the urgency of early diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Gastroesophageal reflux', 'Increased serum lactate', 'Hematemesis', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth** and **neonatal death** may occur in severe, untreated cases due to toxic phenylalanine accumulation affecting neurodevelopment.  
3. **Death in infancy/childhood** aligns with untreated PKU, where elevated phenylalanine leads to irreversible neurological damage, seizures, and systemic complications.  
4. **Hypertyrosinemia** is atypical in classical PKU but could arise from secondary metabolic disturbances or overlapping enzyme deficiencies (e.g., transient tyrosine elevation due to liver immaturity or stress).  
5. **Increased serum lactate** and **hematemesis** may reflect metabolic decompensation, organ failure (e.g., liver dysfunction), or catabolic states triggered by prolonged metabolic imbalance.  
6. **Gastroesophageal reflux** is a nonspecific symptom but could result from neurological dysfunction or feeding difficulties common in severely affected infants.  

Note: Hypertyrosinemia is unusual in PKU and suggests possible comorbid conditions (e.g., tyrosinemia type II) or diagnostic overlap, but PKU remains primary due to hyperphenylalaninemia dominating the clinical picture."
"['Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Neonatal death', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Core features of HMG-CoA lyase deficiency due to impaired ketogenesis and leucine catabolism, leading to toxic metabolite accumulation.  
2. **Dicarboxylic aciduria and 3-Methylglutaric aciduria**: Pathognomonic urinary findings from disrupted HMG-CoA breakdown, causing elevated 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-methylglutaric acids.  
3. **Hepatomegaly**: Caused by hepatic accumulation of unmetabolized fatty acids and intermediates.  
4. **Tachypnea**: Compensatory response to metabolic acidosis.  
5. **Vomiting and fever**: Common triggers or consequences of metabolic decompensation during catabolic states (e.g., infections).  
6. **Neonatal death/infant mortality**: Reflects severe metabolic crises in untreated infants, exacerbated by fasting or illness.  
7. **Elevated urinary carboxylic acids**: Direct biochemical evidence of defective leucine metabolism and ketogenesis.  
The combination of these findings strongly aligns with HMG-CoA lyase deficiency, an autosomal recessive disorder affecting ketone body synthesis and leucine degradation."
"['Ataxia', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Glutaric aciduria', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** and **metabolic acidosis** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from conjugation with glutaric acid for urinary excretion.  
3. **Neurological symptoms (ataxia, dystonia, dyskinesia)** arise from striatal injury and basal ganglia degeneration triggered by neurotoxic metabolites during metabolic crises.  
4. **Generalized hypotonia** in infancy reflects acute or progressive motor dysfunction, often preceding irreversible neurological damage.  
5. **Death in infancy** aligns with severe, untreated GA-I, where metabolic decompensation (e.g., triggered by infections) causes encephalopathy, cerebral edema, or multiorgan failure.  
6. Symptom constellation excludes other organic acidemias (e.g., methylmalonic/propionic acidemia) due to specific metabolite profile (glutaric aciduria) and characteristic neuroimaging findings (frontotemporal atrophy, basal ganglia lesions)."
"['Death in infancy', 'Neonatal death', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Galactosemia; GAL/Galactosemia  
Reasoning: Hypergalactosemia (elevated galactose in blood) is a hallmark of galactosemia, caused by deficient activity of galactose-1-phosphate uridylyltransferase (GALT). Neonatal death and infant mortality align with severe metabolic derangements (e.g., liver failure, sepsis) if untreated.  

Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: Classic galactosemia (Type I) specifically involves GALT enzyme deficiency. Untreated infants develop life-threatening complications (e.g., jaundice, vomiting, E. coli sepsis) within days of galactose exposure (breast milk/formula), explaining neonatal death. Hypergalactosemia confirms impaired galactose metabolism."
"['Cystinuria', 'Argininuria', 'Ornithinuria', 'Abnormal circulating lysine concentration', 'Death in adolescence']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
Reasoning:  
1. **Aminoaciduria Pattern**: The patient exhibits cystinuria, argininuria, ornithinuria, and abnormal lysine levels. These four amino acids share a renal transporter system (SLC3A1/SLC7A9 genes) responsible for their reabsorption. A defect in this system leads to their excessive urinary excretion, confirming cystinuria.  
2. **Genetic Basis**: Cystinuria is an autosomal recessive disorder of dibasic amino acid transport. Mutations in *SLC3A1* (Type A) or *SLC7A9* (Type B) disrupt the transporter, causing accumulation of cystine in urine and stone formation.  
3. **Severity and Mortality**: Death in adolescence suggests severe complications, such as recurrent nephrolithiasis leading to chronic kidney disease, infections, or obstructive uropathy. Without aggressive management (hydration, alkalinization, chelators), renal failure could result in early mortality.  
4. **Exclusion of Alternatives**: Lysinuric protein intolerance (LPI) was considered but ruled out due to the absence of hyperammonemia and hepatosplenomegaly, as well as the presence of cystinuria, which is specific to cystinuria."
"['Strabismus', 'Intellectual disability', 'Seizure', 'Motor delay', 'Cerebellar atrophy', 'Death in infancy', 'Hepatomegaly', 'Hypoproteinemia', 'Hypocholesterolemia', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological involvement**: Cerebellar atrophy/agenesis, motor delay, seizures, and intellectual disability are hallmark features of PMM2-CDG, reflecting disrupted glycosylation critical for brain development and function.  
2. **Hepatic manifestations**: Hepatomegaly, acute/chronic hepatitis, hypoproteinemia, and hypocholesterolemia align with PMM2-CDG’s multisystemic impact, including liver dysfunction due to impaired glycoprotein synthesis.  
3. **Metabolic abnormalities**: Hypocholesterolemia and hypoproteinemia stem from defective glycosylation of apolipoproteins and transport proteins, while lipodystrophy reflects adipose tissue dysregulation.  
4. **Severe infantile course**: Death in infancy is consistent with the life-threatening complications (e.g., organ failure, severe infections) seen in classical PMM2-CDG type Ia.  
5. **Exclusion of mimics**: The combination of cerebellar defects, liver disease, and metabolic derangements distinguishes PMM2-CDG from other metabolic disorders (e.g., Niemann-Pick, peroxisomal disorders) that lack glycosylation-specific biomarkers (e.g., abnormal transferrin isoforms)."
"['Osteoporosis', 'Generalized hypotonia', 'Obesity', 'Abnormal foot morphology', 'Leukopenia', 'Hyperammonemia', 'Hyperglycinemia', 'Clumsiness', 'Poor coordination', 'Hyperalaninemia', 'Severe short stature', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Hyperleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Death in early adulthood']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: PA disrupts propionyl-CoA carboxylase, impairing amino acid catabolism (isoleucine, valine), leading to toxic metabolite accumulation that inhibits the urea cycle (causing hyperammonemia) and secondary glycine elevation.  
2. **Abnormal Amino Acid Concentrations (Hyperleucinemia, Hyperalaninemia)**: Branched-chain amino acid metabolism defects result in elevated leucine and alanine due to blocked degradation pathways.  
3. **Abnormal Carnitine Levels**: Propionyl-CoA conjugates with carnitine for excretion, depleting free carnitine and causing deficiency.  
4. **Leukopenia**: Toxic metabolites (e.g., propionic acid) suppress bone marrow function, reducing white blood cell production.  
5. **Gastrointestinal Inflammation & Failure to Thrive**: Chronic metabolic acidosis and toxin buildup lead to feeding intolerance, vomiting, and malnutrition, contributing to severe short stature.  
6. **Neurological Symptoms (Hypotonia, Clumsiness, Hearing Loss)**: Metabolic crises damage the basal ganglia and nervous system, causing hypotonia, poor coordination, and sensorineural hearing impairment.  
7. **Osteoporosis**: Chronic acidosis leaches calcium from bones, weakening skeletal structure.  
8. **Early Mortality (Childhood/Adolescence/Adulthood)**: Severe metabolic decompensation episodes, cardiomyopathy, or infections result in progressive organ failure and reduced lifespan.  
9. **Abnormal Porphyrins & Aspartate Family Amino Acids**: Secondary disruption of heme synthesis and aspartate metabolism due to enzyme dysfunction and mitochondrial toxicity.  

PA’s hallmark triad of metabolic acidosis, hyperammonemia, and multisystem involvement aligns with the patient’s symptoms, confirming the diagnosis."
"['Pallor', 'Death in infancy', 'Ascites', 'Thrombocytosis', 'Anemia', 'Hepatomegaly', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Aminoaciduria', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Pustule']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia & Aminoaciduria**: Direct biochemical hallmarks of tyrosinemia type 1 (HT-1), caused by fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic tyrosine metabolite accumulation.  
2. **Hepatomegaly & Hypoalbuminemia/Hypoproteinemia**: Severe liver dysfunction due to tyrosine metabolite toxicity, impairing synthetic function and causing edema/ascites.  
3. **Elevated AFP**: Reflects hepatocyte regeneration or malignancy risk, a key marker in HT-1.  
4. **Abnormal circulating porphyrins**: Secondary to succinylacetone accumulation (a tyrosine metabolite), inhibiting δ-aminolevulinic acid dehydratase, disrupting heme synthesis.  
5. **Thrombocytosis & Anemia/Pallor**: Thrombocytosis may arise from splenic dysfunction or inflammation; anemia results from bone marrow suppression or bleeding complications.  
6. **Elevated alkaline phosphatase**: Indicates cholestatic liver injury.  
7. **Ascites**: Due to hypoalbuminemia and portal hypertension from cirrhosis.  
8. **Pustules**: Rare cutaneous manifestations of metabolic toxicity.  
9. **Death in infancy**: Untreated HT-1 causes acute liver failure, renal tubular dysfunction, and neurologic crises, often fatal in early childhood.  

The constellation of liver failure, tyrosine metabolism derangements, and secondary biochemical abnormalities confirms HT-1."
"['Strabismus', 'Intellectual disability', 'Motor delay', 'Cerebellar atrophy', 'Tremor', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development and function.  
2. **Motor delay and tremor**: Result from cerebellar dysfunction, disrupting coordination and motor control.  
3. **Intellectual disability**: Linked to global neurodevelopmental deficits due to abnormal glycosylation of brain proteins.  
4. **Strabismus**: Associated with neurological and muscular involvement from glycosylation defects.  
5. **Death in childhood**: Reflects severe multisystemic complications (e.g., liver failure, cardiomyopathy) common in classical PMM2-CDG.  
6. **Consistent with PMM2-CDG type Ia**: These features align with the phenotype of phosphomannomutase 2 deficiency, the most prevalent and well-characterized CDG subtype."
"['Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Dicarboxylic aciduria', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Abnormal circulating isoleucine concentration', 'Elevated urinary carboxylic acid']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Abnormal BCAA Levels**: Elevated leucine and isoleucine concentrations align with MSUD's hallmark defect in branched-chain amino acid (BCAA) metabolism due to deficient branched-chain α-keto acid dehydrogenase complex.  
2. **Urinary Metabolites**: Dicarboxylic aciduria and elevated urinary carboxylic acids result from accumulation of toxic keto-acid derivatives (e.g., α-ketoisocaproic acid) from unmetabolized BCAAs.  
3. **Aminoaciduria**: Overflow of excess BCAAs in the blood overwhelms renal reabsorption, causing urinary excretion.  
4. **Clinical Symptoms**: Neonatal death, vomiting, and hypotonia reflect acute metabolic decompensation from BCAA toxicity, leading to cerebral edema and neurological decline.  
5. **Rapid Progression**: Early-onset symptoms and infant mortality are consistent with classical/severe MSUD phenotypes.  
6. **Exclusion of Fatty Acid Disorders**: While dicarboxylic aciduria may suggest fatty acid oxidation defects, the specific BCAA abnormalities and lack of hypoketotic hypoglycemia prioritize MSUD."
"['Cleft palate', 'Broad philtrum', 'Long philtrum', 'Wide nasal bridge', 'Anteverted nares', 'Glaucoma', 'Cataract', 'Abnormal external genitalia', 'Syndactyly', 'Generalized hypotonia', 'Death in infancy', 'Deep philtrum', 'Vomiting', 'Pyloric stenosis', 'High, narrow palate', 'Hypocholesterolemia', 'Abdominal distention', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol biosynthesis defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in *DHCR7* leading to impaired cholesterol synthesis.  
2. **Craniofacial features**: Cleft palate, broad/deep philtrum, wide nasal bridge, anteverted nares, and high/narrow palate align with SLOS-associated dysmorphism.  
3. **Ocular anomalies**: Glaucoma and cataracts are linked to abnormal cholesterol-dependent eye development.  
4. **Genital/skeletal abnormalities**: Abnormal external genitalia and syndactyly (classically 2-3 toe syndactyly) are hallmark features.  
5. **Gastrointestinal issues**: Feeding difficulties, vomiting, pyloric stenosis, and abdominal distention reflect cholesterol-dependent digestive dysfunction.  
6. **Poor prognosis**: Neonatal death or death in infancy correlates with severe SLOS phenotypes.  
7. **Hypocholesterolemia**: Directly ties to the biochemical defect in cholesterol synthesis.  
8. **Generalized hypotonia**: Common in SLOS due to disrupted membrane cholesterol in neuromuscular function.  

The combination of sterol abnormalities, syndromic malformations, and metabolic features confirms SLOS."
"['Intellectual disability', 'Coma', 'Motor delay', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Respiratory distress', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['β-ketothiolase deficiency; BKD; Mitochondrial acetoacetyl-CoA thiolase [3-oxothiolase] deficiency/Beta-ketothiolase deficiency/Alpha-Methylacetoacetic aciduria'],"β-ketothiolase deficiency; BKD; Mitochondrial acetoacetyl-CoA thiolase [3-oxothiolase] deficiency/Beta-ketothiolase deficiency/Alpha-Methylacetoacetic aciduria:  
1. **Metabolic acidosis, hypoglycemia, hyperammonemia**: BKD disrupts isoleucine catabolism and ketone metabolism, leading to toxic accumulation of methylacetoacetyl-CoA derivatives. This results in metabolic acidosis, while secondary mitochondrial dysfunction may cause hypoglycemia and mild hyperammonemia.  
2. **Elevated urinary carboxylic acids (e.g., alpha-methylacetoacetate, tiglylglycine, 2-methyl-3-hydroxybutyrate)**: Pathognomonic for BKD due to enzymatic block in isoleucine degradation.  
3. **Neurological symptoms (coma, dystonia, hypotonia, motor delay, intellectual disability)**: Acute metabolic crises cause energy failure and neurotoxicity, leading to coma. Chronic basal ganglia injury from recurrent crises explains dystonia and developmental delays.  
4. **Feeding difficulties, respiratory distress, early mortality**: Episodic decompensation triggered by catabolic stressors (e.g., fasting, infections) leads to vomiting, lethargy, and compensatory respiratory efforts. Untreated crises progress to multiorgan failure and death.  
5. **Abnormal glycine levels**: Secondary glycine elevation may occur due to competition for renal tubular reabsorption by accumulated organic acids."
"['Seizure', 'Dystonia', 'Death in infancy', 'Glutaric aciduria', 'Paraplegia/paraparesis', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Elevated urinary glutaric acid is a hallmark biochemical marker of GA-I, directly caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Seizures & Dystonia**: Neurotoxic accumulation of glutaric acid and 3-hydroxyglutaric acid damages the basal ganglia, leading to acute/subacute striatal injury, manifesting as dystonia and secondary seizures.  
3. **Feeding difficulties**: Infants may exhibit poor feeding due to metabolic instability, encephalopathic crises, or oromotor dysfunction linked to neurological impairment.  
4. **Paraplegia/paraparesis**: Chronic neurodegeneration and corticospinal tract involvement can result in progressive spastic paraparesis.  
5. **Death in infancy**: Untreated GA-I often leads to life-threatening metabolic crises (e.g., during catabolic stress), with striatal necrosis causing irreversible neurological decline and early mortality.  
6. **Temporal consistency**: Symptom onset aligns with GA-I’s typical presentation in infancy (3-36 months), especially following triggers like infections.  
The triad of macrocephaly (often present), movement disorders, and organic aciduria strongly supports GA-I, distinguishing it from other organic acidemias with overlapping features."
"['Microcephaly', 'Facial asymmetry', 'Torticollis', 'Macular degeneration', 'Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Ataxia', 'Spastic diplegia', 'Death in infancy', 'Diarrhea', 'Cerebral atrophy', 'Pneumonia', 'Opisthotonus', 'Athetosis', 'Spastic tetraplegia', 'Abnormal cerebral cortex morphology', 'Neonatal death', 'Death in childhood', 'Dyskinesia']","['Ceroid lipofuscinosis, neuronal, 1']","Ceroid lipofuscinosis, neuronal, 1 (CLN1):  
The patient exhibits hallmark features of CLN1 disease, including **microcephaly** and **cerebral atrophy**, indicative of progressive neurodegeneration. **Seizures**, **ataxia**, **spastic diplegia/tetraplegia**, and **dyskinesia** align with motor and neurological decline. **Macular degeneration** reflects retinal involvement, while **delayed speech** and **hyperactivity** signal early developmental regression. **Abnormal cerebral cortex morphology** and **opisthotonus** correlate with severe CNS deterioration. **Death in infancy/childhood** matches the rapid progression of infantile CLN1. Although **pneumonia** and **diarrhea** are nonspecific, they likely stem from dysphagia and autonomic dysfunction in advanced stages. Symptoms like **facial asymmetry** and **torticollis** may arise from spasticity or dystonia. The combination of neurodegeneration, vision loss, seizures, and early mortality strongly supports CLN1."
"['Generalized hypotonia', 'Death in infancy', 'Bradycardia', 'Hypothermia', 'Apnea', 'Propionic acidemia', 'Neonatal death', 'Feeding difficulties', 'Fatigue']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Propionic acidemia (PA)** is an autosomal recessive disorder caused by defects in propionyl-CoA carboxylase, leading to toxic accumulation of propionic acid.  
2. **Feeding difficulties** and **fatigue** are early neonatal signs due to metabolic acidosis and hyperammonemia, impairing energy metabolism.  
3. **Generalized hypotonia** arises from muscle weakness secondary to energy depletion and acidosis.  
4. **Bradycardia** and **hypothermia** result from metabolic instability and impaired cardiac/thermoregulatory function during crises.  
5. **Apnea** occurs due to central nervous system depression from hyperammonemia or acidotic stress.  
6. **Death in infancy/neonatal death** reflects the severe, rapid progression of untreated PA, often triggered by catabolic states (e.g., fasting, infection).  
7. The explicit mention of **Propionic acidemia** in the symptom list aligns with biochemical confirmation (e.g., elevated propionylcarnitine on newborn screening, organic aciduria).  
8. All symptoms collectively match the acute neonatal-onset phenotype of PA, excluding other metabolic disorders (e.g., methylmalonic acidemia) via specificity of clinical and biochemical markers."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Increased serum lactate', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Increased serum lactate**: Biotinidase deficiency disrupts carboxylase enzymes (dependent on biotin), impairing gluconeogenesis and fatty acid synthesis. This leads to lactic acidosis, a hallmark of the disorder.  
2. **Neonatal death/Death in infancy**: Untreated BTDD causes severe metabolic crises, neurological deterioration (seizures, hypotonia), and respiratory failure, often fatal in early life.  
3. **Abnormality of prenatal development or birth**: While structural birth defects are rare, metabolic dysfunction *in utero* may contribute to intrauterine distress or growth abnormalities. Maternal biotin deficiency (if present) could exacerbate fetal vulnerability.  
4. **Diagnostic alignment**: Symptoms match the ""late-onset"" form of multiple carboxylase deficiency (caused by BTDD), where symptoms emerge postnatally but rapidly progress without biotin supplementation. Early mortality underscores the critical need for newborn screening and prompt treatment."
"['Eczematoid dermatitis', 'Skin rash', 'Seizure', 'Lethargy', 'Death in infancy', 'Constipation', 'Respiratory insufficiency', 'Drowsiness', 'Sleep disturbance', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Abnormal circulating glycine concentration']","['Mitochondrial complex IV deficiency, nuclear type 1']","Mitochondrial complex IV deficiency, nuclear type 1:  
The patient exhibits **ethylmalonic aciduria** and **cytochrome C oxidase (COX)-negative muscle fibers**, which are hallmark biochemical and histopathological findings in mitochondrial complex IV deficiency. This disorder disrupts oxidative phosphorylation, leading to energy depletion in high-demand tissues. **Seizures**, **lethargy**, **drowsiness**, and **respiratory insufficiency** reflect neurological and systemic metabolic dysfunction. **Death in infancy** aligns with severe infantile-onset forms of the disease. **Abnormal circulating glycine concentration** may arise from secondary metabolic disturbances due to impaired mitochondrial function. **Skin rash** and **eczematoid dermatitis** are nonspecific but recurrent in mitochondrial disorders due to oxidative stress and inflammation. **Constipation** and **sleep disturbance** correlate with autonomic nervous system involvement. The collective presentation of multi-organ failure, metabolic acidosis (implied by ethylmalonic aciduria), and COX deficiency confirms the diagnosis."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Bradycardia', 'Acute kidney injury', 'Vomiting', 'Respiratory insufficiency', 'Increased serum lactate', 'Hyperkalemia', 'Hematemesis', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Excessive salivation', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Hypoxemia', 'Chronic kidney disease', 'Increased circulating lactate dehydrogenase concentration', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic Aciduria Patterns**: The presence of **dicarboxylic aciduria** and **3-methylglutaconic aciduria** strongly suggests a defect in leucine catabolism or ketogenesis, both central to HMG-CoA lyase deficiency.  
2. **Energy Crisis Manifestations**: **Increased serum lactate**, **hypoxemia**, and **respiratory insufficiency** align with impaired ketogenesis, leading to energy depletion in critical tissues (e.g., brain, heart).  
3. **Hyperkalemia & Kidney Dysfunction**: **Acute/chronic kidney injury** and **hyperkalemia** result from metabolic acidosis (due to accumulated organic acids) and direct tubular toxicity from toxic metabolites.  
4. **Neurological Symptoms**: **Seizures** and **neonatal death** reflect acute metabolic decompensation with encephalopathy, exacerbated by hypoglycemia (common in HMG-CoA lyase deficiency).  
5. **Enzyme-Specific Biomarkers**: **Elevated urinary carboxylic acids** (e.g., 3-hydroxy-3-methylglutaric acid) and **abnormal aspartate-family amino acids** directly link to HMG-CoA lyase’s role in ketone body synthesis and leucine metabolism.  
6. **Early Lethality**: **Death in infancy/neonatal death** is typical in severe presentations due to rapid metabolic crises triggered by catabolic stressors (e.g., fasting, infection).  
7. **Secondary Organ Effects**: **Hematemesis** and **excessive salivation** may stem from autonomic dysfunction or acid-induced mucosal injury, while **bradycardia** reflects electrolyte imbalances or cardiac energy failure.  
8. **Diagnostic Confirmation**: **Increased lactate dehydrogenase** supports cellular necrosis from metabolic stress, consistent with this disorder.  

The constellation of metabolic acidosis, characteristic organic aciduria, and multisystem collapse in infancy confirms HMG-CoA lyase deficiency."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. Untreated **classic PKU** results in severe neurological damage, seizures, and intellectual disability. In extreme cases, metabolic instability or secondary complications (e.g., infections, failure to thrive) may contribute to **death in infancy** or **neonatal death**, especially in resource-limited settings lacking newborn screening and dietary management.  
3. **Neonatal death** is atypical in well-managed PKU but could occur in severe variants (e.g., BH4-deficient forms) with additional neurotransmitter deficiencies or acute metabolic crises.  
4. The triad of symptoms aligns with undiagnosed/untreated PKU, emphasizing the critical need for early detection via newborn screening to prevent fatal outcomes."
"['Recurrent urinary tract infections', 'Nephritis', 'Hematuria', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
Reasoning:  
1. **Cystinuria, argininuria, hyperlysinuria, and ornithinuria** indicate a defect in renal tubular reabsorption of dibasic amino acids (cystine, ornithine, lysine, arginine), a hallmark of cystinuria.  
2. **Recurrent urinary tract infections (UTIs), nephritis, and hematuria** arise from cystine stone formation in the urinary tract, causing obstruction, inflammation, and secondary infections.  
3. **Death in infancy** suggests a severe phenotype, potentially due to early-onset renal failure or complications from recurrent UTIs and nephritis in untreated cases.  
4. The combined aminoacidurias align with cystinuria’s pathophysiology (defect in SLC3A1/SLC7A9 genes), differentiating it from isolated amino acid transport disorders."
"['Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient's elevated urinary carboxylic acids (e.g., 3-hydroxyisovaleric acid and 3-methylcrotonylglycine) stem from a defect in leucine catabolism due to MCCC1 gene mutations. This disrupts 3-methylcrotonyl-CoA carboxylase activity, causing metabolite accumulation. Aminoaciduria arises from proximal tubule dysfunction secondary to toxic organic acids, while abnormal glycine levels may reflect increased conjugation with 3-methylcrotonyl-CoA, altering its circulating concentration.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: Broadly, this deficiency (encompassing MCCC1/MCCC2 mutations) disrupts leucine breakdown, leading to urinary excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine (explaining elevated carboxylic acids). Aminoaciduria occurs due to renal tubular damage from acidic metabolites. Glycine abnormalities may result from metabolic diversion to conjugate accumulated intermediates, reducing free glycine or altering its homeostasis."
"['Macrocephaly', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Athetosis', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
**Reasoning**:  
1. **Key biochemical markers**:  
   - **Glutaric aciduria** and **elevated circulating glutaric acid** directly indicate a defect in glutaryl-CoA dehydrogenase, the enzyme deficient in GA-I.  
   - **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from binding excess glutaric acid.  

2. **Neurological manifestations**:  
   - **Dystonia**, **dyskinesia**, and **athetosis** result from striatal injury and basal ganglia degeneration, classic in GA-I.  
   - **Generalized hypotonia** and **lethargy** are early signs of metabolic encephalopathy.  

3. **Acute metabolic crises**:  
   - **Vomiting**, **diarrhea**, **fever**, and **drowsiness** often precede or accompany acute crises triggered by catabolic stress (e.g., infections).  
   - **Dyspnea** may reflect metabolic acidosis or neurological respiratory control disruption.  

4. **Macrocephaly**:  
   - A hallmark of GA-I, caused by frontotemporal atrophy or delayed myelination, often evident before symptom onset.  

5. **Poor prognosis**:  
   - **Death in infancy/childhood** and **neonatal death** align with untreated GA-I, as crises cause irreversible neurological damage or cerebral edema.  

6. **Sleep disturbance**:  
   - Linked to basal ganglia dysfunction or neurochemical imbalances from accumulated metabolites.  

**Conclusion**: The triad of macrocephaly, movement disorders, and biochemical evidence (glutaric acid elevation, low carnitine) confirms GA-I. Acute crises exacerbate symptoms, leading to fatal outcomes without early intervention."
"['Lethargy', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Hypoglycemia', 'Dehydration', 'Fever', 'Hyperammonemia', 'Abdominal pain', 'Hypothermia', 'Pneumonia', 'Hyperglycinemia', 'Drowsiness', 'Sleep disturbance', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormality of bone marrow cell morphology', 'Hypervalinemia', 'Hyperisoleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Fatigue', 'Body odor']",['Isovaleric acedemia; IVA/Isovaleric acidemia/Isovaleric acidemia'],"Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Metabolic Abnormalities**: Hyperammonemia, hyperglycinemia, hyperalaninemia, hypervalinemia, and hyperisoleucinemia suggest a defect in branched-chain amino acid (BCAA) metabolism. IVA specifically disrupts isovaleric acid breakdown due to isovaleryl-CoA dehydrogenase deficiency.  
2. **Acute Decompensation Symptoms**: Lethargy, hypoglycemia, dehydration, fever, hypothermia, and drowsiness align with metabolic crises caused by toxic isovaleric acid accumulation, triggering acidosis and energy depletion.  
3. **Hematological Dysfunction**: Thrombocytopenia, leukopenia, and abnormal bone marrow morphology result from bone marrow suppression by toxic metabolites.  
4. **Characteristic Odor**: ""Sweaty feet"" body odor is pathognomonic for IVA, caused by excess isovaleric acid excretion.  
5. **Early Mortality**: Neonatal death, infant/childhood/adolescent fatality reflects severe, untreated IVA progression to metabolic coma, infections (e.g., pneumonia), or organ failure.  
6. **Secondary Carnitine Dysregulation**: Abnormal carnitine levels occur as the body attempts to conjugate isovaleric acid for excretion.  
7. **Feeding Difficulties/Fatigue**: Common in neonates with metabolic stress due to poor feeding tolerance and energy deficits.  
8. **Recurrent Infections**: Immune dysfunction from metabolic instability increases susceptibility to infections like pneumonia.  

IVA is distinguished from other organic acidemias (e.g., propionic acidemia) by its unique biochemical profile (elevated isovalerylcarnitine) and odor. Confirmation requires urine organic acid analysis (elevated isovalerylglycine) and genetic testing."
"['Microcephaly', 'Optic atrophy', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Ataxia', 'Spastic diplegia', 'Thromboembolism', 'Hyperhomocystinemia', 'Spastic tetraplegia', 'Hypomethioninemia', 'Death in childhood', 'Death in adolescence']","['Homocystinuria due to methylene tetrahydrofolate reductase deficiency/Homocystinuria due to deficiency of n(5,10)-methylenetetrahydrofolatereductase activity']","Disease: Homocystinuria due to methylene tetrahydrofolate reductase (MTHFR) deficiency  
Reasoning:  
1. **Hyperhomocystinemia and Hypomethioninemia**: MTHFR deficiency disrupts homocysteine remethylation to methionine, causing elevated homocysteine (hyperhomocystinemia) and low methionine (hypomethioninemia). This distinguishes it from cystathionine beta-synthase (CBS)-deficient homocystinuria, where methionine is typically elevated.  
2. **Neurological Symptoms**: Severe MTHFR deficiency impairs folate metabolism, critical for myelination and neurotransmitter synthesis. Microcephaly, intellectual disability, seizures, ataxia, and spasticity (diplegia/tetraplegia) reflect widespread CNS dysfunction, including white matter abnormalities and cortical/cerebellar damage.  
3. **Optic Atrophy**: Neurodegeneration or metabolic damage to retinal ganglion cells leads to optic nerve degeneration.  
4. **Thromboembolism**: Elevated homocysteine promotes endothelial dysfunction and hypercoagulability, increasing thrombotic risk.  
5. **Early Mortality**: Severe phenotypes of MTHFR deficiency cause progressive neurological decline, respiratory failure, or thromboembolic events, often leading to death in childhood/adolescence.  
6. **Developmental Delays**: Impaired folate-dependent pathways disrupt neuronal development, resulting in delayed speech/language and global intellectual disability.  

The constellation of metabolic derangements, neurodevelopmental deficits, and thromboembolic complications aligns pathognomonically with MTHFR deficiency-associated homocystinuria."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Symptoms of metabolic crisis**: Vomiting and diarrhea are common during acute episodes due to the inability to metabolize medium-chain fatty acids, leading to energy depletion and toxic metabolite accumulation.  
2. **Gastrointestinal inflammation**: Secondary to metabolic stress and mitochondrial dysfunction in gastrointestinal cells.  
3. **Abnormal carnitine levels**: MCADD causes secondary carnitine deficiency as carnitine conjugates with unmetabolized acyl-CoA intermediates (e.g., octanoylcarnitine) for urinary excretion.  
4. **Early mortality**: Neonatal/childhood death aligns with untreated MCADD, as prolonged fasting (e.g., during infections) triggers hypoglycemia, hepatopathy, and encephalopathy.  
5. **Prenatal/developmental abnormalities**: Subtle intrauterine metabolic stress may affect growth, though MCADD typically manifests postnatally.  
6. **Exclusion of other disorders**: Symptoms overlap with long-chain fatty acid oxidation defects (e.g., VLCAD), but gastrointestinal predominance and carnitine pattern favor MCADD.  
**Diagnostic confirmation**: Elevated C6-C10 acylcarnitines (especially C8) on newborn screening, genetic testing for *ACADM* mutations."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Abnormal nervous system physiology', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient’s **hypoglycemia**, **elevated urinary carboxylic acids** (e.g., 3-methylcrotonylglycine), and **abnormal carnitine levels** align with 3-MCC1 deficiency, which disrupts leucine catabolism. **Aminoaciduria** may stem from renal tubular dysfunction secondary to metabolic stress. **Abnormal nervous system physiology** and **neonatal death** reflect severe metabolic crises from toxic metabolite accumulation (e.g., 3-methylcrotonyl-CoA). The **abnormal glycine concentration** could result from secondary metabolic disturbances. Prenatal abnormalities and infant mortality are consistent with acute presentations of this autosomal recessive disorder.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis includes deficiencies in either the MCCC1 or MCCC2 subunits. The patient’s **hypoglycemia** and **elevated urinary carboxylic acids** directly correlate with impaired 3-methylcrotonyl-CoA metabolism. **Abnormal carnitine levels** arise from excessive acyl-carnitine conjugation to clear toxic intermediates. **Aminoaciduria** and **abnormal glycine** suggest systemic metabolic dysregulation. **Neonatal death** and **nervous system abnormalities** indicate a severe phenotype, typical of untreated cases. The absence of hyperammonemia or ketosis differentiates it from other organic acidemias, further supporting 3-MCC deficiency."
"['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids** align with phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) excreted via alternative pathways in untreated PKU.  
3. **Early mortality** (neonatal/infancy/childhood/adolescence) reflects severe, untreated PKU complications: irreversible neurotoxicity, seizures, and failure to thrive prior to modern dietary management.  
4. **Hypertyrosinemia** is atypical in classic PKU (tyrosine levels are usually low due to PAH deficiency). This may suggest a coexisting condition (e.g., tyrosinemia) or a reporting error, but PKU remains the primary diagnosis given hyperphenylalaninemia and urinary findings.  
5. Neonatal screening and dietary restriction of phenylalanine typically prevent progression, but historical cases without intervention explain the fatal trajectory described."
"['Strabismus', 'Delayed speech and language development', 'Intellectual disability', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Hyperuricemia', 'Neoplasm of the liver', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Decreased serum iron']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hepatic involvement**: Cirrhosis, hepatic fibrosis, and liver neoplasms align with HT-1’s hallmark liver damage due to toxic tyrosine metabolites (e.g., succinylacetone). Elevated α-fetoprotein reflects hepatocellular injury or malignancy.  
2. **Metabolic abnormalities**: Hypertyrosinemia and 4-hydroxyphenylpyruvic aciduria directly indicate a tyrosine catabolism defect, specifically fumarylacetoacetate hydrolase (FAH) deficiency in HT-1.  
3. **Renal and systemic effects**: Hyperuricemia and abnormal porphyrins stem from succinylacetone inhibiting renal tubular function and δ-ALA dehydratase, disrupting heme synthesis.  
4. **Early mortality**: Neonatal/childhood death is typical in untreated HT-1 due to acute liver failure or complications like hepatocellular carcinoma.  
5. **Neurological features**: Delayed development and intellectual disability may arise from chronic metabolic instability or secondary neurological damage.  
6. **Iron anomalies**: Decreased ferritin/iron could reflect liver dysfunction impairing storage, though this is less specific.  
7. **Exclusion of mimics**: Symptoms collectively localize to FAH deficiency, distinguishing HT-1 from other tyrosinemias (e.g., HT-2/3 lack severe liver disease) or porphyria (porphyrin abnormalities here are secondary)."
"['Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hypothermia', 'Pneumonia', 'Hyperglycinemia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Elevated hepatic transaminase', 'Hyperglycinuria', 'Elevated circulating alkaline phosphatase concentration', 'Dicarboxylic aciduria', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Fatigue', 'Increased circulating lactate dehydrogenase concentration', 'Acute hepatitis', 'Chronic hepatitis']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **hepatic dysfunction** (elevated transaminases, hepatomegaly, acute/chronic hepatitis) indicate a urea cycle disorder (UCD).  
2. **Oroticaciduria** and **uraciluria** are pathognomonic for OTCD. Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, overproducing orotic acid and uracil.  
3. **Elevated plasma citrulline** may initially seem contradictory (classic OTCD features low citrulline), but partial enzyme activity or alternative metabolic stress (e.g., liver damage) can paradoxically elevate citrulline.  
4. **Hyperglutaminemia** and **hyperalaninemia** reflect nitrogen accumulation via alternative pathways, consistent with UCDs.  
5. **Metabolic acidosis**, **dicarboxylic aciduria**, and **elevated lactate dehydrogenase** suggest secondary mitochondrial dysfunction during metabolic crises.  
6. **Recurrent infections** and **prolonged PTT** align with hepatic synthetic failure (reduced clotting factors/immune proteins).  
7. **Early lethality** (infancy/childhood/adolescence) matches severe OTCD phenotypes, exacerbated by triggers like infection (pneumonia) or catabolism.  

Key differentiators from other UCDs (e.g., citrullinemia): Distinct **oroticaciduria** and **pyrimidine abnormalities** (uraciluria, abnormal circulating pyrimidines) are hallmark features of OTCD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Fatigue']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The patient exhibits key features of MCADD, including hypoglycemia due to impaired fatty acid oxidation during fasting, decreased plasma free carnitine (secondary to conjugation with unmetabolized medium-chain fatty acids), and gastrointestinal symptoms (vomiting, diarrhea, inflammation) triggered by metabolic stress. Neonatal/childhood death and dehydration align with acute metabolic crises, while fatigue reflects energy deficiency. Though MCADD does not directly cause prenatal abnormalities, early mortality and failure to thrive in infancy/childhood are hallmarks of untreated cases. The absence of ketosis during hypoglycemia (not explicitly listed but inferred) further supports this diagnosis."
"['Delayed speech and language development', 'Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Delayed speech/language development**: Untreated PKU causes neurotoxic phenylalanine accumulation, impairing brain development.  
3. **Eczematoid dermatitis/Skin rash**: Elevated phenylalanine disrupts melanin and protein synthesis, leading to dermatologic manifestations.  
4. **Abnormality of prenatal development or birth**: Maternal PKU (untreated) exposes the fetus to high phenylalanine, causing congenital anomalies.  
5. **Death in infancy/childhood/Neonatal death**: Severe untreated PKU results in progressive neurodegeneration, seizures, and metabolic instability, which can be fatal.  
6. **Hypertyrosinemia**: Secondary tyrosine deficiency (from blocked phenylalanine metabolism) may paradoxically elevate tyrosine in some metabolic stress scenarios or assay cross-reactivity.  
7. **Recurrent viral infections/Fever**: Less specific but could reflect compromised health from chronic metabolic imbalance.  

*Note: Hypertyrosinemia and recurrent infections are atypical for classic PKU. These may suggest a concurrent condition (e.g., tyrosinemia type II) or diagnostic complexities (e.g., transient tyrosine fluctuations). However, hyperphenylalaninemia and neurodevelopmental features strongly anchor the diagnosis to PKU.*"
"['Motor delay', 'Obesity', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Motor delay** aligns with untreated PKU, as elevated phenylalanine disrupts myelination and neurotransmitter synthesis, leading to neurodevelopmental deficits.  
3. **Elevated urinary carboxylic acids** may reflect secondary metabolic disturbances from phenylalanine accumulation or dietary management (e.g., high protein substitutes).  
4. **Obesity** could arise from high-carbohydrate/low-protein diets used to manage PKU, promoting caloric imbalance.  
5. **Premature birth** and early mortality (**infancy/childhood/adolescence death**) suggest severe, untreated PKU with metabolic crises or complications like cerebral edema.  
6. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants or due to concurrent metabolic stress affecting tyrosine metabolism.  
7. **Recurrent viral infections** are not directly linked to PKU but may stem from compromised health in severe cases or nutritional deficiencies.  

**Note**: Hypertyrosinemia and elevated urinary carboxylic acids are unusual for classic PKU, suggesting possible comorbid conditions (e.g., tyrosinemia, organic acidemias) or atypical PKU variants. However, hyperphenylalaninemia remains the primary diagnostic anchor."
"['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Feeding difficulties', 'Elevated urinary carboxylic acid', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease; MSUD  
Reasoning:  
1. **Elevated urinary carboxylic acid**: MSUD is caused by a defect in branched-chain α-keto acid dehydrogenase, leading to accumulation of branched-chain amino acids (leucine, isoleucine, valine) and their toxic keto-acid derivatives (carboxylic acids) in urine.  
2. **Body odor**: The distinctive maple syrup or burnt sugar odor in bodily fluids is pathognomonic for MSUD due to urinary excretion of sotolone, a compound derived from accumulated keto-acids.  
3. **Feeding difficulties & vomiting**: Acute metabolic decompensation from protein intake overwhelms the impaired enzymatic pathway, causing gastrointestinal distress.  
4. **Generalized hypotonia & growth delay**: Neurotoxic effects of elevated leucine disrupt cerebral metabolism and myelination, impairing neuromuscular function and growth.  
5. **Neonatal death/death in infancy**: Classic severe MSUD manifests within days of birth; untreated hyperleucinosis causes cerebral edema, seizures, and rapid neurological decline.  
6. **Consistency with metabolic crisis**: Symptom triad of encephalopathy, feeding refusal, and odor aligns with acute neonatal-onset MSUD, distinguishing it from other organic acidurias (e.g., propionic acidemia lacks the maple syrup odor)."
"['Hypospadias', 'Microcephaly', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', '4-hydroxyphenylacetic aciduria', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1 (HT-1)  
Reasoning:  
1. **Metabolic abnormalities**: Hypertyrosinemia, 4-Hydroxyphenylpyruvic aciduria, and 4-hydroxyphenylacetic aciduria directly indicate a defect in tyrosine metabolism. These metabolites accumulate due to fumarylacetoacetate hydrolase (FAH) deficiency, a hallmark of HT-1.  
2. **Liver dysfunction**: Elevated alpha-fetoprotein (AFP) reflects hepatic damage, consistent with HT-1’s hepatotoxic effects, leading to neonatal liver failure and risk of early death (neonatal/infancy/childhood).  
3. **Neurological and developmental features**: Motor delay, hypotonia, and microcephaly may arise from toxic metabolite-induced neurotoxicity or prenatal metabolic disruption.  
4. **Prenatal/structural anomalies**: Hypospadias and prenatal developmental abnormalities could stem from intrauterine metabolic stress, though these are less typical and may suggest severe early-onset disease.  
5. **Mortality**: Early death aligns with untreated HT-1 progression, involving liver failure, renal disease, or neurological crises.  
6. **Hyperphenylalaninemia**: Likely secondary due to downstream tyrosine pathway disruption, though phenylalanine levels are less prominently elevated in HT-1 compared to phenylketonuria.  

Key confirmatory factors: Tyrosine metabolite elevation + AFP + clinical progression."
"['Hyporeflexia', 'Generalized hypotonia', 'Hepatic steatosis', 'Death in infancy', 'Tachycardia', 'Dehydration', 'Fever', 'Vomiting', 'Abdominal pain', 'Dyspnea', 'Increased serum lactate', 'Hypertriglyceridemia', 'Hepatomegaly', 'Tachypnea', 'Skeletal muscle atrophy', 'Hyperalaninemia', 'Aminoaciduria', 'Neonatal death', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Feeding difficulties', 'Abnormal myelination', 'Abdominal mass']","['Hereditary fructose intoleranc; HFI/Hereditary fructose intolerance/Fructose intolerance, hereditary']","Disease: Hereditary fructose intolerance (HFI)  
Reasoning:  
1. **Hepatic steatosis & Hepatomegaly**: Caused by toxic accumulation of fructose-1-phosphate in the liver due to aldolase B deficiency, impairing fructose metabolism and leading to lipid deposition.  
2. **Vomiting, Abdominal pain, Feeding difficulties**: Direct gastrointestinal response to fructose ingestion, triggering aversion to sweet foods and metabolic stress.  
3. **Increased serum lactate & Hypertriglyceridemia**: Inhibition of gluconeogenesis and glycogenolysis by fructose-1-phosphate results in hypoglycemia, driving anaerobic metabolism (lactic acidosis) and impaired lipid processing.  
4. **Hyperalaninemia & Aminoaciduria**: Gluconeogenesis blockade causes accumulation of alanine; renal tubular dysfunction from metabolic stress may contribute to aminoaciduria.  
5. **Hyporeflexia & Generalized hypotonia**: Neurological manifestations of hypoglycemia and metabolic acidosis.  
6. **Tachycardia & Tachypnea**: Compensatory responses to lactic acidosis and dehydration.  
7. **Dehydration & Fever**: Secondary to vomiting and reduced oral intake, exacerbated by metabolic derangements.  
8. **Death in infancy/Neonatal death**: Untreated HFI leads to progressive liver/kidney failure and metabolic crises upon fructose exposure in infancy.  
9. **Skeletal muscle atrophy**: Chronic malnutrition from feeding difficulties and catabolic state.  
10. **Abnormal myelination**: Potential consequence of recurrent hypoglycemia affecting brain development.  
11. **Abdominal mass**: Likely palpable hepatomegaly due to fatty liver enlargement.  

The constellation of liver dysfunction, fructose-triggered metabolic disturbances, and neonatal presentation aligns pathognomonically with HFI. Early diagnosis and strict fructose/sucrose/sorbitol avoidance are critical to prevent fatal outcomes."
"['Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Elevated circulating acylcarnitine concentration', 'Dyskinesia']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** and **elevated circulating acylcarnitine concentration** directly indicate a defect in lysine, hydroxylysine, and tryptophan metabolism, characteristic of GA-I due to **glutaryl-CoA dehydrogenase deficiency**.  
2. **Motor delay** and **generalized hypotonia** arise from toxic accumulation of glutaric acid and 3-hydroxyglutaric acid, causing basal ganglia damage and impaired motor neuron function.  
3. **Athetosis** and **dyskinesia** reflect striatal injury, a hallmark of acute encephalopathic crises in GA-I, often triggered by metabolic stressors (e.g., infections).  
4. **Death in infancy** aligns with untreated GA-I, where metabolic crises lead to irreversible neurological damage, cerebral edema, or secondary complications (e.g., rhabdomyolysis).  
5. Elevated acylcarnitine (C5DC) on newborn screening supports the diagnosis, as glutaric acid conjugates with carnitine, depleting free carnitine and increasing acylated forms.  
6. Exclusion of GA-II (MADD): No hypoglycemia, cardiomyopathy, or organic acid profile suggestive of multiple dehydrogenase deficiencies."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Pneumonia', 'Pregnancy history', 'Neonatal death', 'Death in childhood', 'Hypoargininemia', 'Elevated plasma citrulline', 'Hernia']","['Citrullinemia', 'Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset']","Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia, elevated plasma citrulline, and hypoargininemia, hallmark features of urea cycle dysfunction. Death in infancy/childhood, neonatal death, and premature birth align with the severe neonatal-onset form of citrullinemia type I (argininosuccinate synthetase deficiency). This disorder causes rapid ammonia accumulation, leading to metabolic crises, neurological deterioration, and early mortality without intervention. Pneumonia may arise secondary to metabolic instability or immunosuppression during crises.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Hypoargininemia, hyperammonemia, and elevated citrulline are consistent with citrin deficiency, which disrupts the urea cycle via impaired aspartate transport. Hernia may reflect hepatomegaly or ascites from cholestasis. Premature birth and neonatal death correlate with intrahepatic cholestasis, growth restriction, and liver dysfunction in neonatal-onset type II. Though cholestasis (e.g., jaundice) is not explicitly listed, its inclusion in the disease name and hernia as a potential sign of liver pathology supports this diagnosis."
"['Intellectual disability', 'Thromboembolism', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Death in adolescence', 'Death in early adulthood']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning: The patient exhibits **hyperhomocystinemia**, a hallmark of homocystinuria, alongside **intellectual disability** and **thromboembolism**, which are classic complications of elevated homocysteine levels. Hyperhomocystinemia directly indicates impaired homocysteine metabolism, a core feature of this disorder. The presence of **hypermethioninemia** suggests a defect in the transsulfuration pathway, where homocysteine accumulates due to enzyme deficiencies. Early mortality aligns with severe vascular complications (e.g., strokes, thromboses) from chronic homocysteine toxicity.

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: **Hypermethioninemia** specifically points to cystathionine beta-synthase (CBS) deficiency, as this enzyme converts homocysteine to cystathionine. Its deficiency traps homocysteine in the methionine cycle, elevating both homocysteine and methionine. **Thromboembolism** and **intellectual disability** are consistent with CBS-deficient homocystinuria, where vascular and connective tissue damage are prominent. **Death in adolescence/early adulthood** reflects the life-threatening thromboembolic events and multisystemic progression seen in untreated or severe cases of CBS deficiency."
"['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids**: Reflects alternative metabolism of phenylalanine into phenylketones (e.g., phenylpyruvate, phenyllactate), which are excreted in urine.  
3. **Early mortality (infancy to adulthood)**: Untreated PKU causes severe neurological damage, seizures, and organ failure, often resulting in premature death without dietary intervention.  
4. **Obesity**: May arise from metabolic dysregulation or compensatory high-calorie diets low in phenylalanine.  
5. **Hypertyrosinemia**: Uncommon in classic PKU but could indicate a co-occurring tyrosinemia or secondary metabolic disruption from chronic phenylalanine toxicity.  
6. **Prenatal abnormalities**: Likely reflects maternal PKU syndrome (uncontrolled phenylalanine in a pregnant mother affecting fetal development), though not typical in the affected individual themselves.  

Note: While some symptoms (e.g., hypertyrosinemia) are atypical for isolated PKU, they may suggest complex metabolic interactions or comorbid conditions. The core diagnosis remains PKU due to hyperphenylalaninemia and urinary phenylketone derivatives."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia**: MCADD impairs fatty acid β-oxidation, limiting energy production during fasting. This results in hypoketotic hypoglycemia (reduced ketones despite low glucose).  
2. **Hyperammonemia**: Secondary to metabolic decompensation; impaired urea cycle function from energy depletion or accumulated toxic metabolites.  
3. **Decreased plasma free carnitine**: Excess medium-chain acyl-CoA intermediates bind carnitine, forming acyl-carnitine conjugates (e.g., C8, C10), depleting free carnitine.  
4. **Lethargy/Drowsiness/Vomiting**: Manifestations of acute metabolic crises triggered by fasting or infection, causing encephalopathy.  
5. **Generalized hypotonia**: Chronic energy deficiency in muscles and nervous system.  
6. **Sleep disturbance**: Neurological dysfunction from hypoglycemia or hyperammonemia.  
7. **Death in infancy/childhood**: Untreated MCADD leads to rapid metabolic collapse during catabolic states (e.g., illness, prolonged fasting).  
8. **Key diagnostic clues**: Hypoketotic hypoglycemia + hyperammonemia + low free carnitine with elevated medium-chain acylcarnitines on tandem mass spectrometry.  
**Conclusion**: Symptom constellation and biochemical profile (hypoglycemia, hyperammonemia, carnitine deficiency) strongly indicate MCADD, a fatty acid oxidation disorder."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiency multiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While biotinidase deficiency (BTDD) typically manifests postnatally, severe untreated cases may indirectly contribute to developmental anomalies due to progressive metabolic dysfunction. Prenatal reliance on maternal biotin usually prevents in utero symptoms, but postnatal failure to recycle biotin disrupts carboxylase enzymes, potentially leading to congenital-like metabolic instability.  
2. **Death in infancy/Neonatal death**: Untreated BTDD causes profound metabolic crises (e.g., lactic acidosis, hyperammonemia, organic acidemia) due to impaired carboxylase activity. These crises rapidly progress to neurological decline (seizures, coma) and multisystem failure, often fatal within weeks to months without biotin supplementation. Neonatal death may occur if symptoms onset early and diagnosis/treatment are delayed.  
3. **Late-onset vs. timing**: Despite being termed ""late-onset"" (compared to holocarboxylase synthetase deficiency), BTDD can present acutely in infancy. The absence of newborn screening or delayed intervention explains the fatal trajectory in this case."
"['Death in infancy', 'Glutaric aciduria', 'Neonatal death']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to toxic accumulation of glutaric acid.  
2. **Neonatal death** and **death in infancy** align with severe GA-I phenotypes, where absent enzyme activity triggers acute metabolic crises (e.g., acidosis, encephalopathy) shortly after birth.  
3. GA-I’s biochemical hallmark—elevated urinary glutaric acid—directly correlates with the symptom list, excluding other organic acidurias (e.g., propionic/methylmalonic acidemia) that present with distinct metabolites.  
4. Early lethality in untreated cases supports this diagnosis, as delayed management exacerbates neurotoxicity and multisystem failure."
"['Hypospadias', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Difficulty walking', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Difficulty running']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Generalized hypotonia** and **delayed speech/language development** align with BTDD’s neurological manifestations due to biotin-dependent metabolic dysfunction.  
2. **Difficulty walking, climbing stairs, and running** reflect progressive neuromuscular impairment, common in untreated BTDD.  
3. **Neonatal/childhood death** and **death in infancy** correlate with severe metabolic crises (e.g., lactic acidosis, hyperammonemia) in undiagnosed cases.  
4. **Abnormality of prenatal development or birth** may indicate intrauterine metabolic stress or growth issues secondary to enzyme deficiency.  
5. While **hypospadias** is atypical for BTDD, it could represent an incidental congenital anomaly or a rare association with metabolic disruption during organogenesis.  
6. Symptoms collectively match the late-onset multiple carboxylase deficiency phenotype, where biotinidase deficiency disrupts biotin recycling, impairing carboxylase enzymes critical for metabolism. Early diagnosis is life-saving with biotin supplementation."
"['Lethargy', 'Drowsiness', 'Sleep disturbance', 'Bone pain', 'Hypertyrosinemia', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical finding in PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), which prevents the conversion of phenylalanine to tyrosine.  
2. **Hypertyrosinemia** is atypical in classical PKU but may occur due to exogenous tyrosine supplementation (common in PKU management) or overlapping metabolic disturbances.  
3. **Neurological symptoms** (lethargy, drowsiness, sleep disturbances) align with untreated PKU, as phenylalanine accumulation disrupts neurotransmitter synthesis (e.g., dopamine, serotonin).  
4. **Bone pain** is not classic for PKU but could stem from long-term nutritional deficiencies (e.g., calcium/vitamin D) in poorly managed dietary therapy.  
5. The absence of liver dysfunction or severe tyrosine-related symptoms (e.g., keratitis, skin lesions) argues against primary tyrosinemia, reinforcing PKU as the primary diagnosis.  
6. Hypertyrosinemia may reflect secondary metabolic adaptations or testing artifacts, but hyperphenylalaninemia remains the critical diagnostic marker for PKU."
"['Intellectual disability', 'Lethargy', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **elevated plasma citrulline**: Core indicators of urea cycle dysfunction. While OTCD classically presents with *low citrulline*, partial enzyme activity or compensatory mechanisms (e.g., arginine supplementation) may explain citrulline elevation in some cases.  
2. **Oroticaciduria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, producing excess orotic acid.  
3. **Hyperglutaminemia** and **hyperalaninemia**: Glutamine acts as an ammonia buffer, while alanine transports nitrogen to the liver, both elevated due to ammonia toxicity.  
4. **Neonatal/childhood death, feeding difficulties, lethargy, drowsiness**: Reflect acute hyperammonemic crises, common in severe OTCD.  
5. **Recurrent viral infections**: Metabolic stress from hyperammonemia may impair immune function.  
6. **Abnormal arginine/aspartate family amino acids**: Disrupted urea cycle alters arginine synthesis and aspartate utilization.  
7. **Obesity and sleep disturbances**: Chronic metabolic derangements may contribute to these phenotypes.  

Note: Elevated citrulline is atypical for OTCD but does not exclude the diagnosis, as atypical presentations or confounding factors (e.g., treatment, coexisting conditions) may occur. The triad of hyperammonemia, oroticaciduria, and clinical progression aligns strongly with OTCD."
"['Death in childhood', 'Death in adolescence', 'Impaired glucose tolerance', 'Death in early adulthood']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: MODY (Maturity-onset diabetes of the young, type 1)  
Reasoning:  
1. **Impaired glucose tolerance** aligns with MODY, a monogenic diabetes caused by mutations in genes like *HNF4A* (type 1). MODY typically manifests as early-onset, non-ketotic hyperglycemia, often misdiagnosed as type 1 or 2 diabetes.  
2. **Early mortality** (childhood/adolescence/early adulthood) suggests severe complications from undiagnosed or mismanaged hyperglycemia. For example:  
   - Acute crises (e.g., diabetic ketoacidosis or severe hypoglycemia) due to delayed diagnosis.  
   - Chronic vascular/nephropathy from prolonged poor glycemic control.  
3. MODY type 1 (*HNF4A* mutations) is associated with progressive beta-cell dysfunction and sensitivity to sulfonylureas. Without timely genetic diagnosis and tailored therapy, insulin deficiency worsens, accelerating complications.  
4. Familial autosomal dominant inheritance (common in MODY) could explain multi-generational early deaths if undiagnosed in relatives.  

Disease: Maturity-onset diabetes of the young, type 1  
Reasoning:  
1. **Genetic basis**: *HNF4A* mutations disrupt pancreatic beta-cell function and insulin secretion, causing glucose intolerance.  
2. **Clinical course**: Symptoms often emerge in adolescence/early adulthood but may manifest earlier. Neonatal hypoglycemia (linked to *HNF4A*) could predispose to lethal hypoglycemic events in infancy/childhood if unrecognized.  
3. **Mortality drivers**:  
   - Lack of targeted treatment (e.g., sulfonylureas) leads to reliance on insulin, increasing hypoglycemia risk.  
   - Rapid progression to insulin dependence in some cases, exacerbating metabolic instability.  
4. **Diagnostic delay**: Misclassification as type 1 diabetes may result in suboptimal care, hastening complications (e.g., renal failure, cardiovascular events) and early death.  

Both diagnoses hinge on genetic testing to confirm *HNF4A* variants, enabling precision therapy to mitigate mortality risks."
"['Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Directly indicates abnormal accumulation of glutaric acid, a hallmark of GA-I due to deficient glutaryl-CoA dehydrogenase activity.  
2. **Metabolic acidosis**: Results from toxic buildup of glutaric acid and related metabolites, disrupting acid-base balance.  
3. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to glutaric acid for excretion, reducing free carnitine levels.  
4. **Generalized hypotonia**: Neurotoxic effects of accumulated metabolites impair muscle tone and neuronal function.  
5. **Neonatal death/Death in infancy**: Untreated GA-I causes acute metabolic crises, striatal necrosis, and catastrophic neurological deterioration, often fatal early in life without prompt dietary and metabolic intervention.  
6. **Consistency with GA-I**: The triad of glutaric aciduria, neurologic symptoms, and secondary carnitine deficiency aligns with GA-I pathophysiology, distinguishing it from other organic acidemias (e.g., GA-II involves multiple acyl-CoA dehydrogenases and distinct biochemical markers)."
"['Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA lyase deficiency (HMGCLD)  
Reasoning:  
1. **Biochemical Pathway Context**: HMG-CoA lyase is critical in ketogenesis (fatty acid breakdown) and leucine catabolism. Deficiency disrupts conversion of HMG-CoA to acetoacetate and acetyl-CoA, causing toxic metabolite accumulation.  
2. **3-Methylglutaric Aciduria**: Directly linked to impaired leucine degradation. The enzyme deficiency leads to buildup of 3-methylglutaconyl-CoA, which is converted to 3-methylglutaric acid, excreted in urine.  
3. **Dicarboxylic Aciduria**: Secondary to defective ketogenesis. During fasting, increased fatty acid oxidation overwhelms β-oxidation, producing dicarboxylic acids (e.g., adipic, suberic acids) due to alternative ω-oxidation pathways.  
4. **Elevated Urinary Carboxylic Acids**: Reflects systemic metabolic dysfunction, with spillage of 3-hydroxy-3-methylglutaric acid (primary marker), 3-methylglutaric acid, and 3-methylcrotonylglycine.  
5. **Exclusion of Mimics**: Differentiated from other organic acidurias (e.g., glutaric acidemia type I, multiple carboxylase deficiency) by the specific triad of metabolites and absence of key markers like glutaric acid or holocarboxylase synthetase defects.  
6. **Clinical Correlation**: Patients typically present with hypoglycemia, metabolic acidosis, and lethargy during catabolic stress (fasting/illness), aligning with the biochemical findings."
"['Death in infancy', 'Hypertyrosinemia', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, impairing the conversion of phenylalanine to tyrosine. Untreated PKU results in toxic phenylalanine accumulation, causing neurodevelopmental damage and **death in infancy**. The **hypertyrosinemia** is atypical but may arise secondarily: excessive phenylalanine competitively inhibits tyrosine transport or degradation pathways, leading to its abnormal elevation. This dual metabolic disruption aligns with severe, untreated PKU."
"['Psychosis', 'Eczematoid dermatitis', 'Skin rash', 'Intellectual disability', 'Death in infancy', 'Abdominal pain', 'Vertigo', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Occipital neuralgia', 'Elevated urinary carboxylic acid', 'Death in early adulthood', 'Pustule']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
**Reasoning**:  
1. **Hyperphenylalaninemia**: Core diagnostic marker for PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Classic feature of untreated PKU from neurotoxic phenylalanine accumulation.  
3. **Skin manifestations (eczema, rash, pustules)**: Caused by metabolic disruption affecting skin integrity; eczema is a well-documented symptom.  
4. **Elevated urinary carboxylic acids**: Reflects excretion of phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate).  
5. **Psychosis**: Late-onset neurological complications in poorly managed cases.  
6. **Early mortality (infancy/adulthood)**: Untreated PKU leads to severe neurological damage, infections, or organ failure.  

**Conflicts/Notes**:  
- **Hypertyrosinemia**: Contradicts PKU (expected low tyrosine). Possible lab error, concurrent condition (e.g., tyrosinemia), or variant PKU with secondary tyrosine dysregulation.  
- **Occipital neuralgia/vertigo/abdominal pain**: Atypical for PKU; may indicate comorbidities or nonspecific systemic effects of metabolic stress.  
- **Death timing**: Aligns with untreated cases; modern neonatal screening and dietary management typically prevent fatal outcomes.  

**Conclusion**: Despite conflicting hypertyrosinemia, hallmark features (hyperphenylalaninemia, intellectual disability, urinary metabolites, and skin findings) overwhelmingly support PKU."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormal erythrocyte morphology', 'Thrombocytosis', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Abnormality of vitamin D metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Abnormality of galactoside metabolism**: Directly aligns with galactosemia, a disorder of galactose metabolism due to GALT enzyme deficiency.  
2. **Neonatal death/Death in infancy/Death in childhood**: Untreated galactosemia causes severe complications (e.g., liver failure, sepsis) leading to early mortality.  
3. **Abnormal erythrocyte morphology**: Hemolysis from toxic galactitol accumulation can alter red blood cell structure.  
4. **Thrombocytosis**: May arise secondary to liver dysfunction or splenic dysfunction from chronic hemolysis.  
5. **Abnormal circulating porphyrin concentration**: Hepatic impairment disrupts heme biosynthesis pathways.  
6. **Abnormality of vitamin D metabolism**: Liver damage reduces 25-hydroxylation of vitamin D, impairing activation.  
7. **Abnormality of prenatal development or birth**: Though galactosemia is not congenital in structural development, metabolic stress in utero may contribute to prenatal abnormalities.  

All symptoms collectively point to **classic galactosemia**, where toxic galactose metabolites drive multi-organ dysfunction, consistent with the patient’s presentation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like vomiting and gastrointestinal inflammation align with metabolic decompensation during fasting, a hallmark of MCADD due to impaired fatty acid oxidation.  
2. **Fatality Timeline**: Neonatal/infant/childhood death correlates with untreated MCADD, where prolonged fasting triggers hypoglycemia, lethargy, and fatal metabolic crises.  
3. **Biochemical Markers**: Decreased plasma free carnitine occurs as carnitine binds to unmetabolized medium-chain acyl-CoA derivatives. Reduced 3-hydroxyacyl-CoA dehydrogenase activity (if misreported or a related enzyme) may reflect MCADD’s specific enzyme defect (MCAD).  
4. **Infection Susceptibility**: Recurrent viral infections may stem from energy deprivation impairing immune responses during metabolic stress.  
5. **Prenatal Abnormalities**: While MCADD typically lacks structural birth defects, severe metabolic dysfunction in utero could manifest as growth abnormalities or prenatal distress.  

Key confirmation would require genetic testing for *ACADM* mutations or elevated C6-C10 acylcarnitines on newborn screening."
"['Seizure', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Increased serum lactate', 'Fasciculations', 'Tachypnea', 'Neonatal death', 'Abnormal circulating citrulline concentration', 'Feeding difficulties']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Citrullinemia, classic)  
**Reasoning**:  
1. **Hyperammonemia** and **abnormal circulating citrulline concentration** are hallmark features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency, disrupting the urea cycle.  
2. **Metabolic acidosis** and **increased serum lactate** result from compensatory anaerobic metabolism due to mitochondrial dysfunction from ammonia toxicity.  
3. **Seizures** and **fasciculations** arise from neurotoxicity secondary to hyperammonemia.  
4. **Tachycardia** and **tachypnea** are physiological responses to acidosis (respiratory compensation) and systemic stress.  
5. **Feeding difficulties**, **neonatal death**, and **death in infancy** reflect the severe, early-onset nature of classic citrullinemia, typically manifesting within days of life due to protein intolerance and rapid ammonia accumulation.  
6. **Fever** may occur secondary to metabolic decompensation or intercurrent illness triggering crisis.  

Both listed diagnoses refer to the same entity: **Citrullinemia type I** (OMIM #215700), distinguished by citrulline elevation in serum/urine and confirmatory genetic testing for *ASS1* mutations."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline', 'Uraciluria']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: The combination of **hyperammonemia**, **elevated plasma citrulline**, and **uraciluria** strongly indicates a urea cycle disorder (UCD). Citrullinemia is characterized by a defect in **argininosuccinate synthetase (ASS1)**, which prevents the conversion of citrulline to argininosuccinate. This results in citrulline accumulation (elevated plasma citrulline) and ammonia buildup (hyperammonemia). Uraciluria occurs due to secondary pyrimidine metabolism disruption. Neonatal lethality and early childhood death align with severe metabolic decompensation in untreated UCDs.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Type I (classic citrullinemia) is distinguished by **neonatal-onset** symptoms, including rapid neurological decline, hyperammonemic crises, and biochemical features like extreme citrulline elevation (often >1,000 µmol/L). The prenatal abnormalities (e.g., intrauterine growth restriction) and early mortality (infancy/childhood) correlate with the severe enzymatic deficiency in ASS1. Type II (citrin deficiency) typically presents later in life and lacks uraciluria, ruling it out here."
"['Carious teeth', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Respiratory insufficiency', 'Difficulty walking', 'Spastic tetraplegia', 'Difficulty climbing stairs', 'Excessive salivation', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Difficulty running', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Death in early adulthood']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid elevation**: Presence of hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicates a defect in the branched-chain α-keto acid dehydrogenase complex, the hallmark of MSUD.  
2. **Neurological manifestations**: Spastic diplegia/tetraplegia, seizures, intellectual disability, and motor delays align with neurotoxicity from accumulated amino acids.  
3. **Metabolic crises**: Hyperammonemia, vomiting, diarrhea, and respiratory insufficiency correlate with acute metabolic decompensation, common in MSUD.  
4. **Early mortality**: Neonatal death, death in infancy/childhood/adolescence, and early adulthood are consistent with severe or untreated MSUD variants.  
5. **Supporting features**: Excessive salivation, recurrent infections, and carious teeth may arise from chronic metabolic dysregulation and dietary management challenges.  
6. **Exclusion of mimics**: Symptoms collectively rule out other organic acidemias (e.g., no mention of hypoglycemia or fatty acid oxidation defects) or urea cycle disorders (though hyperammonemia occurs, it is secondary in MSUD)."
"['Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient presents with hyperammonemia, aminoaciduria, and elevated urinary carboxylic acids, indicative of a leucine metabolism disorder. Decreased plasma free carnitine aligns with secondary carnitine depletion due to conjugation with toxic metabolites like 3-methylcrotonylglycine. Neonatal death and growth issues correlate with metabolic crises from enzyme deficiency (MCCC1 gene), impairing 3-methylcrotonyl-CoA conversion.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: Symptoms overlap with the broader enzyme deficiency (MCCC1 or MCCC2 subunits). Elevated urinary 3-hydroxyisovaleric acid and abnormal glycine levels are hallmark biochemical findings. Death in infancy/childhood reflects acute decompensation episodes triggered by catabolic stressors. Small for gestational age suggests prenatal metabolic dysfunction. The combined features confirm disrupted branched-chain amino acid catabolism due to 3-MCC deficiency."
"['Intellectual disability', 'Paresthesia', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Intellectual disability**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting brain development and function.  
3. **Paresthesia**: Chronic neurotoxicity from phenylalanine may cause peripheral neuropathy, manifesting as sensory disturbances.  
4. **Death in early adulthood**: Historically, untreated PKU results in severe neurological decline and systemic complications, though modern dietary management improves prognosis.  
5. **Acute/Chronic hepatitis**: Atypical for classic PKU. May suggest comorbid conditions (e.g., viral hepatitis, metabolic liver disease) or secondary effects from prolonged metabolic stress. PKU itself does not directly cause hepatitis, necessitating further investigation for liver-specific etiologies.  

Key PKU hallmarks (hyperphenylalaninemia, neurocognitive deficits) dominate the diagnosis, while liver abnormalities likely indicate a coexisting or unrelated condition."
"['Seizure', 'Death in childhood', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** suggest impaired carboxylase enzyme activity, which requires biotin as a cofactor. Biotinidase deficiency prevents biotin recycling, leading to functional biotin depletion and subsequent carboxylase dysfunction.  
2. **Seizures** occur due to metabolic acidosis and accumulation of toxic metabolites (e.g., lactate, ammonia) affecting the central nervous system.  
3. **Death in childhood** aligns with untreated BTDD progression, as irreversible neurological damage, respiratory failure, or metabolic crises typically occur without biotin supplementation.  
4. The **late-onset multiple carboxylase deficiency** subtype matches the gradual symptom onset (e.g., after the neonatal period) due to partial enzyme activity before biotin stores are depleted.  

This triad of symptoms strongly supports BTDD, confirmed by biochemical testing (low biotinidase activity) and genetic analysis of the *BTD* gene."
"['Delayed speech and language development', 'Intellectual disability', 'Death in infancy', 'Hyperthreoninuria', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating tyrosine concentration', 'Galactosuria', 'Hypergalactosemia']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with key metabolic abnormalities indicative of galactose processing dysfunction, including hypergalactosemia, galactosuria, and abnormal galactoside metabolism. Classic galactosemia (GALT deficiency) disrupts the Leloir pathway, causing toxic accumulation of galactose-1-phosphate. This explains neonatal/childhood mortality due to fulminant liver failure, sepsis, or CNS complications. Abnormal amino acid concentrations (aspartate, alanine, tyrosine) reflect secondary hepatic dysfunction, while hyperthreoninuria may arise from proximal renal tubular damage from metabolite toxicity. Intellectual disability and speech delays align with long-term neurotoxic effects of untreated galactose metabolites. The constellation of life-threatening metabolic crises in infancy and specific biochemical markers strongly supports this diagnosis."
"['Death in infancy', 'Anemia', 'Hyperhomocystinemia', 'Abnormal circulating porphyrin concentration', 'Abnormal blood folate concentration', 'Abnormal vitamin B12 level']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia**: Directly caused by cystathionine beta-synthase (CBS) deficiency, which disrupts homocysteine metabolism, leading to toxic accumulation.  
2. **Anemia**: CBS deficiency indirectly affects folate and vitamin B12 metabolism, both critical for DNA synthesis and erythropoiesis. Abnormal levels of these vitamins can result in megaloblastic anemia.  
3. **Abnormal vitamin B12/folate concentrations**: Homocysteine remethylation to methionine requires B12 and folate. Dysregulation in this pathway alters their utilization, causing abnormal serum levels.  
4. **Death in infancy**: Severe CBS deficiency manifests neonatally with rapid metabolic decompensation, thromboembolic events, or failure to thrive, often fatal without early diagnosis/treatment.  
5. **Abnormal porphyrins**: While not a primary feature of CBS deficiency, secondary oxidative stress from homocysteine toxicity may disrupt heme biosynthesis, elevating porphyrin levels.  

Disease: Homocysteinemia/Homocystinuria (broader category)  
Reasoning:  
1. **Hyperhomocystinemia**: Defines the condition, encompassing both genetic (e.g., CBS deficiency) and acquired causes (e.g., B9/B12 deficiencies).  
2. **Consistent symptoms**: All listed findings (anemia, abnormal B12/folate, porphyrins) align with systemic metabolic disruption from homocysteine toxicity, even if CBS deficiency is the specific etiology."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria  
Reasoning: The primary symptom of hyperphenylalaninemia strongly indicates PKU, caused by phenylalanine hydroxylase (PAH) deficiency, impairing phenylalanine-to-tyrosine conversion. Hypertyrosinemia is atypical in classic PKU but may arise from secondary mechanisms, such as excessive dietary tyrosine supplementation or competitive inhibition of tyrosine metabolism by elevated phenylalanine. Death in childhood aligns with untreated PKU, where toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and organ failure. This triad of symptoms suggests a severe PKU phenotype with complications driving atypical tyrosine elevation."
"['Nephritis', 'Failure to thrive', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Hepatomegaly', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid']",['Hawkinsinuria/Hawkinsinuria'],"Disease: Hawkinsinuria  
Reasoning:  
1. **Abnormal Tyrosine Metabolism**: The patient's abnormal circulating tyrosine concentration suggests a disorder in tyrosine catabolism. Hawkinsinuria is caused by a partial deficiency of 4-hydroxyphenylpyruvate dioxygenase (HPD), a key enzyme in tyrosine breakdown.  
2. **Elevated Urinary Carboxylic Acids**: Accumulation of intermediates like hawkinsin (a cyclic carboxylic acid derivative) due to HPD deficiency leads to elevated urinary carboxylic acids, a hallmark of the condition.  
3. **Gastrointestinal Symptoms**: Vomiting and diarrhea are common in infancy due to metabolic acidosis from toxic metabolite buildup.  
4. **Hepatomegaly**: Impaired tyrosine metabolism can cause liver enlargement, though liver dysfunction is typically mild compared to other tyrosine disorders (e.g., tyrosinemia type I).  
5. **Failure to Thrive and Nephritis**: Chronic metabolic stress and tubular kidney damage from hawkinsin or its derivatives may result in growth failure and nephritis.  
6. **Death in Infancy**: Severe metabolic crises in untreated cases can lead to early mortality, though symptoms often improve with age if managed (e.g., low-tyrosine diet, ascorbic acid supplementation).  
7. **Exclusion of Other Disorders**: The absence of severe liver failure (tyrosinemia type I) or ocular/skin lesions (tyrosinemia type II) further supports Hawkinsinuria."
"['Apathy', 'Death in infancy', 'Oroticaciduria', 'Neonatal death', 'Feeding difficulties', 'Sepsis']",['Argininosuccinic aciduria/Argininosuccinic aciduria'],"Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Urea Cycle Dysfunction**: Argininosuccinic aciduria is a urea cycle disorder (UCD) caused by argininosuccinate lyase deficiency, impairing ammonia detoxification.  
2. **Hyperammonemia Manifestations**: Neonatal death, feeding difficulties, and apathy align with hyperammonemia-induced encephalopathy and multi-organ failure.  
3. **Oroticaciduria**: Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, producing excess orotic acid, a hallmark of proximal UCDs.  
4. **Sepsis Mimicry**: Hyperammonemia in UCDs often mimics sepsis due to lethargy, vomiting, and metabolic instability, delaying correct diagnosis.  
5. **Early Lethality**: Severe UCDs like argininosuccinic aciduria typically present neonatally with rapid deterioration, explaining infant mortality without prompt treatment.  
6. **Biochemical Confirmation**: Elevated argininosuccinic acid in blood/urine and genetic testing would definitively confirm the diagnosis."
"['Jaundice', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Conjugated hyperbilirubinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine metabolism.  
2. **Hypertyrosinemia** may occur secondarily in PKU due to competitive inhibition of tyrosine metabolism by accumulated phenylalanine, though this is atypical and suggests severe metabolic disruption.  
3. **Neonatal/Infancy/Childhood death** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurodevelopmental damage.  
4. **Jaundice/Conjugated hyperbilirubinemia/Elevated alkaline phosphatase** are unusual in classic PKU but could indicate comorbid liver dysfunction (e.g., prematurity-related immaturity or secondary metabolic stress).  
5. **Abnormality of prenatal development** is inconsistent with PKU (symptoms manifest postnatally), suggesting potential misdiagnosis or overlapping conditions (e.g., maternal PKU syndrome if the mother had untreated PKU during pregnancy).  

**Note:** The diagnosis of PKU primarily rests on persistent hyperphenylalaninemia. The atypical liver-related symptoms warrant investigation for additional disorders (e.g., tyrosinemia type I, biliary atresia) or confounding factors (e.g., sepsis, prematurity). Confirmatory testing (PAH gene analysis, BH4 loading) is critical."
"['Petechiae', 'Abnormality of skin pigmentation', 'Death in infancy', 'Thrombocytopenia', 'Hypoglycemia', 'Hyperammonemia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Pigmentation of the sclera', 'Ichthyosis', 'Abnormal circulating porphyrin concentration']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1 (HT-1)  
Reasoning:  
1. **Metabolic abnormalities**: Hypertyrosinemia, hypermethioninemia, hyperphenylalaninemia, and 4-hydroxyphenylpyruvic aciduria directly indicate a defect in tyrosine metabolism, specifically a deficiency of fumarylacetoacetate hydrolase (FAH) in HT-1.  
2. **Liver dysfunction**: Hypoglycemia, hyperammonemia, elevated alpha-fetoprotein, and hypermethioninemia reflect hepatic injury and impaired tyrosine catabolism.  
3. **Coagulopathy**: Thrombocytopenia, prolonged partial thromboplastin time, and petechiae result from liver failure reducing clotting factor synthesis.  
4. **Skin manifestations**: Ichthyosis, abnormal pigmentation, and scleral pigmentation arise from tyrosine deposition and secondary metabolic disruptions (e.g., porphyrin abnormalities).  
5. **Early fatality**: Death in infancy/childhood aligns with acute HT-1’s rapid progression due to liver failure, renal tubular dysfunction, and metabolic crises.  
6. **Biochemical markers**: Elevated alkaline phosphatase (cholestasis) and hyperammonemia (urea cycle stress) further support hepatorenal involvement.  
**Exclusion**: Other tyrosinemia types (II/III) lack severe liver/kidney phenotypes. HT-1 uniquely combines hepatic, neurologic, and dermatologic features with specific amino acid abnormalities."
"['Cryptorchidism', 'Hypospadias', 'Intellectual disability', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Encephalopathy', 'Failure to thrive', 'Obesity', 'Death in infancy', 'Leukopenia', 'Leukocytosis', 'Hyperammonemia', 'Pyloric stenosis', 'Respiratory insufficiency', 'Hyperglycinemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Sepsis']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia  
Reasoning:  
1. **Metabolic Disturbances**: Hyperammonemia, hyperglycinemia, and abnormal circulating amino acids (aspartate family, alanine) align with PA's defect in propionyl-CoA carboxylase, disrupting the urea cycle and glycine metabolism.  
2. **Neurological Symptoms**: Intellectual disability, seizures, encephalopathy, and hypotonia result from toxic metabolite (propionic acid) accumulation and energy deficiency in the brain.  
3. **Gastrointestinal/Feeding Issues**: Failure to thrive, feeding difficulties, and pyloric stenosis correlate with PA-associated metabolic crises and protein intolerance.  
4. **Carnitine Abnormalities**: Abnormal carnitine levels occur due to secondary carnitine depletion from detoxification of propionyl-CoA.  
5. **Infantile/Childhood Mortality**: Neonatal death, death in infancy/childhood/adolescence reflect PA's severity, often triggered by catabolic states (e.g., infections, fasting).  
6. **Infection/Sepsis Risk**: Leukopenia/leukocytosis and sepsis susceptibility stem from metabolic-induced immunosuppression and mitochondrial dysfunction.  
7. **Congenital Anomalies**: Cryptorchidism/hypospadias may arise from prenatal metabolic stress or mitochondrial dysfunction affecting development.  
8. **Respiratory Insufficiency**: Linked to metabolic acidosis or secondary complications (e.g., cardiomyopathy).  
9. **Obesity Paradox**: May result from chronic dietary management with high-calorie, low-protein regimens.  

**Conclusion**: The constellation of metabolic derangements, neurological deficits, and early mortality strongly supports propionic acidemia, confirmed by biochemical markers (hyperammonemia, hyperglycinemia, carnitine/amino acid abnormalities)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically does not cause structural birth defects, maternal fatty acid oxidation disorders (e.g., in an undiagnosed mother) may indirectly affect fetal energy supply, potentially leading to intrauterine distress.  
2. **Death in infancy/Neonatal death/Death in childhood**: MCADD causes an inability to metabolize medium-chain fatty acids during fasting. Neonates/children with MCADD are at high risk of hypoketotic hypoglycemia, metabolic acidosis, and encephalopathy triggered by catabolic states (e.g., infections, prolonged fasting), leading to sudden death if untreated.  
3. **Decreased plasma free carnitine**: MCADD results in accumulation of medium-chain acylcarnitines (e.g., C6-C10), which are renally excreted, depleting free carnitine. This contrasts with long-chain fatty acid oxidation defects where carnitine is often normal or elevated.  
4. **Diagnostic confirmation**: Elevated C6-C10 acylcarnitines on newborn screening or plasma acylcarnitine analysis, combined with genetic testing confirming *ACADM* gene mutations, solidify the diagnosis. Early intervention with fasting avoidance and emergency protocols prevents mortality."
"['Abnormal saccadic eye movements', 'Abnormality of visual evoked potentials', 'Seizure', 'Spasticity', 'Death in infancy', 'Hypoglycemia', 'Fever', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine', 'Paraplegia/paraparesis', 'Elevated circulating acylcarnitine concentration']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Key biochemical markers**: Elevated glutaric acid (urine/blood) and glutarylcarnitine (acylcarnitine profile) directly result from glutaryl-CoA dehydrogenase deficiency, impairing lysine and tryptophan metabolism.  
2. **Carnitine abnormalities**: Decreased free carnitine and elevated acylcarnitine occur as carnitine conjugates with toxic metabolites (e.g., glutaric acid), leading to secondary deficiency.  
3. **Neurological manifestations**:  
   - **Abnormal cerebral morphology** (macrocephaly, frontotemporal atrophy) and **spasticity/paraparesis** stem from striatal degeneration and white matter damage.  
   - **Seizures** and **abnormal saccadic eye movements** reflect basal ganglia and cortical dysfunction.  
   - **Abnormal visual evoked potentials** suggest optic pathway involvement.  
4. **Metabolic crises**: Triggered by fever/infections, causing **hypoglycemia**, **hyperammonemia**, and encephalopathy due to energy depletion and metabolite accumulation.  
5. **Early lethality**: Untreated crises result in irreversible neurological damage or **death in infancy**.  
6. **Confirmatory findings**: **Glutaric aciduria** and genetic confirmation of GCDH mutations solidify the diagnosis.  

GA-I is distinguished from other organic acidemias by its specific metabolite profile (glutaric acid/glutarylcarnitine) and characteristic neuroimaging findings (striatal injury, frontotemporal atrophy)."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormality of urine homeostasis', 'Neonatal death', 'Death in childhood']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Delayed speech and language development**: Biotinidase deficiency causes neurological impairments, including developmental delays, due to disrupted biotin-dependent carboxylase activity, affecting myelination and neurotransmitter synthesis.  
2. **Abnormality of prenatal development or birth**: While BTDD is typically postnatal in presentation, severe metabolic instability from untreated disease may manifest as perinatal complications or nonspecific congenital anomalies.  
3. **Death in infancy/Neonatal death/Death in childhood**: Untreated BTDD leads to progressive metabolic acidosis, hyperammonemia, and organic aciduria, culminating in fatal metabolic crises or sepsis. Neonatal death may occur if diagnosis is delayed.  
4. **Abnormality of urine homeostasis**: Accumulation of organic acids (e.g., 3-hydroxyisovaleric acid) disrupts renal acid-base regulation, causing metabolic acidosis and abnormal urinary organic acid profiles.  

**Conclusion**: The constellation of metabolic instability, neurological regression, and fatal outcomes aligns with biotinidase deficiency. Early-onset symptoms (e.g., urine abnormalities, developmental delays) and rapid progression without biotin supplementation explain the listed features."
"['Delayed speech and language development', 'Ataxia', 'Dysarthria', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Hyperreflexia', 'Growth delay', 'Death in infancy', 'Abnormal foot morphology', 'Diarrhea', 'Abnormal basal ganglia morphology', 'Increased serum lactate', 'Spastic tetraplegia', 'Ethylmalonic aciduria', 'Increased serum pyruvate', 'Cytochrome C oxidase-negative muscle fibers', 'Death in childhood', 'Death in adolescence']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Neurological and motor deficits**: Symptoms like spastic tetraplegia/diplegia, hyperreflexia, ataxia, dysarthria, and motor delays suggest upper motor neuron involvement and cerebellar dysfunction, consistent with mitochondrial encephalopathies.  
2. **Metabolic abnormalities**: Increased serum lactate and pyruvate, ethylmalonic aciduria, and cytochrome C oxidase (COX)-negative muscle fibers directly indicate a defect in mitochondrial energy metabolism, specifically complex IV (COX) deficiency.  
3. **Systemic manifestations**: Growth delay, diarrhea, and generalized hypotonia reflect multi-organ energy failure. Abnormal basal ganglia morphology aligns with mitochondrial dysfunction in brain regions sensitive to oxidative phosphorylation defects.  
4. **Fatal early course**: Death in infancy/childhood/adolescence is typical in severe mitochondrial disorders due to progressive metabolic crises and neurological decline.  
5. **Nuclear genetic origin**: The ""nuclear type 1"" designation implicates pathogenic variants in nuclear genes (e.g., *SURF1*) critical for COX assembly, distinguishing it from mitochondrial DNA-related complex IV defects.  

The combination of COX-negative fibers, ethylmalonic aciduria, and spasticity with early lethality is pathognomonic for this disorder."
"['Generalized hypotonia', 'Death in infancy', 'Fever', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Decreased plasma free carnitine', 'Prominent forehead', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** and **decreased plasma free carnitine** are hallmark biochemical findings in GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to toxic accumulation of glutaric acid and secondary carnitine depletion.  
2. **Abnormal cerebral morphology** (e.g., frontotemporal atrophy, widened Sylvian fissures) and **prominent forehead** (macrocephaly) are classic neuroimaging and clinical features of GA-I due to striatal injury and impaired brain development.  
3. **Generalized hypotonia** and **feeding difficulties** reflect acute or chronic neurologic dysfunction, common in infancy during metabolic decompensation.  
4. **Fever** often triggers catabolic crises, exacerbating metabolic derangements and neurodegeneration.  
5. **Death in infancy** aligns with untreated GA-I, as acute encephalopathic crises or progressive neurologic damage can be fatal without dietary management (protein restriction, carnitine supplementation) and emergency care during metabolic stress.  
6. The constellation of metabolic, neurologic, and dysmorphic features excludes other organic acidemias or mitochondrial disorders."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG due to abnormal glycosylation affecting cerebellar development.  
2. **Ataxia and motor delay**: Directly linked to cerebellar dysfunction from structural anomalies.  
3. **Generalized hypotonia**: Common in glycosylation disorders due to impaired neuromuscular function.  
4. **Intellectual disability**: Reflects global neurodevelopmental impairment from glycosylation defects.  
5. **Strabismus**: Associated with cerebellar malformation impacting ocular motor control.  
6. **Death in childhood**: Severe PMM2-CDG cases often lead to early mortality from multi-organ failure or infections.  
7. **Systemic confirmation**: PMM2-CDG’s biochemical profile (e.g., abnormal transferrin isoforms) and genetic testing for *PMM2* mutations would confirm the diagnosis."
"['Seizure', 'Death in infancy', 'Metabolic acidosis', 'Tachypnea', '3-Methylglutaric aciduria', 'Neonatal death']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia**: CPS1 deficiency disrupts the urea cycle, impairing ammonia detoxification. Elevated ammonia levels cause neurological symptoms (seizures) and contribute to neonatal lethality.  
2. **Respiratory Findings (Tachypnea)**: Hyperammonemia stimulates the respiratory drive, leading to tachypnea as a compensatory mechanism for associated metabolic acidosis.  
3. **Metabolic Acidosis**: Secondary mitochondrial dysfunction from hyperammonemia or energy depletion may cause lactic acidosis. Concurrent organic aciduria (3-methylglutaric aciduria) suggests disrupted mitochondrial metabolism, potentially due to metabolic stress from ammonia toxicity.  
4. **3-Methylglutaric Aciduria**: Likely a secondary marker of mitochondrial dysfunction, as hyperammonemia can impair leucine catabolism or other pathways, leading to organic acid accumulation.  
5. **Neonatal/Infantile Death**: Severe urea cycle defects like CPS1 deficiency often manifest catastrophically in neonates due to rapid ammonia accumulation, metabolic derangements, and neurological deterioration.  

This diagnosis aligns with the clinical triad of hyperammonemia, metabolic acidosis, and respiratory compensation, alongside the rare but plausible association with 3-methylglutaric aciduria in mitochondrial stress states."
"['Apathy', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hepatomegaly', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['Holocarboxylase synthetas deficiency; HLCS/Holocarboxylase synthetase deficiency/Holocarboxylase synthetase deficiency'],"Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Enzyme Deficiencies**: The patient exhibits decreased pyruvate carboxylase activity and Propionyl-CoA carboxylase deficiency. Both enzymes require biotin as a cofactor, which is activated by holocarboxylase synthetase (HLCS). HLCS deficiency disrupts biotinylation, impairing all biotin-dependent carboxylases.  
2. **Metabolic Abnormalities**:  
   - **Metabolic acidosis** and **elevated serum lactate** stem from impaired gluconeogenesis (pyruvate carboxylase deficiency) and tricarboxylic acid cycle dysfunction.  
   - **Hyperammonemia** arises due to secondary urea cycle inhibition from accumulated organic acids (e.g., propionyl-CoA metabolites).  
   - **Elevated urinary carboxylic acids** (e.g., 3-hydroxypropionate, methylcitrate) reflect Propionyl-CoA carboxylase deficiency.  
3. **Dermatological Features**: **Eczematoid dermatitis** and **skin rash** are classic biotin-responsive manifestations due to defective fatty acid synthesis and keratinocyte dysfunction.  
4. **Systemic Symptoms**: **Apathy**, **hypotonia**, **feeding difficulties**, and **vomiting** result from metabolic decompensation and neurotoxicity (hyperammonemia, acidosis).  
5. **Hepatomegaly**: Linked to fatty infiltration or mitochondrial dysfunction from metabolic stress.  
6. **Aminoaciduria** and **abnormal glycine levels**: Secondary to renal tubular dysfunction and disrupted amino acid metabolism.  
7. **Early Mortality**: Untreated HLCS deficiency causes rapid metabolic crises, leading to **death in infancy**.  

This constellation of symptoms, enzyme deficiencies, and biochemical findings confirms HLCS deficiency as the diagnosis."
"['Generalized hypotonia', 'Death in infancy', 'Weight loss', 'Fever', 'Dyspnea', 'Oroticaciduria', 'Neonatal death', 'Inappropriate crying']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Oroticaciduria**: A hallmark of OTCD due to secondary pyrimidine synthesis disruption. Accumulated carbamoyl phosphate is diverted to orotic acid production.  
2. **Hyperammonemia (implied)**: Neonatal death, hypotonia, and inappropriate crying suggest metabolic encephalopathy from elevated ammonia (unmeasured but pathognomonic in OTCD).  
3. **Neonatal/Infantile lethality**: Severe OTCD manifests shortly after birth with rapid metabolic decompensation, consistent with ""death in infancy"" and ""neonatal death.""  
4. **Respiratory and systemic symptoms**: Dyspnea and fever may reflect secondary metabolic acidosis or triggering infections (common precipitants of urea cycle crises).  
5. **Neuromuscular signs**: Generalized hypotonia aligns with hyperammonemia-induced CNS toxicity.  
6. **Weight loss**: Poor feeding and catabolism during metabolic stress.  

OTCD is strongly supported by the triad of oroticaciduria, neonatal hyperammonemia features, and rapid fatal course. Other urea cycle disorders lack oroticaciduria, while acquired causes (e.g., liver failure) do not explain neonatal onset."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Encephalopathy', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Increased serum lactate', 'Abnormal cerebral white matter morphology', 'Glutaric aciduria', '3-Methylglutaric aciduria', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase deficiency (HMGCL deficiency)  
Reasoning:  
1. **Organic Acidurias**: Elevated urinary 3-methylglutaric acid and glutaric acid are hallmark biochemical markers of HMGCL deficiency due to impaired leucine catabolism and ketogenesis.  
2. **Metabolic Crisis Features**: Hypoglycemia (from defective ketogenesis), hyperammonemia (secondary to metabolic stress), and lactic acidosis (mitochondrial dysfunction) align with acute decompensation episodes in this disorder.  
3. **Neurological Involvement**: Encephalopathy, abnormal cerebral white matter morphology, and delayed development reflect neurotoxic effects of accumulated metabolites (e.g., 3-hydroxy-3-methylglutaric acid).  
4. **Early Lethality**: Neonatal death or death in infancy/childhood is common in severe cases due to metabolic instability and susceptibility to infections.  
5. **Carnitine/Carboxylic Acid Abnormalities**: Secondary carnitine deficiency and elevated monocarboxylic acids occur due to excessive conjugation/excretion of toxic intermediates.  
6. **Systemic Symptoms**: Feeding difficulties, gastrointestinal inflammation, and recurrent infections stem from chronic metabolic dysfunction and energy deficiency.  
7. **Exclusion of Mimics**: Glutaric aciduria type I is ruled out by the absence of striatal necrosis and presence of 3-methylglutaric aciduria, which is specific to HMGCL deficiency.  

The combination of biochemical findings (urinary acids, hyperammonemia, hypoglycemia) and clinical features (neurodegeneration, early mortality) confirms the diagnosis."
"['Delayed speech and language development', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), impairing phenylalanine metabolism.  
2. **Delayed speech and language development**: Untreated PKU leads to toxic phenylalanine accumulation in the brain, damaging myelin and neurotransmitters, resulting in neurodevelopmental delays.  
3. **Severe short stature**: Chronic metabolic disruption and malnutrition (due to strict dietary restrictions) contribute to growth failure in untreated cases.  
4. **Death in childhood**: Severe neurological deterioration, seizures, and systemic complications (e.g., cardiac issues) in classic PKU can lead to early mortality if untreated.  
5. **Confirmation**: PKU is confirmed via newborn screening (elevated phenylalanine, low tyrosine) and genetic testing for PAH mutations. Early dietary intervention prevents symptoms, but untreated cases align with the described presentation."
"['Irritability', 'Hyperinsulinemia', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Thrombocytopenia', 'Abnormal bleeding', 'Hypoglycemia', 'Hyperammonemia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hyperalbuminemia']","['Tyrosinemia I; hepatorenal hyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I']","Disease: Tyrosinemia type 1  
**Reasoning**:  
1. **Hypertyrosinemia, 4-Hydroxyphenylpyruvic aciduria, and Hyperphenylalaninemia**: These indicate a defect in tyrosine metabolism. Tyrosinemia type 1 (HT-1) results from fumarylacetoacetate hydrolase (FAH) deficiency, causing toxic accumulation of tyrosine and its metabolites (e.g., succinylacetone).  
2. **Liver Dysfunction**: Elevated alpha-fetoprotein (marker of hepatic damage/regeneration), hyperammonemia (impaired urea cycle), hypoglycemia (reduced gluconeogenesis), and hypermethioninemia (secondary to liver failure) align with HT-1’s hepatotoxic effects.  
3. **Coagulopathy**: Prolonged partial thromboplastin time, thrombocytopenia, and abnormal bleeding stem from impaired hepatic synthesis of clotting factors and possible platelet dysfunction.  
4. **Renal and Systemic Toxicity**: Succinylacetone damages renal tubules and inhibits porphobilinogen synthase, explaining abnormal porphyrin levels.  
5. **Early Mortality**: Neonatal death, death in infancy/childhood, and prenatal abnormalities reflect the severe, progressive nature of untreated HT-1.  
6. **Hyperinsulinemia**: May arise from stress-induced hypoglycemia or secondary metabolic dysregulation due to liver failure.  
7. **Elevated Alkaline Phosphatase**: Consistent with cholestatic liver injury, a common feature in HT-1.  

The constellation of liver failure, tyrosine pathway abnormalities, coagulopathy, and succinylacetone-mediated toxicity confirms Tyrosinemia type 1."
"['Nephrocalcinosis', 'Epistaxis', 'Failure to thrive', 'Death in infancy', 'Pulmonic stenosis', 'Increased serum lactate', 'Hepatomegaly', 'Hypokalemia', 'Hypermagnesemia', 'Hypercholesterolemia', 'High serum calcitriol', 'Elevated circulating alkaline phosphatase concentration', 'Hyperalaninemia', 'Aminoaciduria', 'Increased serum iron', 'Severe short stature', 'Hypouricemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Death in adolescence']",['Fanconi-Bickel syndrome/Fanconi-Bickel syndrome'],"Disease: Fanconi-Bickel syndrome  
Reasoning:  
1. **Hepatomegaly** and **failure to thrive** are hallmark features of Fanconi-Bickel syndrome (FBS), caused by hepatic glycogen accumulation and metabolic disturbances.  
2. **Aminoaciduria** and **hypokalemia** indicate proximal renal tubular dysfunction (Fanconi syndrome), a core component of FBS.  
3. **Nephrocalcinosis** arises from chronic renal phosphate wasting and hypercalciuria, exacerbated by **high serum calcitriol** due to dysregulated vitamin D metabolism.  
4. **Severe short stature** and **hypercholesterolemia** reflect impaired glucose metabolism and malnutrition from defective GLUT2-mediated transport.  
5. **Hypouricemia** and **elevated serum lactate** align with proximal tubule dysfunction and glycolytic pathway disruptions.  
6. **Abnormal circulating aspartate family amino acids** and **hyperalaninemia** stem from systemic metabolic dysregulation.  
7. **Increased serum iron** and **hepatomegaly** correlate with hepatic dysfunction and glycogen overload.  
8. **Death in infancy/childhood/adolescence** reflects the severe, progressive nature of untreated FBS.  
9. Atypical features like **pulmonic stenosis** and **epistaxis** may represent comorbidities or secondary complications but do not exclude the diagnosis.  

The collective presentation of hepatorenal glycogen storage disease, Fanconi syndrome, and metabolic derangements confirms Fanconi-Bickel syndrome."
"['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Dicarboxylic aciduria', 'Neonatal death', 'Feeding difficulties']",['Glycogen storage disease Ia/Glycogen storage disease Ia'],"Disease: Glycogen storage disease Ia  
Reasoning:  
1. **Metabolic Acidosis & Dicarboxylic Aciduria**: In GSD Ia, glucose-6-phosphatase deficiency prevents glucose release from glycogenolysis, forcing reliance on fatty acid oxidation. Inefficient β-oxidation generates dicarboxylic acids (e.g., adipic, suberic acids), excreted in urine (dicarboxylic aciduria). Anaerobic glycolysis due to hypoglycemia also elevates lactate, worsening acidosis.  
2. **Hypoglycemia-Driven Symptoms**: Severe fasting hypoglycemia triggers seizures and feeding difficulties. Chronic energy deprivation causes generalized hypotonia.  
3. **Neonatal/Infantile Fatality**: Without glucose homeostasis, recurrent metabolic crises (acidosis, hypoglycemia) lead to organ failure or fatal arrhythmias, often resulting in neonatal death or death in infancy if untreated.  
4. **Exclusion of Alternatives**: While fatty acid oxidation disorders (e.g., MCAD) also cause dicarboxylic aciduria, the triad of hypoglycemia, acidosis, and hepatic dysfunction (implied by feeding difficulties) aligns with GSD Ia. Hepatomegaly (common in GSD Ia) may not be listed but is often clinically present.  

This pathophysiological cascade confirms Glycogen storage disease Ia as the diagnosis."
"['Seizure', 'Lethargy', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Hypoglycemia', 'Vomiting', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Feeding difficulties', 'Elevated urinary 3-hydroxybutyric acid']","['Fructose-1,6-bisphosphatase deficiency/Fructose-1,6-bisphosphatase deficiency']","Disease: Fructose-1,6-bisphosphatase deficiency  
Reasoning:  
1. **Hypoglycemia**: Central feature of FBPase deficiency due to impaired gluconeogenesis during fasting.  
2. **Metabolic acidosis & elevated serum lactate**: Blocked gluconeogenesis causes accumulation of lactate (a gluconeogenic precursor), leading to lactic acidosis.  
3. **Elevated urinary 3-hydroxybutyric acid**: Compensatory fatty acid oxidation generates ketone bodies (e.g., 3-hydroxybutyrate) during hypoglycemia.  
4. **Tachycardia & tachypnea**: Compensatory responses to acidosis (e.g., respiratory alkalosis attempt) and hypoglycemia.  
5. **Seizures, lethargy, drowsiness**: Neurological effects of hypoglycemia and metabolic derangements.  
6. **Feeding difficulties, vomiting, death in infancy**: Infants rely on frequent feeding; fasting triggers metabolic crises, risking fatal hypoglycemia/acidosis if untreated.  
7. **Sleep disturbance**: May reflect recurrent hypoglycemic episodes disrupting normal cycles.  
Key exclusion: Symptoms align with gluconeogenesis defects (not glycolysis or mitochondrial disorders). Elevated lactate + ketones + hypoglycemia in infancy is pathognomonic for FBPase deficiency."
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Spasticity', 'Motor delay', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: The presence of elevated phenylalanine levels directly indicates a defect in phenylalanine metabolism, the hallmark of PKU.  
2. **Neurological symptoms (intellectual disability, spasticity, motor/speech delay)**: Untreated PKU causes toxic phenylalanine accumulation, impairing neurotransmitter synthesis and myelination, leading to developmental delays and neurological damage.  
3. **Early mortality (neonatal/infant/childhood death)**: Severe untreated PKU can result in progressive neurological deterioration, seizures, and susceptibility to infections, contributing to early death.  
4. **Prenatal developmental abnormalities**: While PKU itself does not cause prenatal structural defects, maternal PKU (untreated during pregnancy) can lead to congenital anomalies. The listed symptom may reflect this context or overlap with complications from metabolic instability post-birth.  
5. **Exclusion of alternatives**: Symptoms align with PKU’s pathophysiology; no features suggest other metabolic disorders (e.g., maple syrup urine disease) or syndromes with overlapping symptoms."
"['Irritability', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Hyperglycinemia', 'Opisthotonus', 'Methylmalonic acidemia', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Abnormal circulating creatinine concentration', 'Methylmalonic aciduria', 'Abnormality of vitamin D metabolism', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: The patient exhibits **methylmalonic acidemia**, **methylmalonic aciduria**, and **decreased methylmalonyl-CoA mutase activity**, which are pathognomonic for this disorder. Methylmalonyl-CoA mutase deficiency directly impairs propionate metabolism, leading to toxic metabolite accumulation.  
2. **Metabolic derangements**: **Hyperammonemia**, **metabolic acidosis**, and **hyperglycinemia** arise due to disrupted urea cycle function and secondary inhibition of glycine cleavage systems by accumulated methylmalonic acid.  
3. **Neurological features**: **Opisthotonus**, **motor delay**, and **intellectual disability** reflect neurotoxicity from elevated methylmalonic acid, ammonia, and glycine. **Irritability** and **feeding difficulties** are early signs of metabolic decompensation.  
4. **Systemic complications**: **Abnormal carnitine/creatinine levels** and **hypervalinemia** occur due to secondary mitochondrial dysfunction and amino acid metabolism disturbances. **Abnormal vitamin D metabolism** may stem from chronic renal tubular damage.  
5. **Clinical trajectory**: **Neonatal death**, **death in infancy**, and **death in early adulthood** align with severe, treatment-resistant forms of mutase-deficient MMA. B12-unresponsiveness is confirmed by persistent enzyme deficiency despite B12 cofactor availability.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Diagnostic confirmation**: The presence of **methylmalonic acidemia** and **methylmalonic aciduria** in symptomology meets the biochemical criteria for MMA.  
2. **Subtype differentiation**: While overlapping with the mutase-deficient form, this broader diagnosis encompasses all MMA subtypes (e.g., cblA, cblB). However, **decreased methylmalonyl-CoA mutase activity** specifically localizes the defect to the mutase enzyme itself.  
3. **Symptom constellation**: **Hyperammonemia**, **acidosis**, **hyperglycinemia**, and **opisthotonus** collectively form the classic MMA phenotype, distinct from other organic acidemias.  
4. **Prognostic markers**: Early lethality (**neonatal/infant death**) and multisystem involvement (**abnormal carnitine**, **vitamin D metabolism**) reflect disease severity typical of MMA."
"['Microcephaly', 'Carious teeth', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylpyruvate, phenyllactate, and phenylacetate, excreted in urine, aligning with PKU’s biochemical profile.  
3. **Neurological symptoms (Microcephaly, Delayed speech)**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, disrupting brain development and function.  
4. **Hypertyrosinemia**: Secondary tyrosine deficiency due to PAH dysfunction may alter tyrosine metabolism, though this is atypical and could indicate a comorbid metabolic disturbance or variant PKU.  
5. **Prenatal abnormalities/Death in infancy/childhood**: Severe untreated PKU causes progressive neurodegeneration, seizures, and early mortality. Maternal PKU during pregnancy can also induce congenital anomalies (e.g., microcephaly) in offspring.  
6. **Carious teeth**: Chronic metabolic imbalance or high-carbohydrate/low-protein diets (used to manage PKU) may predispose to dental decay.  
**Conclusion**: The constellation of hyperphenylalaninemia, urinary carboxylic acids, and neurodevelopmental deficits strongly supports PKU. Early mortality and prenatal issues reflect untreated or late-diagnosed cases."
"['Nephritis', 'Failure to thrive', 'Growth delay', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid']",['Hawkinsinuria/Hawkinsinuria'],"Disease: Hawkinsinuria  
Reasoning:  
1. **Abnormal Tyrosine Metabolism**: The presence of abnormal circulating tyrosine concentration suggests a defect in tyrosine catabolism, a hallmark of Hawkinsinuria.  
2. **Urinary Carboxylic Acid Elevation**: Elevated urinary carboxylic acids (specifically hawkinsin, a cyclic keto-enol ether derived from 4-hydroxyphenylpyruvate) are pathognomonic for this disorder.  
3. **Infantile Presentation**: Symptoms like vomiting, diarrhea, failure to thrive, and growth delay align with metabolic crises in infancy caused by tyrosine derivative accumulation.  
4. **Renal Involvement**: Nephritis may arise due to tubular damage from toxic metabolites, though this is less common and typically milder compared to other tyrosine metabolism disorders.  
5. **Severity Spectrum**: Death in infancy is rare but reported in severe, untreated cases due to metabolic acidosis or complications from chronic renal dysfunction.  
6. **Exclusion of Other Tyrosinemias**: Unlike tyrosinemia types I/II, Hawkinsinuria lacks severe liver dysfunction or neurological symptoms, focusing the diagnosis on urinary hawkinsin excretion and milder clinical progression."